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ABSTRACT 
 
Background 
Novel therapeutic strategies are required to protect the myocardium against ischaemia-
reperfusion injury. Mitochondria are fundamental for the maintenance of cell function 
and survival in this setting. Although a number of mitochondrial therapeutic targets have 
been identified, their cardioprotective efficacy in vivo remains unknown. 
  
Methods and Results 
This thesis describes the establishment and validation of an important in vivo murine 
model of ischaemia-reperfusion injury for the first time within our laboratory. This model 
was used to investigate the cardioprotective potential of modulating three mitochondrial 
proteins. In addition, this thesis investigates the use of a novel cardiac MRI sequence to 
quantify myocardial area-at-risk, an essential pre-requisite for assessing the 
cardioprotective efficacy of therapeutic interventions.  
Cyclophilin-D:  Cyp-D has been implicated as a critical regulator of cell death by 
mitochondrial permeability transition pore opening upon ischaemia-reperfusion. Cyp-D 
genetic ablation evoked cardioprotection against myocardial ischaemia-reperfusion 
following extended reperfusion; thereby confirming the protective efficacy of this target. 
Sirtuin-3: Post-translational protein deacetylation by Sirt-3 is an important regulator of 
mitochondrial biology and cell survival. Sirt-3 genetic ablation did not affect the 
susceptibility to myocardial infarction upon ischaemia-reperfusion under normal 
conditions. Fasting-induced Sirt-3 overexpression increased myocardial infarct size; 
thereby suggesting that Sirt-3 inhibition may be protective under certain conditions. 
DJ-1: Preservation of mitochondrial function upon oxidative stress by the diverse actions 
of DJ-1 is critical for cell survival upon cerebral ischaemia-reperfusion. DJ-1 genetic 
ablation caused increased mitochondrial fragmentation but did not adversely affect 
cardiac function. DJ-1 knockout mice were more susceptible to myocardial infarction 
suggesting that this may represent an important target for cardioprotection. 
 
Conclusions 
This thesis confirms the role for CypD as an important target for cardioprotection, and 
provides experimental evidence implicating Sirt-3 and DJ-1 as novel mitochondrial 
targets for protecting the heart against ischaemia-reperfusion injury. We also provide 
initial data that arterial spin labelling cardiac MRI may be an important tool for the future 
assessment of novel cardioprotective interventions.  
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Standard units of measurement are used throughout this thesis according to accepted 
conventions. A comprehensive list of non-standard abbreviations is provided below.  
 
AAR Area-at-risk 
ACE Angiotensin-converting enzyme 
Ab Antibody 
ADP Adenosine diphosphate 
ANT Adenine nucleotide translocase 
APS Ammonium persulphate 
ASK1 Apoptosis signal-regulating 
kinase I 
ASL Arterial spin labelling 
ATP Adenosine triphosphate 
A.U. Arbitrary units 
BCA Bicinchoninic acid  
Bcl-2 B-cell lymphoma-2 
Bp Base pairs 
BPM Beats per minute (heart rate) 
BSA Bovine serum albumin 
C106A Cysteine 106 alanine (DJ-1 
mutation) 
CA Carbonic anhydrase 
Cine Cinematic (imaging)  
CK Creatine kinase 
COX-2 Cyclo-oxygenase 2 
CsA Cyclosporine-A 
Cx Circumflex (coronary artery) 
Cyp Cyclophilin 
Daxx Death-domain associated 
protein 
dNTP Dinucleotide triphosphate 
DTPA Diethylene-triamine penta-acetic 
acid 
ECG Electrocardiogram 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
ED End-diastolic 
EGE Early gadolinium enhancement 
ERK Extracellular-regulated kinase 
EM Electron microscopy 
eNOS Endothelial nitric oxide synthase 
ES (cell) Embryonic stem (cell) 
ES End-systolic 
ETC Electron transport chain 
FAIR Flow alternating inversion 
recovery 
FAD
+
 Flavin adenine dinucleotide 
FL Floxed 
FOXO Forkhead box O 
GC Guanine-cytosine 
Gd Gadolinium 
GPCR G-protein coupled receptor 
GSK-3β Glycogen synthase kinase-3β 
H2O2 Hydrogen peroxide 
HAT Histone acetyl transferase 
HDAC Histone deacetylase 
HeLa Human epithelioid cervix 
carcinoma 
HET Heterozygote (+/-) 
HKII Hexokinase II 
HRP Horseradish peroxidase 
HSP Heat shock protein 
IDH2 Isocitrate dehydrogenase-2 
IFM Interfibrillar mitochondria 
IL Interleukin 
IMM Inner mitochondrial membrane 
I.P. Intraperitoneal 
IPC Ischaemic preconditioning 
IPost Ischaemic postconditioning 
IS Infarct size 
I.V. Intravenous 
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KAT Lysine acetyl transferase 
KDAC Lysine deacetylase 
KHB Krebs-Henseleit buffer 
KO Knockout (-/-) 
L116P Lysine 166 proline (DJ-1 
mutation) 
LAD Left anterior descending (artery) 
LGE Late gadolinium enhancement 
LPS Lipopolysaccharide 
LV Left ventricle 
MALDI-
TOF 
Matrix-assisted laser desorption 
/ localisation 
MEF Mouse embryonic fibroblast 
Mer Mutated oestrogen receptor 
MHC Myosin heavy chain 
MMP Matrix metalloproteinase 
MnSOD Manganese superoxide 
dismutase 
mPTP Mitochondrial permeability 
transition pore 
mtCsA Mitochondrial targeted CsA 
mtRFP Mitochondrial red fluorescent 
protein 
mtYFP Mitochondrial yellow fluorescent 
protein 
MRI Magnetic resonance imaging 
NACWO Named animal care welfare 
officer 
NAD
+
 Nicotinamide adenine 
dinucleotide 
Neo Neomycin resistance (gene) 
NOS Nitric oxide synthase 
OMM Outer mitochondrial membrane 
PAF Platelet activating factor 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE Prostaglandins 
PEP Positive end pressure 
Pi Inorganic phosphate 
PI3K Phosphoinositide 3-kinase 
PI Propidium iodide 
PKG Protein kinase G 
PPCI Primary percutaneous coronary 
intervention 
PPIase Peptidyl-prolyl cis-trans 
isomerase 
Ppif Peptidyl-prolyl isomerase F 
PTEN Phosphatase and tensin 
homolog 
RCA Right coronary artery 
RF Radiofrequency 
RIP Receptor interacting protein 
RIPost Remote ischaemic 
postconditioning 
RISK Reperfusion injury salvage 
kinase 
RNAi Interference RNA 
ROS Reactive oxygen species 
RV Right ventricle 
S.C. Subcutaneous 
SDS-
PAGE 
Sodium-dodecyl sulphate 
polyacrylamide gel 
electrophoresis 
SfA Sanglifehrin-A  
sh-RNA Short-hairpin RNA  
Sirt Sirtuin  
Sir Silent information regulator 
SNO S-nitrosylation 
SOD Superoxide dismutase 
SPECT Single photon emission 
computed tomography  
STEMI ST-segment elevation 
myocardial infarction 
TAC Transaortic constriction 
TE Echo time (MRI) 
TEMED Tetramethyl ethylenediamine 
Tm Melting temperature (DNA) 
TMRM Tetramethyl rhodaminemethyl 
TNF Tumour necrosis factor 
TTC Triphenyltetrazolium chloride  
VDAC Voltage-dependent anion 
channel 
WT Wildtype (+/+) 
ZT Zeitgeber time 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1. Cardiovascular disease and acute myocardial infarction 
Coronary artery disease and its end consequence, acute myocardial infarction, is 
currently the leading cause of mortality worldwide. Indeed, almost 450,000 patients were 
admitted to hospital for acute myocardial infarction between 2004 and 2010 in England 
alone (Smolina et al., 2012). Furthermore, recent predictions suggest that the 
prevalence and consequent mortality of acute myocardial infarction will continue to 
increase during the coming decades, such that it will remain the leading cause of death 
worldwide in 2030 (Mathers and Loncar, 2006). These humbling statistics persist despite 
decades of basic and clinical research into the mechanisms of acute myocardial 
infarction and the development and implementation of reperfusion therapies for the 
treatment of myocardial infarction (Thygesen et al., 2007). 
Acute myocardial infarction is the most significant clinical manifestation of coronary 
artery disease (Thygesen et al., 2007). During the progression of coronary artery 
disease, atherosclerosis of the major coronary arteries occurs due to accumulation of 
cholesterol-engorged macrophages which can cause plaques to develop within the 
arteries (reviewed by Lusis, 2000). Acute myocardial infarction is most commonly 
caused by rupture or erosion of an atherosclerotic plaque which results in the formation 
of a thrombus and subsequent distal occlusion of the artery. If the coronary artery 
occlusion is not rapidly removed, then sustained myocardial ischaemia will result in the 
death of cardiomyocytes within this area of ischaemia (Thygesen et al., 2007). 
Clinical diagnosis of acute myocardial infarction is largely based on the presence of 
distinct electrocardiogram (ECG) features and elevated cardiac enzyme levels in blood, 
discussed in detail subsequently. Treatment of acute myocardial infarction comprises 
rapid restoration of coronary artery perfusion by removal of the occluding lesion. Current 
established reperfusion therapy for acute myocardial infarction comprises 
pharmacological thrombolysis or primary percutaneous coronary intervention (PPCI) to 
mechanically disrupt and remove the occluding lesion (Thygesen et al., 2007). Indeed, 
widespread and timely application of these reperfusion therapies has dramatically 
improved the early prognosis of acute myocardial infarction patients (Smolina et al., 
2012). However, as short-term patient prognosis improves, the importance of studying 
long-term morbidity and mortality becomes increasingly important, particularly given the 
predicted increased prevalence of acute myocardial infarction and subsequent 
development of cardiac failure (Mathers and Loncar, 2006). 
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1.2. Myocardial ischaemia-reperfusion injury  
The primary effect of coronary artery occlusion is myocardial infarction which is caused 
by the adverse effects of ischaemia and reperfusion. Myocardial ischaemia disrupts 
normal cellular physiology and initiates a sequence of events that ultimately result in 
death of ischaemic cardiomyocytes. In addition, reperfusion of the previously ischaemic 
myocardium also, paradoxically, causes a degree of damage, termed lethal myocardial 
reperfusion injury, which can result in further cardiomyocyte death (Manning and 
Hearse, 1984). Since it has long been appreciated that the extent of myocardial 
infarction strongly correlates with patient prognosis (Sobel et al., 1972), limiting 
ischaemia-reperfusion injury represents a significant target for the development of 
therapeutic strategies aimed at improving patient prognosis.  
1.2.1. Overview of normal myocardial physiology 
In order to understand the pathophysiology of ischaemia-reperfusion injury, it is 
necessary to appreciate the normal physiology of cardiomyocytes and their cumulative 
roles in normal cardiac function. Cardiomyocytes function as a highly ordered network of 
electrically and physically connected cells to allow efficient propagation of action 
potentials and contractile force. The helical macroscopic structure of the myocardium 
has been suggested to form the basis for efficient electrical and contractile functioning of 
the heart and is therefore important for overall cardiac function (Buckberg et al., 2001).  
The heart is an exceptionally energy demanding organ and as such its constituent 
muscle cells, the cardiomyocytes, are densely packed with mitochondria (Katz, 2001). 
The main energy carrier in mammalian cells is adenosine triphosphate (ATP) which 
releases energy upon hydrolysis to produce adenosine diphosphate (ADP) and 
inorganic phosphate (Pi) (Alberts et al., 2002). Cardiomyocytes normally produce ATP 
by aerobic metabolism, predominantly by fatty acid oxidation and in part by aerobic 
glycolysis (Braunwald and Kloner, 1985). These processes produce acetyl-CoA which 
enters the citric acid cycle to produce ATP (Figure 1.1, stage 1 and 2). Electrons 
produced by the citric acid cycle are transferred along the electron transport chain (ETC) 
complexes in a process which establishes a proton electrochemical gradient across the 
inner mitochondrial membrane (Figure 1.1, stage 3). This causes proton flux across the 
mitochondrial inner membrane in to the matrix which drives ATP synthase to produce 
ATP by oxidative phosphorylation (Figure 1.1, stage 4). Oxidative phosphorylation 
dramatically increases overall ATP production by regenerating ATP from ADP and Pi. 
Importantly, reactive oxygen species (ROS) generated by the ETC are transferred to 
molecular oxygen to avoid oxidative damage (Katz, 2001; Alberts et al., 2002).  
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Figure 1.1: Energy production in normal cardiomyocytes 
In the healthy normoxic heart, cardiomyocytes produce ATP by aerobic metabolism, 
predominantly by utilisation of free fatty acids: (1a) Free fatty acids are converted to acetyl-CoA. 
(1b) Aerobic glycolysis breaks down glucose to form ATP and pyruvate which is oxidised to form 
acetyl-CoA. (2) Acetyl-CoA enters the citric acid cycle which produces ATP and reduced NADH 
and FADH2. (3) Electrons produced by the citric acid cycle are transferred to the ETC where 
transfer along the complexes (I, III and IV – dark blue) drives protons into the mitochondrial 
intermembrane space to create an electrochemical gradient across the IMM. (4) This causes 
proton influx across the IMM via the ATP synthase (orange) to generate ATP. Constructed from 
information provided by Katz (2001) and Alberts et al. (2002). 
 
As with all cell types, energy is required for cellular homeostasis and in turn cellular 
signalling. Cardiomyocytes also utilise a significant amount of energy for contractility 
required for cardiac function (Davies, 1977). In healthy normoxic cardiomyocytes, ATP 
production is coupled to the demand for ATP by the availability of ADP and active 
regulation of ATP synthase (Das, 1998; Carmeliet, 1999). This regulation of ATP 
production ensures that in the normal heart, myocardial energy demands are constantly 
met thus ensuring that the contractile function of the heart is sustained (Katz, 2001).  
Normal and sustained cardiac function therefore requires an uninterrupted supply of 
oxygen and nutrients to the myocardium by the coronary arteries. The myocardium is 
perfused by three main coronary arteries, the left anterior descending (LAD), right 
coronary artery (RCA) and circumflex (Cx), which each perfuse a distinct territory of the 
myocardium. Although there are subtle inter- and intra-species variations in coronary 
anatomy, these arteries consistently perfuse the myocardium in a subepicardial to 
subendocardial manner (Davies, 1977). A more detailed discussion of coronary anatomy 
is provided in chapter 4 with regards to animal models of ischaemia-reperfusion injury.    
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1.2.2. Pathophysiology of myocardial ischaemia 
Coronary artery occlusion causes the region of myocardium normally perfused by the 
affected vessel to become ischaemic. The energy reserves of the ischaemic 
myocardium are rapidly depleted and the demand for oxygen exceeds the available 
supply. Given the substantial energy demands of the heart, ischaemia dramatically 
affects the cardiomyocytes and in turn, cardiac function (Reimer et al., 1977).  
i Myocardial ischaemic milieu  
The effects of myocardial ischaemia on the cardiomyocyte intracellular environment 
have been well-characterised and provide a basis from which to understand the 
pathophysiology of myocardial infarction (Reimer et al., 1977; Jennings and Reimer, 
1981). The key intracellular events resulting from myocardial ischaemia are detailed 
below and their cumulative functional consequences are discussed subsequently. 
Accumulation of ADP and inorganic phosphate: Severe hypoxia means that 
physiological aerobic metabolism cannot be sustained. This causes the affected 
myocardium to switch to anaerobic glycolysis within around 30 seconds of the onset of 
coronary artery occlusion (Davies, 1977; Jennings and Reimer, 1981) (Figure 1.2, stage 
1). The inefficiency of ATP production by anaerobic glycolysis means that ischaemic 
cells are unable to generate sufficient ATP for normal cellular homeostasis and cardiac 
function and this in turn causes a series of cytosolic and mitochondrial changes 
including ADP and Pi accumulation (Katz, 2001; Alberts et al., 2002). 
Intracellular acidosis: Acidification of the intracellular environment (to approximately 
pH 5.8 to 6.0) occurs due to lactate accumulation and hydrolysis of ATP. During 
anaerobic glycolysis the lack of oxygen means that pyruvate is reduced to lactate by 
lactate dehydrogenase in a process which also releases protons (Figure 1.2, stage 2). 
The accumulation of protons is further exacerbated by ATP hydrolysis which releases 
inorganic phosphate and protons (Figure 1.2, stage 3) (Davies, 1977; Katz, 2001). The 
cumulative effect of lactate and proton accumulation is progressive acidification of the 
cytosol and mitochondrial matrix. High lactate levels and intracellular acidosis also 
inhibit important glycolytic enzymes which further decreases the efficiency of ATP 
production and thus exacerbates ATP deprivation (Figure 1.2, stage 4) (Jennings and 
Reimer, 1981). In addition, protons accumulated within the cell can also interact with 
and affect numerous intracellular signalling pathways (Katz, 2001). Notably, voltage-
gated ion channel inhibition and gap junction closure in the presence of high proton 
levels can cause slowed cardiac conduction and which can ultimately result in cardiac 
arrhythmias (Manning and Hearse, 1984; Carmeliet, 1999). 
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Figure 1.2: Energy production and homeostasis in ischaemic cardiomyocytes 
Ischaemic cardiomyocytes respire via aerobic glycolysis. (1) Glucose is converted to pyruvate to 
generate small amounts of ATP. (2) In the absence of oxygen, pyruvate is converted into lactate 
in a process that releases protons. (3) ATP hydrolysis releases protons which exacerbates 
intracellular acidosis. (4) Lactate and proton accumulation decrease glycolytic efficiency. (5) High 
proton concentration causes Ca
2+
 influx and intracellular calcium overloading. (6) High 
intracellular Ca
2+
 leads to mitochondrial Ca
2+
 influx. Constructed from information provided by 
Noll et al. (1992), Katz (2001) and Alberts et al. (2002). 
 
Calcium overloading: Increased intracellular proton concentration also results in 
calcium overloading of ischaemic cardiomyocytes. This is thought to be driven by ionic 
exchange mechanisms which attempt to maintain ionic homeostasis whereby the high 
intracellular proton concentration causes sodium ion influx (due to sodium and hydrogen 
ion exchange) and in turn increased intracellular calcium (due to sodium and calcium ion 
exchange) (Figure 1.2, stage 5) (Manning and Hearse, 1984; Kloner and Jennings, 
2001). Intracellular calcium overloading accelerates interactions between contractile 
proteins which increases energy utilisation and thus exacerbates energy depletion of the 
ischaemic cardiomyocytes (Katz, 2001). Increased intracellular calcium also causes 
mitochondrial calcium overloading by rapid calcium influx by the calcium uniporter 
(Kristian and Siesjo, 1998) (Figure 1.2, stage 6).  
Increased cellular osmotic load: A further effect of intracellular lactate and proton 
accumulation, alongside increased levels of inorganic phosphate, is an increased 
cellular osmotic load. Although this causes only modest cardiomyocyte swelling during 
ischaemia, the effect of increased osmotic load and resultant cellular swelling upon 
reperfusion is an important determinant of cardiomyocyte survival (Braunwald and 
Kloner, 1985; Katz, 2001), discussed below in relation to oedema (see section 1.2.3). 
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Accumulation of reactive oxygen species: Re-energisation of the ETC upon 
myocardial reperfusion generates a burst of reactive oxygen species (ROS). This is 
exacerbated by additional ROS production from ATP hydrolysis and metabolite 
breakdown and further by the loss of scavenging molecules, such as catalase and 
superoxide dismutase (SOD) due to compromised membrane integrity, described below 
(Braunwald and Kloner, 1985). ROS are highly reactive due to the presence of unpaired 
electrons in their outer shell. When ROS interact with cells they cause oxidative damage 
including denaturation of proteins and nucleic acids and lipid peroxidation of 
membranes, which can in turn disrupt membrane integrity (Forman et al., 1989). In 
perfused cardiomyocytes, unpaired electrons are transferred to molecular oxygen and 
combined with protons to form water. However, the lack of oxygen in ischaemic 
cardiomyocytes prevents sequestration of unpaired electrons causing accumulation 
ROS and ultimately oxidative damage (Katz, 2001). 
ii Effects of myocardial ischaemia 
The main pathophysiological effects of myocardial ischaemia are described below, 
where the severity of these effects depends largely on the duration of ischaemia. 
Electrocardiogram changes: The electrocardiogram (ECG) depicts the sum of total 
electrical activity of the heart, where each segment of the integrated ECG trace is most 
heavily influenced by action potentials occurring in a distinct region of the heart. 
Myocardial ischaemia resulting from acute coronary occlusion causes significant 
changes to ventricular action potentials in the affected cardiomyocytes which can be 
visualised in the integrated ECG trace. Since the majority of acute myocardial infarctions 
occur in the left ventricle, it is predominantly the QRST, and specifically ST-segment of 
the integrated ECG trace that is affected (Katz, 2001; Herring and Paterson, 2006).  
The primary cause of ECG ST-segment changes is thought to be differences in resting 
potential between perfused and ischaemic cardiomyocytes which abrogate the tight 
coupling of myocardial electrical activity (Katz, 2001). Slow electrical conduction and 
calcium overloading in the ischaemic myocardium perturb the plateau phase of 
ventricular action potentials, thereby giving rise to changes in the ST-segment of the 
integrated ECG trace. ATP depletion has also been shown to be an important factor in 
determining ST-segment changes upon myocardial ischaemia (Katz, 2001; Herring and 
Paterson, 2006; Sclarovsky, 2013). However, it should be noted that the exact causes of 
ST-segment changes upon myocardial ischaemia are not completely understood. 
Nevertheless, ECG abnormalities provide a useful tool for diagnosis and classification of 
acute myocardial infarction; where ST-segment depression indicates subendocardial 
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ischaemia and ST-segment elevation indicates transmural left ventricular ischaemia. 
ECG ST-segment resolution confirms effective reperfusion (Thygesen et al., 2007). 
Impaired cardiac function: Cardiac contractile function is rapidly reduced upon 
myocardial ischaemia, as evidenced by relative akinesis of the left ventricular free wall 
following LAD occlusion (Katz, 2001). Myocardial hypokinesis immediately upon the 
onset of ischaemia does not reflect impaired cardiomyocyte contractile function per se 
but an adaptive response to reduce ATP and oxygen use in an attempt to minimise the 
severity of ischaemia (Davies, 1977). Since myocardial hypokinesis reduces ejection 
fraction, its protective effect is limited to short ischaemic insults only (Katz, 2001). 
If the period of ischaemia is prolonged then myocardial hypokinesis may persist even 
following reperfusion due to the extent of existing injury to the myocardium (Katz, 2001). 
Cardiomyocyte cell death: If left unresolved, myocardial ischaemia will eventually 
result in death of ischaemic cells. Cardiomyocytes are the myocardial cell type most 
susceptible to ischaemic injury due to their extensive energy requirements (Frantz et al., 
2009). The most effective strategy for reducing cardiomyocyte death, and thus infarct 
size, is rapid and effective restoration of coronary artery perfusion, discussed in detail 
below (see section 1.2.3). The recognition of infarct size progression with ischaemic 
duration was first formally postulated by Reimer et al. (1977) in the ‘wavefront of 
necrosis’ hypothesis which stated that cardiomyocyte death progresses from the 
subendocardial to subepicardial myocardium and is halted by myocardial reperfusion 
(Figure 1.3 B-C). Crucially, short durations of ischaemia (less than approximately 20 
minutes in most species) cause only reversible injury to ischaemic cardiomyocytes 
(Figure 1.3 A) (Reimer et al., 1977; Jennings and Reimer, 1981).  
 
Figure 1.3: Ischaemic ‘wavefront of necrosis’ hypothesis  
Representation of transverse myocardial section; within the ischaemic myocardium (white), 
necrosis (black) progresses from the subendocardium (endo.) to subepicardium (epi.). A) Short 
ischaemic durations cause only reversible injury. B) Intermediate ischaemic durations cause 
infarction in the subendocardial myocardium. C) Extended ischaemic durations cause transmural 
infarction. Adapted from Reimer et al. (1977) and Kloner and Jennings (2001). 
Perfused (non-area-at-risk)
A) Reversible Injury B) Irreversible injury C) Irreversible injury 
- Complete necrosis
Endo. Epi.
Ischaemic (area-at-risk) Infarct
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The driving factor in the initiation of cardiomyocyte cell death following prolonged 
ischaemia is severe ATP depletion which results in deregulation of a number of critical 
cellular processes and pathways, described above (see section i). The distinct 
subendocardial to subepicardial nature of infarction is attributed to differences in 
perfusion and metabolic rates since the subendocardium is only perfused by the 
capillary bed and yet has a higher metabolic demand due to increased wall tension 
compared to the subepicardium (Davies, 1977; Reimer et al., 1993). There is a notable 
rim of non-infarcted subendocardial tissue which is likely spared due to oxygen diffusion 
from the left ventricle (LV) blood pool (Davies, 1977).  
Ischaemic cell death is thought to occur predominantly by necrosis since apoptosis 
requires ATP; although it has been suggested that myocardial ischaemia may initiate 
apoptotic cell death pathways which are then executed in the presence of ATP upon 
reperfusion (Freude et al., 2000). Recent studies suggest that autophagy and 
necroptosis may also be important mediators of myocardial infarction (reviewed by 
Chiong et al., 2011); the contributions of these cell death pathways to myocardial 
infarction are discussed below (see section 1.2.3 ii).  
1.2.3. Pathophysiology of myocardial reperfusion 
Coronary artery reperfusion permits rapid return of oxygenated blood to the previously 
ischaemic tissue. Although early reperfusion is essential for cell survival and ultimately 
cardiac function (Reimer et al., 1977), reperfusion paradoxically also causes some 
injury, termed reperfusion injury. Reperfusion injury is discussed in detail subsequently 
(section ii) in the context of the intracellular events occurring upon reperfusion. 
i Myocardial reperfusion milieu 
The effects of myocardial reperfusion can be understood in the context of the 
intracellular changes caused by the preceding ischaemic insult, where rapid myocardial 
reperfusion temporarily worsens these intracellular imbalances. The ischaemic duration 
determines the extent of the principal intracellular changes (ATP depletion, increased 
osmotic load, acidification and ROS accumulation) and therefore the extent of 
subsequent reperfusion injury (Davies, 1977; Katz, 2001). In addition, myocardial 
reperfusion causes a transient increase in blood supply (reactive hyperaemia) 
proportional to the extent of the ischaemic insult, and this hyperaemia is a driving factor 
of immediate reperfusion injury (Katz, 2001). The intracellular changes occurring upon 
myocardial reperfusion following an intermediate ischaemic insult are described below 
and their cumulative effects discussed subsequently. 
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Rapid ATP production: The rapid restoration of myocardial oxygen supply by coronary 
artery reperfusion allows aerobic metabolism to re-start (Figure 1.4, stage 1). The 
resultant increase in ATP production efficiency redresses the balance of myocardial ATP 
supply and demand which, in turn, permits functioning of ATP-dependent cellular 
homeostatic mechanisms which, alongside washout of lactate, correct pH (Katz, 2001). 
However, rapid re-energisation and the resultant correction of intracellular acidosis may 
cause hypercontracture, discussed below (Piper and Garcia-Dorado, 1999). 
Osmotic swelling – oedema: Ischaemia causes an increased cellular osmotic load 
which causes significant cardiomyocyte swelling upon myocardial reperfusion due to the 
rapid influx of fluids to the myocardium (Braunwald and Kloner, 1985) (Figure 1.4, stage 
2). Homeostatic regulation of cellular swelling causes sodium ion efflux and calcium ion 
influx which exacerbates calcium overloading (Hoffman et al., 2004). Furthermore, 
excessive cell swelling can trigger cell death (Kloner, 1993), discussed below. 
Calcium overloading: Intracellular calcium concentration is an important determinant of 
cardiomyocyte survival and function upon myocardial reperfusion. In moderately 
ischaemic cardiomyocytes, ATP-dependent ionic cellular homeostasis upon reperfusion 
attempts to restore intracellular calcium concentrations and thus preserve 
cardiomyocyte survival and contractile function (Braunwald and Kloner, 1985; Katz, 
2001). However, upon reperfusion of severely ischaemic cardiomyocytes, membrane 
damage combined with homeostatic regulation due to cellular swelling can result in 
increased intracellular and mitochondrial calcium overloading (via the calcium uniporter) 
(Crompton and Costi, 1988; Vermeiren et al., 2000). (Figure 1.4, stage 3).  
Intracellular calcium overloading in the presence of rapid re-energisation and pH 
correction can result in excessive cardiomyocyte contraction, termed hypercontracture, 
which if sustained can cause cell death. Hypercontracture also causes death of adjacent 
cardiomyocytes due to mechanical disruption and exposure to excessive extracellular 
calcium concentrations (Piper and Garcia-Dorado, 1999; Hoffman et al., 2004). 
Further accumulation of ROS: ROS levels are further increased upon reperfusion due 
to increased ROS production in the presence of high tissue oxygen levels that occur 
upon myocardial hyperaemia (Manning and Hearse, 1984) (Figure 1.4, stage 4). ROS 
accumulation is exacerbated by further removal of ROS scavengers resulting from the 
combined effect of cellular leakage and myocardial perfusion (Braunwald and Kloner, 
1985; Hoffman et al., 2004) and ROS production by infiltrating inflammatory cells 
(Braunwald and Kloner, 1985). ROS-induced oxidative damage can itself cause cell 
death (Braunwald and Kloner, 1985; Hoffman et al., 2004) in addition to the effects of 
high ROS levels on mitochondrial permeability transition described below (section iv). 
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Figure 1.4: Energy production and homeostasis in reperfused cardiomyocytes 
Myocardial reperfusion temporarily exacerbates the ionic imbalances caused by ischaemia. (1) 
Aerobic metabolism re-starts which increases ATP availability. (2) Cellular swelling occurs due to 
the increased osmotic load and presence of tissue fluid. (3) Calcium overloading is exacerbated 
by membrane damage and homeostatic attempts to correct osmotic swelling, which in turn cause 
mitochondrial calcium overloading. (4) Mitochondrial ROS accumulates due to ETC leakage 
resulting from oxidative damage. Constructed from information provided by Katz (2001), Alberts 
et al. (2002) and Hoffman et al. (2004). 
 
The severity of these intracellular events upon reperfusion is largely dependent on the 
duration of the preceding ischaemic insult and thus the severity of the intracellular 
changes already initiated prior to reperfusion. The cumulative effects of the intracellular 
changes initiated by myocardial ischaemia and reperfusion are discussed below. 
ii Effect of reperfusion – Lethal reperfusion injury 
The wavefront of necrosis hypothesis postulated by Reimer et al. (1977) stated that 
myocardial reperfusion halts the progression of myocardial injury. However, despite the 
necessity of reperfusion for the preservation of viable cardiomyocytes, it is recognised 
that reperfusion itself results in some injury and cell death, termed reperfusion injury. 
The occurrence and molecular basis of reperfusion injury have been subject to 
extensive research and some controversy over the past decades (Kloner, 1993).  
There are four recognised types of reperfusion injury: (1) lethal reperfusion injury, (2) 
reperfusion arrhythmias, (3) myocardial stunning and (4) no reflow (reviewed by 
Braunwald and Kloner, 1985; Kloner, 1993); summarised in Table 1.1.  
 
CYTOSOL
OMM
IMM
MITOCHONDRIAL MATRIX
Free fatty 
acids
ATP + H+ ADP
Pi + H+
EXTRACELLULAR
H+
Na+
Na+
Ca2+
Glucose
Ca2+
Citric acid 
cycle
H+ H+
I III IV
IIATP
e-
ROS ROS ROS
Osmotic 
swelling
Pi
(1)
(2)
(3)
(4)
Lactate
H+
ATPADP
ATP 
synthase
27 
TYPE OF INJURY THEORETICAL BASIS AND OVERVIEW 
Lethal reperfusion 
injury: 
(Braunwald and Kloner, 
1985) 
Death of cardiomyocytes that were only reversibly injured at the 
end of ischaemia but become irreversibly injured upon reperfusion. 
The occurrence of this form of reperfusion injury has been the most 
controversial – this discussed in detail in the main text. 
 
Reperfusion 
arrhythmias: 
(Manning and Hearse, 
1984) 
Ventricular arrhythmias – experimentally generally only occur after 
brief periods of ischaemia and very rapidly upon reperfusion. 
The clinical occurrence of reperfusion arrhythmias is likely to be 
low and can be managed; if unresolved this can result in death. 
 
Myocardial stunning: 
(Bolli et al., 1989) 
Prolonged dysfunction of viable cardiomyocytes which represents a 
functional form of injury to the salvaged myocardium. This is 
expected to recover within 1 month of reperfusion and can be 
managed by administration of inotropes to stimulate contraction. 
 
No-reflow: 
(Kloner et al., 1974) 
(Thygesen et al., 2007) 
Perfusion defects within the area-at-risk due to vascular damage 
(particularly of the microvasculature) or cardiomyocyte swelling. 
This can result in sustained ischaemia of a region of the area-at-
risk and results in poorer functional recovery. Effective reperfusion 
and thrombolysis are expected to reduce the severity. 
 
 
Table 1.1: Predicted mechanisms of reperfusion injury 
Summary of the four proposed types of reperfusion injury. References are provided for principal 
descriptions of these types of injury and their relevance in acute myocardial infarction. 
 
The clinical occurrence and extent of reperfusion arrhythmias, myocardial stunning and 
the no-reflow phenomena have been largely elucidated and can be clinically treated; 
lethal reperfusion injury however, has been the subject of intense controversy over the 
past three decades (reviewed by Kloner, 1993; Garcia-Dorado et al., 2009). This is 
particularly pertinent given that lethal reperfusion injury is the only form of reperfusion 
injury where there is, as yet, no clinical treatment (Hausenloy and Yellon, 2013).  
Lethal reperfusion injury causes death of some cells that were only reversibly injured by 
the preceding ischaemia (Figure 1.5) (Braunwald and Kloner, 1985; Kloner, 1993). 
Indeed, it has been suggested that in some circumstances lethal reperfusion injury could 
account for approximately 30-50% of myocardial infarct size. Precise delineation of 
ischaemic and reperfusion injury, and therefore direct evidence of lethal reperfusion 
injury, is complicated by the role of the preceding ischaemic insult in the occurrence and 
extent of reperfusion injury. It is now largely accepted that lethal reperfusion injury 
represents a true clinical phenomenon where studies have shown that pharmacological 
and mechanical interventions can reduce infarct size when administered at the onset of 
reperfusion (reviewed by Garcia-Dorado et al., 2009). Furthermore, a clinical study of 
cyclosporine-A administered at reperfusion significantly reduced infarct size (Piot et al., 
2008), thereby confirming the clinical existence of lethal reperfusion injury and its 
potential as a therapeutic target for cardioprotection (discussed in section 1.4.1).  
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Figure 1.5: Lethal reperfusion injury 
Infarct size (red line) increases with ischaemic duration and if left unresolved the total area of 
ischaemic myocardium will become infarcted (projected ischaemic injury– dashed red line). 
Reperfusion limits infarction but, paradoxically, causes some infarction itself, termed lethal 
reperfusion injury (shaded red area). Adapted from Garcia-Dorado et al. (2006). 
 
Cardioprotection during the early phase of reperfusion is consistent with the occurrence 
of the numerous potentially injurious intracellular changes that occur upon myocardial 
reperfusion (reviewed by Garcia-Dorado et al., 2009), described previously (section i).  
Given that early reperfusion is recognised as the most effective intervention for reducing 
infarct size (Kloner, 1993; Thygesen et al., 2007), it has been suggested that lethal 
reperfusion injury is likely to contribute to myocardial injury and therefore remains a 
significant and largely unmet clinical target for the treatment of acute myocardial 
infarction (Thygesen et al., 2007; Hausenloy and Yellon, 2013). This is crucial given the 
correlation between infarct size and patient prognosis (Sobel et al., 1972). 
iii Lethal reperfusion injury – Mechanisms of cell death 
Myocardial reperfusion causes cell death by necrosis, apoptosis, autophagy or 
necroptosis, although the precise contribution of these mechanisms to progression of 
myocardial infarction has not been fully elucidated (reviewed by Oerlemans et al., 2013).  
Necrosis: Necrotic cell death is characterised by cellular swelling, membrane damage 
and ultimately cell rupture resulting in the loss of intracellular substrates which initiate a 
significant inflammatory response (Reimer et al., 1977). Myocardial ischaemia has been 
shown to cause necrosis (Jennings and Reimer, 1981), however, reperfusion has been 
suggested to initiate regulated necrosis by mitochondrial permeability transition (Figure 
1.6 A) (reviewed by Baines, 2009a), discussed in detail subsequently (see section iv). 
TIME
M
Y
O
C
A
R
D
IA
L
 I
N
F
A
R
C
T
 S
IZ
E
REPERFUSION INJURY
ISCHAEMIC INJURY
REPERFUSIONISCHAEMIA
Projected ischaemic injury
29 
Apoptosis: Moderately injured cardiomyocytes may undergo apoptotic cell death which, 
due to the controlled nature of cell shrinkage and maintenance of membrane integrity, 
does not initiate an inflammatory response (MacLellan and Schneider, 1997; Piper and 
Garcia-Dorado, 1999). Apoptosis is triggered by intrinsic or extrinsic pathways: 
Intrinsic apoptotic pathway: The precise mechanism of the intrinsic apoptotic pathway 
remains controversial. Tissue stress causes translocation and integration of pro-death 
B-cell lymphoma-2 (Bcl-2) proteins (Bax, Bak and Bid) into the outer mitochondrial 
membrane to cause its permeation (Figure 1.6 B). This allows release of pro-apoptotic 
proteins, such as cytochrome c, which bind to apoptotic protease activating factor-1 
(APAF-1) to form the ‘apoptosome’ which subsequently activates ‘effector’ caspases, 
which are described in more detail below (Oerlemans et al., 2013). 
Extrinsic apoptotic pathway: The extrinsic apoptotic pathway is the most well studied 
and involves receptor-mediated cell death. Tissue stress causes binding of extracellular 
death ligands (such as TNF-α) to cell surface membrane receptors to activate ‘initiator’ 
caspases including caspase-8 (Figure 1.6 C). Initiator caspases then activate ‘effector’ 
caspases which mediate cell death (Freude et al., 2000; Oerlemans et al., 2013).  
Both intrinsic and extrinsic apoptotic pathways converge on activation of ‘effector’ 
caspases-3 and -9 which mediate destruction of cell structures and deregulation of 
protein activity (Hoffman et al., 2004). This causes membrane blebbing and surface 
exposure of phosphotidylserine residues which trigger phagocytosis by neighbouring 
cells. This complete and controlled removal of designated cells does not initiate an 
inflammatory response (MacLellan and Schneider, 1997; Hoffman et al., 2004). Due to 
its ATP-dependence, apoptosis occurs mainly following reperfusion, although there is 
evidence to suggest that ischaemia initiates apoptotic signalling cascades which are 
then executed in the presence of ATP at reperfusion (Freude et al., 2000).  
Autophagy: Autophagy is a highly conserved process of lysosomal-mediated 
degradation of intracellular components initiated upon cellular stress events including 
hypoxia, nutrient starvation and ROS. Under physiological and mild stress conditions, 
autophagy is an adaptive response triggered by these cell stressors (Levine and 
Kroemer, 2008). Indeed, there is evidence that regulated autophagy in response to mild 
to moderate ischaemia may protect against the development of infarction by 
replenishing energy resources. However, prolonged ischaemia and subsequent 
reperfusion can trigger a dramatic and maladaptive upregulation of autophagy which is 
detrimental to cell survival. The precise molecular mechanisms of autophagy in 
response to acute myocardial infarction remain largely unknown (reviewed by Chiong et 
al., 2011) and thus are not discussed further in this thesis. 
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Necroptosis: More recent studies have suggested that a programmed form of necrosis, 
termed necroptosis, may also mediate cell death. Necroptosis is believed to be initiated 
by activation of classical death receptors such as TNF-α which in turn activate members 
of the receptor interacting protein (RIP) kinase family (reviewed by Long and Ryan, 
2012). There is currently limited knowledge regarding the role of necroptosis in acute 
myocardial infarction and lethal reperfusion injury, however, this represents a potentially 
important cell death pathway for future research; this is not discussed further here. 
 
A summary of the main cell death pathways implicated in lethal reperfusion injury to date 
is provided in Figure 1.6. The specific contribution of these death pathways is likely to 
depend on the prevailing pathophysiological conditions (reviewed by Oerlemans et al., 
2013). It is evident that permeation of the inner and outer mitochondrial membranes 
represents a critical effector of cell death upon reperfusion (Figure 1.6 mechanisms A 
and B). The role of the mitochondrial permeability transition pore is discussed below. 
 
Figure 1.6: Pathways to cardiomyocyte death upon myocardial reperfusion 
Reperfusion causes cell death primarily by necrosis or apoptosis. A) Necrosis can be regulated 
by mitochondrial permeability transition pore (mPTP) opening which causes mitochondrial 
swelling, rupture and cell death. In the presence of ATP, mPTP opening may cause apoptosis. B) 
Intrinsic apoptotic pathway: Mitochondrial permeability transition can be induced by Bcl-2 
permeation of the OMM causing release of pro-apoptotic proteins and apoptosis. C) Extrinsic 
apoptotic pathway: Extracellular death ligand binding activates apoptosis. Constructed from 
information provided by Baines (2009a) and Oerlemans et al. (2013). 
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iv Lethal reperfusion injury – Mitochondrial permeability transition 
The mitochondrial permeability transition pore (mPTP) is a key effector of necrotic and 
apoptotic cardiomyocyte death. The mPTP is a mitochondrial membrane pore that 
remains predominantly closed under physiological conditions. However, the intracellular, 
specifically mitochondrial, changes that occur upon reperfusion can trigger mPTP 
opening and thus permeation of the inner mitochondrial membrane which results in cell 
death. Although the molecular identity of the mPTP has been the subject of intensive 
research and controversy (discussed below), mPTP opening has been implicated in a 
number of pathological conditions (reviewed by Di Lisa and Bernardi, 2009).  
The role of mPTP opening in mediating cell death upon myocardial reperfusion has 
been well characterised. The cellular conditions that activate and inhibit mPTP opening 
have been widely examined as potential therapeutic modulators. The principal activators 
of mPTP opening are: elevated calcium concentration, high levels of Pi and oxidative 
stress; conditions which prevail following myocardial ischaemia, although are strongly 
antagonised by low pH (Figure 1.7 A). Myocardial reperfusion exacerbates calcium and 
ROS accumulation whilst correcting the previous acidosis to remove antagonism of 
mPTP opening. Reperfusion therefore causes rapid and extensive mPTP opening within 
a few minutes (Figure 1.7 B) (Crompton et al., 1987; Baines, 2009a). 
 
Figure 1.7: Cellular modulators of mitochondrial permeability transition pore opening 
(A) Ischaemia: mitochondrial acidosis inhibits mPTP opening despite high calcium and inorganic 
phosphate levels. (B) Reperfusion: rapid pH correction and increased calcium, Pi and ROS levels 
trigger mPTP opening. Mitochondrial permeation allows equilibrium of protons across the 
intermembrane space which halts oxidative phosphorylation and allows mitochondrial swelling 
which in turn may result in OMM rupture and cytochrome c release. Constructed from information 
provided by Crompton et al. (1987) and Baines (2009a).  
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The initial effect of mPTP opening is permeation of the inner mitochondrial membrane 
which dissipates the electrochemical gradient resulting in cessation of ATP production 
by ATP synthase (Crompton et al., 1987; Baines, 2009a). Indeed, collapse of the 
electrochemical gradient may cause ATP hydrolysis by reverse ATP synthase activity. 
Mitochondrial permeability transition allows equilibration of solutes up to 1.5 kDa by 
passive diffusion through the pore, a process which results in mitochondrial swelling. 
Severe mitochondrial swelling can result in rupture of the outer mitochondrial membrane 
and release of pro-apoptotic proteins such as cytochrome c that could ultimately trigger 
apoptotic cell death (reviewed by Bernardi et al., 1999) (Figure 1.7). The final outcome 
of mPTP opening depends on the intensity of the trigger, severity of ATP depletion and 
the number of mitochondria affected (reviewed by Baines, 2009a). Although the mPTP 
is not a unique effector of lethal reperfusion injury, it does appear to be an important 
mediator of cell death in this setting and is investigated further in this thesis. 
 
The proposed significant contribution of lethal reperfusion injury to myocardial infarction 
suggests that optimisation of reperfusion may reduce overall infarct size. This has been 
demonstrated, for example, by ischaemic postconditioning, whereby myocardial 
reperfusion is stuttered to reduce the severity of intracellular changes upon reperfusion 
and thus reduce the extent of cell death (discussed in detail in section 1.3).  
Furthermore, the occurrence of lethal reperfusion injury presents the intriguing possibility 
that targeting both ischaemic and reperfusion injury may exert a combinatorial protective 
effect to further reduce infarct size and improve the prognosis of acute myocardial 
infarction patients (Hausenloy and Yellon, 2013). This thesis investigates mechanisms 
to reduce ischaemia-reperfusion injury in a mouse model of acute myocardial infarction. 
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1.2.4. Long-term effects of ischaemia-reperfusion injury 
Elucidation of the cellular mechanisms of myocardial reperfusion injury demonstrates 
significant interplay of the cellular processes that occur upon ischaemia and reperfusion. 
It is therefore difficult to separate the long-term effects of these processes such that the 
effects of myocardial infarction are often described as a cumulative pathology, described 
here as ischaemia-reperfusion injury. The main phases of long-term progression of 
ischaemia-reperfusion injury are inflammation and ventricular remodelling (Pfeffer and 
Braunwald, 1990; Opie et al., 2006). The severity and outcome of these processes 
depends on the infarct size, area of affected myocardium, duration of ischaemia and 
conditions of reperfusion (reviewed by Frantz et al., 2009).  
Inflammation: Myocardial reperfusion triggers rapid infiltration of neutrophils and 
macrophages which initiate the immediate inflammatory response that is essential for 
infarct healing and ventricular remodelling (Vermeiren et al., 2000; Frantz et al., 2009). 
Neutrophils contribute to the initial inflammatory response by release of pro-oxidant 
cytokines such as tumour necrosis factor alpha (TNF-α) and decrease of anti-oxidant 
cytokines which results in increased ROS production and in turn activation of 
cardiomyocyte apoptosis. Activation and infiltration of macrophages is critical for 
clearance of cellular debris by phagocytosis (Pfeffer and Braunwald, 1990). Successful 
clearance of cellular debris and associated pro-oxidant cytokine release dampens the 
immediate inflammatory response (Frantz et al., 2009).  
Regulation of myocardial inflammation is important since, although crucial for infarct 
healing, extensive inflammation can cause adverse ventricular remodelling and 
subsequent impaired cardiac function (Gonzalez et al., 2011), described in detail below. 
In addition, activated neutrophils may cause direct injury due to microvascular 
obstruction resulting in microcirculatory ischaemia (no-reflow) and release of ROS which 
cause oxidative damage (discussed previously, section i) (Vermeiren et al., 2000).  
Ventricular remodelling: Infarct expansion results in thinning and dilatation of the area 
of infarction (Weisman and Healy, 1987). This may be caused by cardiomyocyte 
‘slippage’ resulting in fewer cardiomyocytes across the infarcted region due to increased 
ventricular wall stress and compromised structural integrity from extensive collagen 
degradation (Olivetti et al., 1990; Opie et al., 2006). Given the importance of the 
extracellular matrix (ECM) in infarct remodelling, the inflammatory response is a critical 
mediator of infarct remodelling due to the actions of neutrophils and macrophages on 
ECM degradation and expansion respectively. Neutrophils release matrix 
metalloproteinase (MMP) enzymes which breakdown extracellular collagen; extensive 
MMP activity can cause severe extracellular scaffold degradation (Vermeiren et al., 
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2000; Gonzalez et al., 2011). Macrophages release pro-fibrotic cytokines such as TGF-β 
which stimulate fibroblasts to synthesise collagen that can cause myocardial fibrosis 
(Pfeffer and Braunwald, 1990; Vermeiren et al., 2000).  
The long-term effects of extensive ventricular remodelling include cardiac rupture and 
myocardial hypertrophy which may ultimately lead to cardiac failure (Frantz et al., 2009). 
Cardiac rupture: Rupture of the myocardium occurs most commonly in patients who 
have suffered LAD occlusion in which a large proportion of the LV wall is affected. Acute 
cardiac rupture occurs within the first few hours of reperfusion and is associated with 
adverse cardiac function and pressure overload. Sub-acute rupture results from 
myocardial thinning and adverse remodelling which render the LV wall incapable of 
sustaining high pressures and wall stress (Wehrens and Doevendans, 2004).  
Myocardial hypertrophy: Extensive transmural myocardial infarction increases the 
workload of functional cardiomyocytes in the non-infarcted myocardium which can, in 
time, cause compensatory ventricular remodelling. Infarct expansion and uncontrolled 
LV remodelling cause increased ventricular volume and pressure load and these 
combined stresses lead to LV dilatation and compensatory hypertrophy. Sufficient 
hypertrophy can normalise ventricular wall stresses to maintain cardiac output (Opie et 
al., 2006); however, progressive LV dilatation with insufficient compensatory 
hypertrophy can cause cardiac failure (van den Borne et al., 2010).  
 
There are currently no therapeutic interventions for treatment of lethal reperfusion injury 
(Hausenloy and Yellon, 2013). Patients with hypertrophy and high risk of cardiac rupture 
are managed by beta-blockers and angiotensin-converting enzyme (ACE) inhibitors 
(Wehrens and Doevendans, 2004; Thygesen et al., 2007). However, given the poor 
long-term prognosis following acute myocardial infarction (Smolina et al., 2012) and the 
predicted increase of acute myocardial infarction (Mathers and Loncar, 2006), the need 
for novel strategies to protect against ischaemia-reperfusion is ever more pertinent. 
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1.3. Cardioprotective interventions 
Protecting the myocardium against the injurious effects of ischaemia-reperfusion injury 
is an essential focus for basic science and clinical research. Cardioprotection is defined 
as a significant reduction in myocardial injury; where myocardial infarct size has been 
the most widely assessed endpoint in this regard (Jennings, 2011) and forms the focus 
of the discussion of therapeutic efficacy of cardioprotective interventions here. 
The notion that the myocardium can be protected from ischaemia-reperfusion injury is 
illustrated by the ‘wavefront of necrosis’ hypothesis which states the progressive 
development of infarction (Reimer et al., 1977). Indeed, early reperfusion is the most 
effective cardioprotective intervention for reducing infarct size (Yellon and Downey, 
2003). The first demonstration of infarct size reduction by an external therapeutic 
intervention was ischaemic preconditioning (IPC) in 1986 (Murry et al.), described 
below. Despite the pre-clinical success of IPC, substantial research efforts are required 
to identify more clinically applicable cardioprotective strategies with similar potency. 
1.3.1. Ischaemic conditioning 
Ischaemic conditioning comprises mechanical administration of sublethal ischaemia 
either directly to the organ of interest or to a distant organ, in the case of remote 
ischaemic conditioning. Significant cardioprotection is elicited when ischaemic 
conditioning is applied either prior (pre-), during (per-) or after (post-) the main ischaemic 
insult. Extensive research has suggested that the molecular pathways elicited by these 
conditioning protocols are similar (reviewed by Hausenloy and Yellon, 2007); as such, 
pharmacological modulation of these pathways may provide a clinically applicable 
therapeutic intervention for cardioprotection. The discussion of ischaemic conditioning 
here will focus on IPC since this is the most widely studied and easily reproducible 
conditioning protocol to date. 
i Classical ischaemic preconditioning 
Ischaemic preconditioning consists of a short sublethal period of myocardial ischaemia 
(usually 3 to 5 minutes) followed by reperfusion (usually 5 minutes) immediately prior to 
the main ischaemic insult. Cardioprotection by IPC was first demonstrated by Murry et 
al. in the in vivo dog heart (Murry et al., 1986) and has since been shown to be 
efficacious in every species tested (Jennings, 2011). Indeed, IPC is recognised as the 
most potent cardioprotective intervention after early myocardial reperfusion (Yellon and 
Downey, 2003). The molecular pathways initiated by IPC are described below. 
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ii Molecular signalling of ischaemic conditioning 
The signalling pathways elicited by ischaemic pre- and postconditioning have been 
largely elucidated and demonstrate striking convergence, although the precise details of 
the specific interactions between these components remains the subject of extensive 
research (reviewed by Hausenloy and Yellon, 2007). Understanding the molecular basis 
of ischaemic conditioning may allow cardioprotection by pharmacological modulation. 
Direct effects: Ischaemic conditioning stimulates release of extracellular triggers, such 
as adenosine and bradykinin, which ultimately elicit cardioprotection. The primary action 
of these signalling autocoids is mediated via binding to G-protein coupled receptors 
(GPCRs) which initiate intracellular signal transduction. The multiple signalling autocoids 
and GPCR binding interactions provide functional redundancy to the conditioning 
stimulus. GPCR binding activates the intracellular reperfusion injury salvage kinase 
(RISK) signalling cascades: phosphoinositide 3-kinase (PI3K), Akt and Erk1/2. RISK 
pathway activation mediates intracellular signal transduction to the end-effector of 
ischaemic conditioning, believed to be the mPTP (Hausenloy et al., 2004b) ( 
Figure 1.8). 
 
 
 
Figure 1.8: Ischaemic conditioning 
Ischaemic conditioning produces autocoids which bind to GPCRs which activate intracellular 
signalling cascades. Activation of the RISK pathway relays the conditioning signal to 
mitochondrial targets which converge to prevent mPTP opening and thus reduce cell death. 
Constructed from information provided by Hausenloy and Yellon (2007). 
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The precise molecular pathways triggered by activation of the RISK pathway may vary 
between conditioning protocols and species, however, a number of common 
downstream effectors of ischaemic conditioning have been identified. 
PI3K-Akt-eNOS-PKG: Phosphorylation of Akt activates endothelial nitric oxide synthase 
(eNOS) resulting in increased nitric oxide, which activates cytosolic protein kinase G 
(PKG). This nitric oxide may also directly inhibit mPTP opening (Hausenloy et al., 2009). 
MitoKATP: PKG in turn phosphorylates mitochondrial PKC-epsilon (PKCε) which has 
been linked to opening of the mitochondrial membrane ATP sensitive potassium channel 
(mitoKATP) (Costa et al., 2005). MitoKATP channel opening upon reperfusion is 
controversial, it has however, been linked with production of signalling ROS and 
prevention of cell death by inhibition of mPTP opening (Hausenloy et al., 2007).  
GSK3β: Akt and Erk1/2 activation cause inactivation of glycogen synthase kinase-3β 
(GSK3β) by phosphorylation. Juhaszova et al. (2004) implicated GSK3β as a point of 
convergence of cardioprotection on the mPTP. Recent evidence shows active GSK3β 
phosphorylates cyclophilin-D (Cyp-D) to enhance mPTP opening; thus inactivation of 
GSK3β reduces Cyp-D activity and mPTP opening (Rasola et al., 2010); section 1.4.1. 
Indirect effects: Ischaemic conditioning may also indirectly inhibit mPTP opening by 
modulating mitochondrial conditions to favour mPTP closure: 
Reduced calcium overloading: The precise mechanisms of reduced calcium overloading 
upon ischaemic conditioning have not been confirmed although there is evidence that it 
is linked to reduced acidosis which in turn reduces calcium influx through sodium-
calcium exchange (see Figure 1.2) (Steenbergen et al., 1993). Ischaemic conditioning 
may also mediate increased calcium uptake by the sarcoplasmic reticulum to reduce 
intracellular and mitochondrial calcium overloading (Murphy and Steenbergen, 2011). 
Reduced mitochondrial calcium levels reduce mPTP opening. 
Reduced detrimental ROS: Ischaemic conditioning reduces ROS production upon 
reperfusion, although the mechanism of this is not clear. Since oxidative stress is an 
important activator of mPTP opening, the effect of ischaemic conditioning on reducing 
ROS may in turn reduce mPTP opening (Murphy and Steenbergen, 2011). The roles of 
ROS in the setting of mPTP opening are complicated by the divergence of ‘signalling’ 
and ‘detrimental’ ROS, since it is well established that IPC-mediated ROS release is an 
essential signal transduction mechanism of the RISK pathway. These divergent effects 
of ROS may result from differences in the localisation, quantity, identity or timing of ROS 
release (Hausenloy and Yellon, 2007). 
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Transient mPTP opening: The precise mechanism of reduced calcium overloading and 
detrimental ROS levels have not been fully elucidated, however, there is evidence that 
these beneficial effects of IPC may be mediated by transient opening of the mPTP to a 
low-conductance state (Hausenloy et al., 2004a). Transient low-conductance mPTP 
opening is hypothesised to create a small diameter pore allowing passage of ions and 
solutes up to 300 Da. This low-conductance pore would therefore permit calcium and 
ROS efflux from the mitochondrial matrix whilst maintaining the electrochemical gradient 
for oxidative phosphorylation (Zoratti and Szabo, 1995; Ichas et al., 1997) (Figure 1.9).  
It has been suggested that transient low-conductance mPTP opening may provide a 
mechanism for rapid regulation of mitochondrial matrix conditions which may in turn 
reduce activation of high-conductance mPTP opening and associated cell death 
(Hausenloy et al., 2004a) (Figure 1.9). It should also be noted that a similar effect may 
be mediated by transitory opening of the mPTP to a high-conductance state. The 
precise mechanism by which IPC triggers transient low-conductance or transient mPTP 
opening remains to be fully identified and has not yet been investigated as a mode of 
ischaemic postconditioning or pharmacological conditioning. The occurrence of transient 
low-conductance mPTP opening may be related to the physiological function of the 
mPTP, discussed subsequently (see 1.4.1). 
 
Figure 1.9: Model of transient mPTP opening in response to ischaemic preconditioning 
IPC triggers transient low conductance mPTP opening which mediates Ca
2+
 and ROS release 
from the mitochondrial matrix which would otherwise trigger high conductance mPTP opening. 
Constructed from information provided by Zoratti and Szabo (1995) and Hausenloy et al. (2004a). 
 
The cumulative effects of RISK pathway activation and decreased mitochondrial matrix 
calcium and ROS accumulation, reduce the probability of high conductance mPTP 
opening and cell death (Steenbergen et al., 1993; Baines, 2009a). Reduced calcium 
load upon ischaemic conditioning may protect against other mechanisms of cell death 
such as unregulated necrosis and hypercontracture (Garcia-Dorado and Piper, 2006). 
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iii Delayed ischaemic conditioning 
The classical early IPC phenomenon described above elicits significant cardioprotection 
only if the delay between conditioning stimulus and ischaemic insult is less than 
approximately 2 hours. Subsequent studies have shown that a second phase of 
protection exists approximately 12 and 72 hours after the initial IPC stimulus, which has 
been termed the ‘second window of protection’ or ‘delayed conditioning’ (Marber et al., 
1993; Baxter et al., 1997). The phenomenon of delayed conditioning suggests that it 
may be possible to target both the early and delayed components of protection to 
maximise cardioprotective potency, although this has not yet been confirmed. 
The precise molecular mechanism for delayed IPC remains unclear; however, the 
temporal separation of the protective phases suggests that the conditioning stimulus 
evokes a memory response likely to involve de novo protein synthesis. The conditioning 
stimulus releases protective triggers, autocoids and cytokines, which in turn activate 
‘early’ mediators to activate transcription factors causing synthesis of ‘distal mediators’ 
12-24 hours later. The end-effectors of delayed conditioning include inhibition of mPTP 
opening (summarised in Figure 1.10) (reviewed by Hausenloy and Yellon, 2010). 
 
 
Figure 1.10: Delayed ischaemic conditioning 
Ischaemic conditioning produces extracellular autocoids and cytokines which activate ‘early 
mediators’, such as the RISK pathway, which elicit early cardioprotection and induce transcription 
factor expression which triggers synthesis of ‘distal mediators’ 12-24 hours later. Distal mediators 
confer a delayed cardioprotective effect which is thought to converge on inhibition of mPTP 
opening. Constructed from information provided by Hausenloy and Yellon (2010). 
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Although the precise actions of these distal mediator proteins in cardioprotection have 
not been fully elucidated, the main roles identified to date are detailed below. 
Manganese superoxide dismutase: MnSOD is an anti-oxidant enzyme elevated 24 
hours after the initial conditioning stimulus, possibly in response to increased signalling 
ROS (Zhai et al., 1996). MnSOD expression is expected to decrease the levels of 
detrimental ROS and thus reduce mPTP opening (Hausenloy and Yellon, 2010). 
Heat shock proteins: The role of heat shock proteins as mediators of cardioprotection is 
controversial, however, there is evidence that HSP70 may reduce calcium overloading 
and thus reduce mPTP opening (Marber et al., 1993; Hausenloy and Yellon, 2010). 
Cyclo-oxygenase 2: Upon myocardial ischaemia, COX-2 produces prostaglandins (PE), 
PGE2 and PGF1α, which have been shown to elicit significant cardioprotection by a yet 
unknown mechanism (Shinmura et al., 2000; Hausenloy and Yellon, 2010).  
Although the clinical applicability of delayed IPC is limited in acute myocardial infarction, 
it presents the intriguing possibility that it may be possible to pharmacologically elicit 
delayed cardioprotection. Furthermore, it may be possible to achieve additive 
cardioprotection by targeting both early and late cardioprotective pathways, for example 
by inhibition of mPTP opening and prostaglandin expression; pharmacological 
conditioning for cardioprotection is discussed below. 
1.3.2. Pharmacological conditioning 
The molecular pathway of ischaemic conditioning provides a basis from which to 
investigate potential pharmacological interventions for clinical cardioprotection. In 
theory, delivery of a pharmacological agent that activates the RISK pathway or directly 
inhibits mPTP opening will elicit significant cardioprotection. Indeed, numerous pre-
clinical studies have shown pharmacological activation of the RISK pathway is 
cardioprotective (Hausenloy and Yellon, 2007), and a proof-of-concept clinical study has 
shown that mPTP inhibition by cyclosporine-A (CsA) significantly reduced infarct size 
(Piot et al., 2008); cardioprotection by CsA is discussed below. Importantly, inhalation 
anaesthetic agents, including isoflurane, have been demonstrated to elicit significant 
cardioprotective effects at certain doses (reviewed by Stowe and Kevin, 2004).  
Transgenic therapy also represents an intriguing possibility for cardioprotection and 
initial pre-clinical studies have shown adenoviral transfection of adult mouse hearts with 
inducible NOS was cardioprotective (Li et al., 2003; reviewed by Hausenloy and Yellon, 
2013). This is less immediately clinically amenable and is outside the remit of this thesis. 
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1.4. Mitochondria as targets for cardioprotection 
Mitochondria are fundamental organelles for the maintenance of cell function and 
survival. The importance of mitochondrial function is particularly pertinent in the heart 
given its substantial energy demand and the imperative nature of cardiac function for 
sustaining life. Indeed, mitochondria occupy around 30% of cardiomyocyte volume and 
supply more than 90% of the ATP required for contractile function (Javadov et al., 2009).  
The central roles of mitochondria in cell survival extend beyond energy production to cell 
fate determination as end-effectors of cell death. This is demonstrated by the 
pathophysiology of ischaemia-reperfusion injury described above whereby mitochondrial 
dysfunction and permeability transition account for a significant extent of myocardial 
infarction (reviewed by Gustafsson and Gottlieb, 2008). Mitochondria therefore 
represent an important target for cardioprotection, whereby prevention of mitochondrial 
dysfunction and permeability transition is expected to reduce cell death and thus 
improve the prognosis of acute myocardial infarction patients. 
This thesis will investigate the potential modulation of mitochondrial function and 
permeability transition to elicit cardioprotection against myocardial infarction.  
 
1.4.1. Mitochondrial permeability transition and cyclophilin-D 
Mitochondrial permeability transition is a key end-effector of cardiomyocyte death 
following ischaemia-reperfusion injury (as described above) and therefore represents an 
important potential target for conferring cardioprotection. Under physiological conditions 
the mPTP remains largely closed which is essential to maintain mitochondrial 
membrane integrity that is fundamental for the maintenance of the inner mitochondrial 
membrane electrochemical gradient (Δψm) for ATP production by oxidative 
phosphorylation (Halestrap et al., 2007; Gustafsson and Gottlieb, 2008). However, 
prolonged high-conductance opening of the mPTP causes loss of inner mitochondrial 
membrane integrity which initiates a complex pathway of events that ultimately results in 
cell death by necrosis or apoptosis (see 1.2.3). 
Given the importance of prolonged high-conductance mPTP opening in mediating cell 
death by necrosis and apoptosis upon myocardial reperfusion, it has been hypothesised 
that reducing mPTP opening will significantly reduce cell death and thus improve the 
prognosis of acute myocardial infarction patients (Hoffman et al., 2004; Yellon and 
Hausenloy, 2007). Extensive research efforts have investigated the potential of reducing 
mPTP opening by targeting the known mPTP regulatory protein, cyclophilin-D (Cyp-D). 
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i mPTP structure and regulation 
Originally the mPTP was suggested to be formed by inner mitochondrial membrane 
adenine nucleotide translocase (ANT) (Tikhonova et al., 1994; Halestrap et al., 1997) 
and the outer mitochondrial membrane voltage-dependent anion channel (VDAC) 
(Szabo and Zoratti, 1993). However, numerous subsequent studies demonstrated that 
genetic ablation of both ANT and VDAC did not ablate mPTP opening (Kokoszka et al., 
2004; Krauskopf et al., 2006) and therefore suggested that they acted only as mPTP 
regulatory proteins (Baines, 2009b). A very recent study by Bonora et al. (2013) 
implicated the c subunit of the ATP synthase enzyme (complex V, F0F1) in mPTP 
formation. Subsequently, Giorgio et al. (2013) extended this finding to provide the most 
direct evidence to date that the ATP synthase enzyme is a constituent component of the 
mPTP, whereby they proposed that dimers of whole ATP synthase form the mPTP in 
the inner mitochondrial membrane (Giorgio et al., 2013). 
Given the only very recent suggestion of ATP synthase as a constituent of the mPTP, 
direct mPTP modulation has not yet been explored. However, interestingly a previous 
study by Giorgio et al. (2009) showed that Cyp-D interacts with the ATP synthase lateral 
stalk in a cyclosporine-A (CsA) dependent manner (Giorgio et al., 2009). Cyp-D 
regulation of mPTP opening is discussed below (see ii). Manipulation of mPTP opening 
to date has examined indirect modulation of mPTP opening by reducing cellular agonists 
of mPTP opening (namely high calcium levels, oxidative stress and high phosphate 
concentrations) and increasing antagonists of mPTP opening (enhanced acidosis). 
Numerous pre-clinical studies have shown that manipulation of the cellular environment 
upon reperfusion (for example by administration of ROS scavengers) can reduce mPTP 
opening and final infarct size (Crompton et al., 1987; Griffiths and Halestrap, 1995).  
Direct manipulation of the known mPTP regulatory protein, Cyp-D represents an 
interesting and more elegant potential therapeutic approach for modulating mPTP 
opening; Cyp-D is the first cardioprotective target investigated in this thesis. 
ii Cyclophilin-D as a mPTP regulatory target 
Although the structural identify of the mPTP has been controversial, Cyp-D has long 
been appreciated as an important mPTP regulatory protein (Nicolli et al., 1996). Cyp-D 
confers calcium sensitivity to mPTP opening whereby it facilitates mPTP opening in 
conditions of elevated mitochondrial matrix calcium (Connern and Halestrap, 1994; 
Nicolli et al., 1996). Given the important regulatory role of Cyp-D, this protein represents 
an important potential target for pharmacological or genetic manipulation to indirectly 
affect mPTP opening and calcium sensitivity. It is predicted that inhibition of Cyp-D 
activity may therefore elicit a significant potential therapeutic benefit. 
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Cyclophilin protein family: Cyp-D is a member of the highly conserved and widely 
expressed cyclophilin (Cyp) protein family. The individual Cyp protein subtypes have 
varied molecular weights and intracellular locations but conserved peptidyl-prolyl cis-
trans isomerase (PPIase) activity (Bergsma et al., 1991). This PPIase activity catalyses 
the otherwise slow cis-trans isomerisation of peptidyl-prolyl bonds. Rotation of proline 
peptide bonds causes conformational changes in the target protein which are crucial for 
facilitating protein folding and functional changes (Fischer et al., 1989; Barik, 2006).  
The Cyp proteins also act as molecular chaperones, although this is less well 
understood and has been shown to be independent of their PPIase activity (Barik, 
2006). The chaperone role of Cyp-D has not been implicated in mPTP opening and 
ischaemia-reperfusion injury and so is not discussed further here. 
Cyclophilin-D: Cyp-D (originally termed hCyP3 and also known as Cyp-F in mice) is the 
only mitochondrial cyclophilin protein. Cyp-D is nuclear encoded by the Ppif (peptidyl-
prolyl isomerase F) gene which contains 5.5 kb of genomic DNA and consists of six 
protein encoding exons separated by five intronic sequences. The Ppif gene is highly 
conserved within eukaryotic organisms (Bergsma et al., 1991; Basso et al., 2005).  
The Cyp-D protein sequence is also highly conserved between eukaryotes and shares a 
large degree of homology to the other Cyp proteins (Bergsma et al., 1991). The full 
length Cyp-D protein (c. 22 kDa) consists of a highly conserved 109 amino acid Cyp 
domain which confers PPIase activity and a hydrophobic NH2-terminus mitochondria-
targeting sequence. This immature Cyp-D protein is produced in the cytosol and then 
specifically transported to mitochondria by the N-terminal mitochondria-targeting 
sequence which is predicted to be a mitochondria-transit peptide recognised by the 
outer mitochondrial membrane (Johnson et al., 1999). The Cyp-D protein is cleaved 
upon entry to the mitochondrial matrix to remove the targeting sequence and produce 
the mature functional protein (c. 18 kDa) (Bergsma et al., 1991; Johnson et al., 1999). 
The mature Cyp-D protein has a tertiary structure containing eight β-strands and two α-
helices which are believed to be essential for PPIase activity (Kajitani et al., 2008). 
Comparison of the human and rodent Cyp-D protein sequences has shown a very high 
degree of conservation in the functional PPIase Cyp domain but some divergence in the 
mitochondria-targeting sequence, although mitochondrial targeting does not seem to be 
affected (Woodfield et al., 1997). Given the large degree of conservation between the 
sequences and predicted structures of human and rodent Cyp-D proteins, it is expected 
that once the targeting sequence is cleaved, the function and regulation of Cyp-D is 
highly conserved between mouse and man (Woodfield et al., 1997; Barik, 2006). 
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Investigations of the role of Cyp-D and indeed the mPTP in both physiological and 
pathological settings require tools to selectively inhibit Cyp-D activity. The methods for 
inhibiting Cyp-D discussed here may also provide opportunities for clinical modulation of 
Cyp-D activity for future potential therapeutic approaches. 
Pharmacological inhibition of Cyp-D: Pharmacological inhibition of protein function is 
the classical approach for investigating the role of a given protein; however, the 
usefulness of this approach is clearly determined by the selectivity and availability of 
inhibitors. The principal pharmacological inhibitors of Cyp-D are described below: 
Cyclosporine-A: CsA is a widely used inhibitor of mPTP opening which led to the 
identification of Cyp-D as an important regulatory protein (Halestrap and Davidson, 
1990) and has since been used to investigate the effects of mPTP opening in a number 
of pathophysiological models (Griffiths and Halestrap, 1993; Hausenloy et al., 2012). 
CsA is a cyclic undecapeptide produced by the fungus Trichoderma polysporum and is 
clinically used for its immunosuppressant activities to prevent tissue rejection in 
transplant patients. Independently of its immunosuppressant activity, CsA inhibits Cyp-D 
activity by binding to the catalytic pocket of the PPIase domain, which is essential for 
Cyp-D regulation of mPTP opening. CsA reduces mPTP opening upon ischaemia-
reperfusion (Crompton et al., 1988; Halestrap and Davidson, 1990) and reduces the 
extent of infarction in a number of in vitro and in vivo animal models (Nazareth et al., 
1991; Griffiths and Halestrap, 1993; Hausenloy et al., 2002). Crucially, since CsA is 
cardioprotective when administered only at reperfusion (Hausenloy et al., 2002), CsA 
(and indeed mPTP inhibition) is a potentially clinically relevant therapeutic strategy. 
To date, relatively few studies have investigated clinical use of CsA for cardioprotection. 
Initial ex vivo studies using isolated human atrial tissue have shown that CsA protects 
against ischaemia-reperfusion injury (Schneider et al., 2003; Shanmuganathan et al., 
2005). Furthermore, a recent clinical proof-of-concept study demonstrated CsA 
administered 10 minutes prior to reperfusion in acute ST-segment elevation myocardial 
infarction (STEMI) patients significantly reduced infarct size (Piot et al., 2008). 
Importantly, since safety and regulatory approval for CsA in place for its clinical use as 
an immunosuppressant, larger clinical trials of CsA to protect as myocardial infarction 
could lead to its introduction as a widespread cardioprotective therapy. 
However, the lack of specificity of CsA for Cyp-D represents an important caveat to the 
use of CsA as a research tool and potential therapeutic agent. As described above, CsA 
binds to the Cyp-D conserved PPIase domain and so also binds to and inhibits the 
PPIase activity of the other Cyp proteins (Kajitani et al., 2008), including cytoplasmic 
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Cyp-A. In addition, the bound complex of CsA–Cyp-A in turn binds to and inhibits 
calcineurin; a calcium / calmodulin dependent phosphatase which is involved in 
regulation of gene expression and other intracellular functions (Liu et al., 1991). This has 
required concurrent investigation of calcineurin inhibitors to confirm that CsA-mediated 
cardioprotection is not the result of calcineurin inhibition (Hausenloy et al., 2012).  
The development of specific pharmacological inhibitors of Cyp-D may overcome this and 
has been the subject of much research in recent years. A number of purported Cyp-D 
selective inhibitors have been published and investigated in relation to their effects on 
Cyp-D inhibition of mPTP opening and protection against ischaemia-reperfusion injury; 
the main advances in pharmacological inhibition of Cyp-D are discussed below. 
Sanglifehrin-A: Sanglifehrin-A (SfA) is an immunosuppressant distinct from CsA which 
tightly binds to and inhibits the Cyp proteins. SfA has been shown to inhibit Cyp-D 
activity and in turn reduce mPTP opening and improve cardiac function and increase cell 
survival upon ischaemia-reperfusion in animal models (Clarke et al., 2002; Hausenloy et 
al., 2003) and isolated human atrial tissue (Shanmuganathan et al., 2005). The main 
advantage of SfA over CsA is that the SfA-Cyp-A complex does not inhibit calcineurin, 
however, since SfA is not selective for Cyp-D, its effects may still be mediated by 
inhibition of other Cyp proteins (Clarke et al., 2002; Hausenloy et al., 2012). 
Non-immunosuppressive CsA analogues: A number of small molecule CsA analogues 
have been developed which do not bind to calcineurin and so do not exert 
immunosuppressant activity (reviewed by Hausenloy et al., 2012). This group of 
inhibitors includes NIM-811 and Debio-025 which inhibit Cyp-D to reduce mPTP opening 
with increased potency compared to CsA (Hansson et al., 2004). Indeed, both NIM-811 
and Debio-025 significantly reduce myocardial infarct size in in vivo models of 
ischaemia-reperfusion injury (Argaud et al., 2005; Gomez et al., 2007). However, these 
inhibitors may still bind to and inhibit other Cyp proteins to exert non-selective effects. 
Mitochondria targeted CsA: Mitochondrial targeting of CsA has been investigated as an 
approach for sequestering CsA in the mitochondria to limit its binding to Cyp-D only. The 
mitochondrial CsA (mtCsA) molecule is formed by conjugation of CsA to a lipophilic 
cation (TPP+) to give it a positive charge to drive its accumulation into the mitochondria 
due to the electrophoretic gradient imposed by the negative potential of the inner 
mitochondrial membrane. Although mtCsA can still bind to the other Cyp proteins, such 
as Cyp-A, sequestration of mtCsA in the mitochondrial matrix renders it selective for 
Cyp-D and thus also prevents its actions on calcineurin (Malouitre et al., 2010).  
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Initial in vitro studies showed that the CsA-TTP+ (mtCsA) molecule is successfully 
accumulated in the mitochondrial matrix of cells and maintains its potency at inhibiting 
Cyp-D (Malouitre et al., 2010). Furthermore, ex vivo studies demonstrated increased 
potency of mtCsA compared to CsA at reducing cell death in ex vivo models of 
simulated ischaemia-reperfusion injury in rat hippocampal neurones (Malouitre et al., 
2010) and cardiomyocyte preparations (Dube et al., 2012). Further studies are now 
required to assess the in vivo safety and cardioprotective efficacy of mtCsA. 
Novel selective Cyp-D inhibitors may now be designed following the identification of a 
number of residues in proximity to the CsA binding site that are not conserved in the 
other Cyp proteins (Kajitani et al., 2008). In the meantime, since mtCsA and the non-
immunosuppressant inhibitors are not widely available, CsA continues to be widely used 
to investigate Cyp-D and mPTP opening in ischaemia-reperfusion injury. 
 
Genetic manipulation of Cyp-D: Genetic manipulation to modify Cyp-D expression 
provides an important tool for investigating the role of Cyp-D in mPTP regulation without 
the confounding effects of non-selective actions on the other Cyp proteins. There are a 
number of useful approaches for Cyp-D genetic manipulation, described below: 
Genetic interference: Interference RNA (RNAi) is an interesting methodological 
approach whereby a recent study has demonstrated that RNAi knock-down of the Cyp-D 
gene product reduced ischaemia-reperfusion induced renal injury (Hu et al., 2010).  
Overexpression: Limited studies have investigated Cyp-D overexpression (Lin and 
Lechleiter, 2002; Baines et al., 2005); however, this approach has been less widely 
employed and does not represent a therapeutic target for cardioprotection. 
Genetic ablation: Whole body genetic ablation of Cyp-D in the mouse was achieved 
independently by several research groups in 2005 (Baines et al., 2005; Basso et al., 
2005; Nakagawa et al., 2005). The precise details of Cyp-D genetic ablation varied 
between these studies but all demonstrated 100% absence of Cyp-D protein in all body 
tissues examined. A detailed description of the Cyp-D knockout mouse created by 
Baines et al. (2005) and used in thesis is provided in chapter 5. 
The Cyp-D knockout mouse line has proved an invaluable tool for investigating the role 
of Cyp-D and mPTP opening in a number of pathological settings, including ischaemia-
reperfusion. This is discussed in detail subsequently in relation to Cyp-D regulation of 
mPTP opening (see iv) and the physiological role of mPTP opening (see v). 
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iii Cyp-D and mPTP opening 
The function of Cyp-D has predominantly been investigated in relation to its regulation of 
mPTP opening. Cyp-D was first implicated in mPTP opening by studies investigating the 
mechanism of mPTP inhibition by CsA, which demonstrated that Cyp-D is the singular 
mitochondrial receptor for CsA (Connern and Halestrap, 1994; Nicolli et al., 1996). CsA 
binds to the catalytic pocket of the Cyp protein PPIase domain thereby inhibiting its 
activity. Since CsA inhibits mPTP opening, it has long been hypothesised that Cyp-D 
facilitates mPTP opening by inducing a conformational change in a constituent protein of 
the pore that renders it open (Connern and Halestrap, 1994; Nicolli et al., 1996).  
However, the precise mechanism by which Cyp-D activates mPTP opening is currently 
largely unknown due to the controversy surrounding the actual constituent proteins of 
the mPTP. The most recent model proposed by Bernardi’s group states that the mPTP 
is formed from dimers of the F0F1-ATP synthase enzyme (Giorgio et al., 2013) (Figure 
1.11 A) and suggests that Cyp-D is likely to mediate a conformational change in these 
dimers to facilitate pore opening (Bernardi, 2013; Giorgio et al., 2013) (Figure 1.11 B). 
The involvement of the ATP synthase enzyme in formation of the mPTP is also 
supported by an earlier study by Bonora et al. (2013) which implicated ATP synthase 
subunit c as a consistent protein of the mPTP. Indeed, a previous study by this group 
showed that Cyp-D interacts with the lateral stalk of the F0F1-ATP synthase to decrease 
its enzymatic activity. Furthermore, this study showed that CsA caused dissociation of 
the Cyp-D-ATP synthase interaction, in line with the CsA sensitivity of mPTP opening 
(Giorgio et al., 2009). This model of Cyp-D regulation of mPTP opening is reviewed by 
Bernardi (2013) and summarised in Figure 1.11. 
 
 
Figure 1.11: Revised model of mPTP and its regulation by Cyp-D 
Proposed model of Cyp-D regulation of mPTP opening: the mPTP is formed of F0F1-ATP 
synthase dimers to which Cyp-D binds to induce a conformational change causing a high-
conductance pore to form between the F0 subunits. This still remains a putative model of the 
mPTP at this stage. Adapted from Bernardi (2013) and Giorgio et al. (2013). 
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The role of Cyp-D regulation in mPTP opening can be examined using pharmacological 
methods; however, Cyp-D genetic ablation has allowed more elegant dissection of the 
roles of Cyp-D. Complete genetic ablation of Cyp-D in mouse lines was completed 
independently by several research groups and reassuringly, demonstrated strikingly 
similar effects on mPTP opening (summarised in Table 1.2) (Basso et al., 2005; Baines 
et al., 2005; Nakagawa et al., 2005; Schinzel et al., 2005). Mitochondria devoid of Cyp-D 
were more resistant to loss of inner mitochondrial membrane potential, mitochondrial 
swelling and mPTP opening in response to common mPTP triggers including calcium 
and oxidative stress. However, it should be noted that these studies were mainly based 
on isolated liver mitochondria although Baines et al. (2005) confirmed these findings in 
cardiac mitochondria (Table 1.2). These studies also confirmed that Cyp-D is not a 
constituent of the mPTP since mPTP opening occurred in Cyp-D knockout mitochondria 
in response to increased severity of triggers (Basso et al., 2005; Baines et al., 2005; 
Nakagawa et al., 2005). Baines et al. (2005) demonstrated that the susceptibility to 
mPTP opening was restored in Cyp-D knockout mitochondria by reintroduction of 
wildtype, but not PPIase deficient Cyp-D protein, proving that Cyp-D PPIase activity is 
crucial in regulating the calcium sensitivity of mPTP opening (Baines et al., 2005). 
Further to this, these studies demonstrated that Cyp-D knockout mouse embryonic 
fibroblast (MEF) cells were more resistant to cell death induced by ROS overload (upon 
treatment with hydrogen peroxide) (Nakagawa et al., 2005; Baines et al., 2005; Schinzel 
et al., 2005); although again it should be noted that these are not cardiac specific cells. 
Importantly, Baines et al. (2005) and Nakagawa et al. (2005) showed that Cyp-D genetic 
ablation significantly reduced susceptibility to in vivo ischaemia-reperfusion injury. This 
provided the first conclusive evidence that Cyp-D ablation is a cardioprotective strategy. 
Subsequent studies have utilised the Cyp-D whole body knockout mouse line to further 
investigate the role of Cyp-D in regulating mPTP opening. Lim et al. (2011) showed that 
Cyp-D knockout mice had improved survival and cardiac function at 28 days of 
myocardial ischaemia, a model of pathological cardiac failure (Lim et al., 2011). 
Further studies are required to investigate whether Cyp-D inhibition upon reperfusion is 
a feasible therapeutic strategy for conferring long-term cardioprotection. This is 
complicated by the unresolved physiological function of the mPTP and recent studies 
suggesting that chronic Cyp-D inhibition may be detrimental; discussed below (see v). 
 
Table 1.2: Protective effects of Cyp-D genetic ablation 
Initial studies examining the effect of whole body total ablation of Cyp-D (KO) on mPTP opening 
in response to environmental stressors. References provided. (Table overleaf) 
 STUDY STRESSOR EFFECT IN CYP-D KNOCKOUT 
ISOLATED MITOCHONDRIA (Liver mitochondria unless otherwise stated) 
Baines et al. (2005)  
 
Observed in heart, liver 
and brain mitochondria 
 
Calcium (250 µM) 
Calcium (25 µM) + atractyloside (200 µM) 
 Resistance to mitochondrial swelling 
 Resistance to mPTP opening 
 Increased calcium uptake before undergoing mPTP opening 
 Less cytochrome c release 
These traits were all overcome by very high calcium loads 
 
Basso et al. (2005) Calcium (various concentrations to produce 
concentration response curves) 
 Resistance to mPTP opening 
 CsA insensitivity 
 
Nakagawa et al. (2005) Calcium (50 µM) 
Atractyloside 
H2O2 
 Resistance to loss of Δψm 
 Resistance to mPTP opening 
 Increased calcium uptake before undergoing mPTP opening 
 Less calcium induced cytochrome c release 
These traits were all overcome by very high calcium loads 
 
Nakagawa et al. (2005) Simulated ischaemia-reperfusion 
(30 min hypoxia) 
 Resistance to loss of Δψm 
 Resistance to mitochondrial swelling 
 Preserved respiratory control compared to WT 
 
Schinzel et al. (2005) 
 
Calcium (100 µM) 
 
 Resistance to mitochondrial swelling 
 Morphologically intact compared to WT (assessed by EM) 
 
CULTURED MOUSE EMBRYONIC FIBROBLASTS 
Baines et al. (2005) H2O2 (500 µM)  Resistance to loss of Δψm and mPTP opening 
 Less cell death 
 
Baines et al. (2005) Calcium overload induced by thapsigargin (20 µM) or 
ionomycin (10 µM) 
 
 Less cell death 
 
Nakagawa et al. (2005) H2O2 (500 µM)  
 
 Less cell death 
 
Schinzel et al. (2005) 
 
H2O2 (various concentrations)  
 
 Less cell death 
IN VIVO 
Baines et al. (2005) Cardiac ischaemia-reperfusion by LAD occlusion 
(60 min ischaemia, 24 hour reperfusion) 
 
KO hearts showed 40% reduction in infarct size  
Nakagawa et al. (2005) Cardiac ischaemia-reperfusion by LAD occlusion 
(30 min ischaemia, 2 hour reperfusion) 
 
KO hearts showed dramatic reduction in infarct size 
Very dramatic reduction in lactate dehydrogenase release 
Schinzel et al. (2005) 
 
Cerebral ischaemia-reperfusion 
(2 hour ischaemia, 24 hour reperfusion) 
 
KO brains showed dramatic reduction in infarct volume and area 
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iv Regulation of Cyp-D activity 
Cyp-D regulation of mPTP opening is crucial in determining cell survival; however, the 
mechanisms regulating Cyp-D activity remain largely unknown. Recent studies suggest 
post-translational modification of Cyp-D regulate its activity and in turn affect mPTP 
calcium sensitivity; the main putative post-translational modifications are described here: 
Phosphorylation: The role of phosphorylation of Cyp-D remains controversial although 
there is evidence suggesting that GSK3β may translocate to the mitochondrial matrix to 
directly phosphorylate Cyp-D (Xi et al., 2009), however, this has not been shown in vivo. 
Rasola et al. (2010) recently showed GSK3β mediated Cyp-D phosphorylation resulted 
in increased mPTP opening and cell death; although this was in a cancer cell line where 
regulatory systems are known to be perturbed. Further studies are required to determine 
whether Cyp-D phosphorylation regulates mPTP opening. 
S-nitrosylation: S-nitrosylation (SNO) is a reversible redox-dependent post-translational 
modification involving attachment of a nitric oxide moiety to a cysteine residue within the 
target protein. Previous studies have implicated SNO in modifying target protein activity 
and associated cardioprotection (Murphy et al., 2012). Cyp-D has been shown to be 
amenable to SNO at cysteine residue 203 (Kohr et al., 2011), where mutation of this 
residue conferred resistance to mitochondrial swelling and ROS-induced cell death 
(Nguyen et al., 2011). However, the causative relationship between Cyp-D SNO and 
mPTP opening remains unclear and it has been suggested that SNO may only indirectly 
affect mPTP opening by preventing its oxidation (Elrod and Molkentin, 2013). 
Deacetylation: Several studies have suggested that deacetylation of lysine residues is 
an important regulatory mechanism. Two recent studies demonstrated that Cyp-D is 
deacetylated by sirtuin-3 (Hafner et al., 2010; Shulga et al., 2010). These studies 
suggest that Cyp-D acetylation increases mPTP opening and therefore, deacetylation by 
sirtuin-3 reduces Cyp-D activity and reduces mPTP opening. The precise mechanisms 
implicated by these two studies vary and are discussed in detail below (see 1.4.2). 
The precise roles of these post-translational modifications in regulating Cyp-D activity 
remain unclear, however, it is likely that these mechanisms are important for ‘fine-tuning’ 
Cyp-D activity and thus mPTP opening and so may represent important cardioprotective 
targets. Indirect regulation of Cyp-D by modulation of post-translational regulation may 
provide a more subtle and therapeutically advantageous approach, given the 
complications of chronic Cyp-D inhibition. Modulation of sirtuin-3 as a potential 
cardioprotective target is discussed below (see 1.4.2) and investigated in chapter 6. 
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v Physiological role of Cyp-D and mPTP opening 
The physiological role of Cyp-D and mPTP opening has remained largely unclear; 
however, Cyp-D genetic ablation has provided insights into the potential effects of long-
term Cyp-D inhibition and the resulting calcium insensitivity of mPTP opening. 
Baseline phenotype of Cyp-D knockout mice: The original publications describing 
generation of whole body Cyp-D genetic knockout mouse lines stated that there were no 
overt baseline phenotypic differences between wildtype and Cyp-D knockout (KO) 
animals (Nakagawa et al., 2005; Baines et al., 2005; Basso et al., 2005). Whole body 
genetic ablation of Cyp-D did not cause any adverse developmental defects and KO 
mice were born at the expected Mendelian ratio and did not show any difference in 
developmental survival (Baines et al., 2005). The baseline physiology and morphology 
of Cyp-D KO mitochondria appeared unaffected. In addition, cardiac function was not 
affected in young animals and there was no indication of cardiomyopathy (Nakagawa et 
al., 2005; Baines et al., 2005). These studies suggested that Cyp-D and mPTP calcium 
sensitivity are dispensable for development and exert only limited physiological function. 
Adverse effects of Cyp-D inhibition: Recent studies, however, have suggested that 
Cyp-D KO mice may develop phenotypic differences with age or upon physiological 
stress. Elrod et al. (2010) showed that chronic Cyp-D inhibition may be detrimental, 
where Cyp-D KO animals exhibited an increased predisposition to hypertrophy and 
cardiac failure induced by physiological stresses such as swimming (Elrod et al., 2010). 
Chronic Cyp-D inhibition by CsA treatment has also been shown to exacerbate cardiac 
failure despite its significant effect in reducing hypertrophy (Oie et al., 2000); although it 
is not possible to preclude CsA effects independent of Cyp-D. However, a study by our 
laboratory showed that Cyp-D knockout mice were less susceptible to cardiac failure 
induced by the pathological stress of prolonged ischaemia (Lim et al., 2011).  
Elrod et al. (2010) proposed that the adverse effects of chronic Cyp-D inhibition upon 
physiological stresses, such as excessive exercise, may relate to the physiological roles 
of mPTP opening, whereby transient low-conductance mPTP opening is critical for 
calcium release from the mitochondrial matrix (Elrod et al., 2010); discussed below.  
Transient low-conductance mPTP opening: Transient low-conductance mPTP 
opening (see 1.3.1; Figure 1.9) may occur physiologically in response to slightly 
elevated mitochondrial matrix calcium, whereby mPTP ‘flickering’ may permit calcium 
homeostasis without affecting inner mitochondrial membrane potential (Figure 1.12 A). 
Chronic Cyp-D inhibition results in elevated mitochondrial matrix calcium which triggers 
a metabolic shift to glycolysis and a resultant propensity to cardiac failure (Figure 1.12 
B) (reviewed by Elrod and Molkentin, 2013).  
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Figure 1.12: Physiological importance of transient low-conductance mPTP opening 
Transient low-conductance mPTP opening is proposed to mediate physiological mitochondrial 
homeostasis (A). Inhibition of Cyp-D (B) or indeed any other mechanism inhibiting mPTP 
opening, causes mitochondrial calcium accumulation which results in a metabolic shift and 
ultimately cardiac failure. Adapted from Elrod and Molkentin (2013). 
 
The metabolic shift associated with increased mitochondrial matrix calcium 
accumulation upon inhibition of mPTP opening is thought to be associated with the 
resulting increased activity of mitochondrial calcium-dependent dehydrogenases (Korge 
et al., 2011; Elrod and Molkentin, 2013). The precise molecular mechanisms of this 
process require further investigation; however, the potential role of Cyp-D in metabolic 
control further highlights the importance of careful modulation of Cyp-D activity as a 
potential therapeutic intervention.  
 
The experimental evidence to date suggests that inhibition of Cyp-D may represent an 
important and efficacious method for reducing mPTP opening and thus preventing cell 
death upon myocardial reperfusion. However, the adverse effects of Cyp-D inhibition on 
prevention of physiological mPTP opening for mitochondrial matrix calcium homeostasis 
suggest that modulators of Cyp-D and mPTP activity should only be administered 
acutely. It remains to be seen whether acute Cyp-D inhibition confers long-term 
cardioprotection against ischaemia-reperfusion injury; this is investigated in chapter 5.  
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1.4.2. Regulation of mitochondrial proteins by sirtuin-3 
Regulation of mitochondrial biology is crucial for cell function and survival in both 
physiological and pathological conditions. Control of mitochondrial biology can be 
exerted at a macro-level, for example by protein expression; however, more subtle and 
immediate regulation of mitochondrial proteins by post-translational modifications can 
also significantly affect mitochondrial physiology. Post-translational modifications of 
proteins regulate protein structure and function and therefore, post-translational 
modification represents an important biological regulatory mechanism (Balaban, 2010).  
Mitochondrial proteins are subject to numerous post-translational modifications, 
including phosphorylation, S-nitrosylation and acetylation. Although phosphorylation has 
been the most widely studied, recent studies have shown that acetylation of proteins has 
a comparably widespread regulatory scope (Choudhary et al., 2009). Acetylation can 
occur on numerous amino acids but is most common on lysine residues. Indeed, acetyl-
lysine residues have been identified in over 20% of mitochondrial proteins, including 
important respiratory proteins (Kim et al., 2006). These studies suggest that acetylation 
is a key regulatory mechanism of mitochondrial biology and as such may be an 
important target for modulating mitochondrial function to confer cardioprotection. 
i Post-translational regulation by acetylation / deacetylation 
Acetylation was identified as a post-translational modification affecting histone proteins; 
however, identification of acetylated non-histone proteins, including key mitochondrial 
proteins, suggested that acetylation may be a widespread and functionally important 
means of protein regulation. Given the prevalence of acetyl-lysine residues in important 
mitochondrial proteins, the balance of acetylation and deacetylation in regulating protein 
function has become an area of interest for mitochondrial research (Balaban, 2010). 
Chemistry of acetylation and deacetylation: Lysine acetylation comprises the 
addition of an acetyl functional group (O=C-CH2) to the ε-amino group of L-lysine (Figure 
1.13 A) (Sauve, 2010). Lysine residues are often located in binding and catalytic sites of 
proteins where the positively charged amino side-chain (Figure 1.13 B) contributes to 
overall protein structure and function by bonding to negatively charged amino acids or 
non-protein atoms (Alberts et al., 2002). Addition of an acetyl group to lysine neutralises 
this positive charge (Figure 1.13 A) and can therefore influence its participation in 
protein binding and active sites which can thus affect overall protein structure and 
function (Choudhary et al., 2009). Deacetylation removes the acetyl functional group 
and restores the free amino group of the affected lysine residue therefore restoring its 
positive charge and functional capacity (depicted in Figure 1.13) 
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Figure 1.13: Schematic of lysine acetylation and deacetylation 
Simplified chemical basis of lysine acetylation (A) and deacetylation (B) by acetyl transferases 
(blue) and deacetylases (red) respectively. Lysine contains a positively charged amino side-chain 
(+) which is neutralised by the addition of the acetyl group. Adapted from Sauve (2010). 
 
Regulation of acetylation and deacetylation: Protein acetylation is a reversible post-
translational modification involving a highly regulated balance between acetylation and 
deacetylation (Choudhary et al., 2009). These processes are catalysed by lysine acetyl 
transferase (KAT; previously known as histone acetyl transferase HAT) and lysine 
deacetylase (KDAC; previously known as histone deacetylase HDAC) enzymes 
respectively (Sauve, 2010; Fritz et al., 2012). Given the importance of lysine residue 
acetyl-status in protein structure and function, regulation of acetylation and deacetylation 
provides an interesting potential mechanism for modulating protein function. 
Acetylation: The precise mechanisms catalysing acetylation in mitochondria have not 
been fully elucidated. It has been suggested that proteins with acetyl transferase activity 
are likely to reside in the mitochondrial matrix. In addition, auto-acetylation has been 
proposed. However, neither of these mitochondrial acetylation mechanisms has been 
confirmed to date and investigation of acetylation is on-going (Fritz et al., 2012). 
Deacetylation: The regulation of deacetylation in mitochondria has been widely 
investigated and is much better understood. Deacetylation involves the removal of the 
acetyl group from lysine to restore its free amino group (Figure 1.13; red) (Sauve, 2010). 
Deacetylation is catalysed by enzymes with deacetylase activity, termed lysine 
deacetylase (KDAC) proteins which are divided into four different classes (I - IV) based 
on sequence homology and function. KDAC proteins are generally zinc-dependent, 
except class III which are structurally and functionally divergent to the other KDAC 
enzymes (Dokmanovic et al., 2007). The sirtuin proteins are a major group of class III 
KDAC proteins which have been implicated in lysine deacetylation in a number of 
physiological and pathological settings (reviewed by Bao and Sack, 2010). Given the 
widespread roles of sirtuin proteins in lysine deacetylation, these proteins are an 
important regulatory mechanism of acetyl-post-translational modifications. 
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ii Sirtuin-3 as a post-translational regulatory protein 
Activation of the catalytic activity of the sirtuin (Sirt) proteins results in rapid removal of 
acetyl groups from lysine residues. The Sirt proteins are known to deacetylate a diverse 
range of transcriptional regulators and intracellular proteins and have been widely 
investigated given the importance of acetyl-post-translational modifications in regulating 
protein activity (Bao and Sack, 2010). Sirtuin-3 (Sirt-3) has been implicated in regulating 
mitochondrial protein deacetylation (Shi et al., 2005) and is therefore an interesting 
target for cardioprotection by modulating mitochondrial function and thus survival. 
Sirtuin protein family: Sirt-3 is a member of the highly conserved Sirt protein family of 
deacetylase enzymes. The yeast Sir2 (silent information regulator-2) protein was the 
first Sirt protein to be identified and there are now seven known mammalian Sirt proteins 
(Sirt 1-7). The mammalian Sirt proteins have varied subcellular locations but conserved 
nicotinamide adenine dinucleotide (NAD+) dependent deacetylation activity. All the 
mammalian Sirt proteins contain a conserved NAD+-binding and catalytic domain, 
termed the ‘sirtuin core domain’ (Frye, 2000) which confers their highly conserved NAD+-
dependence (Sauve, 2010), discussed below (see iii). The mammalian Sirt proteins 
have divergent N- and C-terminals where the N-terminus targeting sequence determines 
the protein subcellular location (Frye, 2000) and thus precise roles of the protein.  
The Sirt proteins (including Sir2) also have putative roles in ribosylation (Onyango et al., 
2002), where this has recently been reported specifically for Sirt-4 and Sirt-7 proteins. 
However, the ribosylation activity of the Sirt proteins is currently poorly understood and 
the source of some controversy; it is therefore not discussed in detail here. 
The mammalian Sirt proteins are sub-divided into four classes defined by the degree of 
homology of the core 250 amino acid domain and their functional activity: class I (Sirt-1, 
-2 and -3), class II (Sirt-4), class III (Sirt-5) and class IV (Sirt-6 and -7) (Frye, 2000). The 
class I Sirt proteins exhibit the closest homology to yeast Sir2 and the most robust 
deacetylase activity. Although Sirt-1 has been the most widely studied member of the 
Sirt protein family, with regards to mitochondrial protein acetylation only Sirt-3, -4 and -5 
proteins are located in the mitochondrial matrix (Shinmura, 2013). Of these 
mitochondrial Sirt proteins, Sirt-3 has been demonstrated to possess the most robust 
deacetylase activity. The role of Sirt-3 as the major Sirt deacetylase in mitochondria is 
demonstrated by extensive mitochondrial protein hyperacetylation in Sirt-3 genetic 
knockout mice (Lombard et al., 2007; Fritz et al., 2012). In comparison, genetic ablation 
of Sirt-4 or Sirt-5 caused very little difference to the acetylation status of mitochondrial 
proteins (Lombard et al., 2007). Sirt-3 is therefore the main focus for investigation of 
acetyl-post-translational regulation of mitochondrial proteins here. 
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Sirtuin-3: Sirt-3 is the main mitochondrial deacetylase protein identified to date. Sirt-3 is 
nuclear encoded to produce a 399 amino acids (c. 44 kDa) full length protein containing 
a 24 amino acid N-terminal mitochondria-targeting sequence and a conserved ‘sirtuin 
core domain’ described above. The immature full length Sirt-3 protein is transported to 
the mitochondrial matrix where this N-terminal sequence is removed to form the 
functionally active mature Sirt-3 protein (c. 28 kDa) (Frye, 2000; Schwer et al., 2002). 
Sirt-3 is known to be enriched in mitochondria, which is evidenced by its high level of 
expression in mitochondria-dense tissues including heart, brain and liver (Lombard et 
al., 2007). Within the mitochondria, Sirt-3 is believed to be soluble in the mitochondrial 
matrix (Schwer et al., 2002; Lombard et al., 2007). An earlier study showing inner 
mitochondrial membrane bound Sirt-3 in cultured cells is likely to be an in vitro artefact. 
In addition to mitochondrial Sirt-3, a smaller nuclear pool of full length Sirt-3 has been 
identified in human brown adipose tissue samples (Scher et al., 2007), although this was 
not seen in mouse samples (Lombard et al., 2007). Although there is still some 
controversy, Sirt-3 is likely to only be active in the mitochondria since cleavage of the N-
terminal sequence in the mitochondrial matrix is required for its function (Frye, 2000). 
The human and rodent Sirt-3 protein sequences show a very high degree of 
conservation of the functional ‘sirtuin core domain’ (Frye, 2000). Initial studies suggested 
that the mouse Sirt-3 protein was shorter than the human isoform (Yang et al., 2000; 
Schwer et al., 2002); however, a subsequent study isolated a novel mouse Sirt-3 splice 
variant of increased length with a clearly identifiable mitochondria-targeting sequence 
(Cooper et al., 2009). Although there remains some controversy concerning the splice 
variants and isoforms of the mouse Sirt-3 protein, conservation of the functional sirtuin 
core domain suggests that the function and regulation of Sirt-3 in acetyl-post-
translational modifications will be highly conserved between these species (Sack, 2011). 
 
Investigations of the role of Sirt-3 in physiological and pathological situations have relied 
primarily on manipulation of Sirt-3 expression levels or activity since there is currently no 
known pharmacological activator or selective inhibitor of Sirt-3 (Sack, 2011). Cloning of 
the human and rodent Sirt-3 isoforms has allowed genetic overexpression, mutation and 
ablation studies in vitro in cultured cell lines (Frye, 1999; Frye, 2000; Michishita et al., 
2005). Further to this, the role of Sirt-3 has been assessed in vivo using a Sirt-3 genetic 
knockout mouse model (Lombard et al., 2007) and by pathophysiological upregulation of 
Sirt-3 expression by fasting (Shi et al., 2005). Detailed descriptions of these approaches 
and the protocols used to manipulate Sirt-3 expression are provided in chapter 6. 
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iii Regulation of Sirt-3 mediated deacetylation 
Deacetylation by Sirt-3 is highly regulated by intracellular and mitochondrial conditions. 
The key mechanisms regulating Sirt-3 are described below and discussed in detail 
subsequently in the relation to physiological and pathological conditions (see iv). 
Regulation of Sirt-3 deacetylase activity: Sirt mediated deacetylation is dependent on 
activation of Sirt proteins by NAD+ binding to the sirtuin core domain. Binding of NAD+ to 
the Sirt protein induces its deacetylase activity thereby catalysing the removal of lysine 
acetyl groups on target proteins. NAD+ also functions as a cofactor in the deacetylation 
reaction to produce nicotinamide, which under normal cellular conditions is regenerated 
to form NAD+ (Revollo et al., 2004). Nicotinamide inhibits Sirt deacetylase activity by 
binding to a conserved regulatory pocket, termed the c-pocket (Bitterman et al., 2002). 
The balance of NAD+ activation and nicotinamide inhibition of Sirt-3 deacetylase activity 
is the principal mediator of Sirt-3 protein activity (Sack, 2011), (Figure 1.14). 
 
Figure 1.14: Regulation of Sirt-3 mediated deacetylation 
Sirt-3 activity is dependent on binding to NAD
+
 which is consumed by the deacetylation reaction. 
Sirt-3 deacetylase activity is regulated by the balance of NAD
+
 which activates Sirt-3 and 
nicotinamide which inhibits Sirt-3. Constructed from information provided by Sack (2011). 
 
Regulation of NAD+ levels: Regeneration of NAD+ from nicotinamide is the major source 
of NAD+ in mammalian cells (Revollo et al., 2004) (Figure 1.14). However the precise 
regulation and availability of NAD+ may vary between cell types and subcellular 
compartments (Bao and Sack, 2010). The processes regulating NAD+ levels have been 
mostly studied in the cytosol in relation to Sirt-1 deacetylation, however, mitochondria-
specific isoforms of the proteins regulating NAD+ biosynthesis have been identified 
(Berger et al., 2005), suggesting that overall regulation of NAD+ levels and thus Sirt 
deacetylase activity is conserved between the Sirt proteins. 
The key role of NAD+ in regulating Sirt (including Sirt-3) activity is likely to reflect the 
importance of Sirt proteins as metabolic sensors. Regulation of Sirt protein deacetylase 
activity by NAD+ is conserved in all mammalian Sirt proteins. In normal cells where 
Acetyl-lysine
(A) (B)
Lysine
NAD+
De novo synthesis
Tryptophan + Nicotinic acid
Sirt-3
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energy production is not restricted, intracellular NADH levels increase at the expense of 
NAD+ levels; therefore under normal conditions NAD+ levels are low which prevents Sirt-
3 mediated deacetylation. However, upon energy starvation, NAD+ levels increase which 
activates Sirt-3 deacetylase activity (Rardin et al., 2013). Indeed, metabolic stress upon 
fasting also causes upregulation of the enzymes that convert nicotinamide to NAD+ 
(Yang et al., 2007a), thereby increasing Sirt-3 activity upon fasting, discussed below. 
Post-translational modification of Sirt-3: Post-translational regulation of Sirt-3 protein 
activity has not been widely investigated to date. It has been suggested that Sirt-3 may 
be carbonylated (carbon monoxide bound) upon certain stress conditions (Fritz et al., 
2011), which inhibits Sirt-3 deacetylase activity (Fritz et al., 2012). It is unclear how 
widespread carbonylation controls Sirt-3 deacetylase activity in other cellular conditions.  
Studies of cytosolic Sirt-1 protein regulation have shown that sumoylation is an 
important post-translational modification which activates Sirt-1 deacetylase activity 
(Yang et al., 2007b). Sumoylation of Sirt-3 has not yet been demonstrated. However, 
this may represent a potential Sirt-3 post-translational modification. 
Regulation of Sirt-3 protein expression: In addition to regulation of Sirt-3 deacetylase 
activity described above, modulation of Sirt-3 protein expression is also likely to be an 
important mechanism of regulating Sirt-3 deacetylation and thus acetyl-post-translational 
modifications. The precise molecular regulatory mechanisms controlling Sirt-3 protein 
levels have not been well characterised, however, numerous studies have shown Sirt-1 
protein expression is tightly regulated by transcription (e.g. Foxo-3a) and RNA stability 
(e.g. miRNA inhibition of Sirt-1 RNA). It is therefore expected that a similar scope of 
regulatory mechanisms will control Sirt-3 expression (Bao and Sack, 2010; Sack, 2011).  
Although the precise molecular mechanisms controlling Sirt-3 protein expression levels 
are not well understood, it is widely appreciated that Sirt-3 protein levels are highly 
amenable to regulation by external cellular conditions. Most notably, calorie restriction 
and total fasting have been shown to trigger significant increases in Sirt-3 expression in 
ex vivo neonatal cardiomyocytes (Sundaresan et al., 2008) and in vivo in the liver (Lu et 
al., 2011). In addition, high ROS levels have been shown to induce increased Sirt-3 
transcript and protein levels (Chen et al., 2011). Further to this, it has been shown that 
calorie restriction and concurrent increased Sirt-3 expression results in a significant 
decrease in mitochondrial protein acetylation in liver tissue samples (Hebert et al., 
2013). Conversely, a high fat diet has been shown to downregulate Sirt-3 expression in 
vivo (Bao et al., 2010). The influence of calorie intake on Sirt-3 expression is likely to 
represent the role of Sirt-3 as an important sensor and regulator of metabolic stress 
(reviewed by Shinmura, 2013). 
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iv Physiological and pathophysiological roles of Sirt-3 
Sirt-3 target proteins: Sirt-3 is known to deacetylate a number of mitochondrial 
proteins. Recent developments in large gene array and mass spectrometry technologies 
have allowed rapid identification of numerous lysine acetylation sites in ex vivo tissues 
(Kim et al., 2006). Furthermore, comparison of the ‘acetylome’ of Sirt-3 wildtype and 
knockout mice has identified lysine residues in at least 136 mitochondrial proteins that 
are specifically deacetylated by Sirt-3 (Fritz et al., 2012; Rardin et al., 2013). 
Sirt-3 deacetylates a number of proteins involved in protein transcription, metabolism 
and cell survival (Sack, 2011; Nogueiras et al., 2012); as summarised in Table 1.3. 
Transcription regulation: Sirt-3 has been shown to mediate deacetylation of Foxo3a, an 
important transcription factor; Foxo3a deacetylation increases its DNA binding activity 
and thus mediates transcription of a number of downstream genes, notably catalase and 
MnSOD (Jacobs et al., 2008; Kim et al., 2010). Sirt-3 induced Foxo3a mediated MnSOD 
expression was shown to protect against increased superoxide levels, where cells 
expressing mutant non-functional Sirt-3 exhibited increased superoxide levels (Jacobs 
et al., 2008). The role of Sirt-3 in regulating ROS levels is discussed further below. 
Respiration: Sirt-3 is a crucial regulator of mitochondrial metabolism whereby Sirt-3 
deacetylates and activates a number of key metabolic enzymes involved in oxidation of 
fatty acids and the electron transport chain (summarised in Table 1.3). Importantly, 
deacetylation of respiratory complexes I, II and V (Ahn et al., 2008; Finley et al., 2011; 
Wu et al., 2013) increases the enzymatic activity of the ETC to increase ATP production. 
The importance of the role of Sirt-3 in regulating metabolism is demonstrated in Sirt-3 
knockout mice which have approximately 50% less cellular ATP (Ahn et al., 2008). 
Cell survival: Sirt-3 mediated deacetylation is likely to influence cell survival by control of 
vital cellular processes including respiration (described above) and ROS scavenging. 
Sirt-3 increases the expression and enzymatic activity of MnSOD (Jacobs et al., 2008; 
Chen et al., 2011). Sirt-3 also deacetylates isocitrate dehydrogenase-2 (IDH2) to 
increase its activity, which as well as participating in the citric  acid cycle, is an important 
antioxidant regulator (Yu et al., 2012). The cumulative actions of enhanced antioxidant 
activity upon Sirt-3 deacetylation, reduces overall ROS levels and thus oxidative 
damage (see section 1.2). 
 
Table 1.3: Sirt-3 deacetylated proteins 
Summary of proteins deacetylated by Sirt-3; this is in no way an exhaustive list of target proteins 
however, attempts to encompass the principal effects of Sirt-3 activity and explain Sirt-3 knockout 
(-/-) phenotypes. References provided. (Table overleaf) 
 STUDY TARGET PROTEIN EFFECT OF DEACETYLATION RESULTANT PHENOTYPE IN SIRT3 -/- 
TRANSCRIPTION / PROTEIN MODIFICATION 
Jacobs et al. (2008) 
Kim et al. (2010) 
 
Foxo3a Increased DNA binding activity: 
 Increased MnSOD transcription  
(See effects of relevant target genes) 
RESPIRATION (OXIDATIVE PHOSPORYLATION / TCA CYCLE) 
Hirschey et al. (2010) Acetyl-CoA dehydrogenase 
 
Increased enzymatic activity 
 Increases fatty acid oxidation 
 
 Sirt-3 -/- exhibit blunted fatty acid oxidation 
Hallows et al. (2006) Acetyl-CoA synthase 2 
 
Activates enzymatic activity  Sirt-3 -/- exhibit blunted fatty acid oxidation 
Lombard et al. (2007) Glutamate dehydrogenase 
(GDH) 
 
Increased enzymatic activity 
 
 Sirt-3 -/- mice exhibit hyperacetylated GDH 
Schlicker et al. (2008) 
Yu et al. (2012) 
Isocitrate dehydrogenase-2 
(IDH2) 
Increased enzymatic activity 
By ≈44-fold (Yu et al., 2012) 
 Sirt-3 -/- mice exhibit increased SO recovered by 
IDH2 deacetylation (Yu et al., 2012) 
 
Ahn et al. (2008) Complex I: NDUFA9 
 
Increased enzymatic activity  Sirt-3 -/- show approximate 20% reduction in 
complex I activity (Ahn et al., 2008) 
 Sirt-3 -/- exhibit compromised ETC complex activity 
and thus impaired ATP production (≈50% lower 
ATP levels) (Ahn et al., 2008) 
 Sirt suppression decreases ATP F0F1 activity 
 
Cimen et al. (2010) 
Finley et al. (2011) 
Complex II: Succinate 
dehydrogenase A / B 
 
Increased enzymatic activity 
(Complex II activity unchanged in Sirt3 -/-) 
Finley et al. (2011) 
Wu et al. (2013) 
 
Complex V: F1α  
OSCP 
 
Increased enzymatic activity 
 Increased ATP synthesis 
CELL SURVIVAL 
Hafner et al. (2010) 
Shulga et al. (2010) 
Verma et al. (2013) 
 
Cyclophilin-D Inhibits Cyp-D PPIase activity 
 Reduces mPTP opening 
Dissociation of hexokinase II: 
 Stimulates OxPhos 
 Allows Bak/Bax apoptosis 
 
 Sirt-3 -/- mice: Cyp-D hyperacetylation and 
increased Cyp-D activity  
 Sirt-3 depletion reduced Bax mediated cell death 
(Verma et al., 2013) 
 
Chen et al. (2011) 
Tao et al. (2010) 
Jacobs et al. (2008) 
Ozden et al. (2011) 
Maganese superoxide 
dismutase (MnSOD) 
Activates enzymatic activity 
 Decreases mitochondrial ROS 
 
 Sirt-3 -/- liver mitochondria exhibit increased 
superoxide levels (Chen et al., 2011) 
 Sirt-3 mutant cells have less SO (Jacobs et al., 
2008) 
 
Pellegrini et al. (2012) Carbonic anhydrase (CA) 
 
Increases enzymatic activity 
 Prevents intracellular acidification 
 
 Sirt-3 silenced cells showed increased cellular 
acidification upon hypoxia 
 
Sundaresan et al. (2008) Ku70 
 
Increased Bax binding – less apoptosis 
 
 Sirt-3 overexpression reduced apoptosis 
Li et al. (2010) p53 
 
Partially inhibits cell growth arrest (Only examined in bladder cancer cell line) 
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Sirt-3 and mPTP opening: In addition to the effects of Sirt-3 on cell survival by 
regulation of respiration and ROS, Sirt-3 deacetylation may also affect cell survival by 
modulating mPTP opening. Recent studies have suggested that Sirt-3 deacetylation 
activity may control excessive mPTP opening due to its actions directly on Cyp-D and 
indirectly by its effects on reducing the intracellular conditions that favour mPTP 
opening. The potential regulatory actions identified to date are described below. 
Cyclophilin-D: Sirt-3 has been shown to deacetylate Cyp-D to reduce its PPIase activity 
and thus reduce mPTP opening (Shulga et al., 2010; Hafner et al., 2010). Hafner et al. 
(2010) identified Cyp-D lysine 166 as the target for Sirt-3 deacetylation and showed that 
aged (16 month old) Sirt-3 knockout animals were more prone to calcium-induced mPTP 
opening. Although there was no difference in cardiac function, when subjected to 
hypertrophic stress by transaortic constriction (TAC), Sirt-3 knockout mice were more 
susceptible to hypertrophy and impaired cardiac function (Hafner et al., 2010). Shulga et 
al. (2010) showed a similar effect upon Sirt-3 inhibition and demonstrated that Cyp-D 
deacetylation causes hexokinase II (HKII) dissociation from the mitochondrial membrane 
to stimulate oxidative phosphorylation (Shulga et al., 2010).  
F0F1 ATP synthase: Sirt-3 has been shown to directly interact with and deacetylate 
components of the F0F1 ATP synthase enzyme. Deacetylation of F0F1 ATP synthase 
significantly increases its enzymatic activity and thus increases ATP production (Finley 
et al., 2011; Wu et al., 2013). Given the recent studies by Bonora et al. (2013) and 
Giorgio et al. (2013) implicating the F0F1 ATP synthase as a constituent component of 
the mPTP, its regulation by Sirt-3 deacetylation poses the intriguing possibility that Sirt-3 
may affect mPTP formation; this is likely to form a focus for future studies. 
Reduced cellular triggers (ROS): Sirt-3 deacetylates several important ROS scavengers 
which increases their enzymatic activity to reduce overall ROS levels (as described 
above). This is particularly important since Sirt-3 deacetylation also increases ETC 
activity (Table 1.3) (Ahn et al., 2008; Finley et al., 2011; Wu et al., 2013), which would 
otherwise increase ROS levels and oxidative damage meaning that Sirt-3 may therefore 
indirectly reduce mPTP opening by reducing this important cellular trigger (see section 
1.2). However, it should be noted that Sirt-3 also influences pH by deacetylation of 
carbonic anhydrase (CA) which has a major role in control of intracellular pH, whereby 
deacetylation of CA increases its enzymatic activity and therefore reduces intracellular 
acidosis upon hypoxia (Pellegrini et al., 2012). The effect of CA activity on mitochondrial 
pH is not known, however, it is possible that decreased intracellular acidosis during 
ischaemia may reduce the knock-on effect of increased mitochondrial acidosis and 
calcium overloading by the pathway described in Figure 1.4. Reduced mitochondrial 
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acidosis during ischaemia may also remove the inhibitory effect of low pH during 
ischaemia which is expected to inhibit mPTP opening during this period. Although the 
precise balance of these factors on indirectly promoting or inhibiting mPTP opening has 
not been investigated, reduced Cyp-D PPIase activity due to Sirt-3 mediated 
deacetylation reduces calcium-induced mPTP opening (Hafner et al., 2010).  
Sirt-3 and apoptosis: Given the importance of mitochondria in mediating apoptosis, the 
role of Sirt-3 in regulating extrinsic apoptosis has been investigated. 
Ku70: Sirt-3 has been shown to deacetylate Ku70 (Sundaresan et al., 2008) which in its 
deacetylated form binds to and sequesters Bax to prevent its translocation to the 
mitochondria where it induces apoptosis. Cytosolic Ku70 has previously been identified 
as an important target protein of Sirt-1; however, in cardiomyocytes Sirt-1 was shown to 
be ineffective at deacetylating Ku70, where Sirt-3 was instead implicated in this role 
(Sundaresan et al., 2008) (Figure 1.15). This remains controversial since it suggests a 
role for Sirt-3 outside the mitochondria and may represent an artefact of the in vitro cell 
expression model used and therefore requires further investigation in an in vivo setting.   
p53: Sirt-3 also interacts with and deacetylates p53, a protein involved in regulating cell 
growth arrest and senescence by its actions in both the nucleus and mitochondria. Sirt-3 
deacetylation of mitochondrial p53 partly abolishes its cell senescent activity to promote 
cell survival (Li et al., 2010) (Figure 1.15). However, this has only been investigated in a 
cancer cell line to date and it is therefore not clear whether Sirt-3-p53 regulation is 
important in normal cells and pathological settings such as ischaemia-reperfusion injury. 
Hexokinase II: Sirt3 deacetylation of Cyp-D also results in dissociation of hexokinase II 
(HKII) from the outer mitochondria membrane. This was reported to be beneficial for cell 
survival since it stimulates oxidative phosphorylation (Shulga et al., 2010), described 
above. However, since binding of HKII to the outer mitochondrial membrane promotes 
membrane integrity, its dissociation upon Cyp-D deacetylation therefore allows Bak/Bax 
to disrupt the membrane to induce apoptosis. This has been demonstrated in human 
epithelioid cervix carcinoma (HeLa) cells where Sirt-3 deacetylation of Cyp-D and 
consequent HKII dissociation promoted apoptotic cell death (Verma et al., 2013). It has 
therefore been suggested that Sirt-3 deacetylation may actually promote cell death in 
certain settings. However, increased sequestration of Bax by deacetylated Ku70 may 
mitigate the susceptibility to Bax-mediated apoptosis upon HKII dissociation. Detailed 
investigations of the interplay between these death pathways are required in non-cancer 
cells to fully understand the effects of Sirt-3 activity on cell survival. 
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In summary, the precise effects of Sirt-3 deacetylase activity on cell survival are likely to 
depend on the cellular conditions and severity of stress which may dictate which cellular 
pathways prevail and determine cell fate. A summary of the potential effects of Sirt-3 on 
cell survival is provided in Figure 1.15 (where putative interactions are indicated in grey). 
 
Figure 1.15: Putative effects of Sirt-3 mediated deacetylation upon cellular stress 
Cell stress upregulates Sirt-3 deacetylation of a number of target proteins which affects their 
activity to influence important mediators of cell death including mPTP opening and putative 
effects on extrinsic apoptosis. Constructed from information provided by Sack et al. (2011). 
 
Baseline phenotype of Sirt-3 knockout mice: Given the diverse targets of Sirt-3 
deacetylation, it is intriguing that total Sirt-3 genetic ablation does not elicit any gross 
phenotypic abnormalities; Sirt-3 KO mice display no difference in oxygen consumption, 
physical activity or cell growth (Lombard et al., 2007) despite 50% less cellular ATP 
(Ahn et al., 2008). However, Sirt-3 KO mice show widespread protein hyperacetylation 
which is further enhanced upon cellular stress (Fritz et al., 2012; Rardin et al., 2013). 
The role of Sirt-3 appears to be more prominent under stress conditions, likely due its 
dependence on NAD+ activation. Indeed, Sirt-3 KO mice develop overt phenotypic 
differences upon hypertrophic stress and aging (Hafner et al., 2010). 
The experimental evidence to date suggests that Sirt-3 plays an important role in 
modifying mitochondrial metabolism and function in conditions of cellular stress. 
Myocardial ischaemia-reperfusion is known to elicit significant cardiomyocyte metabolic 
stress and cellular injury; however, the role of Sirt-3 deacetylase activity in this setting is 
largely unknown. It remains to be seen whether acutely increased Sirt-3 activity could 
provide a target to reduce myocardial infarction; this is investigated in chapter 6.  
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1.4.3. Mitochondrial oxidative stress and DJ-1 
Oxidative stress is a critical mediator of cellular injury and has been implicated in a 
number of pathologies, including ischaemia-reperfusion injury (described in section 1.2). 
Under physiological conditions, mitochondrial respiration produces ROS which are 
usually scavenged by the many anti-oxidant and detoxification proteins. However, under 
pathological conditions, ROS rapidly accumulate and cause oxidative damage to 
mitochondria and wider cellular components, notably the lipid membranes (Anderson et 
al., 2012). Since oxidative damage is a key mediator of cardiomyocyte death following 
ischaemia-reperfusion, methods of reducing oxidative stress provide an important 
potential method to protect against ischaemia-reperfusion (Hoffman et al., 2004). 
i Oxidative stress and mitochondrial function 
Although ROS are known to be important cellular messengers, the effect of ROS 
accumulation caused by cellular insults such as ischaemia-reperfusion has been 
identified as a key factor in cell injury and death in these pathological conditions 
(Hoffman et al., 2004). The intracellular redox state is determined by the balance of 
oxidants (such as ROS) and antioxidants (such as enzymatic ROS scavengers) (Katz, 
2001). Oxidants are produced in part as a by-product of mitochondrial oxidative 
phosphorylation which means that cells with a high metabolic demand, such as 
cardiomyocytes, are suggested to be at greater risk of redox imbalance upon stress 
(Jezek and Hlavata, 2005; Anderson et al., 2012).  
Under physiological conditions, the cellular redox state is maintained by an array of 
homeostatic mechanisms, however, stress, such as myocardial ischaemia-reperfusion, 
disrupts the balance of ROS. The sequelae of events occurring upon myocardial 
ischaemia and reperfusion are outlined in section 1.2. The propagating nature of ROS 
accumulation following ischaemia-reperfusion is a key mediator of oxidative damage, 
whereby the initial increase in ROS further damages mitochondrial proteins which 
causes further ROS accumulation and oxidative damage (see 1.2.3) (Forman et al., 
1989; Katz, 2001). Membrane lipid peroxidation is recognised as a major manifestation 
of oxidative damage resulting from ischaemia-reperfusion where ROS interact with the 
fatty acid side chains of membrane phospholipid proteins to produce lipid peroxidation 
products. Lipid peroxidation itself causes decreased membrane fluidity and increased 
membrane permeability which in turn contribute to mitochondrial dysfunction and cell 
death (Forman et al., 1989; reivewed by Anderson et al., 2012). In addition, the products 
of lipid peroxidation, for example reactive aldehydes, are also potent mediators of 
cellular oxidative damage. These lipid peroxidation products damage cellular proteins 
and nuclei acids including DNA and RNA (reviewed by Anderson et al., 2012). 
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Mitochondria possess an array of antioxidant proteins which are upregulated upon 
cellular oxidative stress. However, oxidative stress is also an important cell signalling 
method, where protein oxidation is a recognised post-translational modification (Shao et 
al., 2012). Since oxidative stress is highly regulated under physiological conditions and 
is a key mediator of mitochondrial dysfunction and cell death in many pathophysiological 
conditions, understanding the regulation of oxidative stress and its signalling effects may 
identify novel targets for protecting against ischaemia-reperfusion. 
ii DJ-1 as a sensor of oxidative stress 
Since mitochondria are regarded as the primary source of ROS under physiological and 
pathophysiology conditions, identification of mitochondrial proteins involved in regulating 
ROS directly by ROS scavenging or indirectly by sensing ROS to mediate wider 
responses, provides interesting scope for future potential targets for cardioprotection.   
DJ-1 has recently been identified as an important stress response protein with purported 
roles in defending cells against ROS and mitochondrial damage. DJ-1 has been 
implicated in a diverse array of pathologies including multiple cancers, Parkinson’s 
disease and cerebral ischaemia-reperfusion injury (reviewed by Cookson, 2010; Wilson, 
2011). Although the precise functions of DJ-1 at baseline and under stress remain 
poorly defined, its apparent involvement as an oxidative stress response protein makes 
it a potential target for modulating cell stress and ultimately cell death. 
DJ-1 protein family: DJ-1 is a member of the DJ-1/ PfpI superfamily of proteins for 
which DJ-1 homologs have been identified across all biological kingdoms. DJ-1 shares 
some homology to the bacterial cysteine protease enzyme PfpI, although the biological 
roles of DJ-1 are thought to extend beyond protease activity. DJ-1 has been investigated 
in Parkinson’s disease where DJ-1 mutations have been implicated in rare heritable 
forms of this disease (reviewed by Wilson, 2011). The precise functions of DJ-1 remain 
elusive; an overview of its structure, regulation and proposed functions is provided here. 
DJ-1 protein: DJ-1 is ubiquitously expressed in a number of human tissues, including 
the heart. DJ-1 is a small nuclear encoded protein of 189 amino acids (c. 20 kDa) which 
is encoded in humans by the PARK7 gene (overview of protein provided by Wilson, 
2011). The crystal structure of the DJ-1 protein was independently solved by five 
research groups which all showed that DJ-1 functions as a homodimer. These studies 
showed that the DJ-1 tertiary protein structure shares some homology to known cellular 
cysteine proteases and has an additional α-helix in the C-terminal region (Wilson et al., 
2003; Honbou et al., 2003; Lee et al., 2003; Tao and Tong, 2003; Huai et al., 2003). This 
additional α-helix was suggested to block the catalytic site of the protein and was 
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therefore identified as a putative regulatory site (Honbou et al., 2003; Tao and Tong, 
2003; Wilson et al., 2003). Importantly, a conserved cysteine residue (Cys106) in this 
region was shown to be critical for regulation of DJ-1 activity (Wilson et al., 2003); 
described in detail below. Dimerisation of DJ-1 was also shown to be critical for its 
activity where mutation of a conserved leucine residue (Leu166) located in the C-
terminal α-helix impedes dimer formation (Huai et al., 2003; Tao and Tong, 2003; 
Olzmann et al., 2004) and results in poor DJ-1 protein folding and degradation. 
Under normal cellular conditions DJ-1 protein is mainly located in the cytosol and to a 
lesser extent in the nucleus; however, cellular stress causes mitochondrial enrichment of 
DJ-1 by increased DJ-1 protein expression and translocation of cytosolic DJ-1 to the 
mitochondria (Canet-Aviles et al., 2004; Blackinton et al., 2005; Lev et al., 2008). 
Specifically, its conserved Cys106 residue is crucial for mitochondrial enrichment of DJ-
1 upon oxidative stress (reviewed by Wilson, 2011); discussed further below. 
Regulation of DJ-1 activity by cysteine oxidation: Cysteine oxidation of DJ-1 is a 
crucial regulatory mechanism serving to increase DJ-1 mitochondrial enrichment and 
activity upon oxidative stress. Although oxidation of proteins can be considered as a 
form of damage, it has also been proposed as an important post-translational 
modification in response to oxidative stress (reviewed by Wilson, 2011).  
DJ-1 contains three potential targets for cysteine oxidative regulation (Cys-46, -53 and -
106), of which Cys106 is the most highly conserved and has been strongly implicated in 
regulation of DJ-1 activity (Wilson, 2011). Potent oxidants cause oxidation of the 
cysteine thiol group to produce cysteine sulfinite (Cys-SO2
–
) or cysteine sulfonate (Cys-
SO3
–
) (Figure 1.16). Cysteine oxidation of DJ-1 therefore produces a more acidic 
isoform of DJ-1 (Mitsumoto et al., 2001). Cysteine sulfonate is the highest oxidised form 
and is considered to be an irreversible modification (Shao et al., 2012). 
Oxidation of DJ-1 Cys106 to cysteine sulfinate has been confirmed by biochemical and 
structural studies of DJ-1 under baseline and oxidative stress conditions. It should be 
noted that although mass spectrometry analysis demonstrated formation of DJ-1 
cysteine sulfonate upon oxidative stress, this has yet to be confirmed by crystal structure 
analysis (reviewed by Wilson, 2011). It has been postulated that DJ-1 cysteine sulfonate 
formation may destabilise and inactivate DJ-1 and coincide with apoptosis (Zhou et al., 
2006). It appears that the extent of DJ-1 oxidation may therefore determine the 
beneficial roles of DJ-1 in protecting against oxidative stress. This is supported by the 
cytoprotective effects of small molecule compounds that allow DJ-1 oxidation to cysteine 
sulfinate but not cysteine sulfonate (Miyazaki et al., 2008; Yanagida et al., 2009). 
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Figure 1.16: Modification of DJ-1 by cysteine oxidation 
The cysteine thiol group can be oxidised to produce cysteine sulfinate or cysteine sulfonate. 
Constructed from information provided by Wilson (2011) and Shao et al. (2012). 
 
Cysteine residues -46 and -53 have also been implicated in DJ-1 regulation by affecting 
Cys-106 oxidation capacity (Shendelman et al., 2004; Waak et al., 2009a); although 
these cysteine residues have been less well studied (reviewed by Wilson, 2011).  
Although oxidation of cysteine residues to cysteine sulfinate (but not cysteine sulfonate) 
is theoretically chemically reversible (Shao et al., 2012), Duan et al. (2008) showed slow 
recovery of reduced DJ-1 protein levels following oxidative stress in vitro. In addition, 
since cyclohexamine (a protein synthesis inhibitor) inhibited the recovery of reduced DJ-
1, it has been suggested that oxidation of DJ-1 is essentially irreversible and requires de 
novo protein synthesis (Duan et al., 2008). Further studies are now required to confirm 
the processes of DJ-1 protein regulation and turnover in vivo following oxidative stress. 
The precise method of regulation of DJ-1 by cysteine oxidation has not been elucidated. 
Studies of other proteins have suggested that in some cases formation of cysteine 
sulfinate causes a conformation change in protein structure which modulates protein 
function (Shao et al., 2012). However, formation of cysteine sulfinate does not appear to 
cause conformational changes to DJ-1 (Canet-Aviles et al., 2004; Zhou et al., 2006).  
Despite the unknown mechanism of regulation of DJ-1 by cysteine oxidation, several 
studies have confirmed the requirement for Cys106 oxidation for enhancing DJ-1 activity 
and translocation and conferring its protection against cell death (reviewed by Cookson, 
2010; Wilson, 2011). Canet-Aviles et al. (2004) showed that mutation of Cys106 to 
alanine (C106A mutant) inhibited DJ-1 translocation to the mitochondria and abrogated 
its protective effect against cell death (Canet-Aviles et al., 2004). Further to this, 
Blackinton et al. (2009b) demonstrated that oxidation, specifically of Cys106, is crucial 
for mitochondrial localisation of DJ-1 in response to cellular stress (Blackinton et al., 
2009b). These studies support the role of DJ-1 as an oxidative stress sensor and 
suggest that cysteine oxidation is an important post-translational modification of DJ-1. 
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iii Physiological and pathophysiological roles of DJ-1 
The precise roles of DJ-1 under physiological and pathophysiological conditions remain 
the subject of intensive research. The requirement for DJ-1 cysteine oxidation (at 
Cys106) for its protective function suggests that DJ-1 has a role in responding to cellular 
oxidative stress. DJ-1 has been implicated in multiple cell survival pathways and the 
main putative roles for DJ-1 are described below: 
ROS scavenger: Given the importance of cysteine oxidation of DJ-1 for mitochondrial 
translocation and increased activity, DJ-1 has been proposed to act directly as a ROS 
scavenger. Indeed, oxidation of DJ-1 necessarily consumes ROS (Wilson, 2011; Shao 
et al., 2012). However, the physiological relevance of direct ROS scavenging by DJ-1 is 
questioned by the relatively low capacity of DJ-1 to accept unpaired electrons and the 
partly irreversible nature of DJ-1 cysteine oxidation (Wilson, 2011). Further investigation 
of the direct ROS scavenging capabilities of DJ-1 is now required. The overall effect of 
DJ-1 function on reducing ROS levels upon oxidative stress has been confirmed by 
increased ROS levels in vivo in DJ-1 KO mice (Andres-Mateos et al., 2007). 
Protease: Resolution of the crystal structure of DJ-1 showed some homology with 
members of the intracellular protease PfipI family (Honbou et al., 2003; Huai et al., 
2003) which led to the suggestion that DJ-1 may function as a protease. Some studies 
have demonstrated that DJ-1 possess weak protease activity (Olzmann et al., 2004; 
Chen et al., 2010). However, it is now largely accepted that DJ-1 exerts minimal 
protease activity and this is unlikely to be a critical role of DJ-1. This is also supported by 
the absence of the conserved PfipI Cys-His-Glu catalytic site (Honbou et al., 2003; Huai 
et al., 2003; Wilson et al., 2003). It has been suggested that DJ-1 may indirectly induce 
protease activity upon cellular stress by regulating a protease enzyme (Wilson, 2011). 
Protein chaperone: DJ-1 was first proposed to undertake putative protein chaperone 
roles based on the structural similarity of DJ-1 to the known chaperone HSP-31 (Lee et 
al., 2003). Shendelman et al. (2004) provided some experimental evidence that DJ-1 
may function as a redox-sensitive chaperone in in vitro assays of protein chaperone 
activity. Interestingly, L166P mutated DJ-1 protein did not possess chaperone activity in 
this study which was interpreted as confirmation of the putative chaperone role of DJ-1 
(Shendelman et al., 2004). However, a similar in vitro study by Olzmann et al. (2004) 
showed that DJ-1 did not mediate any significant chaperone activity (Olzmann et al., 
2004). It is important to note that these in vitro chaperone activity assays may be subject 
to artefacts from the assay conditions and high levels of DJ-1 expression and thus may 
not reveal roles of DJ-1 under specific cellular conditions (reviewed by Wilson, 2011). 
The biological significance of DJ-1 chaperone activity therefore remains unclear. 
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Transcriptional regulator: DJ-1 has been suggested to regulate the transcription of a 
number of proteins and this has been proposed as the mechanism by which it is able to 
affect the diverse multitude of cellular pathways described in the various in vitro and in 
vivo models (van der Brug et al., 2008; reviewed by Wilson, 2011). Cookson’s group 
proposed a model whereby DJ-1 binds to mRNA at nanomolar concentrations to slow 
translation and then dissociates from its mRNA targets upon oxidative stress to allow 
their efficient translation (van der Brug et al., 2008; Blackinton et al., 2009a). The direct 
role of DJ-1 as a transcriptional regulator however, requires further investigation of the 
precise mechanism by which DJ-1 is able to bind to mRNA since it lacks canonical RNA 
interaction motifs (van der Brug et al., 2008). The putative role of DJ-1 as a 
transcriptional regulator may explain the involvement of DJ-1 in modulating apoptotic 
cell death, although these actions may instead be mediated by indirect actions of DJ-1. 
Apoptosis: DJ-1 has been shown to interact with and negatively regulate several critical 
mediators of cell death to promote cell survival upon cellular stress (Wilson, 2011). 
PTEN/PI3K/Akt: DJ-1 directly interacts with phosphatase and tensin homolog (PTEN) to 
negatively regulate the P13K/Akt survival pathway (Kim et al., 2005a). PTEN is a pro-
apoptotic phosphatase which antagonises the PI3K cell survival pathway resulting in 
reduced Akt phosphorylation and worsened cell survival upon cellular stress (reviewed 
by Mocanu and Yellon, 2007). DJ-1 inhibition of PTEN therefore causes increased PI3K 
and Akt phosphorylation and improved cell survival (Kim et al., 2005a). This DJ-1-PTEN 
interaction is also dependent on DJ-1 Cys106 oxidation (Kim et al., 2009). Although the 
biochemical nature of this DJ-1-PTEN interaction is unclear, the role of DJ-1 activity in 
enhancing PI3K/Akt pro-survival signalling has been implicated as an important 
protective response to oxidative stress (Kim et al., 2009; reviewed by Wilson, 2011). 
p53: DJ-1 has also been shown to negatively regulate p53, an important tumour 
suppressor protein which is involved in transcriptional regulation of a number of proteins 
and can initiate apoptosis. Bretaud et al. (2007) showed that manipulation of DJ-1 
expression levels in a zebrafish model showed concurrent changes to p53 levels and 
neuronal cell death (Bretaud et al., 2007). Further to this Fan et al. (2008b) showed that 
DJ-1 mediated inhibition of p53 activity causes decreased Bax expression and thus 
reduced caspase activation (Fan et al., 2008b). This group also suggested that DJ-1 
sumoylation may be critical for its regulation of p53 activity (Fan et al., 2008a); although 
the precise roles of DJ-1 sumoylation have not been widely investigated. DJ-1 regulation 
of p53 activity and its subsequent effects on Bax-mediated cell death appears to be an 
important cytoprotective mechanism of DJ-1 activation in response to oxidative stress. 
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ASK1/p38/MAPK: DJ-1 activation has also been implicated in preventing Daxx/ASK1 
mediated apoptosis by binding to death-domain associated protein (Daxx; a pro-
apoptotic protein) to prevent its activation of apoptosis signal-regulating kinase 1 (ASK1) 
(Junn et al., 2005). Subsequent studies have shown direct interaction between DJ-1 and 
ASK1 (Waak et al., 2009a; Mo et al., 2010). These studies confirm further involvement 
of DJ-1 in reducing cell death and infer a cytoplasmic role for DJ-1. It is now widely 
accepted that DJ-1 activation reduces cell death from oxidative stress. 
 
Genetic manipulation of DJ-1: As with many basic science studies, genetic 
manipulation provides an invaluable tool for investigating the roles of a specific protein 
both in vitro and in vivo. Many in vitro cell expression models have been used to assess 
the effect of overexpression of DJ-1 on important cell survival endpoints. Expression of 
mutant forms of DJ-1 has also provided insights into the importance of DJ-1 regulation 
by cysteine oxidation (reviewed by Wilson, 2011); this is discussed further in chapter 7. 
Genetic knockout: The generation of DJ-1 genetic knockout mice has also led to a 
wealth of understanding of the roles of DJ-1 at baseline and following oxidative stress. 
The majority of studies of DJ-1 knockout mice have examined its effects on the brain. A 
summary of the main effects of genetic ablation of DJ-1 is provided above in Table 1.4. 
 
 
 
 
 
 
 
 
 
 
Table 1.4: Effects of genetic ablation of DJ-1 
Effects of whole body total ablation of DJ-1 (KO). This is in no way an exhaustive list of studies of 
genetic ablation of DJ-1 and attempts to encompass the principal effects of DJ-1 KO. A summary 
of in vitro studies is not provided here as an overview of these studies is provided in the main text 
in the description of the structure and regulation of DJ-1. References provided. (Table overleaf) 
 STUDY BASELINE MEASURE / STRESSOR EFFECT IN DJ-1 KNOCKOUT 
CULTURED MOUSE EMBRYONIC FIBROBLASTS 
Giaime et al. (2012) Baseline phenotype 
 
 Reduced mitochondrial membrane potential 
 Increased mPTP opening 
 Increased ROS production 
 Reduced ATP levels 
 No effect on mitochondrial respiration or calcium 
 
Krebiehl et al. (2010) Baseline phenotype  Reduced mitochondrial membrane potential 
 Increased ROS production 
 Impaired mitochondrial respiration 
 Accumulation of defective mitochondria 
 Reduced basal autophagy 
 
Irrcher et al. (2010) 
 
Baseline phenotype  Increased mitochondrial fragmentation 
PRIMARY EX VIVO PREPARATIONS 
Irrcher et al. (2010) 
 
 
Isolated mitochondria - Baseline phenotype  Increased ROS levels 
 Increased mitochondrial fragmentation 
 
Waak et al. (2009b)  
 
 
Isolated astrocytes - Lipopolysaccharide (LPS) stress 
 
 Increased pro-inflammatory mediators; COX-2 and IL-6 
 Increased nitric oxide (NO) by approximately 10-fold 
 
Aleyasin et al. (2007) Granule neurones - Glutamate excitotoxicity (ROS)  Increased cell death 
 
Andres-Mateos et al. (2007) 
 
Brain mitochondria - Rotenone induced stress  Increased hydrogen peroxide levels 
Kim et al. (2005b) 
 
Embryonic cortical neurones – H2O2 treatment (30 µM)  Increased cell death 
Martinat et al. (2004) 
 
 
Cultured embryonic stem cells - H2O2 treatment 
(increasing concentrations) 
 Increased cell death 
 No difference in ROS levels 
 
IN VIVO 
Billia et al. (2013) Myocardial infarction (Permanent LAD ligation) 
 
 Increased myocardial infarct size 
Billia et al. (2013) Cardiac failure model of transaortic constriction (TAC) 
 
 Increased susceptibility to hypertrophy and cardiac failure  
 Increased indicators of lipid peroxidation (4-HAE and MDA) 
 Decreased ATP levels 
 
Lev et al. (2013) Parkinson’s disease model 6-hydroxydopamine (6-
OHDA). 
 
 Increased vulnerability to neuronal cell death 
 Lower expression of cell survival proteins; principally Nrf2 
 
Aleyasin et al. (2007) 
 
Cerebral focal ischaemia induced by endothelin-1   Increased cerebral infarct size (approx. 4-fold increase) 
 
Aleyasin et al. (2007) 
 
Cardiac failure model of TAC 
 
 Increased susceptibility to hypertrophy and cardiac failure 
 Increased oxidative damage to DNA 
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Pharmacological modulation of DJ-1: Pharmacological methods of increasing DJ-1 
protein expression and activity have been investigated as potential therapeutic targets.  
Small molecule regulators of DJ-1 oxidation: Miyazaki et al. (2008) undertook a screen 
of small molecule compounds which bind to the Cys106 region of DJ-1 to permit its 
oxidation to cysteine sulfinate but not cysteine sulfonate. Administration of these 
compounds was shown to reduce cell death in a drug-induced model of Parkinson’s 
disease cell death suggesting that prevention of maximal oxidation of DJ-1 to prolong 
DJ-1 activation under oxidative stress may provide therapeutic benefit (Miyazaki et al., 
2008). Further investigation of one of these, UCP0054278, showed a reduction in 
neuronal cell death in a cerebral ischaemia-reperfusion model (Yanagida et al., 2009). 
Sodium phenylbutyrate: Several in vitro and in vivo studies have shown that treatment 
with sodium phenylbutyrate increases DJ-1 protein levels in neuronal cells and that this 
causes significant protection against oxidative-induced cell death (Zhou et al., 2011). 
However, sodium phenylbutyrate is not a selective pharmacological compound and is 
likely to exert other effects independent of DJ-1, indeed this compound is widely used as 
a histone deacetylase (HDAC) inhibitor (reviewed by Iannitti and Palmieri, 2011). 
 
Although modulation of DJ-1 has been examined for potential therapeutic benefit in a 
number of pathologies, including cerebral ischaemia-reperfusion, its role in the heart 
remains largely unknown. The potential for modulation of DJ-1 as a therapeutic target to 
protect against myocardial ischaemia-reperfusion injury is investigated in chapter 7.  
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1.5. The future of cardioprotection 
Cardioprotection has been an intense focus for basic science and clinical research for a 
number of decades, particularly following the first demonstration of significant protection 
against myocardial ischaemia-reperfusion injury by IPC in 1986 (Murry et al., 1986). 
However, despite numerous mechanical and pharmacological strategies showing 
promising reductions in infarct size pre-clinically in animal models, translation of these 
interventions to the clinical setting has proved incredibly poor (reviewed by Dirksen et 
al., 2007; Hausenloy et al., 2010). Although clinical translation is challenging in most 
fields of research, this appears to have been particularly severe for cardioprotection 
studies. Indeed, reperfusion therapy remains the only effective clinical intervention for 
reducing infarct size in acute myocardial infarction patients and there is currently no 
therapy for lethal reperfusion injury (Yellon and Hausenloy, 2007; Heusch, 2013). 
Future studies of cardioprotection must attempt to address the shortcomings of previous 
experimental pursuits that may have contributed to their poor clinical translation. 
1.5.1. Obstacles to clinical translation 
The causes of poor clinical translation have been the subject of intense discussion 
within the field of cardiovascular research, leading to the publication of a number 
thought-provoking review articles on the subject by eminent researchers in the field 
(Kloner and Rezkalla, 2004; Hausenloy et al., 2010; Heusch, 2013). There appears to 
be good consensus of the principal obstacles to clinical translation concerning the 
design of animal models and notable differences compared to the clinical situation; 
indeed these same considerations are likely to apply to basic science studies in many 
research areas (Bolli et al., 2004). An overview of the main potential shortcomings of 
current research efforts into acute myocardial infarction is provided below and discussed 
subsequently in relation to the aims of this thesis.  
i Experimental models 
As with any pre-clinical research, experimental models emulating the pathology of 
interest are required to investigate, develop and refine potential interventions prior to 
their clinical application. A number of models of ischaemia-reperfusion injury have been 
developed and employed to investigate the mechanisms of ischaemia-reperfusion and 
efficacy of potential therapeutic interventions. This thesis will not examine in vitro 
models of ischaemia-reperfusion since these are employed mainly for the dissection of 
molecular pathways and interactions but will instead focus on the merits and limitations 
of current in vivo models and their relevance for clinical translation. 
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Good scientific practice requires the research model best represent the clinical situation 
and yet also controls possible experimental variables between subjects. Unfortunately 
this has often led to very simplified models of pathology. Pre-clinical studies are often 
only undertaken using young, male and otherwise healthy animals where the pathology 
of interest is initiated with a defined onset and severity. The potential effects of this for 
subsequent clinical translation are discussed below for acute myocardial infarction. 
Gender: Epidemiological studies have highlighted the increased risk of cardiovascular 
disease in males suggesting that there is some inherent physiological difference in 
susceptibility to myocardial infarction. The majority of basic science research models 
utilise only male animals in efforts to reduce potential variables between study subjects, 
although clinical trials of potential cardioprotective therapies are necessarily conducted 
on mixed gender cohorts (reviewed by Bolli et al., 2004; Miura and Miki, 2008).  
The potential effects of this bias of male subjects in the study of ischaemia-reperfusion 
injury are highlighted by studies comparing susceptibility to infarction between male and 
female animals where it has been demonstrated that females exhibit significantly lower 
occurrence of arrhythmias (Humphreys et al., 1999), improved functional recovery and 
reduced infarct sizes compared to their male counterparts (Song et al., 2003; Wang et 
al., 2005). Furthermore, young female mice have been shown to be more resistant to 
IPC and there is evidence to suggest that these sex differences may in part be due to 
increased Akt phosphorylation in females (Camper-Kirby et al., 2001; Turcato et al., 
2006). Indeed, this increased Akt phosphorylation has been confirmed in human post-
mortem myocardial samples (Camper-Kirby et al., 2001). It may be useful to use mixed 
sex groups with sufficient sample sizes to compare cardioprotection between sexes. 
Co-morbidities and age: Acute myocardial infarction patients are often aged and 
present with comorbidities such as diabetes, hypercholesterolemia and hypertension 
and yet the majority of experimental studies utilise young otherwise healthy animals 
(reviewed by Bolli et al., 2004; Miura and Miki, 2008). This is particularly important since 
a number of co-morbidities cause altered pro-survival signalling, for example the PI3K-
Akt signalling pathway is perturbed in the diabetic rat heart (Tsang et al., 2005).  
A further effect of comorbidities is that acute myocardial infarction patients often have a 
background of long-term pharmacological treatment, for example with anti-diabetic or 
anti-hypertension agents. The potential effect of background of drug therapy was 
stressed by Ferdinandy et al. (2007) who highlighted the potential confounding effects of 
‘poly-pharmacology’ and comorbidities on the response to ischaemia-reperfusion and 
cardioprotective therapies (Ferdinandy et al., 2007).  
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An exhaustive review of the effects of gender, comorbidities (including age) and 
concomitant drug therapies is beyond the scope of this thesis. However, the potential 
effects of these often neglected clinical variables may account in part for the poor clinical 
translation of cardioprotection research and should be considered when interpreting the 
results of basic science research models where these variables are not included. 
ii Experimental endpoints 
Further to concerns over the simplification of experimental models compared to the 
clinical setting, the focus and clinical relevance of endpoints for assessing efficacy are 
important potential factors affecting clinical translation of basic science research. 
The majority of basic science cardioprotection studies use histological measurement of 
infarct size as the primary endpoint to assess cardioprotective efficacy. Infarct size is 
considered to be an important predictor of the long-term prognosis of acute myocardial 
infarction patients, as first formally demonstrated by Sobel et al. (1972) by correlation of 
serial serum creatine kinase (CK) levels with cardiac complications and long-term 
patient survival (Sobel et al., 1972). Given the prognostic value of infarct size, it is 
expected that histological assessment of infarct size in basic science studies should 
provide a good indicator of cardioprotective efficacy with some further considerations. 
Time-points of infarct size assessment: Many basic science experiments measure 
infarct size at a single time-point and often following only a relatively short reperfusion 
duration. It is not clear whether infarct size at reperfusion durations as short as 2 hours 
correlates well with long-term infarct size and cardioprotection (Bolli et al., 2004). This is 
a potential factor affecting poor clinical correlation since clinical studies often use serial 
assessments of serum enzymes to assess infarct size (Thygesen et al., 2007). 
Crucially, reductions in infarct size observed at short periods of reperfusion may not 
represent a true cardioprotective effect but may instead represent a temporary delay in 
infarct development and not an ultimate decrease in final infarct size (Kloner, 1993). 
This has been reported for platelet-activating factor (PAF) receptor antagonists which 
significantly reduced infarct size at 3 hours reperfusion but not at 6 hours reperfusion 
suggesting that PAF receptor antagonists delay but do not ultimately reduce infarct size 
in dog hearts (reviewed by Black and Rodger, 1996). 
The duration of reperfusion at which infarct size is examined at may also reflect 
differences in infarct size limiting effects and long-term remodelling effects meaning that 
it is therefore pertinent that basic science studies of cardioprotection examine infarct 
size at reperfusion durations which are closely matched to meaningful clinical correlates. 
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Clinical correlates: Clinically, blood serum levels of cardiac enzymes are used as an 
important predictor of infarct size. However, small animal studies rely on histological 
measures of infarct size and rarely measure cardiac enzyme levels; this difference in 
endpoints of injury may affect the cardioprotective efficacy viewed between these 
studies and may therefore contribute to poor clinical translation (Miura and Miki, 2008).  
It would be beneficial for pre-clinical and clinical studies to employ similar methods for 
determining primary endpoints, although this has been complicated by technical issues 
with repeated blood sampling of small animals and direct infarct size assessment in 
patients. Recent advances in pre-clinical and clinical imaging may ameliorate these 
differences in clinical correlates by enabling increasingly accurate in vivo measurements 
of infarct size (Thygesen et al., 2007); discussed in detail subsequently (see 1.5.2). 
Myocardial salvage: Although imaging techniques permit in vivo assessment of 
myocardial infarct size and therefore longitudinal tracking of infarct size over prolonged 
reperfusion durations, these studies do not yet allow assessment of myocardial salvage. 
Myocardial salvage considers the area of ischaemic myocardium, termed the ‘area-at-
risk’ (AAR) and therefore provides a more robust evaluation of the extent of protection 
(Reimer et al., 1977). However, current in vivo AAR measurements have not been fully 
validated and are often not undertaken in clinical assessments of infarct size. Since AAR 
is a strong determinant of final infarct size and is highly variable in patients, failure to 
consider AAR reduces the statistical power and thus ability to detect significant 
protection (reviewed by Miura and Miki, 2008). 
Since clinical trials of potentially cardioprotective interventions often do not consider 
myocardial AAR when reporting infarct size as an endpoint, it is possible that the 
statistical power of these trials is insufficient to detect changes in absolute infarct size. 
This is beginning to be addressed in both pre-clinical and clinical studies by the use of 
novel in vivo imaging methods; this is discussed below and investigated in this thesis. 
 
Although it is not feasible for each cardioprotection study to address all of the concerns 
of experimental design that may contribute to poor translation of pre-clinical research, it 
is advisable that the potential limitations of basic science studies are evaluated for the 
interpretation results. This thesis will investigate the use of longitudinal endpoints to 
assess cardioprotective efficacy of the mitochondrial targets described above (see 1.4).  
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1.5.2. Magnetic resonance imaging for evaluating cardioprotection 
Magnetic resonance imaging (MRI) is a valuable, non-invasive imaging modality with 
significant potential for pre-clinical and clinical evaluation of cardiac function and infarct 
size in the setting of acute myocardial infarction (Thygesen et al., 2007).  
i Basic overview of MRI 
MRI provides an in vivo method to interrogate the characteristics of tissues within the 
body, including the heart, by exploiting its inherent physical properties and the effects of 
paramagnetic contrast agents on this. An in-depth discussion of the physical basis of 
MRI is beyond the scope of this thesis however, the specific MRI techniques employed 
in this thesis are described in detail in chapter 3. Briefly, a high strength magnetic field 
causes the natural proton spins of hydrogen atoms within the tissues to align in the 
direction of the magnetic field. Radiofrequency (RF) energy is then applied in short 
pulses which temporarily excite the proton spins away from the magnetic field direction. 
Between RF pulses, the protons release this energy and return to directional alignment 
with the magnetic field. The energy dissipated upon relaxation of the proton spins is 
recorded by array coils and is defined by two parameters: T1 and T2 which are 
characteristic of the tissue interrogated and the presence of any contrast agents 
(McRobbie et al., 2006; Edwards et al., 2009). 
T1 relaxation time: also termed spin-lattice relaxation time; this describes the rate 
constant of time taken for proton spins to realign with the main magnetic field and is 
greatest in water based tissues which appear dark on T1-weighted MRI. 
T2-relaxation time: also termed spin-spin relaxation time; this describes the rate constant 
of time taken for proton spins to loose synchronicity with each other (i.e. become out of 
phase) and is greatest in water based tissues which appear bright on T2-weighted MRI. 
Since tissues vary in their inherent T1- and T2-relaxation characteristics, MRI allows 
interrogation of specific tissue characteristics and potential pathological changes. 
Contrast agents that specifically affect relaxation characteristics can provide further 
characterisation of tissues (McRobbie et al., 2006; Edwards et al., 2009). 
Given its non-invasive and detailed tissue characterisation abilities, MRI represents an 
important tool for longitudinal studies of cardioprotective efficacy. A number of pre-
clinical and clinical studies have examined the use of cardiac MRI to determine infarct 
size and cardiac function following acute myocardial infarction. The principal uses and 
advances in cardiac MRI are described below and investigated in chapter 8. 
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ii Infarct size assessment by MRI 
Late-gadolinium enhancement (LGE) MRI allows in vivo assessment of infarct size. LGE 
imaging relies on administration of a paramagnetic gadolinium (Gd)-based contrast 
agents such as Gd-DTPA (diethylene-triamine penta-acetic acid). Gd-DTPA is a stable 
and highly paramagnetic contrast agent which reduces T1-relaxation time at very low 
concentrations (Weinmann et al., 1984). Gd-DTPA is cell membrane impermeable and 
thus remains in the extracellular space; however, where membrane integrity is 
compromised, for example by infarction, Gd-DTPA enters damaged cells and therefore 
shows an increased distribution and thus hyperenhanced area on T1-weighted MRI 
(McRobbie et al., 2006), (Figure 1.17).  
 
Figure 1.17: Late-gadolinium enhancement MRI of infarction 
(A) Gadolinium-based contrast agents (indicated in yellow) are cell impermeable and thus remain 
in the extracellular space. (B) In areas of infarction, loss of cell membrane integrity permits a 
wider distribution of Gd and delayed T1-relaxation. Modified from Ordovas and Higgins (2011). 
 
LGE MRI was first used to assess myocardial infarction in 1984 to study dog hearts ex 
vivo following 24 hours coronary artery ligation (Wesbey et al., 1984). However, 
improved imaging techniques were required to facilitate the use of LGE imaging for 
infarct size quantification, namely increased magnetic field strengths and the 
development of inversion-recovery sequences (reviewed by Arai, 2011b). T1-weighted 
inversion-recovery imaging increases the contrast of T1-weighted images to produce 
heavily weighted T1-images. This allows the signal from the normal myocardium to be 
effectively nulled to allow accurate delineation of the area of Gd-DTPA accumulation, 
which appears bright. Increased magnetic field strengths have also allowed relatively 
high resolution images of small animal hearts, including the mouse heart, using ECG-
gated image acquisition (McRobbie et al., 2006). 
LGE MRI is now commonly used to image myocardial infarction clinically and also a 
number of small animal models of ischaemia-reperfusion injury (reviewed by Geelen et 
al., 2012). LGE MRI has also been applied to assess chronic infarct remodelling since 
the extracellular space remains increased following fibrosis and infarct healing; this is 
discussed further in chapter 8 (reviewed by Ordovas and Higgins, 2011). 
EXTRACELLULAR SPACE
(A) NON-INFARCTED (B) INFARCTED
CELLS
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Validation of infarct size quantification: Numerous studies have validated the use of 
LGE MRI for infarct size quantification. Kim et al. (1999) first investigated the use of LGE 
MRI for infarct size quantification in dog hearts subjected to ischaemia with or without 
reperfusion by comparing LGE MRI quantification of infarct size to ‘gold-standard’ 
histological staining using triphenyltetrazolium chloride (TTC) (described in chapter 3). 
This study showed excellent correlations between infarct size quantification by LGE MRI 
and histology in both non-reperfused and reperfused hearts at 1 and 3 days and 8 
weeks (Kim et al., 1999). Further studies have also validated the use of LGE MRI pre-
clinically in numerous animal models of ischaemia-reperfusion injury, including the 
reperfused mouse heart. The seminal study by Yang et al. (2004) provided the first 
validation of LGE MRI determination of infarct size in mice following 60 minutes 
ischaemia and 24 hours reperfusion. Pre-clinical LGE MRI of small animals has since 
been established at a number of research centres.  
Validation of LGE MRI for clinical assessment of myocardial infarct size has proved 
more challenging since it is not often possible to compare LGE and histological 
quantifications of infarct size. An initial study of LGE MRI for assessing patients prior to 
revascularisation surgery (non-acute patients) demonstrated that LGE was able to 
delineate areas of reversible myocardial dysfunction, however, this study did not 
quantify infarct size (Kim et al., 2000). A subsequent study by this group demonstrated 
that infarct size determined by LGE MRI is reproducible within patients and also 
correlated well with infarct size determined by single photon emission computed 
tomography (SPECT) (Mahrholdt et al., 2002). Further to this, Arai’s group showed that 
infarct size quantification by LGE MRI in acute myocardial infarction patients correlated 
well with clinical indices of infarct size including serum cardiac enzyme level (troponin I), 
ejection fraction and regional wall thickening (Ingkanisorn et al., 2004). This was further 
confirmed in a large multi-centre study in 2008 which showed excellent agreement 
between LGE infarct size and creatine kinase (CK) serum levels (Kim et al., 2008). This 
latter study also constitutes an important landmark in the use of LGE since it confirmed 
that the technique is sufficiently robust to permit valid multi-centre trials.  
These initial pre-clinical and clinical studies validated the use of LGE MRI to accurately 
determine the presence, spatial localisation and extent of infarction and formed the 
basis for the now widespread application of LGE MRI in vivo determination of infarct size 
(reviewed by Ordovas and Higgins, 2011). Given its non-invasive nature, LGE MRI 
provides an important tool for investigating infarct size in longitudinal studies of 
cardioprotective efficacy and will be examined further in this thesis. 
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iii Myocardial salvage – Quantification of area-at-risk 
Infarct size is clearly an important factor in determining the prognosis of acute 
myocardial infarction patients and is therefore the most commonly assessed endpoint 
for clinical and pre-clinical studies of cardioprotective efficacy. However, interpretation of 
infarct size data requires an appreciation of the area of the myocardium that was ‘at 
risk’, termed the ‘area-at-risk’ (AAR). Assessment of infarct size alone does not consider 
the area of myocardium at risk of injury and therefore reduces the statistical power; this 
was discussed above in relation to poor clinical translation of cardioprotection studies 
and is therefore an important area for development of future studies. 
In pre-clinical studies, AAR can be quantified by ex vivo histological staining following 
re-occlusion of the coronary ligation and perfusion of coloured dyes (such as Evans 
blue) or fluorescent microspheres (reviewed by Black and Rodger, 1996). However, this 
is not possible in clinical or longitudinal basic science studies and therefore presents the 
need for a method of quantifying AAR in vivo. A number of MRI-based protocols have 
been examined to this end; a basic overview and the theoretical basis of these methods 
is provided in Table 1.5 and further discussed below (reviewed by Arai, 2011a). 
 
MRI METHOD THEORETICAL BASIS AND OVERVIEW 
T2-weighted: 
(Aletras et al., 2006) 
(Friedrich et al., 2008) 
 
Based on oedema. Relies on assumption that oedema is confined 
to AAR such that the area of oedema is equal to the AAR. 
Good agreement in AAR quantification with histology. 
 
Pre-contrast T1-
weighted: 
(Ugander et al., 2012) 
(Ferreira et al., 2012) 
 
Same basis as T2-weighted MRI; Good agreement in AAR 
determined by pre-contrast T1 and T2 with histology – not as widely 
investigated. Likely to give similar problems as T2-MRI (see text). 
 
Early Gd enhancement: 
(EGE) 
(Matsumoto et al., 2011) 
 
Gd enhancement images taken 2-3 minutes after Gd bolus. 
Good correlation of AAR determined by EGE and T2-weighted MRI. 
May not be feasible in small animals due to longer scan times 
needed. 
 
Late Gd enhancement: 
(O'Regan et al., 2009) 
(Ubachs et al., 2010) 
(Fuernau et al., 2011) 
 
Estimate AAR based on transmural and circumferential extent of 
infarction. Shown to underestimate AAR. Unlikely to provide valid 
estimate in cardioprotected hearts. Poor correlation to AAR in 
patients  (Fuernau et al., 2011) - Table 1.6 
 
First pass perfusion: 
(Gonzalez et al., 2008) 
 
Administration of Gd during ischaemia. Clinically impractical. 
Potentially beneficial since single administration allows AAR and 
infarct size quantification at different time-points.  
Gonzalez et al. (2008) have used first pass perfusion imaging to 
assess microvascular obstruction at reperfusion.  
 
Manganese contrast: 
(Natanzon et al., 2005) 
 
Manganese (paramagnetic cation) usually enters cells via voltage-
gated calcium channels; uptake impaired during ischaemia. 
Administered during ischaemia and imaged 2 hours after 
reperfusion to accurately quantify AAR. Not ready for clinical tests. 
 
 
Table 1.5: Potential MRI-based methods for in vivo quantification of AAR 
Summary of MRI methods to quantify AAR in vivo. References provided for principal studies 
describing these methods and validation against histology. Reviewed by Arai (2011a). 
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Cardiac MRI therefore represents an important tool for potentially quantifying AAR in 
vivo in both pre-clinical and clinical studies of cardioprotection. Of the MRI methods 
detailed above, T2-weighted based MRI has been most widely investigated, likely due to 
its methodological simplicity (reviewed by Arai, 2011a); AAR assessment by T2-based 
MRI is discussed in detail below and examined in chapter 8. 
Area-at-risk assessment by T2-weighted MRI: Assessment of AAR by T2-based MRI 
methods is based on the pathophysiology of ischaemia-reperfusion injury whereby the 
area of myocardium subjected to ischaemia and reperfusion develops oedema, as 
described previously (see 1.2.3). It has therefore been hypothesised that only the AAR 
(i.e. the area subjected to ischaemia) will develop significant oedema and thus the area 
of oedema may be used to approximate the AAR (Garcia-Dorado et al., 1993). Indeed, 
Abdel-Aty et al. (2009) showed that oedema develops within the AAR following only 
short durations of ischaemia that did not induce any infarction (Abdel-Aty et al., 2009). 
T2-weighted MRI exploits the known linear correlation between tissue water content and 
T2-relaxation time, whereby areas exhibiting oedema and thus increased water content 
appear bright on T2-weighted MRI images (reviewed by Garcia-Dorado et al., 2012). 
MRI T2-relaxation times within the infarcted myocardium were first investigated by 
Higgins et al, in 1983 and were shown to correlate well with established measurements 
of myocardial water content (reviewed by Arai, 2011a). A number of pre-clinical and 
clinical studies have since investigated the use of T2-based MRI to quantify myocardial 
AAR (reviewed by Ordovas and Higgins, 2011; Arai, 2011a). The first demonstration that 
in vivo cardiac T2-weighted MRI could be used to accurately quantify myocardial AAR 
was published by Aletras et al. (2006) in dog hearts following 2 days reperfusion. 
Subsequent studies have extended these findings to numerous pre-clinical animal 
models of ischaemia-reperfusion injury and have demonstrated good correlations 
between the putative AAR determined by in vivo T2-MRI and the true AAR determined 
by established histological methods (Bohl et al., 2010; Mewton et al., 2011; Beyers et 
al., 2012). Furthermore, recent clinical studies have suggested that T2-weighted cardiac 
MRI may also permit in vivo AAR quantification in reperfused acute myocardial infarction 
patients (Berry et al., 2010; Fuernau et al., 2011).  
A summary of the main studies validating the use T2-MRI for in vivo quantification of 
AAR following ischaemia-reperfusion injury is provided in Table 1.6. 
 STUDY METHODOLOGICAL DETAILS SUMMARY OF FINDINGS 
DOG 
Aletras et al. (2006) 90 minutes ischaemia and 2 days reperfusion, n=9; 
Cardiac T2-weighted MRI; 
Compared to histological microsphere perfusion. 
 
Good correlation between T2-MRI and microsphere AAR 
(r=0.84). 
Oedema had completely resolved at 2 months reperfusion. 
Ugander et al. (2012) 120 minutes ischaemia and 4 hours reperfusion, n=9; 
Cardiac T2-weighted and T1-weighted MRI 
Compared to histological microsphere perfusion. 
 
Good correlation between T2-MRI and histology AAR (r=0.96); 
Good correlation between T1-MRI and histology AAR (r=0.94); 
Agreement in T2- and T1-MRI assessments of AAR (r=0.95). 
PIG 
Mewton et al. (2011) 40 minutes ischaemia and 90 minutes reperfusion, n=15; 
Cardiac T2-weighted MRI – both T2(STIR) and T2(ACUTE) - 
hybrid of SSFP and TSE. 
Compared to histological perfusion of Uniperse blue dye. 
 
Good correlation between MRI and histology AAR for both T2-
MRI methods tested: 
T2(STIR) (r=0.72); 
T2(ACUTE) (r=0.65). 
MOUSE 
Bohl et al. (2010)  
 
Abstract only – few 
methodological details 
 
45 minutes ischaemia and 24 hours reperfusion 
Cardiac T2-mapping MRI; 
Compared to histological perfusion of dye (details not given) 
 
Correlation of MRI and histology AAR depended on analysis 
method (T2-value 1, 2 or 3 S.D. ± mean): Best correlation using 1 
S.D. ± mean with manual correction (r=0.99). 
 
Beyers et al. (2012) 20 minutes ischaemia and 2 days reperfusion, n=10; 
Cardiac T2-weighted MRI; 
Compared to histological perfusion of phthalo blue. 
 
AAR varied by differential placement of ligating suture to allow 
powerful correlation analysis. 
Good correlation between T2-MRI and histology (r=0.86). 
HUMAN – ACUTE MYOCARDIAL INFARCTION PATIENTS (Reperfusion durations approximate only) 
Berry et al. (2010) Acute myocardial infarction patients, n=50; 
Cardiac T2-SSFP 
Compared to angiography jeopardy score (APPROACH). 
 
Good correlation between MRI and angiography jeopardy score 
(r=0.78). 
Fuernau et al. (2011) Acute myocardial infarction patients, PPCI within 12 hours of 
onset of ischaemia, 2-4 days reperfusion, n=197; 
Cardiac MRI: T2-weighted, LGE. 
Compared to angiography jeopardy score (APPROACH). 
 
Good correlation between T2-MRI and angiography jeopardy 
score (r=0.87). 
Poor correlation between LGE AAR and angiography (r=0.44) 
and between LGE AAR and T2-MRI AAR (r=0.56). 
 
Table 1.6: Area-at-risk quantification by in vivo T2-based MRI 
Summary of principal studies validating the use of in vivo T2-based MRI for the quantification of myocardial AAR. Selected references provided for principal studies 
describing these methods and validation against histology. 
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Evaluation of area-at-risk quantification by T2-based MRI: Given the promising 
nature of these initial studies validating the use of T2-based cardiac MRI for quantifying 
myocardial AAR in vivo, there is considerable interest in the use of this technique for 
calculation of myocardial salvage (AAR minus infarct size) in studies of cardioprotection. 
As discussed previously, assessment of myocardial salvage is expected to improve 
clinical trials and longitudinal basic science studies by controlling for variation in AAR 
(see 1.5.1). Application of this method to the mouse heart is likely to prove more 
challenging given its smaller size and rapid heart rate. However, recent studies by Bohl 
et al. (2010) and Beyers et al. (2012) have shown that T2-weighted based MRI can be 
used to quantify AAR in the reperfused mouse heart. T2-mapping cardiac MRI protocols, 
such as that used by Bohl et al. (2010), are likely to provide improved resolution of 
myocardial oedema due to the averaging effect of combining the T2-relaxation values 
from multiple images at different echo times; this approach is investigated in chapter 8. 
However, despite these initial validation studies, there remain concerns over the 
robustness of T2-based MRI quantification of AAR, particularly concerning the potential 
effects of cardioprotective interventions on the development of oedema (Wince and Kim, 
2010; Mewton et al., 2011). To date this has not been sufficiently investigated and 
represents an important area of future research. Thuny et al. (2012) demonstrated that 
ischaemic post-conditioning (IPost) of acute myocardial infarction patients significantly 
reduced the area exhibiting oedema. This is supported by an early pre-clinical study of 
IPost in dog hearts where both IPC and IPost were shown to significantly reduce the 
extent of myocardial oedema (Zhao et al., 2003). Crimi et al. (2013) also recently 
showed a similar reduction in the area of myocardial oedema in patients treated with 
remote ischaemic postconditioning (RIPost) (Crimi et al., 2013). These studies therefore 
appear to invalidate the use of T2-based MRI for quantification of AAR in subjects 
treated with these interventions. However, Lonborg et al. (2012a; 2012b) showed that 
infarct size reduction by exenatide did not affect myocardial oedema. These apparently 
conflicting results suggest a need for further validation of T2-based MRI methods for in 
vivo AAR quantification and more robust MRI methods may be required.  
Cardiac MRI represents a valuable tool for interrogating numerous myocardial 
parameters following ischaemia-reperfusion injury. There is a clear requirement for an in 
vivo method of determining AAR (combined with current methods for quantifying infarct 
size) for clinical and pre-clinical studies of cardioprotection. Although LGE MRI allows 
accurate and robust infarct size quantification, in vivo measurement of AAR remains a 
significant challenge. This thesis will investigate the use of small animal MRI to develop 
and validate a cardiac MRI method for determining AAR in vivo to facilitate subsequent 
longitudinal pre-clinical studies; described in chapter 8.  
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CHAPTER 2: RESEARCH OBJECTIVES 
  
The overall aim of this thesis was to investigate the potential modulation of mitochondrial 
proteins to elicit long-term cardioprotection against myocardial ischaemia-reperfusion 
injury. The main objectives and research aims examined in this thesis are summarised 
below and described in detail in the following chapters. 
 
Objective 1: The first objective of this thesis was to develop and characterise a mouse 
in vivo recovery model of ischaemia-reperfusion injury for subsequent investigations of 
long-term cardioprotective efficacy. The principal research aims to achieve this were: 
(1) Establish a mouse in vivo recovery model of ischaemia-reperfusion injury; 
 
(2) Validate this in vivo recovery model of ischaemia-reperfusion by application of 
known therapeutic interventions to demonstrate significant cardioprotection; 
 
(3) Characterise this in vivo recovery model of ischaemia-reperfusion injury to 
determine the optimum protocol for subsequent applications of the model. 
The completion of this objective is described in chapter 4. 
 
Objective 2: The second objective was to investigate the role of Cyp-D inhibition (by 
genetic ablation) as a therapeutic target against the long-term effects of myocardial 
ischaemia-reperfusion injury. The principal research aims to achieve this were: 
(1) Investigate the long-term cardioprotective efficacy of Cyp-D inhibition in the 
established model of global genetic ablation of Cyp-D; 
 
(2) Investigate the role of Cyp-D in the heart by establishing and investigating a 
model of cardiac-specific genetic ablation of Cyp-D. 
This objective was examined in chapter 5 of this thesis. 
 
Objective 3: The third objective was to investigate modulation of Sirt-3 as a potential 
therapeutic target against the effects of in vivo myocardial ischaemia-reperfusion. The 
principal research aims to achieve this objective were: 
(1) Investigate the effect of Sirt-3 genetic ablation on the development of myocardial 
infarction in response to in vivo myocardial ischaemia-reperfusion; 
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(2) Investigate the effect of fasting-induced Sirt-3 overexpression on development of 
myocardial infarction in response to in vivo myocardial ischaemia-reperfusion. 
This objective was examined in chapter 6 of this thesis. 
 
Objective 4: The fourth objective was to investigate the role of mitochondrial DJ-1 in 
the heart, specifically its potential role in the pathophysiology of ischaemia-reperfusion. 
The principal research aims to achieve this objective were: 
(1) Investigate the role of DJ-1 in normal cardiac physiology and function; 
 
(2) Investigate the role of DJ-1 in the pathophysiology of myocardial ischaemia-
reperfusion injury. 
This objective was examined in chapter 7 of this thesis. 
 
Objective 5: The final objective of this thesis was to characterise and validate a 
method for determining area-at-risk in vivo in the mouse heart following ischaemia-
reperfusion injury. The principal research aims to achieve this objective were: 
(1) Develop and validate an in vivo cardiac MRI method/s for accurate assessment 
of myocardial area-at-risk in mice subjected to ischaemia reperfusion; 
 
(2) Investigate the validity of these in vivo cardiac MRI assessments of AAR in the 
presence of cardioprotective strategies. 
This objective was examined in chapter 8 of this thesis. 
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CHAPTER 3: GENERAL RESEARCH METHODS 
 
This chapter describes the methodological approaches employed in this thesis with 
specific experimental details subsequently provided in the relevant results chapters. 
 
3.1. Experimental use of animals 
The use of animals in these studies was in accordance with the United Kingdom Animal 
(Scientific Procedures) Act of 1986 and local guidelines. All mice were subject to an 
initial examination prior to experimental use and any animals showing signs of poor 
health or barbarisation were excluded from use. Surgery was performed in accordance 
with best practice described by the Handbook of Laboratory Animal Management and 
Welfare (Wolfensohn and Lloyd, 2003) and extensive advice sought from the Named 
Animal Care Welfare Officer (NACWO) at the facility at University College London, UK. 
Mice were housed in 12 hour light / dark cycles with standard chow provided ad libitum. 
All experiments used male mice aged 10-16 weeks old, unless otherwise stated. Daily 
care of animals was provided by technical staff at University College London, UK. 
3.1.1. Standard mouse strains 
All characterisation experiments presented here were undertaken using commercially 
available mouse strains of either B6/SV129 or C57BL/6 genetic backgrounds. B6/SV129 
(B6SV129F1) mice were purchased from Harlan Laboratories, UK and C57BL/6 mice 
(inbred sub-strain C57BL/6NCrl) were purchased from Charles River Laboratories, UK. 
Mice were purchased aged 9-10 weeks and allowed a minimum of one week 
acclimatisation at the animal facility prior to experimental use. Most studies using 
commercially available mice presented here were undertaken on B6/SV129 mice since 
these were used previously within our laboratory and were considered the closest 
genetic background to the original Cyp-D genetic knockout mice utilised subsequently. 
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3.1.2. Transgenic mouse lines 
A number of transgenic mouse lines were employed in this thesis; an overview of the 
methods concerning their use is provided here and specific details given subsequently.  
Generation of transgenic mice: The transgenic animals used here were generated by 
external sources and imported into our facility. Transgenic animals were created using 
standard genetic modification methods involving generation of specifically mutated 
embryos and re-implantation to produce mutated progeny; this is summarised in Figure 
3.1 and the specific details of each colony are provided in the subsequent chapters. 
Briefly, transgenic animals were created by transfection of cultured embryonic stem (ES) 
cells with a targeting construct designed to disrupt or delete the target gene (Figure 3.1 
A). Targeting vector constructs were specifically designed to contain homologous 
sequences to the target region of the endogenous ES cell genome and a neomycin-
resistance gene (neo). Upon homologous recombination of the targeting vector and 
endogenous ES cell genome, the vector sequence becomes integrated into the ES cell 
genome causing mutation or total deletion of the target gene (Figure 3.1 B). Concurrent 
insertion of the neo gene confers neomycin resistance, which allows selection of mutant 
ES cells upon neomycin treatment which therefore kills only untargeted cells (Figure 3.1 
C). Mutant ES cells were injected into blastocysts from donor mice and subsequently re-
implanted into host mice to generate chimeric and wildtype progeny (Figure 3.1 D). 
Chimeric animals were crossed with wildtype mice to generate progeny including 
animals heterozygous for the mutation (Figure 3.1 E). Variations of this technique using 
sophisticated targeting vectors can be used for insertion or overexpression of the target 
gene, including cardiac-specific expression systems described below. This method of 
genetic modification produces stable germ line mutations to allow the subsequent 
generation of transgenic colonies (Mortensen, 1993; reviewed by Alberts et al., 2002).  
All transgenic mice used here were backcrossed to differing degrees onto a C57BL/6 
genetic background. Standard terminology is used throughout this thesis to describe the 
genotypes: wildtype (WT; +/+), heterozygote (HET; +/-) and knockout (KO; -/-).  
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Figure 3.1: Standard method for generating transgenic mouse colonies 
A) A targeting vector complementary to the target gene is inserted into ES cells. B) Homologous 
recombination occurs between the targeting vector and endogenous ES cell gene to disrupt the 
target gene and insert neo. C) Mutant ES cells can be selected by resistance to neomycin 
treatment. D) Mutant ES cells are microinjected into donor blastocysts to create progeny chimeric 
for the mutation. E) Chimeric animals are crossed with WT mice to produce heterozygous mice. 
Constructed from information provided by Mortensen (1993) and Alberts et al.(2002).  
 
Generation of transgenic animals was completed by other research groups or commercial 
suppliers and animals from stage E imported into our laboratory. 
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i Global genetic ablation 
The most widely used and simple transgenic system utilised in this thesis is global 
genetic ablation of the target gene. Global genetic knockout animals were originally 
created using the method described in Figure 3.1 above and imported into our 
laboratory. The precise details of these mice are provided in the results chapters. 
Colony maintenance: All breeding of animals undertaken as part of this thesis was in 
accordance with UK Home Office procedures and local guidelines. The health of all 
animals was closely monitored with particular attention given to breeding females. 
Animals were bred as a ratio of two females per male and progeny weaned at 3-4 weeks 
old. All experiments using genetically modified animals were undertaken using true 
littermate control animals to minimise any effects of divergence of in-bred colonies over 
extended breeding periods. All transgenic colonies in these studies were maintained by 
heterozygote breeding crosses to give progeny of all combinations of genotypes 
according to expected Mendelian ratios (Figure 3.2). The genotype of each animal was 
determined prior to experimental use as described below in section iii.  
 
Figure 3.2: Standard maintenance of genetically modified mice colonies 
A) Genetically modified mouse strains were maintained as heterozygote crosses (HET x HET). B) 
This produced progeny of all genotypes at expected Mendelian ratios (indicated in brackets). 
 
ii Cardiomyocyte-specific genetic ablation  
Temporal and spatial genetic ablation of a target gene was investigated using an 
inducible cardiomyocyte-specific knockout model. Inducible and tissue-specific genetic 
ablation of a gene of interest allows investigation of tissue- and time-specific roles of that 
gene; theoretically providing tissue and target selectivity advantages over many 
pharmacological inhibition studies (reviewed by Doetschman and Azhar, 2012). 
HET HET
X
A) Breeding Regime
WT HET KO
(25%) (50%) (25%)
B) Expected Progeny
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Rationale of inducible cardiomyocyte-specific genetic ablation: Temporal and 
spatial regulation of genetic ablation is achieved by inducible site-specific genetic 
recombination. Generation of these animals was based on the transgenic method 
described above (Figure 3.1). An overview of the cardiac-specific model of genetic 
ablation used here is provided in Figure 3.3 and described below and in chapter 5. 
Temporal regulation: Genetic recombination can be induced using Cre-recombinase 
technology which was first developed and successfully applied to mouse transgenic 
models in 1995 (Metzger et al., 1995). The Cre-recombinase protein (referred to as 
‘Cre’) causes recombination of DNA recognition sites, loxP sites, placed flanking the 
target gene sequence (Figure 3.3 B). LoxP sites are specific 34 base pair (bp) 
sequences containing a core sequence (8 bp) surrounded by inverted repeated 
sequences (13 bp). The orientation of loxP sites determines whether Cre-recombination 
causes deletion or inversion of the flanked sequence (Figure 3.3) (Metzger et al., 1995). 
Regulation of Cre-recombination is mediated by fusion of Cre to a mutated oestrogen 
receptor (Mer) which is insensitive to oestrogen but activated by tamoxifen (an 
oestrogen receptor antagonist) (Metzger et al., 1995). A double Mer-Cre fusion protein 
(MerCreMer) with significantly higher Cre-recombinase activity was used in this thesis 
(Sohal et al., 2001). MerCreMer is continually expressed and remains in the cytoplasm; 
however, upon tamoxifen exposure, MerCreMer enters the nucleus where it exerts its 
effect to cause loxP site recombination. This ensures that recombination occurs only 
upon tamoxifen treatment, thus providing temporal regulation (Metzger et al., 1995).  
In addition to the use of loxP genetic manipulation for temporal regulation, a simplified 
protocol using insertion of loxP recombination sites surrounding the target gene (or 
specific exons) can be used to generate global genetic ablation models. This method 
involves crossing floxed animals with EIIa Cre-recombinase mice (developed by Lakso 
et al., 1996) which ubiquitously express Cre during early embryonic development, 
thereby allowing the genetic modification resulting from Cre-recombination to be 
transmitted to the progeny (Lakso et al., 1996). This method allows generation of mice 
with global genetic modifications for the development of a standard transgenic colony. 
Spatial regulation: Tissue specificity of this genetic modification system is achieved by 
fusion of the MerCreMer complex to the cardiac-specific alpha-myosin heavy chain (α-
MHC) promoter (Figure 3.3 A). This causes expression of Mer-Cre in cardiomyocytes, 
thereby meaning that Cre-driven loxP site recombination only occurs in cardiac tissue 
(Figure 3.3 C) (Sohal et al., 2001; Doetschman and Azhar, 2012). It is important to note 
that loxP target sites are inserted flanking the target gene in all tissues, where the 
tissue-specificity of recombination is driven by localised expression of MerCreMer, in 
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this case in cardiac tissue only. This α-MHC-MerCreMer – loxP system allows temporal 
and spatial regulation of a gene (Sohal et al., 2001; Doetschman and Azhar, 2012). 
 
Figure 3.3: Inducible cardiac-specific genetic ablation 
A) Cre-recombinase is expressed in a tamoxifen-sensitive manner due to fusion of MerCreMer to 
the α-MHC promoter. B) The target gene is flanked by loxP sites throughout the body. C) 
Treatment with tamoxifen drives MerCreMer expression in the heart which causes loxP site 
recombination to delete or disrupt the target gene in the heart. Constructed from information 
provided by Sohal et al. (2001) and Doetschman and Azhar (2012). 
 
Colony maintenance: The precise details of the breeding schedule for the inducible 
cardiac-specific transgenic model used in this thesis are described in chapter 5.  
Standard terminology is used to describe the genotypes of animals: the presence of the 
MerCreMer construct is described as wildtype (WT; +/+), heterozygote (HET; +/Cre) and 
mutant (Cre/Cre) and the presence of loxP sites is described as wildtype (WT; +/+), 
heterozygote (HET; +/FL) and mutant (FL/FL). The genotype of each animal was 
determined prior to use as described below (section iii) and in further detail in chapter 5.  
Tamoxifen dosing: The MerCreMer – loxP system for genetic ablation described above 
requires induction of Cre-recombinase activity by tamoxifen (Figure 3.3). The final 
tamoxifen dosing regime used here was 18 mg/kg (thus 4.5 mg per 25 g mouse) 
administered as a single intraperitoneal bolus daily for 5 days. Tamoxifen (Sigma-Alrich, 
UK) was dissolved in vehicle comprising ethanol-100% and corn oil (1 part ethanol to 9 
parts corn oil) agitated at 37ºC for a minimum of 4 hours until completely dissolved. 
Tamoxifen solutions were freshly prepared for each study and stored for a maximum of 
A.  MerCreMer fusion construct
B. Floxed gene
MerCreMer fusion construct
Genomic sequence
α-MHC promoter Mer MerCre
loxlox
C. Heart specific knockout
lox
Mer MerCre + Tamoxifen
loxP recombination site
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6 days at 4ºC. This approximate tamoxifen dose and vehicle have been employed 
previously within our laboratory and in published literature (Sohal et al., 2001; 20 
mg/kg). The precise details of this tamoxifen dosing regime are discussed in chapter 5. 
Animals were dosed daily with tamoxifen between 09:00 and 10:00 and monitored 
closely for the duration of the protocol. Consistent timing of dosing was adhered to 
throughout the protocol to ensure that the effects of tamoxifen were matched between 
groups. Control animals were administered a matched volume of vehicle. 
Experimental groups: Given the complexity of the genetic manipulation and treatment 
combinations employed by this genetic ablation model, it is necessary to include a 
number of control groups to assess the potential confounding effects of floxing (insertion 
of loxP sites) and tamoxifen toxicity. The experimental groups required are outlined in 
Table 3.1 (reviewed by Davis et al., 2012). Although many studies using this loxP – α-
MHC MerCreMer system do not employ all of these control groups, it is important to 
appreciate the potential confounding effects in this model to select appropriate controls. 
 
GROUP 
(Genotype and treatment) 
DESCRIPTION 
(Effect examined) 
Gene
FL/FL
 MCM 
WT/Cre  
+ Tamoxifen Experimental group – genetic knockout 
Gene
FL/FL
 MCM 
WT/Cre  
+ Vehicle Experimental group – genetic wildtype 
Gene
FL/FL
 MCM 
WT/WT  
+ Tamoxifen Control group – controls for tamoxifen toxicity 
Gene
WT/WT
 MCM 
WT/Cre  
+ Tamoxifen Control group – controls for Cre toxicity 
Gene
FL/FL
 MCM 
WT/WT 
+ Vehicle Control group – controls for insertion of loxP sites 
 
Table 3.1: MerCreMer – loxP experimental groups 
Experimental groups required for studies of inducible genetic ablation to control for confounding 
effects of insertion of loxP sites and tamoxifen toxicity. Reviewed by Davis et al. (2012). 
 
It is crucial to examine the potential effects of tamoxifen toxicity in this genetic system 
since tamoxifen has been shown to reduce cardiac function associated with some 
cardiac remodelling (although this usually resolved 7 – 14 days post-treatment) (Davis et 
al., 2012). Appropriate use of these control groups is discussed in chapter 5 (see 5.5.2). 
Assessment of efficacy of cardiac-specific genetic ablation: The α-MHC-
MerCreMer system is expected to result in approximately 70-90% knockdown of gene 
expression following 5-7 days tamoxifen treatment (Sohal et al., 2001; Davis et al., 
2012). The effect of treatment on the levels of the target protein was assessed by 
Western blot analysis of heart samples isolated from mice following varied durations of 
tamoxifen dosing. The time-course of protein level reduction depends on the efficiency 
of genetic ablation and the turnover rate of the existing protein; this is discussed in 
chapter 5. A description of the Western blot technique used is provided below (see 3.4). 
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iii Genotyping genetically modified mice 
Since all transgenic animals were bred as mixed genotypes (i.e. usually heterozygote 
crosses as described in Figure 3.2), it was necessary to determine the precise genotype 
of each animal. Genotyping was undertaken using standard polymerase chain reaction 
(PCR) of mouse DNA samples. The genotyping method is described below and specific 
details for each transgenic colony provided in the relevant chapters subsequently. 
Mouse biopsies: Ear biopsies for genotyping were obtained from mice immediately 
following weaning (at approximately 3-4 weeks old). Ear biopsies were taken in a coded 
manner to allow subsequent identification of animals for genotyping. Ear biopsies were 
stored at 4ºC for a maximum of one week prior to processing for genotyping, after which 
ear biopsy lysates were stored at -20ºC until completion of the study. 
Preparation of crude DNA lysates: DNA samples were obtained from ear biopsies by 
protein denaturation using Proteinase-K 1 mg/ml (Qiagen, UK) incubated in lysis buffer, 
Direct-PCR buffer (Ear, Bioquote, UK), at 55ºC in a heating block overnight. Samples 
were then mixed and incubated at 55ºC for a further one hour to ensure maximal lysis. 
Lysis was stopped by Proteinase-K denaturation by incubation at 85ºC for 45 minutes. 
Crude DNA lysates were cleared of hairs by centrifugation at 8000 RPM for 30 seconds, 
after which the pellet was discarded and the supernatant used for PCR as below. 
Amplification of DNA – Polymerase chain reaction: DNA was amplified by PCR 
using a thermal cycler (Peltier Thermal Cycler, MJ Research, Canada) fitted with a 
heated lid. This genotyping technique relies on amplification of a specific region of DNA 
by assembly of DNA nucleotides (dNTPs) by Taq DNA polymerase. A commercially 
available DNA polymerase kit (Qiagen, UK) was used for all PCR genotyping reactions. 
Primer design: Specific primers (short lengths of DNA) were designed for 
complementary binding to the template DNA to confer the specificity of DNA 
amplification which permits determination of the genotype of each animal. Primers were 
specifically designed with optimal DNA sequence, guanine-cytosine (GC) content and 
melting temperature, informed by established PCR protocols for each mouse strain. 
Primers were purchased from Eurofins (MG Operon, Germany) manufactured to 
standard PCR primer quality with MALDI-TOF (matrix-assisted laser desorption / 
localisation) mass spectrometry analysis and diluted to a stock concentration of 100 µM. 
During the PCR, following separation of the double-stranded DNA template, the primers 
are able to specifically bind to the region of interest on the template DNA to allow 
amplification of this region only. The resulting DNA PCR products can be distinguished 
on the basis of their length depending upon the design of the primers. For example, for 
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genotyping Cyp-D global KO animals used here, primers were designed to bind to Exon-
4, Exon-3 and Neo regions of the Cyp-D gene; since the knockout was created by 
deletion of Exons 1-3 and insertion of Neo, Cyp-D KO animals could be distinguished by 
generation of a shorter DNA product from Exon-4 (common) and Neo regions compared 
to the larger product produced by extension of Exon-3 and Exon-4 in wildtype samples. 
PCR reactions: PCR reactions were based on a commercially available DNA 
polymerase kit (Taq PCR Core Kit, Qiagen, UK), where the precise constituents of these 
buffers is detailed in the manufacturer’s guidelines (Qiagen, 2010). A PCR master mix 
was freshly made for each experiment, containing PCR buffer, dNTPs, DNA Taq 
polymerase, appropriate primers and autoclaved distilled water. The PCR buffer 
contained red and orange dyes (CoralLoad dye) to allow visualisation of the migration of 
the reaction upon electrophoresis. Crude DNA lysates were added to each reaction. All 
protocols were optimised to give a final reaction volume of 20 µl; precise details of PCR 
reactions are described for each transgenic colony in the subsequent chapters. 
All PCR experiments included a negative control for DNA contamination comprising an 
aliquot of master mix (19 µl) and an equivalent volume of autoclaved distilled water (1 
µl) in place of a DNA sample. The presence of DNA bands in this reaction indicated 
DNA contamination of some component of the master mix meaning that total PCR 
experiment was discarded and re-run using fresh reagents. In addition, all PCR 
experiments included positive controls for each band (a known heterozygote DNA 
sample) to confirm the presence and location of the DNA bands produced by the PCR. 
Visualisation of DNA products – Gel electrophoresis: Since PCR amplification of 
DNA is expected to produce PCR products of distinct sizes (number of base pairs), the 
amplified DNA could be visualised by separation of PCR products using standard gel 
electrophoresis. Agarose gel electrophoresis allows separation of PCR DNA products on 
the basis of size whereby the agarose gel provides a matrix through which the DNA 
progresses upon application of an electrical charge due to the negative charge of DNA. 
This allows separation of DNA products where smaller DNA fragments travel easier 
through the gel (and thus further in a set time). The composition of the agarose gel 
determines DNA separation and so was optimised for the expected sizes of DNA bands. 
PCR products obtained from the reactions described above were run on an agarose gel 
using a standard electrophoresis tank (Owl Easycast, BioRad, UK) set at 120 V for 45-
60 minutes. Gel electrophoresis was conducted in a TAE running buffer (containing Tris 
40 mM, acetic acid 20 mM and EDTA 1 mM). Electrophoresis of the PCR products was 
continued until the migration front of the PCR products had travelled approximately half 
the length of the gel. The approximate separation of DNA bands was determined by the 
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location of the red and orange dyes contained in the CoralLoad buffer: 2.0% agarose gel 
– red dye at 100 bp, orange dye at <10 bp; 1.5% agarose gel – red dye at 250 bp and 
orange dye at 20 bp. Agarose gels were made in TAE buffer with the addition of the 
fluorescent agent Syto60™ (0.001%: 1 µl in 100ml; Molecular Probes, USA). Syto60™ 
is a red fluorescent nucleic acid stain that is cell-permeant and binds to nucleic acid and 
therefore allows visualisation of distinct bands of DNA when the electrophoresed gel is 
scanned using a fluorescent imaging scanner (Odyssey, Licor, UK). DNA gels were 
scanned using a 700 nm laser at a resolution of 169 µm with focus offset of 2.0 mm for 
the standard thickness of gels used. 
The molecular weights of the resulting PCR product bands were compared against a 
control molecular weight ladder (100 kbp Plus or MidRange, Qiagen, UK) and the 
genotype of each animal was determined by the presence or absence of each PCR 
product DNA band (representative example shown in Figure 3.4). 
 
Figure 3.4: Representative visualisation of PCR products following gel electrophoresis 
DNA lysates were amplified by PCR and separated by gel electrophoresis where DNA products 
migrate from the negative to positively charged ends of the gel. The Syto60™ containing gel was 
imaged using a fluorescent imaging scanner to visualise DNA bands: lane 1) molecular weight 
ladder, 2) KO band, 3) WT and KO bands corresponding to HET and 4) WT band.  
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3.2. Ischaemia-reperfusion in vivo recovery model 
This thesis describes the development and characterisation of a mouse in vivo recovery 
model of ischaemia-reperfusion injury for the first time within our laboratory. An overview 
of the experimental rationale and surgical method is provided here and detailed 
descriptions of the precise surgical protocol and refinements provided in chapter 4. 
This model of ischaemia-reperfusion injury comprised occlusion and reperfusion of the 
left anterior descending (LAD) coronary artery in the in vivo mouse heart followed by 
recovery of animals for subsequent investigation. This model was first described by 
Michael et al. (1995) and the method developed in this thesis was based on that 
presented by Fisher and Marber (2002) with modifications informed by van Laake et al. 
(2007). The use of animals was in accordance with the United Kingdom Animal 
(Scientific Procedures) Act of 1986 and local guidelines. General surgical advice was 
informed by the Handbook of Laboratory Animal Management and Welfare (Wolfensohn 
and Lloyd, 2003) and the NACWO at University College London, UK. 
3.2.1. Surgical protocol 
i Overview of surgical methodology 
Experimental setup: All recovery surgeries were undertaken following strict aseptic 
operating practices in a sterile surgical theatre at University College London, UK. 
Animals were maintained on a thermostatically controlled heated operating table (Peco 
Services Ltd, UK) and body temperature was monitored (using a K-type thermocouple 
thermometer, Hanna Instruments, UK) and maintained at 37.0±0.5°C. 
Electrocardiograms (ECGs) were recorded throughout the procedure by a Powerlab 
setup coupled to Chart 7 software (AD Instruments, UK). All recovery surgeries were 
conducted with the aid of a high-powered surgical microscope set at custom 
magnifications (Zeiss Universal S2, Zeiss, Germany). 
Surgical procedure: A simplified overview of the surgical procedure is summarised in 
Figure 3.5 and described below; chapter 4 provides a detailed methodological 
description of this protocol and the development and characterisation of this model. 
For the main studies presented here, mice were anaesthetised by inhalation of 
isoflurane (Isoflo, Abbott Animal Health, USA) vaporised in oxygen (5% to 1.8% 
isoflurane in 1.5 L/minute oxygen) (Figure 3.5 A). Isoflurane is a halogenated ether 
which when vaporised provides rapid onset and stable maintenance of anaesthesia 
which has been reported for use in several experimental surgical models (Wiersema et 
al., 1997). Anaesthesia was initiated in an induction box supplied with isoflurane and 
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subsequently maintained by connection to a small animal ventilator connected to an 
isoflurane supply. Artificial respiration was provided by ventilation at a volume 200 µl 
and stroke rate 200 strokes/minute and supplied with oxygen (1.5 L/minute) (MiniVent 
Type 845, Hugo Sachs Electronik, Germany) (Figure 3.5 A). Surgical anaesthesia was 
confirmed by loss of the toe-pinch reflex and was continually monitored throughout. 
Open-chest surgery was performed via a fourth intercostal space thoracotomy and 
retraction of the ribs using a small animal chest retractor (all surgical instruments are 
detailed in chapter 4) (Figure 3.5 B). The pericardium was gently opened to gain access 
to the heart. The LAD coronary artery was identified and under-run approximately 2 mm 
below the tip of the left atrium with an 8-0 polypropylene suture (8-0 prolene non-
absorbable suture, W2775, Ethicon, USA). A custom-made snare system was 
assembled from polyethylene-50 tubing (PE50, Deutsch and Neumann, Germany) and a 
modified standard pipette tip (Figure 3.5 C); the precise components and assembly of 
this snare system are provided in chapter 4. 
Myocardial ischaemia was induced by tightening the snare system to occlude the LAD, 
confirmed by: (1) ST-segment elevation, (2) myocardial pallor and (3) relative akinesis of 
the ischaemic area (AAR). Myocardial reperfusion was induced by release of the snare 
system for reperfusion of the LAD and was confirmed by resolution of the changes 
observed upon ischaemia, detailed above. Animals were excluded from the study where 
the onset of ischaemia or reperfusion was not accompanied by observations (1) and (2). 
Following the onset of reperfusion, the snare system was disassembled and the LAD 
suture cut and left in place for subsequent analysis (Figure 3.5 D). All surgical openings 
were closed and the animal was recovered by cessation of the isoflurane supply (Figure 
3.5 E). Ventilation was stopped only upon full return of independent breathing due to the 
known effect of isoflurane on reducing respiration rate (Abbott Animal Health, 2006).  
Animals were monitored closely at regular intervals in the immediate post-operative 
period. Analgesia was provided by buprenorphine (0.1 mg/kg intramuscular, Vetergesic 
[Alstoe Animal Health, UK]) administered at the start and 6 and 24 hours post-surgery. 
Buprenorphine is a potent semi-synthetic opioid that exerts analgesic affects by its 
actions on opioid receptors (Reckitt Benckiser, 2011). Adequacy of pain relief was 
assessed by movement and general activity and advice sought from the NACWO if 
required. An additional buprenorphine dose was given 48 hours post-surgery if required. 
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Figure 3.5: Overview of in vivo ischaemia-reperfusion injury recovery procedure 
A) Mice were anaesthetised and ventilated by oral intubation and connection to a small animal 
ventilator. B) Access to the heart was gained by thoracotomy and opening of the pericardium. C) 
Myocardial ischaemia was induced by LAD ligation using a custom-made snare. Reperfusion was 
initiated by release of the LAD occlusion. D) The LAD snare system was removed leaving short 
lengths of ligating suture. The thoracotomy was closed. E) Animals were recovered by cessation 
of isoflurane supply and extubated. In depth surgical details are provided in chapter 4. 
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ii Ischaemia-reperfusion protocol 
The standard protocol for in vivo recovery ischaemia-reperfusion was 30 minutes 
ischaemia and 72 hours reperfusion (Figure 3.6 B). Sham operated mice were subjected 
to the same surgical procedure including assembly of the snare system but without 
occlusion (Figure 3.6 A). Adjustment of the stabilisation duration in sham operated 
animals ensured that the anaesthetic duration of all in vivo recovery procedures was as 
closely matched as possible, unless specifically stated in the subsequent chapters. 
 
Figure 3.6: Standard ischaemia-reperfusion in vivo recovery protocol 
A) Sham: 45 minutes stabilisation followed by disassembly of snare and recovery. B) Control: 15 
minutes stabilisation followed by 30 minutes ischaemia and 72 hours reperfusion. 
 
iii Surgical exclusion criteria 
The pre-defined surgical exclusion criteria applied to this model were informed by the 
non-recovery in vivo model of ischaemia-reperfusion injury previously established at our 
laboratory. Animals were excluded from the experiment for the following reasons: 
(1) Body temperature recorded was less than 35.5ºC or greater than 38.5ºC. 
(2) LAD ligation caused severe mechanical damage or the myocardial AAR was 
clearly inappropriate (adequacy of AAR is described further below). 
(3) Myocardial ischaemia or reperfusion was not confirmed by ST-segment elevation 
and myocardial colour changes (as described above). 
The application of these exclusion criteria is described in detail in chapter 4 (see 4.3.2 
iv). Further exclusion criteria concerning myocardial AAR were applied during the 
analysis stage of this model, as described below (see 3.2.4). 
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3.2.2. Treatments and interventions 
i Ischaemic preconditioning 
IPC is a well-recognised cardioprotective strategy whereby brief non-lethal periods of 
ischaemia immediately prior to the main ischaemic insult protects the heart against 
ischaemia-reperfusion injury (reviewed by Yellon and Downey, 2003). A standard IPC 
protocol of one cycle of 5 minutes ischaemia and 5 minutes reperfusion was applied 
prior to the main ischaemic insult. This IPC protocol significantly reduces infarct size in a 
similar non-recovery model of ischaemia-reperfusion within our laboratory (Lim et al., 
2007). Control mice underwent 15 minutes stabilisation prior to the main ischaemic 
insult to ensure that the anaesthetic durations were equal between groups (Figure 3.7). 
 
Figure 3.7: Standard ischaemic preconditioning protocol 
A) Control: 15 minutes stabilisation, 30 minute ischaemia and 72 hours reperfusion. B) IPC: 5 
minutes stabilisation, one cycle IPC of 5 minutes ischaemia and 5 minutes reperfusion, 30 
minutes ischaemia and 72 hours reperfusion.  
 
ii Pharmacological treatment 
All pharmacological interventions were applied 5 minutes prior to the onset of 
reperfusion. Pharmacological agents were administered as a single intravenous (I.V.) 
bolus via either the left or right lateral tail vein using a 0.5 ml syringe (Beckton 
Dickinson, UK). Since core body temperature affects final myocardial infarct size 
(discussed in chapter 4), it was not possible to pre-warm animals to facilitate tail vein 
injections in accordance with standard practice for this procedure. Instead, a tissue 
swab soaked in warmed water was applied locally to the injection site to cause local 
dilation of the tail vein to aid placement of the injection needle.  
Successful delivery of the intravenous bolus was confirmed by visualisation of washout 
of blood in the vein upon administration and subsequent return of blood following 
removal of the injection needle. Animals were excluded from the study if successful 
intravenous delivery of the pharmacological intervention could not be confirmed. 
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The optimal volume for administration was approximately 60 µl per 30 g animal (2 ml/kg; 
informed by previous studies within our laboratory) and all pharmacological interventions 
employed in this thesis were diluted such that this dosing volume was adhered to. 
 
Figure 3.8: Standard pharmacological intervention protocol 
Administration of pharmacological interventions was as a single I.V. bolus 5 minutes prior to the 
onset of reperfusion. A) Control: matched volume of vehicle. B) Drug treatment: 60 µl per 30 g 
mouse (2 ml/kg). Successful administration was confirmed by washout of blood in the tail vein. 
 
iii Fasting 
All animals were provided with standard chow and water ad libitum, unless specifically 
stated. A fasting protocol was employed in chapter 6 to investigate the effect of fasting 
on susceptibility to myocardial infarction. Fasting for a maximum of 16 hours is permitted 
without a specific Home Office protocol since it is not considered to be a procedure and 
therefore the fasting protocol employed here did not exceed 16 hours. Free access to 
water was ensured throughout this protocol and animals were carefully monitored. 
3.2.3. Endpoint 1 – Survival 
Survival of animals subjected to the in vivo recovery ischaemia-reperfusion procedure 
was recorded. Where animals died during the surgical procedure, the suspected cause 
of death was recorded and was most commonly the result of surgical error or in some 
cases cardiac failure during ischaemia. Deaths occurring post-surgery were investigated 
by post-mortem analysis to determine the suspected cause of death. Where there was 
no evidence of excessive surgical trauma or cardiac rupture, post-surgery deaths were 
thought to most often result from cardiac or respiratory failure. Cardiac rupture was 
evidenced by blood in the chest and visual rupture to the heart. However, death due to 
cardiac rupture was rare due to the relatively short ischaemic durations used. Surgical 
and recovery survival rates are reported in the subsequent chapters of this thesis. 
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Statistical analysis: Survival rates of animals subjected to this surgical protocol are 
presented as standard Kaplan-Meier survival plots constructed using GraphPad Prism® 
version 5.0 (GraphPad Software, USA). Statistical significance of survival was analysed 
by log-rank tests (Mantel-Cox) using GraphPad Prism® version 5.0 (GraphPad 
Software, USA). Log-rank tests were used since this analysis method places equal 
weight on deaths at all time-points, which is the most appropriate method for this 
analysis and is the more standard statistical analysis test applied to this type of data. 
Statistical significance was reported where P<0.05 using standard significance coding: 
*P<0.05, **P<0.01 and ***P<0.001. No statistical significance was reported where 
P>0.05 and was indicated as not significant (NS). Sample sizes and statistical 
significance are presented alongside all statistical tests. 
3.2.4. Endpoint 2 – Histological staining for infarct size and area-at-risk 
The primary endpoint of the in vivo ischaemia-reperfusion injury model was myocardial 
infarct size as a percentage of AAR (IS/AAR%). The AAR is defined as the region of 
myocardium subject to ischaemia. Infarct size and AAR were determined by histological 
staining of ex vivo heart preparations (summarised in Figure 3.9).  
The area of myocardial infarction was determined by TTC staining whereby TTC serves 
as an enzymatic substrate for intracellular dehydrogenases in living cells causing it to 
change colour from an off-white precipitate to an intense red colour. Dead cells no 
longer contain these dehydrogenase enzymes meaning that TTC remains an off-white 
colour in areas of infarction. The colour of TTC stained tissues allows accurate 
distinction between the living and dead regions of myocardium (see Figure 3.9). This 
TTC-based staining method has been validated in numerous previous studies against 
classical microscopic histological indicators of cell death (reviewed by Kloner, 1993; 
Black and Rodger, 1996). The area of myocardium deemed ‘at-risk’ was delineated by 
perfusion of Evans blue dye following re-occlusion of the LAD suture which results in 
blue staining of the area of myocardium that was perfused during the ischaemic event; 
this staining method is summarised in Figure 3.9. 
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i Histological staining method 
Hearts were extracted from mice anaesthetised with ketamine (100 mg/kg [Vetlar, 
Bioniche Animal Health, Canada]), xylazine (20 mg/kg [Rompun, Bayer, UK]) and 
atropine (0.6 mg/kg [Sigma-Aldrich, UK]). The chest was rapidly opened and the heart 
extracted by cutting the aorta immediately before the aortic loop. The aorta was 
cannulated onto a 21 gauge (G) standard metal perfusion cannula to allow retrograde 
perfusion of the heart (Figure 3.9 A).  
The heart was perfused manually taking care not to exert excessive pressure that may 
damage the coronary system. The heart was first washed by perfusion of saline (1 ml) to 
remove blood from the coronary system (Figure 3.9 B). The area of infarction was then 
delineated by perfusion of TTC (7 ml of 1% TTC in phosphate-buffered saline [PBS], 
pre-warmed to 37°C) (Figure 3.9 C). The LAD suture from the surgical procedure was 
securely re-occluded and Evans blue dye (1.5 ml 0.5% Evans blue made in distilled 
water) then perfused under running water to delineate the AAR (Figure 3.9 D).  
 
Figure 3.9: Histological staining method for myocardial infarction and area-at-risk 
A) Hearts were extracted and the aorta cannulated for manual perfusion. B) Residual blood was 
removed by perfusion of saline. C) Staining for infarction was by TTC perfusion at 37ºC where 
living tissue stains bright red and dead tissue remains off-white in colour. D) The AAR was 
delineated by perfusion of Evans blue dye following re-occlusion of the LAD ligating suture 
whereby the non-AAR stains blue and the AAR remains unstained by Evans blue.  
 
ii Processing of stained hearts 
Hearts were immediately stored at -20°C for 1–2 days and then manually sliced using a 
sharp scalpel to give 5 transverse slices from the apex of the heart with the uppermost 
slice at the approximate level of LAD occlusion (Figure 3.10). Heart slices were washed 
in saline and fixed in 10% formalin for 90-120 minutes at room temperature. The right 
ventricle was dissected from each heart slice and the resulting left ventricle slices were 
imaged in a custom-made acrylic block spaced by 0.5 mm using an Epson scanner 
(Epson Perfection V100 Photo, Epson, UK) at 1200 dpi, 0%, 15% and 100% brightness.  
B. C. D.A.
Cannulation Saline TTC Evans blue
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Figure 3.10: Processing method of preparing histologically stained hearts for imaging 
A) Hearts were rapidly sliced using a sharp scalpel to take five transverse slices from the apex of 
the heart to the approximate level of the LAD suture. B) After briefly washing and formalin fixation 
for 90-120 minutes, the right ventricle (RV) was removed from each heart slice and discarded. C) 
Left ventricle (LV) slices were imaged using a scanner – example of mid-heart slice with area of 
infarction (off-white colour) and AAR (all of the area not stained blue) indicated. 
 
iii Quantification of infarct size and area-at-risk 
Infarct size and AAR were quantified by planimetry using ImageJ software (version 
1.45s, National Institutes of Health, USA). Raw images (at 15% brightness) were 
assessed by manual thresholds to identify the total left ventricular area (LV area), area 
of Evans blue staining and area of infarction. Myocardial AAR as a percentage of left 
ventricle area (AAR/LV%) was calculated as: (LV area – Evans blue area) / (LV area). 
Infarct size as a percentage of AAR (IS/AAR%) was calculated as: (Infarct area) / 
(AAR/LV%). This method is summarised in in Figure 3.11 and the precise details and 
validation of this method is provided in chapter 4. 
 
Figure 3.11: Planimetry method for quantification of infarct size and area-at-risk 
A) Raw heart images were prepared by removal of the background image. B) AAR was quantified 
by manual threshold of the green channel image and the number of pixels of Evans blue staining 
recorded. C) Infarct area was quantified by manual threshold of the red channel image and the 
number of infarct pixels (off-white) recorded. Total LV area was quantified by manual threshold to 
record the number of pixels. AAR was calculated as (LV area – Evans blue area) / (LV area). 
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Hearts were excluded from the dataset if the myocardial AAR was outside the 
predefined inclusion range of 40–75% AAR/LV. No statistically significant differences 
were observed in AAR/LV% between groups within experiments presented. Mean 
AAR/LV% for each group are reported alongside the results for each experiment. 
Statistical analysis: All percentage areas are reported as mean ± standard error of 
mean (SEM). Note that regression analysis values for slopes are given as the 
regression parameter ± standard deviation, as detailed below. Statistical analysis was 
completed using GraphPad Prism® version 5.0 (GraphPad Software, USA) or subsidiary 
GraphPad StatMate software version 2.0 (GraphPad Software, USA), as detailed below. 
Details of statistical tests and sample sizes are provided alongside all results. 
Comparison of means: Sample means were compared using an appropriate statistical 
test determined by the number of groups and type of data being compared. Where two 
independent groups were compared, data were analysed using an unpaired t-test. 
Where more than two independent groups were compared, data were analysed by one-
way ANOVA and Bonferroni test comparing relevant columns of data as indicated.  
In cases where two dependent groups were compared, data were analysed using a 
paired t-test since measurements were made of the same parameter by two different 
methods. Paired t-tests were only appropriate for the comparison of histological and 
cardiac MRI endpoints where the use of paired t-tests is specifically reported in the text. 
For all these statistical analyses, the statistical significance level was set at 5% (α=0.05) 
and statistical significance reported where the computed P-value was less than 0.05. 
Significance was reported using standard significance coding: *P<0.05, **P<0.01 and 
***P<0.001. No statistical significance was reported where P>0.05 (indicated as ‘NS’). 
Regression: Where appropriate, regression analysis of myocardial infarct size and AAR 
was undertaken using the Deming (Model II) regression method. Standard regression 
analysis was not appropriate in this case since it assumes that only the Y variable is 
subject to error, whereas in this case both measurement of AAR (X variable) and infarct 
size (Y variable) are subject to a similar degree of error. Deming regression analysis 
was therefore undertaken where the error of both the X and Y variables was assumed to 
be approximately equal. This regression analysis was used to define the relationship 
between infarct size and AAR and reported as: y=mx+c where m is the slope and c is 
the intercept when x=0. Regression slope is reported as mean ± standard deviation 
(SD) and Y intercept reported for when x=0.  
Regression values were reported as r2 and the relationship determined for each group 
compared by evaluating the slopes. Where the slopes of the two groups were not 
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statistically significant, the elevation of the lines (intercepts) was compared. Statistical 
significance was set at 5% (α=0.05) and significance was reported when the computed 
P-value was less than 0.05 using standard significance coding. 
Statistical power: Statistical power calculations were performed to determine the 
approximate sample sizes required for a prospective study or to retrospectively evaluate 
statistical power to ensure that sufficient sample sizes were investigated. For all tests, a 
statistical power of 80% was deemed the minimal acceptable level of power in 
accordance with published guidelines (Cohen, 1988; Townend, 2002). All power 
calculations were performed using GraphPad StatMate software version 2.0 (GraphPad 
Software, USA) according to the statistical power equations published by Cohen (1988). 
Where no statistical significance was observed, the statistical power of the analysis was 
assessed using the observed sample sizes and standard deviations to determine the 
difference between groups that could be detected with 80% statistical power.  
Sample size calculations for prospective studies were estimated based on 5% 
significance level (α=0.05) and 80% statistical power (β=0.2) and the required sample 
size estimated based on the predicted effect size. Specific details of power and sample 
size calculations for the assessment of statistical power are provided alongside results. 
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3.3. Ischaemia-reperfusion in vivo non-recovery model 
A non-recovery in vivo model of ischaemia-reperfusion was also undertaken to permit 
assessment of myocardial infarct size following short durations of reperfusion. The 
surgical protocol was as described above (see 3.2.1) with minor modifications.  
3.3.1. Non-recovery anaesthetics 
It was not possible to undertake non-recovery surgery using isoflurane anaesthesia 
within our laboratory due to the constraints of ventilation systems and apparatus. A 
standard non-recovery injectable anaesthetic cocktail was therefore used for all non-
recovery in vivo procedures undertaken. Mice were anaesthetised with an injectable 
anaesthetic cocktail containing ketamine (100 mg/kg [Vetlar, Bioniche Animal Health, 
Canada]), xylazine (20 mg/kg [Rompun, Bayer, UK]) and atropine (0.6 mg/kg [Sigma-
Aldrich, UK]) administered as a single intraperitoneal bolus. Anaesthetic depth was 
monitored and maintained by additional anaesthetic doses. Ventilation stroke volume 
was 200 µl and stroke rate was 120 strokes/minute supplied with oxygen (1.5 L/minute).  
3.3.2. Surgical procedure 
The non-recovery in vivo procedure was undertaken using an identical surgical setup to 
that described for the recovery procedure but was performed within our laboratory (non-
sterile environment) and used a standard surgical microscope (Gallenkamp, Weiss, UK). 
Immediately following the initiation of myocardial reperfusion, the thoracotomy was 
loosely closed using a 5-0 braided suture (5-0 mersilk non-absorbable suture, W595, 
Ethicon, USA) and covered with a moistened tissue drape to prevent tissue desiccation. 
The standard protocol for non-recovery surgeries was 30 minutes ischaemia and 2 
hours reperfusion (Figure 3.12). Animals were anaesthetised for the total duration (2 
hours 50 minutes) and hearts then subjected to staining as above (see 3.2.3).  
 
 
Figure 3.12: Ischaemia-reperfusion in vivo non-recovery protocol 
Mice were anaesthetised using an injectable anaesthetic cocktail. The LAD ligating snare system 
was assembled and stabilised for 15 minutes followed by 30 minutes ischaemia and 2 hours 
reperfusion. Total anaesthetic duration was approximately 2 hours 50 minutes (pale grey box). 
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3.4. Analysis of myocardial protein levels 
Myocardial protein levels were examined using standard Western blot techniques 
described below and detailed further in the relevant results chapters of this thesis. 
3.4.1. Preparation of heart samples 
i Extraction and processing of ventricular tissue 
Hearts were extracted from anaesthetised mice and cannulated for manual perfusion 
exactly as described above (see 3.2.3: cannulation and saline perfusion only). Hearts 
were washed by perfusion of 1 ml chilled saline (4ºC) whilst submerged in ice-cold 
saline to remove residual blood from the ventricle lumen and coronary system. During 
processing, efforts were made to ensure that the ice-cold conditions were observed and 
the cannulation and perfusion process was completed as rapidly as possible to avoid 
changes occurring to the tissues. The atria were removed and discarded and the 
ventricles immediately transferred to a small container of liquid nitrogen and crushed 
using a cooled plastic tool to ensure rapid freezing of the tissue. Ventricle samples were 
stored in liquid nitrogen for 30 minutes and at -80ºC until processing. 
Tissue samples were manually homogenised in standard homogenisation buffer for 
subsequent assays using a small glass pestle and mortar. This homogenisation buffer 
was based on a phosphate buffered saline (PBS) solution containing (in mmol/L): NaCl 
(137), KCl (2.7), Na2HPO4.2H20 (10), KH2PO4 (2), pH 7.4 and supplemented with 
protease inhibitor and phosphatase inhibitor cocktails (diluted to 1X concentrations in 
PBS) and EDTA (pH 8.0) (Thermo Scientific, UK). The homogenisation buffer was 
freshly made for each experiment. Heart tissues were homogenised to a concentration 
of 0.1 g tissue in 0.1 ml buffer and stored at -80ºC prior to use in subsequent assays. 
ii Isolation of mitochondria 
Mitochondrial proteins were isolated from ventricular heart samples where required. 
Hearts were extracted from anaesthetised mice and cannulated for manual perfusion 
exactly as described previously. Hearts were washed by perfusion of 1 ml chilled saline 
(4ºC) whilst submerged in ice-cold saline to remove residual blood from the ventricle 
lumen and coronary system. The atria were removed and discarded and the left and 
right ventricular tissue immediately homogenised using a glass pestle and mortar in 
standard homogenisation buffer as previously described. Mitochondrial proteins were 
isolated using a commercial kit (Qproteome mitochondria isolation kit, Qiagen, UK) 
according to the manufacturer’s instructions. Briefly, homogenised tissue was 
suspended in lysis buffer which selectively disrupts the cellular plasma membrane. The 
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resulting pellet (containing mitochondria, nuclei and other organelles) was re-suspended 
in disruption buffer to ensure complete disruption of the cells. The supernatant (which 
contained mitochondria) was re-centrifuged to pellet the mitochondria. Mitochondria 
were washed and re-suspended prior to Western blot analysis. 
iii Quantification of protein concentration 
The protein concentration of each tissue homogenate was assessed using a 
bicinchoninic acid (BCA) – copper(II) sulphate (CuSO4) assay. This assay is based on 
the reduction of Cu2+ to Cu1+ by proteins in alkaline assay conditions where 2 molecules 
of BCA chelate one Cu1+ ion causing BCA to change from a green to purple colour 
where the purple intensity is proportional to the amount of protein (Figure 3.13). 
 
Figure 3.13: Molecular basis of BCA assay quantification of protein quantification 
The chemical basis of this is described in the datasheet provided by Thermoscientific (2010). 
 
Proteins were quantified by comparison to a normalised curve of BCA colour produced 
by known concentrations of bovine serum albumin (BSA) in homogenisation buffer. 
Heart samples and known BSA concentration control samples were added to the BCA 
and CuSO4 solution and incubated for 30 minutes at 37 ºC with agitation. The resulting 
colour intensity was measured by a FLUOstar Omega microplate reader (BMG Labtech, 
USA) and the protein concentration of samples calculated by automatic software 
calculations using the standard concentration curve from the BSA samples.  
Heart samples were subsequently diluted to a set concentration of the most dilute heart 
sample by addition of the calculated volume of homogenisation buffer required.  
3.4.2. Western blotting protocol 
i Gel electrophoresis 
Western blotting was performed by standard sodium-dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE). This allows separation of proteins based on size and 
charge where SDS causes protein linearisation and negative charge.  
Diluted heart samples (detailed above) were prepared for gel electrophoresis (100 µl 
aliquots) by addition of laemmli buffer (100 µl) and β-mercaptoethanol (10 µl). Laemmli 
buffer (containing mercaptoethanol and SDS) and additional mercaptoethanol cause 
denaturation of proteins within the samples so that they can subsequently be separated 
Cu2+ Cu+ Cu+ - BCA(2)
Green
Purple 
(Quantification)PROTEIN
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by size upon gel electrophoresis. Laemmli buffer also contains glycerol to increase the 
density of the protein samples to facilitate their loading into the gel sample wells. These 
prepared heart samples were then incubated at 100ºC for 10 minutes prior to running. 
SDS-PAGE gels were made using standard BioRad Mini Protean® Western blotting 
apparatus (BioRad, UK). Resolving gels were made containing 15% acrylamide, 0.1% 
SDS and Tris-HCl (pH 8.8) to a final concentration of 375 mM, tetramethyl 
ethylenediamine (TEMED, 7.5 µl) and the setting agent 10% ammonium persulphate 
(APS, 75 µl) added immediately prior to pouring the gels. Isopropanol water was gently 
poured onto the resolving gel whilst it set to ensure that a straight edge was formed. 
Following setting of the resolving gel and removal of isopropanol water, stacking gels 
were made containing 4.5% acrylamide, 0.1% SDS and Tris-HCl (pH 6.8) to a final 
concentration of 125 mM and TEMED (7.5 µl) and 10% APS (75 µl) added prior to 
pouring and 15 well combs inserted for loading. 
The completed gels were placed in running cassettes (BioRad, UK) filled with running 
buffer comprising glycine (200 mM), SDS (1%) and Tris (25 mM). Gels were loaded with 
equal concentrations of proteins as calculated from the BCA protein assay (described 
above) such that 12.5 µl of heart homogenate was loaded per lane. A protein reference 
marker was loaded (7.5 µl Prevision plus, BioRad, UK) to allow determination of protein 
sizes. Gels were run at 180 volts for 1 hour or until separation of the protein ladder. 
ii Western blot transfer to membrane 
Following electrophoresis, proteins were transferred to nitrocellulose membranes by 
semi-wet transfer (Semi-Wet Transfer Cell, BioRad, UK) to allow interrogation of 
membranes by antibody binding (described below). Transfer of proteins was performed 
by mounting gels between wet blotting paper (Whatman, GE Healthcare, UK) next to a 
pre-prepared nitrocellulose membrane. This membrane was first prepared in 100% 
methanol for 2 minutes and washed in transfer buffer. Transfer buffer comprised glycine 
(200 mM) and Tris (25 mM) and 20% methanol. It was imperative that all air bubbles 
were removed from the assembly to avoid incomplete protein transfer. The transfer was 
run at 10 volts (<1 amp) for 45 minutes and confirmed by protein ladder transfer. 
iii Antibody probing of gels 
All washes of the membrane were conducted using PBS supplemented with Tween 
(0.1% Tween-20). Immediately prior to interrogating the membranes for proteins using 
selective antibodies, it was necessary to block non-specific antibody binding. Blocking 
was achieved by incubation in 5% milk (Marvel milk powder [Premier International Food 
Limited] made in PBS containing 0.1% Tween) for 45 minutes at room temperature.  
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Primary antibodies were diluted 1:1000 in 5% milk / PBS + Tween solution. Primary 
antibodies were incubated for 45-60 minutes at room temperature with agitation. The 
primary antibody epitopes were designed to recognise the protein of interest, as 
subsequently described in the relevant chapters. Excess unbound primary antibody was 
then removed by washing the membrane six times for 10 minutes each in PBS + Tween. 
Primary antibodies were detected by labelled secondary antibodies directed at a site-
specific portion of each primary antibody. Secondary antibodies were diluted 1:5000 in 
5% milk PBS + Tween solution. Secondary antibodies were incubated for 1 hour at room 
temperature with agitation. Secondary antibodies were conjugated to a horseradish-
peroxidase (HRP) enzyme to allow subsequent detection by a standard 
chemiluminescence reaction (described below).  
Details of the specific antibodies used for Western blot analysis of protein levels in these 
studies are provided in the applicable results chapters. The protein level of interest was 
normalised to the level of a relevant protein to control for differences in protein loading of 
the gels. For whole cell samples, α-tubulin was used as a loading control. Mitochondrial 
protein samples were compared against VDAC levels, however, since VDAC protein 
levels also appeared to be affected by the treatment tested, absolute protein levels of 
the mitochondrial protein of interest were assessed; described further in section 6.3.3.  
iv Chemiluminescence detection of antibody binding 
Protein bands were visualised using a standard HRP chemiluminescence reaction. 
Membranes were incubated in enhanced chemiluminescence (ECL) reaction (GE 
Healthcare, UK) for approximately 2 minutes. The HRP enzyme catalyses conversion of 
the ECL substrate into a luminescent product which can then be visualised using 
photographic development (Figure 3.14). Membranes were imaged using photographic 
film placed over the membrane and ECL for 10 seconds to 2 minutes Photographic films 
were scanned using an Epson scanner (Epson Perfection V100 Photo, Epson, UK).  
 
Figure 3.14: Molecular basis of 
enhanced chemiluminescence 
detection of antibody binding 
Secondary antibodies were 
conjugated to HRP which catalyses 
conversion of the ECL substrate to 
evoke luminescence which can be 
detected by development of 
photographic film. 
Modified from Cell Signalling (2012). 
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Quantification of protein levels: Since the intensity of chemiluminescence produced 
by the ECL reaction described above is proportional to antibody binding and therefore 
the amount of protein present on the membrane, the resulting bands produced on the 
photographic film are representative of the protein levels. This was quantified by 
densitometry of protein bands using ImageJ software (version 1.45s, National Institutes 
of Health, USA). Final protein levels were quantified and normalised against the loading 
control for each sample, where appropriate, and expressed as arbitrary units (A.U.).  
All values are presented as mean A.U. ± standard error of mean (SEM). Data were 
analysed by one-way ANOVA followed by Bonferroni test comparing relevant columns of 
data using GraphPad Prism® version 5.0 (GraphPad Software, USA). The statistical 
significance level was set at 5% (α=0.05) and statistical significance was reported where 
the computed P-value was less than 0.05 using standard significance coding. 
 
3.5. Assay of myocardial ATP levels 
3.5.1. Langendorff preparation of heart samples 
A Langendorff perfusion setup was used to prepare heart samples to assess ATP levels 
and permit investigation of the effects of myocardial ischaemia. A basic Langendorff 
constant pressure perfusion system was used to perfuse the hearts and initiate 
ischaemia. A detailed description of this model is beyond the scope of this thesis; a 
simplified overview is illustrated in Figure 3.15 and reviewed by Bell et al. (2011).  
Mice were anaesthetised with ketamine (100 mg/kg [Vetlar, Bioniche Animal Health, 
Canada]), xylazine (20 mg/kg [Rompun, Bayer, UK]) and atropine (0.6 mg/kg [Sigma-
Aldrich, UK]) administered as a single intraperitoneal dose. Upon surgical anaesthesia, 
hearts were extracted and rapidly cannulated onto a 21 G standard perfusion cannula as 
described above (see 3.2.3). The ideal time to perfusion was less than 3 minutes 
although this rarely took more than 2 minutes for the experiments presented here. 
Langendorff perfusion chambers were filled with Krebs-Henseleit buffer (KHB) 
containing (in mmol/L): NaCl (118), glucose (11), NaHCO3 (25), KCl (4.7); CaCl2 (1.8), 
MgSO4.7H2O (1.2) and pyruvate (0.5), equilibrated with 95% oxygen and 5% carbon 
dioxide to pH 7.4 and perfused at 80 mmHg. Physiological temperature of the heart was 
maintained by warming of the perfusion buffer and monitored by insertion of a fine 
tipped temperature probe into the LV wall (via Powerlab coupled to Chart 7 software, AD 
Instruments, UK). The temperature of the heart was maintained at 37.0±0.5ºC by subtle 
changes to the submersion of the heart in the warmed perfusate.  
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Figure 3.15: Overview of Langendorff perfusion system for preparation of heart samples 
Simplified diagram of the constant perfusion pressure Langendorff system used to prepare 
control and ischaemic heart samples. Hearts were perfused with warmed Krebs-Henseleit buffer 
(KHB; indicated in pale blue). Buffer was gassed with 95% oxygen and 5% carbon dioxide 
(gassing rod shown in dark blue) and warmed by a system of heated jackets (indicated in faint 
red). A bubble trap system was used to ensure that no air bubbles could enter the perfusate. The 
heart was perfused in a retrograde manner via the aorta whilst submerged in a warmed organ 
bath. Buffer flow was regulated by opening and closing the flow regulator tap (iii) to allow 
perfusion (for stabilisation) and cessation of perfusion (for simulated ischaemia). 
 
Immediately following cannulation of the heart, it was connected to the Langendorff 
apparatus and perfused at approximately 80 mmHg. Hearts were seen to contract 
rapidly upon perfusion and good function was confirmed prior to starting the experiment. 
Cardiac function was not formally assessed given the complications of inserting the 
pressure transducing balloon and often unreliable measurements using this system 
obtained with this setup in our laboratory. Perfusion of the heart was controlled by 
means of the flow regulator tap (see Figure 3.15) which remained in the open position 
for perfusion. Simulated ischaemia was induced by closure of the flow regulator tap and 
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Heated by water jacket (faint red colour)
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thus cessation of perfusion and confirmed by the lack of effluent from the heart and the 
relatively rapid onset of dramatically reduced cardiac contractility. 
Hearts were randomised to control and ischaemic groups, where control hearts were 
subjected to 30 minutes stabilisation and ischaemic hearts to 10 minutes stabilisation 
and 20 minutes global ischaemia (Figure 3.16). Upon completion of this protocol, hearts 
were removed from the Langendorff apparatus and the left ventricles dissected and 
immediately frozen by submersion into liquid nitrogen and then stored at -80ºC. 
The period of stabilisation was started once the heart was securely attached to the 
Langendorff apparatus and good cardiac contractility had resumed. If the heart did not 
start contracting sufficiently it was discarded and the experiment started again to avoid 
any confounding effects on the final ATP assay conducted on this tissue. Two 
simultaneous perfusion experiments were conducted using this Langendorff system and 
the condition (control or ischaemia) randomised between hearts and perfusion rigs. 
 
 
Figure 3.16: Langendorff perfusion protocol for the preparation of hearts for assay of ATP 
Hearts were extracted from mice and cannulated to allow Langendorff perfusion. A) Control: 30 
minutes stabilisation. B) Ischaemia: 10 minutes stabilisation and 20 minutes global ischaemia by 
cessation of perfusion. Left ventricles were then immediately frozen for subsequent processing. 
 
Frozen heart samples were subsequently homogenised in ice-cold conditions in the 
standard homogenisation buffer described previously and the protein concentration of 
each sample assessed using a BCA assay, described above (see 3.4.1). 
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3.5.2. ATP luminescence assay 
Myocardial ATP levels were measured using a commercial ATP assay kit (ATP 
Bioluminescent Assay Kit, Sigma-Aldrich, UK). This is a luciferase based assay whereby 
luciferin (the assay substrate) is converted to oxyluciferin by the luciferase enzyme in an 
ATP-dependent manner. When ATP is the limiting reagent, the intensity of the 
luminescence is proportional to the amount of ATP present (summarised in Figure 3.17). 
 
Figure 3.17: Molecular basis of luciferase assay quantification of tissue ATP levels 
The chemical basis of this reaction is described in the datasheet by Sigma-Aldrich (2009). 
 
This ATP assay was conducted in accordance with manufacturer’s instructions (detailed 
by Sigma-Aldrich, 2009). This kit supplied an ATP assay mix (containing luciferase, 
luciferin, MgSO4, dithiothreitol [DDT], BSA and tricine buffer salts) and ATP dilution 
buffer (containing MgSO4, DDT, EDTA, BSA and tricine buffer salts). 
Sample plate: Heart homogenates, prepared as described above, were diluted ten-fold 
in TAE buffer (buffer as above) and then incubated at 85ºC for 30 seconds. These heart 
samples were then transferred to a sample plate (standard clear 96-well microplate) to 
allow rapid transfer of samples when required, as detailed below.  
Assay plate: The required volume of ATP assay mix was diluted 25-fold in the supplied 
ATP assay dilution buffer and vigorously mixed and rapidly transferred to the assay 
plate (white, clear bottom 96-well microplates; 100 µl diluted assay mix per well). The 
assay plate was swirled vigorously and incubated for 3 minutes to allow the signal from 
any endogenous ATP to be quenched to reduce any background luminescence signal.  
Immediately following the 3 minute assay plate incubation period, the pre-prepared 
diluted heart samples were then rapidly added to the assay plate using a multi-channel 
pipette (100 µl heart sample per well) to ensure simultaneous addition of the heart 
samples to the assay plate for consistency of the luciferin reaction. The assay plate was 
then vigorously swirled and rapidly transferred to the microplate reader for assessment 
of luminescence every 5 seconds for 2 minutes using the FLUOstar Omega microplate 
reader (BMG Labtech, USA). 
Assay substrate 
Luciferin
Adenyl-luciferin Oxyluciferin
Luminescence
Detected by spectrophotometer 
mircroplate reader
ATP
Luciferase
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Statistical analysis of ATP levels: Luminescence values recorded during the first 20 
seconds were used for all statistical analyses. These values were normalised to the 
average value recorded for wildtype control samples and expressed as a percentage of 
control ± standard error of mean (SEM). Data were analysed by one-way ANOVA, 
followed by Bonferroni test comparing relevant columns of data using GraphPad Prism® 
version 5.0 (GraphPad Software, USA). Statistical significance was reported where 
P<0.05 using standard significance coding.  
 
3.6. Electron microscopy analysis of mitochondrial morphology 
 
Examination of mitochondrial morphology in ex vivo tissues was undertaken using 
electron microscopy to evaluate mitochondrial length in ex vivo prepared heart samples. 
3.6.1. Preparation of heart samples 
Hearts samples were prepared from mice at baseline and following a sublethal 
ischaemic insult using the standard in vivo non-recovery ischaemia-reperfusion model 
exactly as described above (see 3.3.2). Mice were randomised to control or ischaemic 
treatment groups where the control group were subjected to 25 minutes stabilisation and 
the ischaemic group to 5 minutes stabilisation and 20 minutes ischaemia (Figure 3.18).  
 
Figure 3.18: Non-recovery in vivo model protocol for assay of mitochondrial morphology 
Mice were randomised to control or ischaemic groups. A) Control: 25 minutes in vivo stabilisation. 
B) Ischaemia: 5 minutes stabilisation and 20 minutes in vivo regional ischaemia by LAD ligation. 
 
Hearts were then immediately extracted (with the LAD occluding snare still in place for 
the ischaemic group) and the aorta cannulated as described previously. Once 
cannulated the LAD occluding snare was released (in the ischaemic group) and residual 
blood removed by gentle perfusion of cold saline (1ml at 4ºC). Hearts were fixed for 
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electron microscopy (EM) imaging by perfusion of a standard EM fixative buffer 
consisting of standard PBS solution (described above) supplemented with 
paraformaldehyde 1%, glutaraldehyde 1%, CaCl2 0.5mM, glucose 0.031%, pH 7.3 and 
stored in this EM fixative buffer until further processing. 
3.6.2. Electron microscopy 
Subsequent processing and EM imaging described here was undertaken by Mr M. 
Turmaine (Electron Microscopy Services Facility, University College London, UK). 
Hearts were prepared for EM imaging by removal of a 2 mm transverse slice of 
myocardium approximately 3 mm from the apex of the heart. Heart slices were fixed in 
an osmium buffer (consisting of: OsO4 1% in standard PBS solution, pH 7.3) at 4ºC for 
90 minutes and then washed in PBS buffer. Heart slices were En bloc stained with 
uranyl acetate (0.5% in distilled water) at 4ºC for 30 minutes to enhance the subsequent 
contrast of images. Heart samples were washed in distilled water and dehydrated in a 
graded ethanol-water series and then infiltrated with Agar-100 resin overnight (Agar 
Scientific, UK). Semi-thin sections of these slices were then cut at 1µm intervals and 
mounted on glass slides for staining with toluidine blue (1% in distilled water). Ultrathin 
sections were cut at 70-80nm using a microtome diamond knife (Reichert Ultra-cut, 
Reichert Microscope Services, USA). Sections were collected on mesh copper grids and 
stained with uranyl acetate and lead citrate. These processing steps were completed 
within one month of initial fixation of the heart samples.  
Electron microscopy was performed on the stained ultra-thin sections and a random 
selection of 7 electron micrographs displaying longitudinally arranged cardiomyocytes 
taken for each heart (Jeol 1010 transition electron microscope, Jeol Ltd, UK). 
Statistical analysis of mitochondrial morphology: Mitochondrial morphology was 
evaluated by assessment of the length of interfibrillar mitochondria (IFM) compared to 
sarcomere length where normal mitochondrial length was considered to be 
approximately 1 sarcomere length. Mitochondria were defined as less than 1 sarcomere 
length (fragmented morphology), equal to 1 sarcomere length (normal morphology) or 
greater than 1 sarcomere length (fused morphology). This method of evaluating 
mitochondrial morphology from in vivo prepared hearts has been previously validated by 
our laboratory (Ong et al., 2010). Analysis of EM images was performed by Dr S.B. Ong 
(previously of the Hatter Institute, UCL) who was blinded to the treatment groups. 
The proportion of mitochondria defined as normal, fragmented or fused was calculated 
for each heart (total of 500-600 mitochondria per heart) and expressed as mean 
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percentage of mitochondria ± standard error of mean (SEM). All statistical analysis was 
completed using GraphPad Prism® version 5.0 (GraphPad Software, USA) to perform a 
one-way ANOVA and Bonferroni test comparing relevant columns of data. Statistical 
significance was reported where P<0.05 using standard significance coding.  
 
3.7. Cardiac phenotyping by echocardiography 
Echocardiography evaluation of mice in this thesis was undertaken in collaboration with 
Dr A. Dyson (Department of Medicine, University College London, UK). 
 
Echocardiography examination of transgenic mice was undertaken to determine whether 
ablation of a particular gene of interest caused any overt cardiac phenotype. 
3.7.1. Cardiac function at baseline 
Assessment of cardiac function in transgenic mice was undertaken using ultrasound 
echocardiographic imaging to visualise in vivo functioning heart. Echocardiography was 
undertaken using a Vivid 7 dimension setup with 14 MHz probe (GE Healthcare, UK). 
Mice were anaesthetised with isoflurane vaporised in room air (3% isoflurane for 
induction and then maintained at 1.8-2.0% isoflurane). Animals were placed in the 
supine position for imaging and hair removed in the region of the heart to enable 
uninterrupted contact of the imaging probe. Upon steady anaesthesia using the minimal 
concentration of isoflurane required, echocardiographic measurements of cardiac 
dimensions and function were taken. Left ventricular end-diastolic (ED) and end-systolic 
(ES) dimensions were determined from a parasternal short-axis view at the papillary 
muscle level using time-motion (M) mode which allowed a quick succession of images to 
be taken to permit assessment of cardiac function (Rottman et al., 2007). The following 
echocardiographic measurements were taken: 
(1) Anatomical measurements – Internal dimension of the left ventricle and the 
thickness of the left ventricle anterior and posterior walls (see Figure 3.19).  
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Figure 3.19: Anatomical measurements of the heart by echocardiography 
M-mode echocardiography of parasternal short axis view of the heart at the level of the 
papillary muscle. Anatomical measurements taken at diastole and systole. 
 
(2) Aortic blood flow velocities – These were determined using pulsed-wave Doppler 
in the aortic arch immediately prior to the bifurcation of the right carotid artery. 
Blood flow direction was confirmed by colour Doppler. Peak aortic blood flow 
was measured as the average maximum velocity from 6 velocity-time traces. 
 
(3) Heart rate – This was calculated by measuring the time between 6 consecutive 
cycles from the start of each Doppler trace. 
 
(4) Stroke volume = velocity time integral * vessel cross sectional area 
Where the vessel cross sectional area was calculated as: (π x [0.5 x diameter]2) 
where the diameter was assumed to be 1.34 mm based on a previous pilot study 
in age-matched wildtype mice (informed by Dr A. Dyson). 
 
(5) Cardiac output  = Heart rate * stroke volume 
 
(6) Fractional shortening  = (LV ED diameter - LV ES diameter) *100 
                                                    LV ED diameter 
3.7.2. Cardiac function under pharmacological stress 
The effect of a known cardiac stressor on the cardiac function of these mice was also 
examined. Isoproterenol is a non-selective β-adrenergic agonist that activates β1-
receptors on the heart to induce increased heart rate and force of contraction (Hoit et al., 
1997). Normal functioning hearts are able to respond to this inotropic and chronotropic 
stimulation which should elicit a substantial increase in heart rate. Isoproterenol stress is 
commonly used to investigate potential differences in systolic or diastolic function that 
may not be evident at baseline (reviewed by Rottman et al., 2007). An isoproterenol 
stress protocol was optimised and used to assess cardiac function under stress.  
Diastole:
i) Anterior wall
ii) LV cavity
iii) Posterior wall
Systole:
iv) Anterior wall
v) LV cavity
vi) Posterior wall
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i iv
v
vi
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Mice were administered isoproterenol (4 ng/g; intraperitoneal bolus) and 
echocardiographic measurements repeated after a 4 minute incubation period. This 
dosing protocol was optimised for use in this thesis and is described further in chapter 7. 
3.7.3. Statistical analysis of echocardiography measurements 
All values are presented as mean ± standard error of mean (SEM). Data were analysed 
by a one-way ANOVA and Bonferroni test comparing relevant columns of data using 
GraphPad Prism® version 5.0 (GraphPad Software, USA). Statistical significance was 
reported where the computed P-value was less than 0.05 and indicated using standard 
significance coding described above. No significance was reported where P>0.05. 
 
3.8. Cardiac magnetic resonance imaging 
Cardiac magnetic resonance imaging was undertaken in collaboration with Dr A. 
Campbell-Washburn and Mr T. Roberts, who were supervised by Prof M. Lythgoe 
(Centre for Advanced Biological Imaging, University College London, UK). 
 
An overview of the relevant theory of magnetic resonance imaging (MRI) and its use for 
interrogating the physical properties of tissues in vivo is provided in chapter 1 (see 
1.5.2). This thesis does not concern the development of the specific cardiac MRI 
sequences used here but assesses their application as potential tools for interrogating 
the reperfused mouse heart and for potentially assessing myocardial salvage.  
The cardiac MRI sequences employed here were developed by our collaborators at the 
Centre for Advanced Biomedical Imaging (CABI) at University College London, UK. The 
development of the computational codes for the MRI sequences and data analysis used 
in this thesis have been reported by Dr A. Campbell-Washburn in the form of a PhD 
thesis. Readers are referred to Campbell-Washburn et al. (2012; 2013) for detailed 
descriptions of the arterial spin labelling MRI sequence and its development. Technical 
assistance for the later work presented here was provided by Mr T. Roberts at CABI. 
The work presented in this thesis represents the first application of the MRI sequences 
developed at CABI to mice subjected to myocardial ischaemia-reperfusion injury. 
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3.8.1. Small animal magnetic resonance imaging setup 
i Small animal cardiac MRI setup 
MRI was undertaken using a 9.4 tesla horizontal bore scanner (Agilent Technologies, 
USA) fitted with 1000 mT/m gradient inserts (inner diameter of 60mm; Agilent 
Technologies, USA) running VNMRJ software (version 2.3A). Volume resonator 
quadrature RF coils (RAPID biomed, Ripmar, Germany) were used for RF transmission 
and signal reception. A detailed description of the MRI instrumentation at CABI is 
provided by Price et al (2011). MRI was undertaken according to the standard MRI 
protocol optimised at CABI and performed by Dr. A. Campbell-Washburn with final 
experiments assisted by Mr T. Roberts. 
Mice were anaesthetised using isoflurane (approximately 1.5-2.0% isoflurane vaporised 
in 1.5 L/minute oxygen) and upon reaching a steady state of anaesthesia were 
transferred to the MRI small animal cradle (supplied with 1.0-2.0% isoflurane vaporised 
in 1.5 L/minute oxygen). Mice were securely fixed into the cradle and monitoring devices 
attached for real-time recording of respiration (neonatal apnoea sensor placed on the 
abdomen), ECG (two-lead setup, SA Instruments, USA) and body temperature (rectal 
thermometer attached to SA Instruments, USA). Body temperature was maintained at 
36.5±0.5ºC using circulating warmed water (contained within tubing in close proximity to 
the animal) and a warm air fan placed at the entrance to the bore of the scanner. An 
intraperitoneal (I.P.) perfusion line containing gadolinium was attached to allow 
subsequent administration of gadolinium.  
MRI acquisition was double-gated for both respiratory and cardiac gating to reduce 
motion artefacts. Respiration gating was applied by detection of chest movements using 
a pressure sensor (described above) to trigger image acquisition immediately following 
exhalation. Cardiac gating was achieved by detection of the integrated ECG trace to 
allow triggering of image acquisition immediately following detection of the ECG R-wave. 
This cardiac gating method ensured that images were obtained at the same phase of 
the cardiac cycle to allow compilation of final datasets of the whole heart and to allow 
subsequent quantification of cardiac parameters from these imaging protocols. 
The main cardiac MRI protocol applied in this thesis comprised: (1) arterial spin labelling 
imaging (ASL) and (2) T2-mapping and (3) late-gadolinium enhancement imaging; an 
overview of this protocol is shown in Figure 3.20 and described further below. 
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Figure 3.20: Cardiac MRI protocol 
Animals underwent MRI comprising Cine imaging (volumes and function), T2-mapping (putative 
AAR), arterial spin labelling (putative AAR) and late-gadolinium enhancement (infarct size). 
Immediately following cardiac MRI, mice were anaesthetised and hearts subjected to histological 
staining for validation of MRI measurements. 
 
Cardiac MRI was performed by Dr A. Campbell-Washburn and Mr T. Roberts. 
 
3.8.2. Cine imaging – Cardiac function 
Cinematic (cine) images of the heart were first acquired to allow calculation of cardiac 
volumes and function of the reperfused mouse hearts examined in this thesis. 
Theoretical basis: Cine imaging allows a series of single frame images of the heart to 
be captured throughout the cardiac cycle which can subsequently be used to create 
moving images of the heart to evaluate its contractile function. Cine imaging of the heart 
can be undertaken to give four-chamber (both ventricles and both atria), two-chamber 
(left ventricle and left atria) and short-axis (left ventricle and right ventricle) views of the 
heart. These images can be used to identify functional defects in contractile function and 
regional abnormalities in myocardial thickness. Cine imaging therefore allows an overall 
assessment of cardiac structure and function and is a widely used cardiac MRI protocol 
for animal and clinical studies of the heart (reviewed by McRobbie et al., 2006). 
Method: The precise parameters of Cine imaging of the mouse heart used in this thesis 
are detailed by Price et al. (2011) and the salient points highlighted here. Initial scout 
images of the heart were first acquired in order to plan the two-chamber, four-chamber 
and short-axis views of the heart. For short-axis imaging of the heart, 10 myocardial 
slices of 1 mm thickness were imaged to approximately correspond to the whole left 
ventricle from apex to base. Cine imaging was performed using a double gated spoiled 
gradient echo sequence as detailed by Price et al. (2011). Two- and four-chamber cine 
images were used to assess cardiac contractile function and myocardial thickness only. 
Quantification: Cardiac function was assessed from short-axis cine images. The 
myocardium was selected in these images by delineation of the epicardial and 
endocardial borders using semi-automated analysis by Segment software version 8 
(Segment, http://segment.heiberg.se/). The blood pool volume (defined as the area 
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encompassed by the endocardial border) was then plotted against time to allow 
delineation of the phases of the cardiac cycle, specifically end-diastole (ED) and end-
systole (ES). Manual correction of the segmentation of epicardial and endocardial 
borders was undertaken for the slices at ED and ES to ensure accurate calculations of 
cardiac function. Cardiac function was evaluated as detailed below: 
(1) Anatomical measurements – Left ventricular wall mass (µg) was calculated as: 
Myocardial wall volume x 1.05 g/ml. 
 
 
(2) Heart rate – This was calculated as the mean time between ECG traces. 
 
(3) Stroke volume = (end-diastolic volume) – (end-systolic volume)  
 
(4) Cardiac output  = Heart rate * stroke volume 
 
(5)  Ejection fraction  = (LV end-diastolic volume - LV end-systolic volume) *100 
LV end-diastolic volume 
Statistical analysis: Quantification of these cardiac function measures was presented 
as mean ± standard error of mean (SEM). All statistical analysis was completed using 
GraphPad Prism® version 5.0 (GraphPad Software, USA). Where two groups were 
compared, data were analysed using an unpaired t-test. Where more than two groups 
were compared, data were analysed by one-way ANOVA and Bonferroni test comparing 
relevant groups. Statistical significance was reported where P<0.05. 
3.8.3. Arterial spin labelling – Putative area-at-risk 
This thesis investigates the use of arterial spin labelling (ASL) perfusion imaging as a 
potential method to quantify myocardial AAR in vivo in the reperfused mouse heart.  
Theoretical basis: ASL MRI uses magnetically tagged water as an endogenous tracer 
to assess the movement of fluid within the myocardium. ASL uses radiofrequency (RF) 
pulses to affect the proton spins and in turn magnetically tag the blood water molecules 
(an excellent overview of this technique is provided by Petersen et al., 2006).  
The ASL sequence applied in this thesis was a multi-slice flow alternating inversion 
recovery (FAIR) ASL (for precise details of this specific method see Campbell-Washburn 
et al., 2012). FAIR ASL uses two different inversion pulses to affect the proton spins 
within the tissue: (1) slice-selective inversion pulse (control condition – affects only 
proton spins in the imaging slice) and (2) global inversion pulse (tagged condition – 
affects proton spins throughout the body). ASL imaging is based on the T1-relaxation 
(spin-lattice relaxation time) of protons spins. The global pulse inverts the proton spins 
of all blood within the myocardium such that the proton spins of the blood perfusing the 
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slice of interest are undergoing T1-recovery with the T1-relaxation parameters of blood. 
In comparison, the slice-selective inversion pulse inverts only the proton spins within 
that slice. The time delay between magnetic labelling (RF pulse inversion of proton 
spins) and acquisition (termed the inversion delay) allows new, unlabelled blood (with 
proton spins in equilibrium) to flow into the slice, thereby giving the appearance of 
accelerated T1-recovery. Since the difference between control T1-recovery (global 
inversion) and tagged T1-recovery depends on the rate of myocardial perfusion, 
comparison of the T1-values from control and tagged conditions can be used to provide 
an estimation of myocardial perfusion; further overview the theory of ASL MRI and its 
use for quantifying tissue perfusion is provided by Petersen et al. (2006). 
Method: The ASL cardiac MRI method applied in this thesis was developed for 
application to the mouse heart by our collaborators at CABI (Campbell-Washburn et al., 
2012; 2013). The studies presented in this thesis represent the first application of multi-
slice ASL cardiac MRI to the reperfused mouse heart (discussed further in chapter 8).  
Following completion of the cine imaging sequence, the multi-slice ASL cardiac 
sequence was initiated. T1-relaxation was measured following slice-selective (control 
condition) and global (tagged condition) inversion RF pulses using a multi-slice 
segmented ECG-gated Look-Locker method. Scanning parameters were as follows: 
TE/TR(inv)/TR(RF) = 1.18 ms/13.5 s/3 ms, flip angle = 5°, FOV = 25.6 mm x 25.6 mm, 
matrix = 128 x 128, slice thickness = 1 mm, 6 slices total (3 slices/acquisition), number 
of points in recovery curve = 50 (as detailed by Campbell-Washburn et al., 2012; 2013). 
This ASL sequence was cardiac gated but not respiration gated which therefore resulted 
in some respiratory noise which is discussed in more detail subsequently. Multi-slice 
perfusion maps were calculated by comparison of T1-recovery curves following slice-
selective and global RF inversion pulses. This was performed on a pixel-by-pixel basis 
to generate ASL perfusion maps for each heart slice using scripts written in-house by Dr 
A. Campbell-Washburn (MATLAB Student Version R2008b, The MathWorks, USA).  
The initial pilot study investigating the application of this ASL imaging method to 
reperfused mouse hearts in this thesis showed a large degree of variation in the 
perfusion values obtained for the most apical slice. This signal noise is thought to have 
resulted from respiratory motion since this ASL sequence was not respiratory gated. 
Since the perfusion values of the most apical slice did not seem reliable in the pilot 
studies, this slice was not acquired in the ASL imaging for the final datasets presented 
here. Since this method allowed acquisition of only 3 slices simultaneously, two 
acquisitions were required to image the whole left ventricle (6 short-axis slices). 
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Quantification: Perfusion was assessed from the ASL perfusion maps of 6 myocardial 
slices. Perfusion maps of myocardial slices produced by MATLAB compilation of raw T1-
values were displayed as heat-maps where normal perfusion appears in ‘hot’ colours 
(red – orange) and low perfusion appears in ‘cold’ colours (cyan - blue) (Figure 3.21). 
 
Figure 3.21: ASL perfusion map 
Representative image of cardiac 
ASL perfusion map of mid-ventricle 
myocardial slice. Normal perfusion 
appears in ‘hot’ colours (red – 
orange) and low perfusion appears 
in ‘cold’ colours (cyan - blue). 
Segmentation of the myocardium 
means the background appears 
dark blue – this does not represent 
perfusion in these areas. 
 
Normal perfusion values were defined for each heart by selection of a region of interest 
in the second from most basal slice, which is expected to be normal (corresponding to 
the non-AAR) in this mouse model of ischaemia-reperfusion. This area was used to 
define the mean normal perfusion. Reduced perfusion was defined as exhibiting a T1-
value less than 1 standard deviation below the mean normal T1-value. This threshold 
analysis was performed by custom MATLAB scripts (as described above). The area of 
reduced perfusion was calculated as a percentage of the total number of myocardial 
pixels (area of perfusion deficit / myocardial area %). The area of reduced perfusion was 
investigated as a putative measure of myocardial AAR as described below (see 3.8.7). 
3.8.4. T2-mapping – Putative area-at-risk 
Since previous studies have suggested that T2-weighted based cardiac MRI can be 
used to determine the AAR in vivo, this thesis also investigated the use T2-mapping MRI 
as a method to quantify myocardial AAR in vivo in the reperfused mouse heart.  
Theoretical basis: T2-weighted based MRI imaging is based on the T2-relaxation (spin-
spin relaxation time) of protons spins. T2-relaxation is caused by interactions between 
proton spins whereby slower relaxation causes a faster T2-relaxation time and reduction 
in the MRI signal. Since free water (fluid) contains small molecules that are far apart and 
rapidly moving, there are fewer spin-spin interactions resulting in slower T2-relaxation 
(longer T2-relaxation times). This slower T2-relaxation results in less loss of T2-signal at 
a given time thereby appearing bright on T2-weighted images of the myocardium. T2-
weighted MRI exploits the known linear correlation between tissue water content and T2-
relaxation time to characterise pathological increases in tissue water content (McRobbie 
et al., 2006). Tissue oedema with increased fluid accumulation will therefore cause 
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slower T2-relaxation resulting in increased T2-relaxation times and brighter signals on T2-
weighted images. T2-weighted based MRI sequences measure T2-relaxation at a range 
of echo times (termed TE: defined as the time between RF pulse and signal 
measurement). At increased echo times there is more time for the protons to undergo 
T2-relaxation resulting in reduced MRI signal, described by an exponential relationship. 
The T2-relaxation times at multiple echo times can be used to construct exponential 
decay curves to determine the T2 time constant (as described by McRobbie et al., 2006).  
Method: The T2-mapping cardiac MRI method applied here was developed for 
application to the mouse heart by Dr A. Campbell-Washburn at CABI. This method was 
loosely based on that briefly described in a presentation abstract by Bohl et al.(2010).  
The MRI setup was as described above where 7 short-axis slices of the myocardium 
were interrogated. Following completion of ASL imaging, the multi-slice T2-mapping 
cardiac protocol was initiated. T2-relaxation was measured using a cardiac-gated spin 
echo sequence, with sequence parameters as follows: TE = (3.5, 7, 10, 12, 15, 17, 20, 
25, 30) ms, repetition time (TR) = RR-interval, matrix = 128 x 128, field-of-view (FOV) = 
25.6 mm x 25.6 mm, 7 slices, slice thickness = 1mm. A delay following the R-wave was 
introduced to this sequence to ensure that the MRI signal was measured at the same 
cardiac phase. Exponential decay curves of T2-relaxation time were used fit to the 
myocardial signal intensity on a pixel-wise basis for each slice using scripts written by Dr 
A. Campbell-Washburn (MATLAB Student Version R2008b, The MathWorks, USA).  
Quantification: Myocardial T2-signal was assessed from the T2-maps of the 7 
myocardial slices. T2-maps of each myocardial slice produced by MATLAB analysis 
were displayed as heat-maps in which normal T2-signal appears in ‘colder’ colours 
(green-yellow) and elevated T2-signal appears in ‘hot’ colours (red) (Figure 3.22).  
 
Figure 3.22: MRI T2-map 
Representative image of cardiac 
T2-map of mid-ventricle slice. 
Normal T2-signal appears in ‘cold’ 
colours (green – yellow) and 
increased T2-signal appears in 
‘hot’ colours (red). Segmentation 
of the myocardium means the 
background appears dark blue – 
this does not represent T2-signal 
in these areas. 
 
Normal T2-signal values were defined for each heart by selection of a region of interest 
in the septum of the second from most basal slice, which is expected to be normal (non-
AAR) in this mouse model. This area was used to define the mean normal T2-value. 
Elevated T2-values were defined as greater than 1 standard deviation above the mean 
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normal T2-value. This threshold analysis was performed by custom MATLAB scripts (as 
described above). The area of elevated T2-signal was calculated as a percentage of the 
total number of myocardial pixels (area of elevated T2-signal / myocardial area %). 
3.8.5. Late-gadolinium enhancement – Infarct size 
Late-gadolinium enhancement (LGE) cardiac MRI has been widely used to quantify 
myocardial infarct size in experimental animal and clinical studies. This thesis applied a 
multi-slice LGE cardiac MRI protocol optimised and validated for use in rodents by our 
collaborators at CABI and described by Price et al. (2011). 
Theoretical basis: The use of exogenous contrast agents can be used to affect T1- or 
T2-relaxation times and therefore provide enhanced signal within a region of interest. 
Gadolinium-based contrast agents have been widely used to highlight regions of 
myocardial infarction in cardiac MRI and have become a reference standard for this 
purpose. Gadolinium (Gd) acts as a paramagnetic agent due to its seven unpaired 
electrons which shorten T1-relaxation time. Gd distributes throughout the vasculature 
and extracellular space but cannot transverse cell membranes due to its size and 
charge. However, in regions of infarction, disruption of cell membranes and the resulting 
increased extracellular space allows an increased Gd distribution which results in 
shorter T1-relaxation times in this region of tissue. Late-gadolinium enhancement (LGE) 
imaging exploits this effect of Gd-enhanced T1-relaxation by imaging the myocardium 10 
minutes after Gd administration to allow sufficient Gd accumulation within the infarcted 
area. LGE allows clear visualisation of areas of infarction and has been widely validated 
to provide accurate infarct size quantification (overview provided by McRobbie et al., 
2006); see 1.5.2 for a further overview of this method. 
Method: The precise LGE imaging method used here is described by Price et al. 
(2011). Gadolinium diethylene-triamine penta-acetic acid (Gd-DTPA) was administered 
via an intraperitoneal infusion line as a single bolus of 0.6 mmol/kg Gd-DTPA 
(Magnevist, Germany). Following a delay of 10 minutes to allow for enhancement by Gd 
within the area of infarction, a further set of T1-weighted images was acquired. A Look-
Locker-style gradient echo acquisition was used to determine the null point of healthy 
myocardium in one mid-ventricle slice (one acquisition per cardiac cycle, TR(RF) = RR-
interval, TE = 1.1 ms, FOV = 25.6 mm x 25.6 mm, slice thickness = 1 mm, flip angle = 
10°, recovery delay= 1 s, acquisition time ~ 3 minutes). LGE images were acquired 
using the single inversion time point chosen with Look-Locker acquisition (typically 3 
RR-intervals) (7 short axis slices acquired sequentially during systole per cardiac cycle, 
TE = 1.1 ms, TR(slice) = 3.1 ms, FOV = 25.6 mm x 25.6 mm, matrix = 128 x 128).  
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Quantification: Areas of infarction appear with an enhanced (brighter) signal on T1-
weighted images of the myocardium (Figure 3.23). Infarct area was determined using an 
automated delineation method constrained by the myocardial borders using Segment 
software (version 8, http://segment.heiberg.se/). Infarct size was calculated as the 
number of pixels with hyperenhanced T1-signal as a percentage of the total number of 
pixels in the left ventricle. Analysis of this quantification is described below (see 3.8.7). 
 
Figure 3.23: Cardiac MRI LGE image 
Representative image of LGE imaging of 
mid-ventricle myocardial slice. T1-images of 
the myocardium obtained at the null point of 
healthy tissue (appears dark). Accumulation 
of gadolinium within the area of infarction 10 
minutes post-Gd-DTPA administration 
results in shorter T1-relaxation within this 
area (seen as the region of bright signal 
intensity).  
 
 
3.8.6. Histological staining for validation of cardiac MRI 
In order to validate cardiac MRI measurements of infarct size and AAR, hearts were also 
subjected to classical ex vivo histological staining using TTC and Evans blue staining as 
described previously (see 3.2.4). Seven transverse slices of approximately 1 mm 
thickness were taken from apex towards base and imaged exactly as described above. 
3.8.7. Statistical analysis of cardiac MRI and histological measurements 
Percentage areas are reported as mean ± standard error of mean (SEM). All statistical 
analysis was completed using GraphPad Prism® version 5.0 (GraphPad Software, 
USA). Details of statistical analyses and sample sizes are provided alongside results 
presented in the subsequent chapters of this thesis. Validation of cardiac MRI 
quantification of myocardial infarct size and AAR was assessed by paired t-test 
comparison of MRI and histology endpoints for each group. For all statistical tests, 
statistical significance was reported where P<0.05 using standard significance coding.  
To assess the overall agreement in cardiac MRI and histological methods, Bland-Altman 
plots were constructed for each experimental group. Although Bland-Altman plots do not 
provide a formal structure for statistical testing, they provide a useful method of 
visualising the differences between these two methods. The endpoint for each method 
was plotted for each heart as the difference between histological and MRI quantification 
(Δ = cardiac MRI – histology endpoint) against the average quantified by these methods.   
Increased T1-signal
= Infarction
Null T1-signal
= Normal tissue
(Blood pool)
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CHAPTER 4: ESTABLISHMENT OF AN IN VIVO MODEL OF 
MYOCARDIAL  ISCHAEMIA-REPERFUSION   INJURY  
 
4.1. Introduction 
Ischaemia-reperfusion injury is the main clinical consequence of acute myocardial 
infarction. During acute myocardial infarction blockage of a coronary artery causes 
ischaemia within the area normally perfused by this vessel. Rapid reperfusion of the 
ischaemic myocardium is required to preserve the viability of ‘at-risk’ cardiomyocytes 
and is achieved clinically by primary percutaneous coronary intervention (PPCI) or 
pharmacological thrombolysis (Thygesen et al., 2007). However, myocardial reperfusion 
itself paradoxically causes a degree of myocardial injury (including cardiac arrhythmias, 
stunning and no-reflow) and cell death (lethal reperfusion injury). Although the former 
types of myocardial injury can be clinically managed, there remains no clinical therapy to 
protect against lethal reperfusion injury (reviewed by Hausenloy and Yellon, 2013). 
Lethal reperfusion injury is thought to account for a significant proportion of the final 
myocardial infarct size in acute myocardial infarction patients. Since myocardial infarct 
size is a critical determinant of acute myocardial infarction patient prognosis (Sobel et 
al., 1972), lethal reperfusion injury represents a significant and largely unmet clinical 
target for cardioprotection (reviewed by Garcia-Dorado et al., 2009; Hausenloy and 
Yellon, 2013). It is therefore pertinent to investigate methods to protect the myocardium 
against both ischaemic and reperfusion injury. To this end, the first aim of this thesis 
was to establish an appropriate model of ischaemia-reperfusion injury which could be 
applied to investigate potential therapeutic targets for long-term cardioprotection. 
There are numerous experimental research models of ischaemia-reperfusion including 
simulated ischaemia-reperfusion (hypoxia-reoxygenation) of preparations of in vitro 
cultured cells and ex vivo primary isolated cells. However, since this thesis aimed to 
investigate the long-term efficacy of cardioprotective interventions, an in vivo ischaemia-
reperfusion model with long-term recovery of experimental subjects was essential. 
 
The first results chapter of the thesis describes the establishment and validation of a 
mouse in vivo recovery model of ischaemia-reperfusion and the effects of important 
experimental variables central to the design of subsequent studies in this thesis. 
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4.2. Research objective and aims 
The first aim of this thesis was to develop and characterise a mouse in vivo recovery 
model of ischaemia-reperfusion injury for subsequent investigations of long-term 
cardioprotective efficacy. The principal research aims to achieve this objective were: 
(1) Establish a mouse in vivo recovery model of ischaemia-reperfusion injury; 
 
(2) Validate this in vivo recovery model of ischaemia-reperfusion by application of 
known therapeutic interventions to demonstrate significant cardioprotection; 
 
(3) Characterise this in vivo recovery model of ischaemia-reperfusion injury to 
determine the optimum protocol for subsequent applications of the model. 
 
4.3. Aim 1: Establish in vivo recovery model of ischaemia-
reperfusion  
4.3.1. Background 
Experimental models of in vivo ischaemia-reperfusion injury have been widely employed 
in this research field and have most commonly utilised large animal species including 
dog and pig (reviewed by Black and Rodger, 1996). However, although it is technically 
more challenging to establish in vivo models in mice due to their small size and rapid 
heart rate, recent advances in genetics and the resulting scope of genetically modified 
models make the mouse an important tool for investigating long-term cardioprotection. 
Experimental research models of in vivo ischaemia-reperfusion injury most commonly 
comprise artificial occlusion of a main coronary artery to cause ischaemia followed by 
release of the occlusion to initiate reperfusion. This can be achieved using intra-
coronary devices (for example coronary balloon inflation) in larger animals. However, in 
small animals this is usually undertaken by ligation and release of a fine suture placed 
around the coronary artery (reviewed by Verdouw et al., 1998; Klocke et al., 2007). 
Clinically, occlusion of one of the main coronary arteries perfusing the left ventricle (LAD 
or circumflex arteries) results in the most significant patient morbidity and mortality due 
to the large area of myocardium affected and the essential role of the left ventricle in 
normal cardiac contractile function (Thygesen et al., 2007). Most animal models of 
ischaemia-reperfusion therefore comprise occlusion of one of these main left ventricle 
arteries, commonly the LAD (Verdouw et al., 1998). The LAD perfuses the majority of 
the left ventricle meaning that occlusion of the main LAD branch causes a large 
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regionally distinct area of ischaemia, termed the AAR (reviewed by Verdouw et al., 
1998; Klocke et al., 2007). There are subtle differences in the LAD branch patterns of 
mice compared to other species; specifically, the mouse LAD does not perfuse the left 
ventricle septal wall (Kumar et al., 2005); this is, however, unlikely to influence the 
validity of the mouse model for cardioprotection studies. The mouse coronary anatomy 
exhibits a similarly low number of collateral vessels (those vessels serving the same 
vascular bed) as the healthy human heart. However, it should be noted that the 
occurrence of acute myocardial infarction in patients is preceded by the chronic 
pathological processes of cardiovascular disease which is likely to result in the develop 
and opening of collateral vessels (reviewed by Verdouw et al., 1998). These are 
important considerations for the development and interpretation of the model here. 
The mouse in vivo recovery model of ischaemia-reperfusion was first described by 
Michael et al. in 1995 (Michael et al., 1995) and further refined by Fisher and Marber 
(2002). However, the mouse in vivo recovery model of ischaemia-reperfusion remains 
recognised as a challenging model to establish and further publications have aimed to 
provide detailed methodological protocols to expedite the setup of this model. Notably 
van Laake et al. (2007) published extensive troubleshooting advice which alongside the 
protocols from Michael et al. (1995) and Fisher and Marber (2002), provided a 
foundation for the establishment of the model in this chapter. 
The main objective of this chapter was to establish and characterise a mouse in vivo 
model of ischaemia-reperfusion for the first time within our laboratory. The principal 
attributes of this model are: (1) use of mice to exploit genetic models, (2) defined periods 
of ischaemia and reperfusion and (3) recovery to permit long-term investigation.  
 
Aim 1: The first aim of this chapter was to establish a mouse in vivo recovery model of 
ischaemia-reperfusion injury. The crucial milestones for development of the model were:  
(1) Sufficient surgical survival – this is required by the UK Home Office to be greater 
than 75% immediate surgical survival of animals subjected to this protocol. 
 
(2) Minimal and quantified effects of potentially confounding factors – this primarily 
concerns investigation of the potential conditioning effects of anaesthetic regime 
used and is described in more detail subsequently in this chapter. 
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4.3.2. Detailed methods 
The mouse in vivo recovery model of ischaemia-reperfusion injury comprised occlusion 
and reperfusion of the LAD coronary artery followed by recovery of the animals for long-
term investigation. The surgical procedure was based on that described by Fisher and 
Marber (2002) with modifications informed by van Laake et al. (2007). In addition to the 
brief description of the surgical model provided in chapter 3, this section provides a 
detailed description of the precise surgical protocol developed during the course of this 
study with the aim of providing a comprehensive resource for future operators. 
i Ischaemia-reperfusion injury in vivo recovery model 
Surgical setup: All recovery surgical procedures were conducted in a controlled sterile 
surgical theatre at University College London, UK. An overview of the surgical setup is 
illustrated in Figure 4.1 and the key components described below. 
Aseptic operating practices were adhered to throughout the procedure as defined by the 
Handbook of Laboratory Animal Management and Welfare (Wolfensohn and Lloyd, 
2003). Animals were prepared for surgery by hair removal and chlorhexidine cleansing 
of the chest and neck regions. Chlorhexidine washes were also undertaken prior to skin 
opening and immediately upon skin closure to reduce the possibility of infection.  
Specialised small animal surgical instruments were used for all surgical procedures 
(instruments shown in Figure 4.1; purchased from World Precison Instruments, UK 
unless otherwise stated). All instruments were autoclaved prior to each operating 
session and a hot bead steriliser was used to sterilise instruments between surgeries.  
Surgeries were conducted on a thermostatically controlled heated operating table (Peco 
Services Ltd, UK) covered with a sterile material drape. ECG recordings were taken 
throughout surgery by means of a three-lead ECG with electrodes attached 
subcutaneously on both forelimbs (positive and negative leads) and the right hind limb 
(reference lead) (Powerlab coupled to Chart 7 software, AD Instruments, UK). 
Temperature was monitored via a rectal thermometer (K-type thermocouple 
thermometer, Hanna Instruments, UK) and maintained at 37.0±0.5°C by manual 
adjustment of the heated operating table. All surgery was conducted with the aid of a 
surgical microscope (Zeiss Universal S2, Zeiss, Germany).  
Figure 4.1: Surgical setup for in vivo model 
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Figure 4.1: Surgical setup for in vivo model
A) Surgical setup: isoflurane vaporiser connected to oxygen
supply, heated operating table prepared with sterile surgical
drape, small animal ventilator and ECG setup. B) Operating
table: ventilator, nose cone (red), temperature probe and
ECG leads. C) Instruments: From World Precision
Instruments, UK, unless stated otherwise in the text.
i) Fine forceps
ii) Small needle holder
iii) High temperature cautery
iv) Rat-toothed rib holder
v) Large needle holder
vi) Blunt round ended scissors
vii) Serrated tweezers
viii)Sharp microdissection scissors
ix) Smooth tweezers
x) Goldstein chest retractor
xi) Blunt stay hooks
C
B
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Surgical procedure: Surgical depth of anaesthesia was assessed before starting the 
surgical procedure and regularly thereafter, where sufficient anaesthetic depth was 
confirmed by the loss of pedal reflex to toe-pinch stimulus. The anaesthetic regimes 
used are detailed subsequently. For isoflurane anaesthesia, breathing rate was also 
observed as an indication of anaesthesia; where slow shallow or deep gasping breaths 
were suggestive of too deep anaesthetic depth, as described by Wiersema et al. (1997).  
The precise in vivo ischaemia-reperfusion surgical procedure is detailed below: 
(1) Intubation – Mice were placed in the supine position and the neck extended using a 
suture hooked around the incisors and secured using adhesive tapes. Direct 
observation of the trachea was used to aid intubation by creating a small skin 
incision to the neck directly above the visible midline of the salivary glands. The 
trachea was exposed by gently teasing apart the skin, submaxillary glands and 
paratracheal muscles in turn. The ventilation cannula was passed through the mouth 
into the trachea (see Figure 4.4 i).  
 
Successful intubation was confirmed once the intubation cannula could be directly 
visualised inside the trachea and further confirmed by observing regular chest 
movements upon ventilation. Unsuccessful intubation, corresponding to the 
placement of the ventilation cannula in the oesophagus, was judged by absence of 
the cannula inside the trachea and regular movements to the lower abdomen upon 
ventilation. In the event of unsuccessful intubation, the ventilation cannula was 
removed and further attempts at intubation made. Intubation was ideally completed 
within two attempts. The ventilation cannula was only connected to the ventilator 
once successful intubation was confirmed (see section ii). The final ventilation 
technique developed here is illustrated in Figure 4.6. 
 
(2) Thoracotomy – For access to the LAD the mouse was repositioned by crossing the 
left leg over the body. A skin incision was made laterally across the chest at the 
approximate position of the fourth intercostal space. The major and minor pectoral 
muscles were blunt dissected and reflected outwards using blunt hook stays (Figure 
4.1 xi); caution was taken to preserve integrity of the pectoral muscles for effective 
chest closure. The fourth intercostal space was identified by evaluation of the lung 
position - the fourth space being the one prior to the curvature of the base of the lung 
and confirmed by the presence of a large branching vessel along the surface of the 
rib. Opening of the intercostal space was performed by dissection to create a small 
entry hole using sharp pointed scissors (Figure 4.1 xiii) followed by insertion of a 
small animal chest retractor (Figure 4.1 x). Opening of the chest retractor was aided 
135 
by diathermic dissection using a high temperature cautery (Figure 4.1 iii; Bovie, 
USA). See Figure 4.4, stages ii-iv. 
 
In occasional circumstances where the lung was positioned in close proximity to the 
chest wall opening, a small saline soaked swab was placed between the heart and 
lung in order to protect the lung. Extreme care was taken not to damage the lung. 
This swab was then removed at the end of the procedure prior to chest closure.  
 
(3) Ischaemia / Reperfusion – Access to the LAD was facilitated by opening of the 
pericardium using blunt tweezers (Figure 4.1 vii, see Figure 4.4 v). The LAD was 
identified by its brighter red colour and often by its pulsating appearance; in cases 
where the LAD could not be visualised, the suture position was approximated from 
experience. The pericardium was used to slightly rotate the heart to facilitate access 
to the LAD. The LAD was under-run with an 8-0 polypropylene suture (8-0 prolene 
non-absorbable suture, W2775, Ethicon, USA) approximately 2 mm below the tip of 
the left atrium. A snare system consisting of several precisely cut lengths of 
polyethylene tubing (PE50, Deutsch and Neumann, Germany) and modified pipette 
tip was assembled onto the suture to allow LAD occlusion and release (Figure 4.2).  
 
Figure 4.2: LAD snare system for 
ischaemia and reperfusion 
Custom-made snare system for induction of 
ischaemia and reperfusion consisting of (a) 8-
0 polypropylene suture, (b) suture tubing PE-
50, (c) conical tubing pipette tip, (d) brake 
tubing PE-50 and (e) protective tubing PE-50. 
Ischaemia was induced by occlusion of the 
snare system and reperfusion initiated by 
release of the snare system. 
 
(See Figure 4.4 for in vivo snare assembly) 
 
 
Successful ischaemia upon occlusion of the snare system was confirmed primarily 
by appreciable myocardial pallor distal to the suture and ECG ST-segment change. 
Since the AAR was expected to be transmural across the free wall of the left 
ventricle, ischaemia was expected to induce elevation of the ST-segment (Figure 4.3 
A). In cases where depression of the ST-segment was observed (indicative of 
subendocardial left ventricular ischaemia) the procedure was continued since AAR 
inclusion criteria were applied subsequently upon analysis (see section vi). In 
addition, successful ischaemia of a sufficiently large myocardial AAR was expected 
to cause noticeable akinesis of the left ventricle. Reperfusion upon release of the 
snare was confirmed by return of myocardial colour and resolution of the ECG ST-
segment change (Figure 4.3 B). Precise exclusion criteria are detailed in section iv. 
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Figure 4.3: Confirmation of successful ischaemia and reperfusion 
 (A) Snare system in vivo (1 cm scale bar). (B) Example ECG for (i) stabilisation – loose 
assembly of snare and normal ECG trace, (i) ischaemia – occlusion of snare and ST-
segment elevation and (ii) reperfusion – release of snare and resolution of ST-segment. 
 
In sham operated mice the snare system was assembled but not occluded and all 
surgical timings observed to ensure equal anaesthetic duration between groups. 
 
(4) Chest closure – Immediately following reperfusion, the snare system was 
disassembled and the suture cut leaving sufficient lengths for re-occlusion upon 
extraction of the heart. All parts of the snare except the LAD suture were removed 
and the ends of the LAD suture placed securely inside the chest cavity.  
 
The intercostal space was closed using two 5-0 braided silk sutures (5-0 mersilk 
non-absorbable suture, W595, Ethicon, USA), where the lateral suture was tightened 
first to approximate the ribs and protect the lung. Ventilation positive end pressure 
(PEP) was then applied by submersion of the ventilator outlet tube in 2 cm of water 
to completely re-inflate the lungs, which was expected to improve respiratory 
function upon recovery. The medial suture was tightened upon simultaneous 
application of gentle chest compression to expel excess air to prevent 
pneumothorax. Effective closure of the intercostal space was facilitated by tissue 
glue (Vetbond, 3M, UK) applied to the suture sites and muscle opening. The major 
and minor pectoral muscles were unfolded to cover the underlying intercostal space 
opening and the skin closed with interrupted 5-0 braided silk sutures. Careful 
dissection of these muscles in stage 2 of this protocol preserves muscle integrity 
which in turn facilitates good closure of the intercostal space (see Figure 4.4 ix). 
ii
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(5) Recovery – Cessation of anaesthesia is detailed for each anaesthetic regime below. 
When the animal had recovered independent breathing, extubation was facilitated by 
gentle removal of the ventilation cannula. Supplemental oxygen was provided via a 
nose cone for approximately 5 minutes after which animals were expected to have 
fully regained mobility. Animals were housed individually post-surgery and monitored 
hourly for the first six hours and twice daily thereafter. 
 
Analgesia was provided by buprenorphine (0.1 mg/kg intramuscular, Vetergesic 
[Alstoe Animal Health, UK]) administered at the start of the procedure and 6 and 24 
hours into recovery, as described previously in chapter 3. 
 
A detailed pictorial summary of each stage of the mouse in vivo ischaemia-reperfusion 
surgical protocol is provided below in Figure 4.4. 
 
Figure 4.4: Summary of in vivo ischaemia-reperfusion injury recovery model 
Main procedural stages (1 cm scale bar): i) Ventilation via oral intubation and connection to 
ventilator. ii) Preparation and opening of skin to reveal pectoral muscles. iii) Retraction of pectoral 
muscles using blunt hook stays. iv) Thoracotomy with the aid of a small chest retractor. v) 
Opening of pericardium to access the heart. vi) Placement of 8-0 suture around LAD and 
assembly of snare. vii) Occlusion of snare to induce ischaemia, followed by release and removal 
of snare. viii) Intercostal space closure using 5-0 sutures and tissue glue. ix) Release of pectoral 
muscles to complete chest closure. 
 
i ii iii
iv v vi
vii viii ix
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The standard recovery in vivo ischaemia-reperfusion injury protocol was 30 minutes 
ischaemia and 72 hours reperfusion (Figure 4.5). A 15 minute stabilisation period was 
allowed prior to the onset of ischaemia to allow for extended durations of ischaemia or 
IPC in modified protocols without extending the total surgical duration. The total 
anaesthetic duration for this model was approximately 55±5 minutes and the anaesthetic 
duration was kept as consistent as possible between animals to reduce any potential 
interference of anaesthetic conditioning (discussed in section 4.6.1 i).  
 
Figure 4.5: Standard in vivo recovery ischaemia-reperfusion protocol 
Stabilisation was for 15 minutes followed by occlusion of the snare for 30 minutes ischaemia 
(blue box) and release of the snare to initiate reperfusion. Animals were recovered immediately 
upon reperfusion. Total anaesthetic duration was 55±5 minutes (indicated by pale grey box). 
Reperfusion was for 72 hours and hearts extracted for histological staining. 
 
Recovery anaesthetics: Injectable and inhalation anaesthetic regimes were examined; 
the protocols are detailed below and their suitability discussed in section 4.6.1. 
Injectable anaesthetics – This anaesthetic regime was based on that published by Cruz 
et al. (1998) and had previously been successfully employed within our laboratory for a 
short in vivo recovery procedure in mice. Mice were anaesthetised with an injectable 
cocktail containing ketamine (75 mg/kg [Vetlar, Bioniche Animal Health, Canada]) and 
medetomidine (1 mg/kg [Domitor, Orion Pharma, UK]) administered as a single 
intraperitoneal bolus. Commonly, two additional doses of 0.1 ml anaesthetic cocktail 
were required at 20-30 and 40-50 minutes to maintain surgical depth of anaesthesia. 
Ventilation stroke volume was 200 µl and stroke rate was 160 strokes/minute where the 
ventilator inlet was supplied with oxygen at 1.5 L/minute. This anaesthetic cocktail 
reduced heart rate to 200-250 BPM and had a profound effect on reducing body 
temperature, in line with published reports (Cruz et al., 1998), meaning that temperature 
control was critical for this anaesthetic regime.  
Recovery of consciousness was induced by atipamezole (5 mg/kg [Antisedan, Pfizer, 
USA]) administered as a single intraperitoneal bolus matching the total volume of 
anaesthetic administered. Extubation was expected within approximately 15 minutes 
and recovery of movement within 3 hours, although animals remained drowsy and 
relatively inactive for several hours after this. 
Stab
15 min
Ischaemia
30 min
Extract
Assemble 
snare
Tighten 
snare
Release 
snare
≈72 hrsAnaesthetic Duration 50 550 5 20
Recover
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Inhalation anaesthetics – Mice were anaesthetised with isoflurane (Isoflo, Abbott Animal 
Health, USA) vaporised in oxygen. Induction of anaesthesia was in a gas chamber 
supplied with 1.5 L/minute oxygen and 5% isoflurane, reduced to 2% after 1 minute. 
Intermediate maintenance of anaesthesia was via a nose cone (custom made from the 
barrel of 2 ml syringe) supplied with 1.5 L/minute oxygen and 2% isoflurane. Long-term 
anaesthesia was via the ventilator supplied with 1.5 L/minute oxygen and 1.8-2% 
isoflurane, stroke volume of 200 µl and stroke rate of 200 strokes/minute. Isoflurane was 
regulated to the minimum concentration for the maintenance of surgical anaesthesia and 
ventilation parameters were optimised for each mouse strain to ensure there were no 
deep gasping breaths and surgical anaesthesia was easily maintained. Gasping breaths 
resulted from either lighter anaesthesia (despite absence of a toe-pinch reflex) or deep 
anaesthesia and in both cases correlated with poor recovery. Heart rate under this 
anaesthetic regime was 500–600 BPM and was unaffected by anaesthetic depth. This 
anaesthetic regime did not affect body temperature. 
Recovery of consciousness was achieved by termination of the isoflurane supply, after 
which animals regained consciousness within 3-5 minutes. Recovery of movement was 
expected within 10 minutes and mice were expected to be active and alert within 1 hour. 
ii Surgical complications 
The in vivo recovery model of ischaemia-reperfusion is recognised to be complicated to 
establish in the mouse due to difficulties in part resulting from: (1) its small size, (2) its 
rapid heart rate and (3) the prolonged anaesthetic duration required (Fisher and Marber, 
2002). During the course of establishing this model, several problems were encountered 
which required further refinement of the surgical protocol; the principal refinements are 
described below and extensive troubleshooting guidance is provided in Table 4.1. 
Following these refinements it was possible to produce a reliable and robust model of 
ischaemia-reperfusion in vivo with recovery using isoflurane anaesthesia. The suitability 
of the anaesthetic regimes is described in the results section below (see 4.3.3). 
Ventilation technique: Initial surgeries showed that a number of mice subjected only to 
intubation and recovery exhibited poor recovery or death, thus indicating a potential 
problem with the anaesthetic regime or ventilation technique. Post-mortem examination 
of these mice revealed inflation of the bowels which sometimes resulted in distension of 
the diaphragm. The most likely cause of this was poor intubation technique where the 
intubation cannula was momentarily inserted into the oesophagus (the route of least 
resistance during intubation). The ventilation procedure was modified to only connect 
the cannula to the ventilator following confirmation of successful intubation to prevent 
bowel inflation; this seemed  to resolve this complication and improved surgical survival. 
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This modified ventilation technique using inhalation anaesthesia is illustrated in Figure 
4.6 below. It is imperative to note that the ventilation procedure had to be completed 
very rapidly during the periods in which the animal was not receiving isoflurane 
(highlighted in red in Figure 3.5). This ventilation technique required redirection of the 
gas supply and change of connection hoses, as indicated below, to ensure that the 
duration during which the animal received no isoflurane was minimised. Surgical survival 
of animals subjected to this procedure was improved following this procedural 
modification. This ventilation technique was used for all subsequent surgeries. 
 
Figure 4.6: Modified ventilation procedure using isoflurane anaesthesia 
Optimised ventilation technique developed for use with isoflurane anaesthesia. A) Anaesthesia 
was induced in a standard induction box after which animals were transferred to the operating 
table (B) where anaesthesia was maintained by connection to a custom made nose cone 
(modified 2 ml syringe barrel with metal clip to stabilise its location). C) Dissection of the neck 
region to visualise the trachea. D) The nose cone was removed to allow oral intubation. E) Mice 
were ventilated only upon confirmation of successful placement of the tracheal cannula. 
 
 
A. Induction of anaesthesia   
Onset of anaesthesia in an
inhalation induction box
B. Transfer to nose cone
Animal moved to operating table
Anaesthesia maintained by nose
cone delivery
E. Ventilation
Connection of tracheal cannula to 
ventilator
Isoflurane 
5% for approximately 1 minute 
Reduced to 2% until unconscious
Dissection of salivary glands 
and paratracheal muscles
Isoflurane 2% supplied via 
custom made nose cone
C. Preparation for intubation
Dissection to visualise trachea
D. Oral intubation
Careful placement of cannula
into trachea 
To MiniVent ventilator
Isoflurane 1.8-2.0%
NO ISOFLURANE 
SUPPLY
Must be completed 
within 30-40 seconds
Remove nose cone
Change gas 
connector to 
ventilator
Switch gas regulator 
direction to nose cone
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COMPLICATION POSSIBLE CAUSE SOLUTION AND PROGNOSIS 
(1) INDUCTION OF ANAESTHESIA AND INTUBATION 
Gasping on 
ventilation 
 
(Note - C57BL/6 
mice gasp slightly 
under isoflurane 
anaesthesia which 
is normal) 
 
Incorrect placement of ventilation 
cannula in oesophagus. 
Re-intubate. 
Poor recovery prognosis due to 
inflation of bowels. 
 
Anaesthesia too deep or not 
deep enough. Check toe-pinch 
reflex and observe gasps: 
i) Too deep – very deep gasps, 
check toe-pinch reflex 
ii) Too light – frequent shallow 
gasps  
 
i) Reduce isoflurane 
ii) Increase isoflurane 
Good prognosis provided rapidly 
corrected. Avoid problem by careful 
regulation of isoflurane dosing. 
Poor prognosis if unresolved. 
Blockage of ventilation tubing. 
Confirm by lack of bubbles from 
ventilator exhaust when 
submerged in water. 
i) Tubing blocked – rapidly replace 
tubing. Good prognosis. 
ii) Intubation cannula blocked – prior 
to thoracotomy, remove and clean 
cannula and re-intubate (good 
prognosis). Cannot be resolved after 
thoracotomy - terminate experiment 
if any signs of respiratory distress. 
 
(2) THORACOTOMY 
Difficulty identifying 
correct intercostal 
space 
Lung is likely to be fully inflated 
over the heart meaning the edge 
of the lung cannot be used as a 
guide. 
i) Manoeuvre angle of left leg over 
body to rotate heart and lungs. 
ii) Count ribs to identify fourth space. 
Easily resolved. 
 
Left ventricle and 
atrium are not 
visible upon 
opening of the 
chest 
Incorrect intercostal space. 
i) If only left atrium is visible then 
thoracotomy was at third 
intercostal space. 
ii) If only apex of left ventricle is 
visible then thoracotomy was at 
fifth intercostal space. 
 
Open correct intercostal space in 
addition and continue with 
procedure. At the end of the 
procedure close thoracotomy by 
approximating 3 ribs. 
Prognosis is medium to poor 
depending on success of closure, 
pneumothorax may occur. 
Upon opening the 
chest, the lung is 
covering the heart 
Occurs even under optimal 
ventilation parameters. 
 
i) Manoeuvre angle of left leg over 
body to rotate heart and lungs within 
chest. Good prognosis. 
ii) Move lung away using a sterile 
swab. Medium to good prognosis. 
 
(3) ISCHAEMIA – REPERFUSION 
LAD is not readily 
visible. 
 
Observing incorrect region of the 
left ventricle. 
Use atrial appendage to identify 
correct region of left ventricle. Rotate 
the heart gently using the 
pericardium.  
Easily resolved. 
 
Anatomy of LAD – vessel runs 
deeper into the myocardium. 
i) Increase microscope light intensity. 
ii) Approximate location by reference 
to atrial appendage. 
Good prognosis with experience. 
 
Bleeding on 
placement of 
suture 
Suture needle passed through a 
vessel. 
Terminate experiment if bleeding is 
severe or if there is any visible 
damage to the myocardium 
 
Suture needle came into contact 
with the lung – evidenced by the 
lung becoming a deep red colour. 
Terminate experiment if bleeding is 
severe or if there is any visible 
damage to the lung affecting 
ventilation. 
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COMPLICATION POSSIBLE CAUSE SOLUTION AND PROGNOSIS 
No ST-segment 
elevation or 
myocardial colour 
change on 
ischaemia 
Occlusion of snare system was 
not sufficient to induce complete 
ischaemia. 
Immediately increase occlusion 
pressure. Note – this must be done 
simultaneously on induction of 
ischaemia to avoid potential 
inadvertent preconditioning, 
otherwise terminate the experiment. 
 
Incorrect placement of occluding 
suture. 
Terminate experiment. 
Take detailed description of incorrect 
location to facilitate learning process. 
 
Bleeding on 
occlusion of suture 
Mechanical damage to 
myocardium (with or without 
severing the LAD). Caused by 
poor suture placement: 
i) Suture too wide  
ii) Suture too shallow  
Terminate experiment if bleeding is 
severe or if there is any visible 
damage to the myocardium. 
If experiment is continued then take 
particular care to confirm reperfusion 
was successful.  
 
ST-segment 
resolution or return 
to red myocardial 
colour during 
ischaemic period 
 
Occluding snare system 
loosened during the procedure. 
Caused by: 
i) Incorrect tension of snare 
ii) Accidental movement of snare 
Terminate experiment. 
ST-segment 
elevation or 
myocardial colour 
change do not 
resolve upon 
reperfusion 
Slight delay in total reperfusion 
due to normal processes. 
Carefully observe LAD to determine 
whether it has fully reperfused. If 
changes have not occurred within 1 
minute then terminate experiment. 
 
Mechanical damage to LAD or 
surrounding myocardium 
meaning LAD reperfusion will not 
occur. 
 
Terminate experiment. 
 
(4) CHEST CLOSURE 
Difficult or 
incomplete closure 
of intercostal space 
Thoracotomy was too wide 
creating a large opening. 
Place intermediate 5-0 suture to 
approximate ribs and then continue 
to close with 2 further sutures.  
Prognosis is medium to poor 
depending on success of closure, 
pneumothorax may occur. 
 
Gasping 
immediately 
following chest 
closure 
i) Increased depth of breathing 
upon chest closure is normal. 
ii) If very deep gasping occurs 
this may indicate unsuccessful 
re-inflation of the lungs. 
 
i) Slight increased depth of breathing 
is normal, no action need be taken. 
ii) Upon deep gasping, further 
compress chest to remove residual 
air and apply tissue glue 
simultaneously. 
(5) RECOVERY 
Independent 
breathing does not 
resume within 10 
minutes 
Slight overdose of isoflurane 
meaning recovery will be 
prolonged. 
 
Stop oxygen supply to ventilator and 
wait a further 5 minutes if ECG 
confirms heart is still beating.  
Other problem with surgery 
meaning recovery may not be 
successful. 
If independent breathing has not 
resumed following above step then 
remove ventilation cannula and 
observe. If breathing does not occur 
confirm death by cervical dislocation. 
 
 
Table 4.1: Surgical refinements and troubleshooting for in vivo recovery model 
Refinements to the in vivo recovery surgical protocol; identification of the common problems and 
their possible causes and solutions. Note that this table relates specifically to the isoflurane 
inhalation anaesthetic regime, although many problems were common to all anaesthetic regimes. 
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iii Ischaemia-reperfusion injury in vivo non-recovery model 
A non-recovery in vivo model of ischaemia-reperfusion was developed for studies 
requiring assessment of infarct size after only short reperfusion durations. This model 
was previously established within our laboratory; however, the protocol was modified to 
ensure consistency of the in vivo procedures used in this thesis. The in vivo non-
recovery protocol was exactly as above (section i) with the modifications detailed here. 
Non-recovery anaesthetics: Mice were anaesthetised with an injectable anaesthetic 
cocktail containing ketamine (100 mg/kg [Vetlar, Bioniche Animal Health, Canada]), 
xylazine (20 mg/kg [Rompun, Bayer, UK]) and atropine (0.6 mg/kg [Sigma, UK]) 
administered as a single intraperitoneal bolus. Surgical depth of anaesthesia was 
continually monitored and maintained by additional doses of as required.  
This anaesthetic regime reduced heart rate from 500-600 BPM to 300-400 BPM at 
surgical depth of anaesthesia. Ventilation stroke volume was 200 µl and stroke rate was 
120 strokes/minute where the inlet was supplied with oxygen at 1.5 L/minute.  
Surgical procedure: Non-recovery surgeries were undertaken in the laboratory instead 
of in a sterile operating theatre. The non-recovery surgical setup was identical to that 
described above (see section i) but used a standard dissection microscope 
(Gallenkamp, Weiss, UK). Following successful onset of reperfusion, the intercostal 
muscle opening was loosely closed using one 5-0 braided suture and covered with a 
moistened tissue drape to prevent tissue desiccation. Surgical anaesthesia was 
maintained throughout the reperfusion duration. At the end of reperfusion, hearts were 
extracted for histological staining (see section vi). 
The standard protocol for the non-recovery ischaemia-reperfusion injury model was 30 
minutes ischaemia and 2 hours reperfusion (Figure 3.12). The total anaesthetic duration 
was approximately 2 hours 50 minutes; however, this was more variable than the 
isoflurane recovery procedure due to the less predictable onset of anaesthesia. 
 
Figure 4.7: Standard in vivo non-recovery ischaemia-reperfusion protocol 
Stabilisation was for 15 minutes followed by occlusion of the snare for 30 minutes ischaemia and 
release of the snare to initiate reperfusion. Reperfusion was for 2 hours. Animals were 
anaesthetised for the whole procedure (anaesthetic duration indicated by pale grey box). 
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iv Surgical exclusion criteria   
Consistency of the surgical model was ensured by application of surgical exclusion 
criteria concerning: (1) body temperature, (2) LAD ligation and (3) ischaemia-
reperfusion, described below. Following initial establishment of the model, exclusion of 
animals from a study on the basis of these criteria was rare. 
(1) Body temperature – Body temperature was maintained at 37.0±0.5ºC throughout 
the surgical procedure. All efforts were made to ensure that body temperature 
was maintained within this ideal range. If temperature deviated by more than 1ºC 
(i.e. less than 35.5ºC or greater than 38.5ºC) the animal was excluded. Strict 
temperature control was imperative given the known cardioprotective effect of 
extremes of body temperature (van den Doel et al., 1998). 
 
(2) LAD ligation – Ideal placement of the ligating LAD suture was approximately 2 
mm below the tip of the left atrium. If the location of the ligating suture was 
visually too high or low then the suture was removed prior to snare assembly and 
replaced for a maximum of two attempts. If any visible damage to the 
myocardium or severe bleeding occurred from placement of the suture then the 
animal was excluded from the study to avoid any confounding mechanical injury 
to the myocardium. Further LAD ligation exclusion criteria were applied at the 
point of analysis of AAR as described below (see section vi). 
 
(3) Ischaemia / Reperfusion – Successful ischaemia and reperfusion were confirmed 
by: (1) ECG ST-segment change, (2) myocardial colour change (3) contractile 
movement of the AAR. Animals were excluded where the onset of ischaemia or 
reperfusion was not accompanied by at least observations (1) and (2). 
Animals were rarely excluded from the study due to unsuccessful ischaemia. 
Unsuccessful reperfusion was the most common cause of exclusion from a study 
and this was more frequent following extended ischaemic durations (for example 
45 minutes ischaemia) or IPC due to mechanical damage to the myocardium. 
v Endpoint 1 – Surgical survival   
Surgical survival was evaluated by close monitoring of all animals post-surgery. Deaths 
were recorded to the nearest hour in the immediate post-operative period and the cause 
of death defined as: (1) surgical death from operative error, (2) surgical death from 
unexplained cause, (3) post-operative death from respiratory failure, (4) post-operative 
death from cardiac rupture or (5) post-operative death from unexplained cause. 
Statistical analysis: Kaplan-Meier survival plots were plotted using GraphPad Prism® 
version 5.0 (GraphPad Software, USA). Statistical significance was analysed by log-rank 
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tests (Mantel-Cox) since this is the more standard and powerful relevant statistical test. 
Statistical significance was reported where P<0.05 using standard significance coding. 
vi Endpoint 2 – Histological staining for infarct size and area-at-risk 
Infarct size and AAR were assessed by classical histological staining in animals which 
survived to the pre-defined reperfusion duration. Staining for infarct size and AAR was 
by ex vivo perfusion of TTC and Evans blue dye.  
For ex vivo histological staining, mice were anaesthetised with ketamine (100 mg/kg 
[Vetlar, Bioniche Animal Health, Canada]), xylazine (20 mg/kg [Rompun, Bayer, UK]) 
and atropine (0.6 mg/kg [Sigma, UK]) administered as a single intraperitoneal dose. 
Upon surgical anaesthesia, the chest was rapidly opened and the heart extracted by 
cutting the aorta immediately before the aortic loop. The aorta was cannulated onto a 21 
G perfusion cannula to allow retrograde perfusion of the heart. Extreme caution was 
taken to maintain the location and integrity of the LAD ligating suture. The ideal time to 
perfusion was less than 4 minutes and with experience very rarely exceeded 3 minutes. 
Residual blood in the coronary system was removed by manual perfusion of saline (1 
ml). TTC solution (7 ml of 1% in PBS) was pre-warmed to 37°C and perfused within 3 
minutes of heart extraction. For delineation of the AAR, the LAD ligating suture was re-
occluded and Evans blue (1.5 ml of 0.5% Evans blue in distilled water) perfused whilst 
the heart was submerged in running water to prevent surface staining. All perfusion was 
completed manually with extreme care not to damage the coronary circulation. 
Hearts were stored at -20°C for 1–2 days to facilitate slicing. Frozen hearts were 
manually sliced using a sharp scalpel to take 5 transverse slices from the apex with the 
uppermost slice at the approximate level of LAD occlusion. Heart slices were washed in 
distilled water and fixed in 10% formalin for 90-120 minutes at room temperature. The 
right ventricle was removed by careful dissection and the left ventricular slices placed in 
a custom-made acrylic block spaced by 0.5 mm and images taken using an Epson 
paper scanner (Epson Perfection V100 Photo, Epson, UK). Images were taken at 
consistent settings: 1200 dpi resolution, 0%, 15% and 100% brightness where 15% 
brightness images were used for analysis. 
Images were analysed by planimetry using ImageJ software (version 1.45s, National 
Institutes of Health, USA). Raw heart images were prepared for analysis by manual 
removal of the background image to leave only the heart slices. These red-green-blue 
(RGB) images were then automatically split into separate colour channels for analysis. A 
threshold of pixel intensity was applied to each slice where the threshold level was 
determined manually by matching the highlighted areas to the representative regions of 
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the raw image. The area of Evans blue staining was quantified using the red channel 
image and the area of infarction quantified using the green channel image. Myocardial 
AAR was calculated as a percentage of LV area: (LV area – Evans blue area) / (LV 
area). Infarct size was calculated as a percentage of AAR: (Infarct area) / (AAR/LV%).  
Quantification of infarct size and AAR using this threshold method was validated by 
assessing inter- and intra-observer variability. A batch of control operated hearts were 
analysed by two blinded observers and the IS/AAR% and AAR/LV% compared. The 
final quantifications for this batch of hearts was not significantly different between 
observers (assessed using paired t-test). In addition, IS/AAR% and AAR/LV% 
quantification by one observer was assessed between analyses of three blinded 
replicates of this batch of hearts and showed excellent consistency. All subsequent 
datasets were analysed by one blinded observer where all groups were blinded until 
completion of analysis for the total dataset. 
The extent of AAR was determined by the location of the occluding suture in relation to 
the coronary anatomy. Hearts were excluded from the dataset if the AAR was outside 
the predefined inclusion range of 40–75% AAR/LV. This exclusion criterion was 
important since the assumed linear relationship between AAR and infarct size was 
expected to only apply to the central ranges of AAR (Fisher and Marber, 2002). For 
each dataset, the AAR (AAR/LV%) was compared between all groups to ensure that 
there were no differences in the extent of the myocardium subjected to ischaemia.  
Statistical analysis: All values are presented as mean ± SEM. All statistical analysis 
was completed using GraphPad Prism® version 5.0 (GraphPad Software, USA). Where 
two groups were compared, data were analysed using an unpaired t-test. Where more 
than two groups were compared, data were analysed by one-way ANOVA and 
Bonferroni test comparing relevant groups. For all statistical tests, statistical significance 
was reported where P<0.05 using standard coding. 
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4.3.3. Results 
This thesis describes the first successful establishment of this complex mouse in vivo 
recovery model within our laboratory. Initial surgeries encountered a diverse and 
somewhat extensive array of surgical complications, largely resulting from surgical 
inexperience. All initial surgeries were conducted using the recovery anaesthetic 
injectable regime described above (ketamine and medetomidine). A number of non-
recovery surgeries were first undertaken in order to develop and refine the detailed 
surgical skills required for mouse cardiac surgery. The surgical procedure was refined 
incrementally and final myocardial infarct size and AAR determined for a batch of non-
recovery procedures; the results of these preliminary studies are not presented here.  
Further to this, incremental changes to the in vivo recovery protocol were refined where 
animals were recovered following each of the key surgical stages identified in the 
detailed description of the method provided above (induction of anaesthesia and 
intubation, thoracotomy, sham LAD ligation and ischaemia-reperfusion). These studies 
were conducted in mice from breeding stock within our laboratory and were of mixed 
genetic backgrounds (usually albino:SV129) and genotypes. Attempts were made to 
recover animals at each of these stages in order to establish and refine the procedure 
and identify recurrent complications. Several problems were identified primarily 
concerning correct identification and ligation of the LAD and recovery of animals 
subjected to long anaesthetic durations. These problems were largely overcome with 
extensive surgical practice and modification of the anaesthetic regime detailed below. 
Histological staining of ex vivo prepared hearts from these surgeries was undertaken to 
refine the extraction, cannulation and staining protocols necessary for good quality 
staining and thus quantification of infarct size and AAR in subsequent studies. Infarct 
size was not formally quantified in these animals due to the mixed genetic backgrounds 
and genotypes; however, assessment of AAR in these early surgeries showed 
substantial variation in LAD suture location and thus AAR between animals. 
These initial experiments led to extensive refinements of the surgical protocol 
(presented in Table 4.1 above) to eventually result in a relatively robust and reproducible 
model of in vivo ischaemia-reperfusion injury with reasonable recovery of animals. 
Following this, subsequent studies aimed to determine the most appropriate anaesthetic 
regime for use in consequent studies and investigate the potential anaesthetic 
conditioning effects of isoflurane; the key results of these studies are presented here. 
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i Anaesthetic regime 
Surgical survival: An initial study aimed to establish surgical survival and infarct size in 
commercially available C57BL/6 and B6/SV129 mice using the injectable anaesthetic 
regime. However, this was hindered by very poor surgical survival in the pilot studies 
conducted on C57BL/6 mice using the injectable anaesthetic protocol of ketamine and 
medetomidine (Figure 4.8: surgical survival of sham operated animals to 72 hours was 
25%; survival of 2/8 animals). Since these animals were only subjected to the sham 
procedure, this poor survival rate suggested a problem with a direct element of the 
surgical protocol itself. Attempts were made to further investigate this in B6/SV129 mice; 
however, this injectable anaesthetic regime (ketamine and medetomidine) did not 
provide sufficient depth of anaesthesia in a number of surgeries meaning that surgery 
could not be undertaken in these mice. Due to these complications, this ketamine and 
medetomidine injectable anaesthetic cocktail was not used for any further surgeries. 
An alternative isoflurane inhalation anaesthetic regime was investigated for surgeries in 
both C57BL/6 and B6/SV129 mice. Surgical survival rates of sham operated animals for 
both mouse strains were greatly improved using this anaesthetic regime (Figure 4.8: 
C57BL/6 sham operated animal survival 100% to 72 hours post-surgery, B6/SV129 data 
not shown). This anaesthetic regime, however, did not reduce heart rate (500-600 BPM) 
meaning that identification and ligation of the LAD was appreciably more difficult in 
these animals compared to the recovery injectable anaesthetic regime used previously 
(ketamine and medetomidine, heart rate 200-250 BPM). Animals excluded from this 
study due to poor or incorrect placement of the LAD suture are not reported below. 
 
Figure 4.8: Surgical survival for injectable and inhalation anaesthetic regimes 
Immediate post-operative survival of C57BL/6 mice subjected to sham operation using injectable 
(ketamine and medetomidine; solid line) or inhalation (dashed line) anaesthesia. Survival to 6 
hours recovery was 25% for injectable anaesthesia (2/8 mice) and 100% for inhalation 
anaesthesia (6/6 mice). Statistical significance assessed by log-rank test, **P<0.01, (n≥6/group). 
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All subsequent validation and characterisation of the in vivo recovery model of 
ischaemia-reperfusion injury presented in this chapter was conducted in B6/SV129 mice 
since these were considered to be the closest genetic background to the cyclophilin-D 
genetically modified mice that were subsequently used (see chapter 5). 
 
Potential anaesthetic conditioning: Given the reported cardioprotective effects of 
inhalation anaesthetics, including isoflurane (reviewed by Kato and Foex, 2002; Stowe 
and Kevin, 2004), subsequent experiments aimed to investigate the potential effects of 
the isoflurane dose used here. To this end, infarct size in B6/SV129 mice subjected to 
ischaemia-reperfusion injury under inhalation and injectable anaesthetic protocols was 
assessed. However, due to the complications of obtaining sufficient anaesthetic depth 
and surgical survival using the recovery injectable anaesthetic cocktail (ketamine and 
medetomidine), the non-recovery model of ischaemia-reperfusion injury had to be used. 
Surgical survival of sham operated B6/SV129 mice using this non-recovery model with 
injectable anaesthesia (ketamine, xylazine and atropine) was 100% (n=6).  
It is important to note that this injectable anaesthetic regime (ketamine, xylazine and 
atropine) significantly reduced heart rate in these animals to approximately 300-400 
BPM depending upon the anaesthetic depth. The potential effects of this with regards to 
infarct size are discussed subsequently (see section 4.6), however, the immediate result 
of this was an increased success rate of suitable AAR resulting from improved ligation of 
the LAD facilitated by the decreased heart rate. The surgical survival statistics presented 
below do not include animals excluded from the study based on inappropriate AAR. 
Comparison of myocardial infarct size (IS/AAR%) in B6/SV129 mice subjected to 30 
minutes ischaemia and 2 hours reperfusion between the injectable (ketamine, xylazine 
and atropine) and recovery inhalation anaesthetic regimes showed a striking agreement 
(Figure 4.9: IS/AAR% injectable anaesthesia 38.8±3.2 versus isoflurane 38.4±3.4; 
n≥6/group, NSP>0.05). There was no significant difference in AAR between these groups 
(AAR/LV% injectable anaesthesia 61.8±3.3 versus isoflurane 63.1±5.0; n≥6/group, 
NSP>0.05). Surgical survival of animals undergoing these regimes was not significantly 
different (surgical survival: injectable 85.7%, n=7 versus inhalation 88.9%, n=9). 
150 
 
Figure 4.9: Infarct size using injectable and inhalation aesthetic regimes 
Infarct size following 30 minutes ischaemia and 2 hours reperfusion in B6/SV129 mice using 
injectable (non-recovery: ketamine, xylazine and atropine) and isoflurane inhalation (recovery: 
isoflurane) anaesthetic regimes. IS/AAR% was not significantly different between anaesthetic 
regimes: IS/AAR% injectable anaesthesia 38.8±3.2 (n=6) versus inhalation 38.4±3.4 (n=7). 
Statistical significance assessed by unpaired t-test,
 NS
P>0.05. 
 
This study was subsequently repeated following complete refinement and establishment 
of the surgical protocol to ensure the validity of this finding; this study also showed no 
difference in myocardial infarct size using these two anaesthetic regimes (data not 
shown). Given the lack of any profound cardioprotective effect of this anaesthetic 
regime, this protocol was used for all recovery surgeries of the in vivo ischaemia-
reperfusion injury model presented here. Further investigation of a potential anaesthetic 
conditioning effect using this protocol is provided subsequently (see section 4.6) 
Additional refinement of the surgical protocol was required to improve the success of 
LAD ligation using this isoflurane anaesthetic regime; these refinements are described in 
Table 4.1 and following extensive practice of this model, the surgical success rates in 
terms of survival and appropriate AAR were both substantially improved. Early studies 
aimed at characterising and establishing this in vivo recovery ischaemia-reperfusion 
model are not presented here due to the large variability of infarct sizes within 
experimental groups thereby questioning the validity of such data. During the first year 
of this project, extensive refinement of the model and staining techniques was 
completed to perfect the final model that was applied for the studies presented here. 
All subsequent data presented in this thesis was conducted following this extensive 
refinement and establishment of the model and is therefore deemed robust and reliable.  
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4.4. Aim 2: Validation of the ischaemia-reperfusion injury model 
4.4.1. Background 
The overall aim of this thesis was to investigate the long-term cardioprotective efficacy 
of potential therapeutic interventions at reducing myocardial infarct size upon ischaemia-
reperfusion. With any experimental model it is pertinent to validate the principal endpoint 
in order to verify that the model is robust and reproducible and capable of detecting 
differences between experimental groups. It was therefore important to ascertain 
whether the infarct size elicited by the mouse in vivo recovery of myocardial ischaemia-
reperfusion injury developed in the first part of this chapter was sufficiently robust to 
allow a significant reduction in infarct size to be detected. 
Validation of infarct size reduction requires the application of cardioprotective 
interventions which are known to elicit a significant cardioprotective effect, as tested by 
numerous previous research groups. As described in chapter 1 of this thesis, several 
mechanical and pharmacological interventions have been examined and shown to be 
cardioprotective in pre-clinical research models. IPC is considered to be the most 
powerful cardioprotective intervention after early reperfusion (Yellon and Downey, 2003) 
and thus represents an ideal positive control for cardioprotective efficacy here. IPC has 
been extensively tested and proven to significantly reduce cell death in ex vivo and in 
vivo models of ischaemia-reperfusion injury. Importantly, IPC has shown to be effective 
in every mammalian species tested to date and consistently reduces myocardial infarct 
size in the region of 50% (reviewed by Yellon and Downey, 2003; Jennings, 2011).  
In addition to cardioprotection by the mechanical intervention IPC, it was important to 
demonstrate significant cardioprotective efficacy of a pharmacological intervention, for 
which the extent of infarct size reduction is expected to be more variable and slightly 
lower. This was critical to evaluate the robustness of the in vivo recovery model of 
ischaemia-reperfusion developed here with regards to the statistical power and thus 
sample sizes required to detect statistical significance. The smaller effect size elicited by 
pharmacological interventions such as cyclosporine-A (CsA) was predicted to be similar 
to those produced by genetic ablation of mitochondrial proteins investigated 
subsequently in this thesis (chapters 5 and 6). Cyclosporine-A is a pharmacological 
inhibitor of calcineurin and the cyclophilin proteins and has been shown to reduce infarct 
size in a number of in vitro and in vivo animal models (Nazareth et al., 1991; Griffiths 
and Halestrap, 1993; Hausenloy et al., 2002); see section 1.4.1. 
This section describes validation of the in vivo recovery model of ischaemia-reperfusion 
injury recovery using two positive controls for cardioprotection: IPC and CsA. 
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Aim 2: The second aim of this chapter was to validate the in vivo recovery model of 
ischaemia-reperfusion injury by assessing the cardioprotective efficacy of two well-
described cardioprotective interventions. The central hypotheses to validate and test the 
robustness of this model were: 
(1) A standard IPC protocol would elicit a significant reduction in myocardial infarct size 
upon ischaemia-reperfusion. 
 
(2) Administration of a known therapeutic dose of CsA immediately prior to reperfusion 
would elicit a significant reduction in infarct size upon ischaemia-reperfusion. 
 
4.4.2. Detailed methods 
Myocardial infarct size and AAR were assessed in mice subjected to the in vivo recovery 
model of ischaemia-reperfusion injury developed in part 1 of this chapter. The in vivo 
procedure was exactly as described above using isoflurane anaesthesia. The dose and 
duration of anaesthesia for each animal was kept as constant as possible where the 
specific surgical protocols for each group are detailed below. Following 72 hours 
reperfusion, mice were anaesthetised and hearts extracted for ex vivo histological 
staining using TTC and Evans blue exactly as described above. The surgical and 
myocardial AAR exclusion criteria were as described previously. 
i Ischaemic preconditioning 
B6/SV129 mice were randomised to receive ischaemia-reperfusion injury, with or 
without IPC. Control mice were subjected to 15 minutes stabilisation, 30 minutes 
ischaemia and 72 hours reperfusion (Figure 4.10 A). IPC mice were subjected to one 
cycle of 5 minutes ischaemia and 5 minutes reperfusion immediately prior to the main 
ischaemic insult (Figure 4.10 B). This IPC protocol has been shown to significantly 
reduce infarct size in a mouse in vivo non-recovery model of myocardial ischaemia-
reperfusion within our laboratory (Lim et al., 2007). 
Particular care was taken to ensure effective reperfusion in these groups since the IPC 
regime was more prone to causing mechanical damage to the surrounding myocardium 
which could impede successful reperfusion upon release of the snare system following 
the main ischaemic insult. Where clear recovery of myocardial colour and ECG ST-
segment was not observed upon reperfusion, animals were excluded from the study. 
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Figure 4.10: Ischaemic preconditioning protocol 
A) Control: 15 minutes stabilisation, 30 minute ischaemia and 72 hours reperfusion. B) IPC: 5 
minutes stabilisation, one cycle IPC consisting of 5 minutes ischaemia and 5 minutes reperfusion 
prior to the main ischaemic insult of 30 minutes and 72 hours reperfusion. Following 72 hours 
reperfusion, hearts were extracted for histological staining for infarct size. 
 
ii Cyclosporine-A 
B6/SV129 mice were randomised to vehicle control or CsA treatment groups. CsA or 
vehicle was administered during ischaemia, 5 minutes prior to the onset of reperfusion 
(Figure 4.11). This CsA dose has been shown to significantly reduce infarct size in the 
non-recovery ischaemia-reperfusion model within our laboratory (Lim et al., 2007). 
CsA was dissolved in a solution of cremophor and ethanol-94% (0.65 g cremophor per 1 
ml 94% ethanol where 94% ethanol was prepared in sterile saline). This vehicle solution 
was prepared under sterile conditions and stored at 4ºC for a maximum of 1 month with 
vigorous shaking prior to use. CsA solutions were made fresh on each operating day to 
ensure that there was no loss of drug activity between experiments. The CsA dosing 
stock solution was made directly in cremophor/ethanol-94% at a concentration of 5 
mg/ml. The CsA dosing stock was administered at a volume of 2 ml/kg, and therefore 60 
µl per 30 g mouse, to give a final dosing concentration of 10 mg/kg. Vehicle treated 
animals received a matched volume of cremophor/ethanol-94% instead of CsA.  
CsA or vehicle was administered as a single intravenous bolus via either the left or right 
lateral tail veins immediately following regional warming of the tail vein using local 
application of a warmed tissue swab. Successful dosing was confirmed by washout of 
blood in the vein and return of blood following removal of the needle. Animals were 
excluded from the study where dosing could not be confirmed. 
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Figure 4.11: Cyclosporine-A protocol 
A) Vehicle mice received a matched volume of cremophor/ethanol-94%. B) CsA mice received 
CsA 10 mg/kg in cremophor/ethanol-94%. All compounds were administered as a single I.V. 
bolus 5 minutes prior to reperfusion. All mice were subjected to 15 minutes stabilisation, 30 
minutes ischaemia and 72 hours reperfusion. Hearts were extracted for staining for infarct size. 
 
 
 
4.4.3. Results 
To ascertain the scope for cardioprotection, the infarct size of animals subjected to the 
sham procedure (open chest surgery with no myocardial ischaemia) and control 
procedure (30 minutes ischaemia) was examined. The infarct size in sham operated 
B6/SV129 mice, in which the LAD snare system was assembled but not occluded and 
all surgical timings adhered to, was 6.2±0.2 IS/AAR%, n=4 (Figure 4.12 Ai). This was 
deemed an acceptable extent of injury for sham operated animals and was in the region 
of that obtained for the non-recovery ischaemia-reperfusion model within our laboratory. 
The control infarct size resulting from 30 minutes ischaemia and 72 hours reperfusion 
was 32.0±3.7 IS/AAR%, n=7 (Figure 4.12 Aii). This was lower than expected based on 
the non-recovery in vivo model where 30 minutes ischaemia and 2 hours reperfusion 
resulted in 38.8±3.2 IS/AAR% (Figure 4.9). The absolute difference between sham and 
control infarct sizes (i.e. the effect size) in this model was 25.7 IS/AAR%, which was 
lower than expected from the non-recovery model; this is discussed in section 4.6.2. 
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i Ischaemic preconditioning 
A standard IPC protocol of 5 minutes ischaemia and 5 minutes reperfusion known to be 
cardioprotective was applied to the in vivo recovery model developed here. IPC 
significantly reduced the infarct size in B6/SV129 mice subjected to 30 minutes 
ischaemia and 72 hours reperfusion (Figure 4.12: IS/AAR% control 32.0±3.7 versus IPC 
16.2±0.7; n≥6/group, **P<0.01). There was no difference in AAR (AAR/LV% control 
57.0±1.8 versus IPC 55.9±5.5; n≥6/group, NSP>0.05) or survival between control or IPC 
groups (survival to 72 hours reperfusion: control 87.5% versus IPC 75%, NSP>0.05). 
 
Figure 4.12: Infarct size reduction following ischaemic preconditioning in vivo  
A) Representative infarct size in B6/SV129 mice subjected to i) sham, ii) control 30 minutes 
ischaemia and 72 hours reperfusion or iii) IPC (5 minutes ischaemia and 5 minutes reperfusion) 
prior to 30 minutes ischaemia and 72 hours reperfusion. B) Infarct size in sham operated mice 
was 6.2±0.2% (n=4). Infarct size was significantly reduced by IPC: IS/AAR% control 32.0±3.7 
(n=7) versus IPC 16.2±0.7 (n=6). Statistical significance assessed by one-way ANOVA 
comparing sham versus control and control versus IPC, n≥4/group, **P<0.01 and ***P<0.001.  
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ii Cyclosporine-A 
Treatment with a known cardioprotective dose of CsA treatment 5 minutes prior to the 
onset of reperfusion in this model also significantly reduced infarct size resulting from 
the standard protocol of 30 minutes ischaemia and 72 hours reperfusion (Figure 4.13: 
IS/AAR% vehicle control 43.1±1.5 versus CsA 29.9±3.1; n=4/group, *P<0.05). There 
was no difference in AAR (AAR/LV% vehicle 67.7±8.8 versus CsA 69.7±2.0; n=4/group, 
NSP>0.05) or survival between vehicle and CsA treated mice (survival to 72 hours 
reperfusion: vehicle 100% versus CsA 100%, NSP>0.05, excluding those animals 
excluded due to unconfirmed dosing). 
 
Figure 4.13: Infarct size reduction following CsA administration in vivo  
Infarct size resulting from 30 minutes ischaemia and 72 hours reperfusion in B6/SV129 mice 
administered either vehicle or CsA bolus I.V. 5 minutes prior to reperfusion. IS/AAR% was 
significantly reduced by CsA: IS/AAR% vehicle control 43.1±1.5 (n=4) versus CsA 29.9±3.1 
(n=4). Statistical significance assessed by unpaired t-test, *P<0.05. 
 
The infarct size in B6/SV129 mice treated with vehicle only (cremophor/ethanol-94%) 
was slightly larger than for control only animals (IS/AAR%: Figure 4.13 vehicle 43.1±1.5 
n=4, versus Figure 4.12 control 32.0±3.7 n=7). It was not appropriate to perform 
statistical analysis of these groups since they were completed as separate experiments 
and so were not randomised. Although no firm conclusions regarding the effect of the 
vehicle on infarct size could be made, this is an important consideration. 
These initial experiments demonstrate that two known cardioprotective interventions, 
IPC and CsA, elicit significant cardioprotection against ischaemia-reperfusion injury in 
the in vivo recovery model developed in this thesis using a standard protocol of 30 
minutes ischaemia and 72 hours reperfusion, thereby validating this model for further 
studies of cardioprotection undertaken subsequently in this thesis. 
Vehicle CsA
0
10
20
30
40
50
**
*
IS
/A
A
R
%
157 
4.5. Aim 3: Characterisation of ischaemia-reperfusion injury model 
4.5.1. Background 
With any research model it is essential to control all possible confounding experimental 
variables in order to reduce the variability within groups and to enhance the statistical 
power and reduce the sample sizes required. Further characterisation of the in vivo 
ischaemia-reperfusion recovery model developed here was examined to determine the 
optimal experimental design of subsequent studies to be undertaken. 
Optimisation of the ischaemic duration was particularly important in the present study 
given the smaller infarct size of control operated animals subjected to 30 minutes 
ischaemia and 72 hours reperfusion demonstrated in part 2 of this chapter (see 4.4.3). 
This 30 minute ischaemic protocol was used since this was the standard protocol used 
within our laboratory for the mouse in vivo non-recovery ischaemia-reperfusion injury 
model to generate control infarct sizes in the region of 40% (IS/AAR). Despite the 
demonstration of significant infarct size reduction using known cardioprotective 
interventions, it was pertinent at this stage to investigate the optimal ischaemic duration 
for subsequent studies in this thesis. Given the wavefront of necrosis hypothesis 
postulated by Reimer et al. (1977), it is expected that increased ischaemic duration will 
increase the extent of myocardial infarction. The optimal ischaemic duration is a trade-
off between a sufficiently large infarct size to obtain large effect sizes in experimental 
treatment group balanced with the potential complications associated with a greater 
extent of injury including surgical survival and other forms of injury including cardiac 
arrhythmias and rupture (reviewed by Sane et al., 2009). The effect of ischaemic 
duration on infarct size in this model was investigated and is reported in this section. 
Reperfusion duration may also influence the quantification of infarct size, whereby the 
processes of infarct expansion and subsequent myocardial thinning may affect the 
quantification of myocardial AAR and thereby unduly affect infarct size calculation 
(IS/AAR%). Myocardial thinning is known to occur during infarct remodelling and 
although this is expected to be more profound in non-reperfused infarcts (Michael et al., 
1999; Vandervelde et al., 2006), it is possible that subtle changes to myocardial 
thickness may affect the calculation of IS/AAR% in this study. Furthermore, there is 
some debate as to the validity of infarct size quantification based on TTC staining at 
various durations of reperfusion due to the enzymatic nature of the staining reaction and 
impaired metabolic function of irreversibly injured cardiomyocytes at early durations of 
reperfusion (Black and Rodger, 1996; Redel et al., 2008). These potential confounding 
factors are discussed in detail in section 4.6. 
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A number of experimental variables have been reported to affect myocardial infarct size 
following ischaemia-reperfusion injury including temperature, time of day and gender 
(reviewed by Black and Rodger, 1996). It is therefore imperative to control as many of 
these potentially confounding variables as possible and this has led to a bias in the use 
of male subjects only in many studies of cardioprotection, as discussed in chapter 1.  
Operative time of day has also been suggested to affect myocardial infarct size, where 
an elegant study by Durgan et al. (2010) demonstrated a 3.5 fold increase in infarct size 
across the extremes of the operating day (12 hour spacing of surgeries). The potential 
effects of these experimental variables are particularly important given the identification 
of significant differences in cardioprotective signalling pathway activation, for example 
the level of phosphorylated Akt (Durgan et al., 2010). The final part of this chapter 
investigates the effect of operative time of day and gender, on the infarct size obtained 
in the mouse in vivo recovery model of ischaemia-reperfusion injury developed here. 
The final section of this chapter describes characterisation of the optimal ischaemia and 
reperfusion durations and the effect of potentially important experimental variables to 
inform the methodological details and acceptable variables for subsequent studies. 
 
Aim 3: The final aim of this chapter was to characterise the potential effects of 
experimental variables on infarct size resulting from the in vivo recovery model of 
ischaemia-reperfusion. The hypotheses relating to these experiments were: 
(1) Ischaemic duration: Increased ischaemic duration would increase infarct size. 
 
(2) Reperfusion duration: Infarct size would increase slightly over the initial period of 
myocardial reperfusion. 
 
(3) Operative time of day: Mice subjected to ischaemia-reperfusion in the afternoon may 
exhibit slightly larger infarct sizes than those in the morning. 
 
(4) Gender: Infarct size resulting from ischaemia-reperfusion in females would be 
slightly lower than in male mice. 
 
It was not expected that operative time of day or gender would elicit statistically 
significant differences in infarct size in this model; however, it was imperative to 
investigate and quantify the effect of these variables on infarct size in order to inform the 
experimental design of subsequent studies to be undertaken in this thesis. 
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4.5.2. Detailed methods 
The in vivo procedure was exactly as described above using the isoflurane anaesthetic 
regime. Following the defined period of reperfusion, mice were anaesthetised and hearts 
extracted for ex vivo staining using TTC and Evans blue exactly as described above. 
The surgical and myocardial AAR exclusion criteria were as described previously and 
there were no differences in AAR between groups. The survival of animal subjects was 
recorded, including the number of animals excluded on a procedural basis (e.g. due to 
unsuccessful reperfusion) in order to evaluate the optimal protocol for subsequent 
studies. The precise calculation of survival statistics is detailed here. 
Statistical power calculations were performed to retrospectively evaluate the statistical 
power of tests undertaken to facilitate the interpretation of these results. When it was 
clear that statistical power was not reached using the sample sizes presented here, a 
prospective calculation based on the expected effect size and standard deviation of 
these studies was used to determine the sample size required to reach sufficient 
statistical power. For all tests, the minimal level of statistical power was judged to be 
80%, in accordance with published guidelines (Cohen, 1988; Townend, 2002). All power 
calculations were performed using GraphPad StatMate version 2.0 (GraphPad Software, 
USA) according to the statistical power equations published by Cohen (1988).  
i Ischaemic duration 
B6/SV129 mice were randomised to receive 30 or 40 minutes ischaemia followed by 72 
hours reperfusion (Figure 4.14). The stabilisation period for each group was modified to 
ensure that the total anaesthetic duration was equal between experimental groups.  
 
Figure 4.14: Ischaemic duration protocol 
B6/SV129 mice were randomised to either A) 30 minutes or B) 40 minutes ischaemia. 
Stabilisation duration was modified to ensure total anaesthetic duration was approximately equal 
between experimental groups. Following 72 hours reperfusion hearts were extracted for staining. 
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ii Reperfusion duration 
B6/SV129 mice were subjected to 30 minutes ischaemia and hearts extracted following 
defined reperfusion durations of 2, 6, 24 or 72 hours (Figure 4.15). Separate groups of 
animals were required for each of the reperfusion durations examined due to the 
terminal nature of the histological endpoint for infarct size and AAR assessment. All 
groups, including those subject to short reperfusion durations only, underwent the 
recovery procedure with isoflurane anaesthesia to ensure consistency protocols. 
 
 
Figure 4.15: Reperfusion duration protocol 
B6/SV129 mice were randomised to receive 30 minutes ischaemia followed by reperfusion for i) 2 
hours, ii) 6 hours, iii) 24 hours or iv) 72 hours. Following the defined duration of reperfusion, 
hearts were extracted for histological staining (indicated by arrows). 
 
iii Operative time of day 
All surgeries presented in thesis were conducted during full day operating sessions from 
08:00-18:00. A retrospective analysis of infarct size from morning and afternoon 
surgeries was conducted for B6/SV129 mice subjected to the standard protocol (30 
minutes ischaemia and 72 hours reperfusion) and standard IPC protocol (5 minutes 
ischaemia, 5 minutes reperfusion and standard ischaemia and reperfusion insult) 
described above (Figure 4.10). For this retrospective analysis, previously operated 
animals were assigned to morning or afternoon operative sessions depending on the 
time of the onset of ischaemia; where morning sessions were defined as onset of 
ischaemia 08:00-11:00 and afternoon sessions were defined as onset of ischaemia 
14:00-17:00. Animals were excluded from this sub-analysis where the start of ischaemia 
was outside of these morning and afternoon operating session definitions. 
iv Gender 
All previous studies described in this thesis were conducted on male mice only. To 
investigate the potential difference in infarct size with gender, commercially available 
male and female B6/SV129 mice were subjected to the standard in vivo recovery 
protocol of 30 minutes ischaemia and 72 hours reperfusion described previously. 
  
Stab
15 min
Ischaemia
30 min
72 hr6 hr 24 hr
Anaesthetic Duration 500 5 10
2 hr
55
161 
4.5.3. Results 
i Ischaemic duration 
The standard ischaemic protocol employed in this thesis was 30 minutes ischaemia, 
however, increasing this to 40 minutes ischaemia only slightly increased infarct size, 
where this difference was not significant (Figure 4.16: IS/AAR% 30 minutes ischaemia 
32.0±3.7 versus 40 minutes ischaemia 40.1±5.0; n=7/group). However, the small effect 
size and relatively large variability meant that an unfeasibly large sample size would be 
required to reach statistical power; thus limiting the conclusions of this experiment. 
There was no significant difference in AAR between groups (AAR/LV% 30 minutes 
ischaemia 57.0±1.8 versus 40 minutes ischaemia 61.1±2.1; n=7/group, NSP>0.05).  
 
Figure 4.16: Infarct size following increased ischaemic insult 
Infarct size resulting upon 30 or 40 minutes ischaemia and 72 hours reperfusion in B6/SV129 
mice. There was a slight but non-significant increase in infarct size upon 40 minutes ischaemia: 
IS/AAR% 30 minutes ischaemia 32.0±3.7 (n=7) versus 40 minutes ischaemia 40.1±5.0 (n=7). 
Statistical significance assessed by unpaired t-test, however, this is statistically underpowered. 
 
The surgical and post-operative survival of animals subjected to the 30 and 40 minute 
ischaemic protocols was also recorded, including exclusion of animals from the study 
based on procedural reasons such as unsuccessful reperfusion. Recovery of animals to 
72 hours reperfusion (the pre-defined endpoint) was slightly lower in the 40 minute 
ischaemic groups compared to the standard 30 minute ischaemic protocol (Figure 4.17: 
% survival to 72 hours reperfusion: 30 minutes ischaemia 87.5% n=8, versus 40 minutes 
ischaemia 63.6% n=11). The majority of animals lost in the 40 minute ischaemic group 
were excluded due to unsuccessful reperfusion (time 0, Figure 4.17). 
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Figure 4.17: Survival following increased ischaemic insult 
Survival of B6/SV129 mice subjected to 30 or 40 minutes ischaemia and 72 hours reperfusion. 
Survival was slightly lower in 40 minute ischaemic group: survival % 30 minutes ischaemia 87.5% 
(7/8) versus 40 minutes ischaemia 63.6% (7/11). However this was not statistically significant; 
significance assessed by log-rank test (Mantel-Cox), 
NS
P>0.05. 
 
 
Further to this, a standard IPC protocol was investigated in animals subjected to 40 
minutes ischaemia and 72 hours reperfusion and was shown to significantly reduce 
infarct size by approximately 44% (40 minutes ischaemia with standard IPC protocol; 
IS/AAR% control 40.1±5.0 versus IPC 22.5±2.1, n=7/group **P<0.01). However, 
inclusion of the IPC protocol in this 40 minute ischaemic protocol meant that the total 
anaesthetic duration (and thus isoflurane dose) was increased by 10 minutes compared 
to the other surgeries in this chapter since the standard protocol devised in part 1 was 
not designed to accommodate this extended protocol. 
 
Although the difference in survival rates between the two ischaemic protocols (30 
minutes and 40 minutes ischaemia) was not statistically significant, the increased 
exclusion of animals subjected to the 40 minute ischaemic protocol meant that the 30 
minute ischaemic protocol represented a more feasible protocol. All surgeries for this 
thesis were conducted using 30 minutes ischaemia unless otherwise stated. 
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ii Reperfusion duration 
The effect of reperfusion duration on infarct size development was examined to 
investigate the potential reason for slightly reduced infarct size in the in vivo recovery 
model (standard protocol: 72 hours reperfusion) compared to the well-established in vivo 
non-recovery model (standard protocol: 2 hours reperfusion) within our laboratory.  
B6/SV129 mice were subjected to 30 minutes ischaemia and hearts extracted at defined 
reperfusion periods. Increased reperfusion duration over the time-points investigated did 
not significantly affect infarct size, although there was a non-significant trend of 
decreased infarct size at extended reperfusion durations (24 and 72 hours) compared to 
earlier time-points (Figure 4.18). There was no significant difference in AAR between 
groups, however, AAR in the 2 hour reperfusion group was slightly smaller compared to 
later time-points (AAR/LV% 2 hours 63.1±5.0 versus 6 hours 57.1±3.9, 24 hours 
57.5±4.4 and 72 hours 57.0±1.8; n≥7/group, NSP>0.05).  
Although this experimental model is not sufficiently sensitive to detect such small effect 
sizes, this study provides an important interpretation of the slightly lower infarct sizes 
obtained following the standard in vivo recovery protocol at 72 hours reperfusion as 
compared to the previous studies reported within our laboratory at 2 hours reperfusion. 
 
Figure 4.18: Infarct size following varied reperfusion duration 
Infarct size resulting from 30 minutes ischaemia and varied durations of reperfusion in B6/SV129 
mice.  Infarct size was slightly decreased at longer durations of reperfusion: IS/AAR% 2 hours 
38.4±3.4 (n=7), 6 hours 37.4±1.4 (n=8), 24 hours 31.4±3.5 (n=8) versus 72 hours 32.0±3.7 (n=7). 
However this was not statistically significant; statistical significance assessed by one-way 
ANOVA comparing all groups, 
NS
P>0.05. 
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iii Operative time of day 
The effect of operative time of day on myocardial infarct size in this model was 
investigated in B6/SV129 mice subjected to standard control and IPC protocols. Infarct 
size data was retrospectively grouped into morning or afternoon sessions defined by the 
time of onset of ischaemia. There was no significant difference between morning and 
afternoon surgeries for control (Figure 4.19 A: n≥6/group, NSP>0.05) or IPC operated 
animals (Figure 4.15 B: n≥3/group, NSP>0.05); although it should be noted that the 
sample size for the IPC comparison is low. There was no significant difference in AAR or 
survival between these (AAR/LV% control AM 56.0±1.9 versus PM 56.9±4.0; n≥6, 
NSP>0.05; AAR/LV% IPC AM 54.5±4.8 versus PM 63.7±8.3; n=4/group, NSP>0.05). 
 
Figure 4.19: Infarct size resulting from morning and afternoon surgeries 
B6/SV129 mice were subjected to ischaemia and reperfusion during morning (white bars, 08:00 – 
11:00) and afternoon (black bars, 14:00-17:00) operative sessions. A) Control mice subjected to 
30 minutes ischaemia and 72 hours reperfusion. There was no statistically significant difference 
in infarct size between morning or afternoon sessions (IS/AAR%: morning 35.5±4.3 (n=8) versus 
afternoon 32.7±5.2 (n=6), 
NS
P>0.05). B) IPC mice subjected to IPC 5 minutes ischaemia and 5 
minutes ischaemia prior to main ischaemic insult of 30 minutes and 72 hours reperfusion 
(IS/AAR%: 15.7±4.4 (n=4) versus afternoon 14.3±2.6 (n=3), 
NS
P>0.05). Statistical significance 
assessed by unpaired t-test comparing AM (white bar) versus PM (black bar), 
NS
P>0.05. 
 
An additional sub-analysis of control infarct size data was conducted to compare infarct 
size at the extremes of time of day (onset of ischaemia defined as 08:00-09:00 or 16:00-
17:00). In line with the analysis presented above, there was no statistically significant 
difference in infarct size between these groups. This sub-analysis could not be 
undertaken for the IPC group due to its small sample size.  
All subsequent experiments presented were conducted in full day operating sessions 
and mice were randomly assigned to morning or afternoon surgeries and an equal mix 
of operating sessions ensured between groups. 
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iv Gender 
All previous experiments presented in this thesis were conducted on male mice only. 
The effect of gender on infarct size in the present study was investigated in male and 
female B6/SV129 mice subjected to the standard control ischaemia and reperfusion 
protocol (30 minutes ischaemia and 72 hours reperfusion). This demonstrated that there 
was no significant difference in myocardial infarct size between male and female mice 
(Figure 4.20: IS/AAR% males 34.8±3.8 versus females 36.2±5.1; n=7/group, NSP>0.05). 
There was no significant difference in AAR between these groups (AAR/LV% male 
58.7±2.2 versus female 61.5±5.8; n=7/group, NSP>0.05). 
 
Figure 4.20: Infarct size in male and female mice 
Infarct size in male and female B6/SV129 mice subjected to 30 minutes ischaemia and 72 hours 
reperfusion. There was no statistically significant difference in infarct size between males and 
females: IS/AAR% males 34.8±3.8 (n=7) versus females 36.2±5.1 (n=7). Statistical significance 
assessed by unpaired t-test, 
NS
P>0.05. 
 
All subsequent surgeries in this thesis were undertaken in male mice only, other than 
where this is specifically indicated in the methods of the relevant section. 
 
This chapter has described the standard protocol for the mouse in vivo ischaemia-
reperfusion injury model subsequently applied in this thesis for the investigation of 
cardioprotective efficacy of a number of potentially therapeutic interventions. 
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4.6. Discussion 
The main objective of this chapter was to develop and characterise a mouse in vivo 
model of ischaemia-reperfusion injury for subsequent investigations of cardioprotective 
efficacy. Although this model has been established by other research groups, this was 
the first establishment of this important research model within our laboratory.  
This chapter describes the extensive development and characterisation of the in vivo 
recovery ischaemia-reperfusion model undertaken in this thesis and intends to provide a 
comprehensive surgical protocol to facilitate transfer of this protocol to future operators. 
4.6.1. Aim 1: Establish in vivo recovery model of ischaemia-reperfusion 
The mouse in vivo recovery model of ischaemia-reperfusion injury developed here was 
loosely based on previously published surgical protocols (Michael et al., 1995; Fisher 
and Marber, 2002; van Laake et al., 2007). This model comprises open-chest surgery 
for occlusion of the LAD coronary artery to induce regional myocardial ischaemia 
followed by release for myocardial reperfusion and recovery. The key attributes of this 
model are described in detail in the introduction of this chapter (see 4.3.1) and include: 
(1) use of mice to exploit genetic models, (2) defined periods of ischaemia and 
reperfusion and (3) recovery to permit long-term investigation.  
This in vivo recovery model is recognised as being complex to establish in mice due to 
their small size and rapid heart rate (Fisher and Marber, 2002; van Laake et al., 2007). 
The first part of this chapter describes the difficulties encountered in efforts to establish 
this model within our laboratory. Despite the difficulties encountered with initial 
establishment of this model, it was imperative to persevere with this recovery model in 
order to permit the subsequent investigation of long-term cardioprotective efficacy. 
Extensive development and refinement of surgical skills and the protocol itself led to the 
establishment of a robust and reproducible model of in vivo ischaemia-reperfusion 
injury, described in part 1 of this chapter. The early results from this model are not 
presented in this thesis due to the large degree of variability in myocardial infarct size 
within experimental groups. All data presented in this thesis were conducted following 
the refinement of this model to ensure validity of the data and interpretations presented. 
Surgical survival and anaesthetic regime: Initial surgeries were conducted using a 
recovery anaesthetic protocol (consisting of ketamine and medetomidine and reversal 
by atipamezole) which was previously published and used within our laboratory for in 
vivo recovery procedures of short anaesthetic durations (Cruz et al., 1998; Lim et al., 
2011). However, modification of this anaesthetic regime to the substantially longer 
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anaesthetic duration required for the ischaemia-reperfusion model presented here 
resulted in very poor surgical survival of animals (Figure 4.8: surgical survival to 6 hours 
post-surgery 25%) which was clearly unacceptable for an experimental model.  
Further to this, the insufficient depth of anaesthesia of B6/SV129 mice observed in initial 
trials of this anaesthetic regime meant that it was not appropriate to continue with this 
anaesthetic protocol. The additional effects of this anaesthetic regime on heart rate and 
body temperature are discussed below. Given the strict UK Home Office guidelines and 
local rules governing in vivo recovery procedures it was not feasible to investigate other 
injectable regimes without rapid reversal agents, such as sodium pentobarbital and 
ketamine xylazine regimes (Nossuli et al., 2000; Fisher and Marber, 2002; Pons et al., 
2003) since this would have substantially reduced the throughput of this model. 
Initial investigations of the isoflurane inhalation anaesthetic regime demonstrated 
substantially improved surgical survival (Figure 4.8: surgical survival to 6 hours post-
surgery 100%) and permitted the assessment of myocardial infarct size as a percentage 
of AAR in a number of animals subjected to this protocol (Figure 4.9). Isoflurane 
anaesthesia also conferred several further procedural advantages including: (1) rapid 
onset and reversal of anaesthesia, (2) ease of delivery and modulation of dosing and (3) 
no effect on physiological heart rate or body temperature. The lack of interference on 
heart rate and body temperature confer clear advantages over the injectable regimes 
described in this thesis given the known effects of lowered cardiac function (Appleton et 
al., 2004) and temperature (Schwartz et al., 1997; van den Doel et al., 1998) on infarct 
size. Indeed, Kober et al. (2004; 2005) reported that isoflurane exerts significantly less 
effect on haemodynamics and cardiac function than ketamine and xylazine anaesthesia. 
Anaesthetic conditioning: The use of isoflurane anaesthesia in this model presents 
the possibility of anaesthetic conditioning effects which have been reported to reduce 
final myocardial infarct size in some previous studies (reviewed by Kato and Foex, 
2002). Investigation of this in animals subjected to this protocol using non-recovery 
injectable (ketamine, xylazine and atropine) and isoflurane inhalation anaesthetic 
regimes showed a striking agreement in myocardial infarct size between them (Figure 
4.9), thereby suggesting that the isoflurane protocol here does not exert an appreciable 
cardioprotective effect. However, interpretation of this effect is limited by the short 
reperfusion duration (2 hours only) imposed on this study due to the complications of the 
recovery protocol described above, whereby it is possible that this isoflurane dose may 
exert delayed conditioning effects that would not be detected in this study. Tsutsumi et 
al. (2006) showed that isoflurane mediated cardioprotection elicited an acute memory 
phase up to two weeks following in vivo ischaemia-reperfusion in mice. However, the 
168 
isoflurane dose examined in this published study was sustained for 30 minutes prior to 
the onset of ischaemia (Tsutsumi et al., 2006), which differs substantially from the 
protocol used in this thesis. Indeed, the main studies reporting significant 
cardioprotective effects of isoflurane in this model of ischaemia-reperfusion use similarly 
high and prolonged isoflurane doses (reviewed by Kersten, 2011). 
Interestingly, a comprehensive study of the cardioprotective effects of isoflurane dosing 
by Redel et al. (2009) showed that 30 minutes and not 15 minutes administration of 
isoflurane prior to ischaemia-reperfusion in mice was required to significantly reduce 
myocardial infarct size. However, it should be noted that 18 minutes post-conditioning by 
isoflurane dosing also significantly reduce myocardial infarct size (Redel et al., 2009), 
confirming the potential postconditioning effect of isoflurane in mice. This study 
demonstrates that, as expected for any cardioprotective intervention, the threshold 
required for cardioprotection is dose and time dependent, where it appears that the 
isoflurane protocol used in this thesis does not reach the threshold required for 
cardioprotection. This further demonstrates the importance of strict control of isoflurane 
concentration and duration of dosing in the model presented here. 
Furthermore, since it has been suggested that anaesthetic and ischaemic conditioning 
are mediated by the same cardioprotective pathways (see chapter 1) (Kober et al., 
2004; Stowe and Kevin, 2004; Tsutsumi et al., 2006), the demonstration of a significant 
reduction in myocardial infarct size by IPC (Figure 4.12), in the region of that expected 
from previous IPC studies (reviewed by Yellon and Downey, 2003), also suggests that 
this isoflurane protocol does not elicit significant cardioprotection.  
It should be noted however, that it is possible that isoflurane may be mediating more 
subtle effects including (1) lowering the threshold for other conditioning protocols with 
shared pathways, such as IPC (Kober et al., 2004; Stowe and Kevin, 2004; Tsutsumi et 
al., 2006) or (2) exhibiting delayed conditioning effects that could be observed at 
prolonged reperfusion durations (Tsutsumi et al., 2006). Further investigation of potential 
anaesthetic conditioning by examining the isoflurane dosage required to significantly 
reduce infarct size is outside the remit of this thesis. However, this may have provided 
further confirmation that the dose used in the present study was not approaching the 
threshold dose required for cardioprotection.  
An additional possible mechanism of inadvertent cardioprotection in the in vivo 
ischaemia-reperfusion model developed here is the administration of the analgesic 
buprenorphine; a semi-synthetic opioid which exerts its analgesic effects by acting on 
opioid receptors (specifically mu and kappa receptor subtypes) (McCormack and 
Chapleo, 1998). Opioid compounds have been reported to exert significant 
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cardioprotective effects in in vivo models of ischaemia-reperfusion (reviewed by Peart et 
al., 2005). However, for the same reasons as discussed above relating to similarity of 
infarct sizes obtained using the non-recovery (injectable anaesthesia without 
buprenorphine administration) and the recovery (isoflurane anaesthesia) protocols and 
the demonstration of significant cardioprotection by IPC, it is not expected that 
buprenorphine administration here exerts any significant cardioprotective effect here. 
Consistency of buprenorphine dosing was ensured to minimise the interference of any 
possible effects in the studies presented in this thesis. 
In summary, consideration of possible complications due to inadvertent isoflurane or 
opioid conditioning should not be discounted in the model presented here; however, 
attempts were made to limit any potential conditioning effects by using the minimal 
dosing concentration required for effect and close matching of dosing between animals. 
This isoflurane anaesthetic protocol permitted establishment of a robust and 
reproducible in vivo recovery model of ischaemia-reperfusion in mice. The subsequent 
sections of this chapter described the validation and characterisation of this model. 
4.6.2. Aim 2: Validation of ischaemia-reperfusion injury model 
Since this thesis intended to apply the in vivo ischaemia-reperfusion model developed 
here to investigate the long-term cardioprotective efficacy of therapeutic interventions, it 
was necessary to validate the use of this model for detecting reductions in myocardial 
infarct size. This was completed by application of two well-described cardioprotective 
strategies, IPC (Figure 4.12) and CsA (Figure 4.13). Both of these interventions 
significantly reduced myocardial infarct size at 72 hours reperfusion and thus confirmed 
that the infarct size evoked by this model is amenable to modification. This was 
particularly important in the present study given that the infarct size in control operated 
animals at 72 hours reperfusion was smaller than that expected from previous studies 
with 2 hours reperfusion, meaning that the absolute infarct size difference between the 
sham and control infarct sizes was only 26% IS/AAR. 
Cardioprotection by ischaemic preconditioning: IPC is a powerful cardioprotective 
intervention whereby brief sublethal episodes of ischaemia immediately prior to the main 
ischaemic insult protect against ischaemia-reperfusion injury (Murry et al., 1986). 
Although this specific intervention is of limited clinical relevance since it must be 
administered prior to the main ischaemic event, it provides a useful experimental tool 
since it elicits a robust cardioprotective effect that has been confirmed in every 
mammalian species tested to date (reviewed by Jennings, 2011). A standard IPC 
protocol of one cycle of 5 minutes ischaemia and 5 minutes reperfusion prior to the main 
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ischaemic insult elicited significant cardioprotection against both 30 minute (Figure 4.12) 
and 40 minute (data not shown) ischaemic insults. Importantly, this experiment 
demonstrated that the variation of infarct size within these groups and the 
cardioprotective effect size were sufficient to demonstrate statistical significance to 
**P<0.01 with six animals per group (Figure 4.12). Furthermore, the extent of infarct size 
reduction by IPC (49% reduction) is in agreement with that expected from previous 
studies of IPC in numerous models (reviewed by Yellon and Downey, 2003); as 
discussed above in relation to potential inadvertent conditioning effects. 
Cardioprotection by cyclosporine-A: Administration of CsA 5 minutes prior to the 
onset of myocardial reperfusion also mediated significant cardioprotection in this model 
(Figure 4.13). Although the extent of infarct size reduction was lower than that conferred 
by IPC (IS/AAAR% reduced by approximately 31% for CsA compared to 49% for IPC), 
statistical significance was obtained with small sample sizes (Figure 4.13: n=4/group).  
It should be noted that the control infarct size in vehicle treated animals in this CsA 
study was slightly larger than control animals previously (Figure 4.13: 43.1% in vehicle 
treated controls compared to Figure 4.12: 32.0% in controls). This suggests that the 
vehicle used in this study (cremophor/ethanol-94%) evoked increased myocardial injury. 
The potentially injurious effect of this vehicle has not been investigated further in this 
thesis and it remains unclear which component of the vehicle exerted this effect. Ethanol 
has previously been reported to be cardioprotective in this model (reviewed by Krenz et 
al., 2002), although only as a preconditioning mimetic which is distinct to the timing of 
administration in this study. A previous study by Tatou et al. (1996) in an ex vivo working 
heart model of myocardial infarction showed that cremophor significantly impaired 
cardiac function (Tatou et al., 1996); however, this has not been confirmed in vivo.  
Since all animals in this study received matched doses of vehicle (either with or without 
CsA) this does not affect the interpretation of the cardioprotective effect of CsA. 
However, the increased control infarct size may increase the absolute effect size of 
infarct size reduction in this study, thereby increasing the statistical power at this small 
sample size. The precise influence of this increased control infarct size on effect size 
cannot be evaluated from this data because infarct size was not assessed in sham 
operated mice receiving this vehicle. Although administration of this vehicle could not be 
avoided due to the solubility properties of CsA, this study highlights the importance of 
well-designed studies with appropriate control groups, where the inclusion of vehicle 
treated controls in this experiment permits the conclusion that CsA treatment is 
cardioprotective in this model. This was also an important consideration for the 
experimental design of a further CsA study in chapter 8. 
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In summary, this initial validation study confirmed that the infarct size evoked by this 
model is amenable to reduction by known cardioprotective interventions. The scope for 
increased infarct size has not been examined here since this was not the focus of the 
subsequent applications of this model; this is however, discussed further in chapter 6. 
4.6.3. Aim 3: Characterisation of ischaemia-reperfusion injury model 
Further characterisation of the in vivo ischaemia-reperfusion model developed in this 
thesis was examined to determine the optimal ischaemic and reperfusion durations and 
the effect of other experimental variables on the infarct size evoked by this model.  
Ischaemic duration: The optimal myocardial infarct size of control operated animals 
should be such that it permits scope for increase or decrease upon application of 
experimental treatments. The optimal ischaemic duration, in terms of the resultant infarct 
size, was examined in this section since it is known that ischaemic duration correlates 
with infarct size, as explained by the wavefront of necrosis hypothesis by Reimer et al. 
(1977) described in chapter 1 (see 1.2.3). This investigation of infarct size was 
particularly pertinent in the present model given the slightly smaller infarct size obtained 
in this recovery model (Figure 4.12; 30 minutes ischaemia, 72 hours reperfusion) than 
that expected in animals subjected to the in vivo non-recovery model within our 
laboratory (Figure 4.9; 30 minutes ischaemia, 2 hours reperfusion). 
An additional 10 minutes myocardial ischaemia resulted in a slight but non-significant 
increase in myocardial infarct size (Figure 4.16, comparing 30 versus 40 minute 
ischaemic insults). Although there was no statistical difference, there was a trend 
towards decreased survival in the group subjected to the increased ischaemic duration 
(Figure 4.17: 40 minutes ischaemia 63.6% survival compared to 30 minutes ischaemia 
87.5% survival), where the majority of those animals that did not survive to the pre-
defined endpoint were actually excluded due to incomplete reperfusion upon release of 
the occluding snare. This is important for evaluating the most appropriate ischaemic 
duration for subsequent studies, where a standard model of 30 minutes ischaemia was 
used in all subsequent experiments unless otherwise stated. 
Although the increased ischaemic duration examined in this study did not significantly 
increase myocardial infarct size, it is likely that this reflects an insufficient increase in the 
ischaemic duration tested, such that this produced only a small effect size for which this 
study is likely to be underpowered to detect. It is unlikely that the lack of a significantly 
increased infarct size following 40 minutes ischaemia reflects secondary selection of 
smaller infarct size by death of animals with larger infarcts, since the majority of ‘non-
survivors’ were excluded and did not die spontaneously (Figure 4.17), described above. 
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The wider potential effects of secondary selection for smaller infarct sizes by death of 
animals with larger infarct sizes are discussed in detail below. Further studies could 
have assessed the effect of further incremental increases in ischaemic duration, 
however, given the increased exclusion of animals in the 40 minute ischaemic group 
due to poor myocardial reperfusion; this would be unlikely to lead to the development of 
an improved model and was not therefore investigated further. 
It is important to note that neither of the ischaemic durations tested in this chapter 
resulted in any noticeable myocardial haemorrhage within the AAR (which would have 
been visualised by the rust-red appearance of blood upon scanning of the hearts). This 
is in line with the expected progression of infarction predicted by Reimer et al. (1977) 
where myocardial haemorrhage is predominantly expected in fully transmural infarcts. A 
further interesting observation of the myocardial infarctions evoked by this in vivo model 
is the unusual subepicardial dominance of infarction (see Figure 4.12 A), which is not as 
predicted by the wavefront of necrosis hypothesis demonstrated by Reimer et al. (1977) 
in dog hearts (see 1.2.3). This may result from species differences between coronary 
anatomy and myocardial thickness, specifically in terms of the proportion of 
subendocardial tissue that is amenable to residual delivery of oxygen by diffusion from 
the lumen of the left ventricle. The unexpected morphology of infarction in the mouse 
heart does not impact on the overall applications of this model; however, it is important 
to highlight a potential confounding factor that may affect the visualisation and 
measurement of infarction in subsequent applications of this model. 
A further consideration for the interpretation of infarct sizes in this thesis is that infarct 
size was only assessed in animals which survived to the pre-defined reperfusion 
endpoint, in order to ensure consistency of the model. However, this may have 
introduced some selection of animals with smaller infarcts which are expected to have 
an increased survival rate. It was not feasible to quantify infarct size in those animals 
which died spontaneously, due to the questionable validity of delayed TTC staining for 
infarction in dead animals where further cell death will occur and enzymatic washout 
may not be complete; this has not been directly addressed in the literature. Although a 
previous study by Pons et al. (2003) did report post-mortem measurements of infarct 
size and showed a trend towards larger infarct sizes in animals that died spontaneously, 
caution should be exercised in the interpretation of this study especially since the time 
delay between death and TTC staining is not detailed. In the present thesis, exclusion of 
animals that died spontaneously during the reperfusion period may result in some 
secondary selection of lower myocardial infarct sizes. This is likely to be more acute in 
experiments resulting in larger infarct sizes and is therefore discussed in more detail in 
relation to the results presented in chapter 6. 
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Reperfusion duration: The overall aim of this thesis was to investigate the long-term 
efficacy of potentially cardioprotective interventions and it was therefore pertinent to 
investigate the effect of extended reperfusion duration on myocardial infarct size 
assessed in this model. It was hypothesised that infarct size would increase over the 
immediate reperfusion duration as the full extent of infarction due to ischaemic and 
lethal reperfusion injury and the initial remodelling effects of myocardial thinning and 
infarct expansion occur. This was based on studies of larger species and it is important 
to note that the metabolic rate and velocity of remodelling in the mouse heart are known 
to be faster (Patten et al., 1998; Fisher and Marber, 2002; Dewald et al., 2004).  
This study showed that although there was no statistically significant difference in infarct 
size between the reperfusion durations tested, there was a trend towards decreased 
infarct size at the extended reperfusion durations (24 and 72 hours) compared to earlier 
reperfusion durations (2 and 6 hours) (see Figure 4.18). Closer examination of published 
studies revealed that Tsutsumi et al. (2006) observed a similar non-significant decrease 
in myocardial infarct size at 2 hours and 14 days reperfusion (Tsutsumi et al., 2006).  
The study presented here was not adequately powered to detect a significant difference 
between each of these reperfusion durations since this model is not sufficiently sensitive 
to undertake such studies. The terminal nature of this histological staining method used 
for infarct size and AAR quantification further decreases the statistical power of this 
study, whereby an in vivo method of examining the progression of infarct size within the 
same cohort of animals would likely provide a valuable insight into the processes of 
infarct development. The use of cardiac MRI for in vivo myocardial infarct size and AAR 
is the focus of chapter 8 and may provide a valuable tool for future studies.  
It is also important to note that although TTC is considered to be a ‘gold-standard’ 
method for identifying and quantifying infarct size, it is recognised that there are 
potential factors that can affect its validity including: (1) time for enzymatic washout 
(Redel et al., 2008), (2) impaired metabolic activity of living cells (Tsutsumi et al., 2006) 
and (3) lack of distinction between cell types. The time required for enzymatic washout 
and recovery of metabolic activity of cells following ischaemia and reperfusion should 
not affect the infarct sizes reported in this study since the shortest reperfusion duration 
examined was 2 hours. It is possible that the slight reduction observed in infarct size at 
72 hours compared to 2 hours reflects an artefact from positive TTC staining of 
infiltrating inflammatory cells at this later reperfusion endpoint. Further investigation of 
the effect of reperfusion could be undertaken using immunohistochemical approaches; 
however, the lack of a validated method for determining AAR using this method would 
hinder interpretation of this data and has not therefore been undertaken here. 
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An additional consideration for interpreting the data presented in this study is the 
potential effect of remodelling whereby extensive myocardial thinning at extended 
reperfusion durations would be expected to reduce the measured AAR. This is unlikely 
to represent a significant bias in the present study since no appreciable myocardial 
thinning was observed at any endpoint and furthermore, there was no difference in AAR 
between these groups. This is further supported by Vandervelde et al. (2006) who 
concluded that myocardial thinning of the mouse heart following a similar ischaemic 
insult is very limited (Vandervelde et al., 2006). Potential changes in the measured AAR 
at extended reperfusion durations remain an important consideration, particularly since 
remodelling may be further affected by interventions. This is discussed further in chapter 
8 which aims to develop an in vivo method for determining AAR to overcome the 
problems associated with extended reperfusion. 
The effect of reperfusion duration on infarct size was not investigated further in this 
thesis given the recognised limitations of this study design. However, the experiment 
presented here was important to further evaluate and support the infarct size reported at 
72 hours reperfusion in this model since it suggests that this is not an unduly small 
infarct size but is actually in good agreement with the extent of infarction obtained at 2 
hours reperfusion (non-recovery model) by previous operators within our laboratory and 
previously in this thesis (Figure 4.9). 
Operative time of day: A further important consideration for the experimental design of 
subsequent studies in this thesis is the potential effect of diurnal changes that have 
previously been shown to affect myocardial infarct size in a similar in vivo mouse model. 
Durgan et al. (2010) demonstrated a 3.5 fold increase in infarct size (following 45 
minutes ischaemia and 24 hours reperfusion) in mice subjected to this ischaemic insult 
at zeitgeber time (ZT) zero (equivalent to 06:00) compared to ZT12 (equivalent to 
18:00). Further to this, levels of phosphorylated Akt and GSK-3β were shown to 
decrease during the period, in accordance with the inverse correlation with infarct size 
(Durgan et al., 2010), as expected given the cardioprotective actions of these kinases.  
All surgeries in this thesis were conducted during full day operating sessions during 
which the time of onset of ischaemia was between approximately 08:00 and 18:00. A 
retrospective analysis of myocardial infarct size in morning and afternoon operated 
animals in the present study demonstrated that there was no significant difference in 
infarct size for either control or IPC groups (Figure 4.19 i and ii). An additional more 
detailed sub-analysis was conducted for control operated animals to compare only early 
and late surgeries (08:00-09:00 versus 16:00-17:00) and this also showed no significant 
difference in infarct size. Although it is possible that diurnal variations may be exerting 
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more subtle effects that cannot be seen in this retrospective investigation of infarct size, 
to reduce the potential of any such effects, an equal mix of morning and afternoon 
surgeries was ensured between groups for all studies reported in this thesis. Although 
this variation in operating time may slightly increase the variability of final infarct size 
data, it was not feasible to restrict the operating day to only morning or afternoons due 
to the long surgical protocol and throughput required. 
Investigation of diurnal variations in infarct size resulting from this in vivo recovery model 
of ischaemia-reperfusion injury was not a primary objective of this thesis; however, it is 
reassuring to demonstrate that the variation in operating time of day in the model 
developed here does not significantly affect infarct size. The absence of any obvious 
diurnal effects on myocardial infarct size may result from the less extreme operating 
times investigated (8:00 versus 17:00) or compared to those examined by Durgan et al. 
(2010) (6:00 versus 18:00). It should also be noted that the model of infarction 
investigated here comprised 30 minutes ischaemia and 72 hours reperfusion compared 
to 45 minutes ischaemia and 24 hours reperfusion investigated by Durgan et al (2010). 
The precise reasons for the absence of obvious diurnal effects on infarct size resulting 
from the model presented in this chapter was not investigated further since it was not 
the focus of the overall research objectives of this thesis. This finding supported the use 
of full day operating sessions for all other studies presented in this thesis. 
Gender: Previous basic science and clinical studies have shown that females are 
inherently more cardioprotected than males, in part due to oestrogen levels (reviewed by 
Murphy and Steenbergen, 2007). The majority of basic science cardioprotection studies 
have historically only investigated male subjects due to the potential increased variation 
between females due to oestrogen-cycling (Black and Rodger, 1996). It has, however, 
been suggested that this gender bias of pre-clinical studies may affect the success of 
clinical translation; this is discussed in detail in chapter 1 (see 1.5.1). Gender did not 
appear to significantly affect infarct size observed in the model presented here (Figure 
4.20). The absence of a significant difference in infarct size between male and female 
mice in this study may result from the relatively young age of these animals (10-12 
weeks old), although these animals are expected to be sexually mature. It is likely that 
any subtle effect of gender on myocardial infarction in the experiments presented here 
would be minimal based on this study, however, the majority of studies in this thesis 
continued to use male subjects only since this is more conventional for publication 
purposes. The gender of animals used in subsequent studies is specifically detailed. 
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In summary, part three of this chapter has investigated the effects of a number of 
potentially important experimental variables to define the optimal experimental protocol 
for the subsequent applications of this in vivo recovery model of ischaemia-reperfusion. 
4.6.4. Potential limitations of the ischaemia-reperfusion injury model 
An important consideration for the suitability of the model of ischaemia-reperfusion 
presented here is the invasive nature of the surgical protocol concerning: (1) open-chest 
preparation of the animal and (2) direct mechanical occlusion and reperfusion of the 
LAD. It is likely that these surgical interventions will evoke a confounding inflammatory 
response concurrent with that resulting from myocardial ischaemia-reperfusion itself.  
Nossuli et al. (2000) have reported a closed-chest model of ischaemia-reperfusion injury 
by externalisation of the LAD ligating suture for subsequent ischaemia-reperfusion one 
week post-surgery (Nossuli et al., 2000). Further studies have attempted to enhance the 
closed-chest surgical protocol and Gao et al. (2010) recently reported a closed-chest 
model of ischaemia-reperfusion without the need for artificial ventilation which resulted 
in lower inflammatory responses and improved surgical recovery. More recently, Liao et 
al. (2013) published a modified closed-chest method to allow application of ischaemic 
conditioning protocols. However, there remain potential limitations with these closed-
chest models including the lack of direct visualisation of the AAR in the delayed model 
presented by Nossoli et al. (2000) and the relatively poor surgical survival reported by 
Liao et al. (2013). Given the complications associated with establishing the recovery 
model of ischaemia-reperfusion presented in this thesis, subsequent modifications to 
this protocol to enable closed-chest induction of ischaemia were not investigated here. 
Although the open-chest model of ischaemia-reperfusion developed here is likely to 
evoke a significant background inflammatory response, which limits the investigation of 
precise inflammatory pathways, the effect of this on the measurement of infarct size and 
cardiac function is likely to be limited. The effect of background responses to injury 
evoked by open-chest surgery is discussed further in chapter 6, where it was shown that 
sham operated animals exhibited a significant increase in myocardial expression of Sirt-
3, an important mitochondrial stress protein (see 6.3.3).  
Another potential confounding variable in the open-chest model of ischaemia-
reperfusion injury presented in this thesis is myocardial temperature. Although it is 
known that core body temperature profoundly affects myocardial infarct size (van den 
Doel et al., 1998), Schwartz et al. (1997) showed that myocardial temperature may vary 
despite the use of a thermostatically controlled operating table. Although myocardial 
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temperature was not examined in this thesis, use of sterile drapes covering the chest 
opening may have helped to reduce any variations in myocardial temperature.  
Direct external manipulation of the LAD using a suture occlusion to induce ischaemia is 
notably different from the spontaneous occlusion of a vessel by atherosclerotic plaque 
rupture in the clinical setting (reviewed by Black and Rodger, 1996). It is not clear 
whether the difference in means of occlusion between these settings would dramatically 
affect results from this model; however, it is difficult to overcome this given the technical 
restraints concerned with using an intra-coronary device in the mouse. 
It is also important to note that this model of ischaemia-reperfusion injury has been 
developed in otherwise young, healthy animals which is distinct from the clinical setting 
of acute myocardial infarction whereby patients usually present with several comorbities 
(as discussed in 1.5.1. i). In particular, the pathophysiological responses induced by the 
defined onset of ischaemia in an otherwise healthy vessel (as in the model presented 
here) may differ from the pathological setting of chronic cardiovascular disease. 
Although it is complicated to develop a research model including this pathological 
background, this potential limitation of the current model should be appreciated. 
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4.6.5. Summary 
This chapter describes the development and characterisation of a reproducible and 
robust model of ischaemia-reperfusion to permit future investigation of long-term 
cardioprotective efficacy. The key findings of this chapter are summarised below: 
(1) The surgical protocol for the mouse in vivo recovery model of ischaemia-reperfusion 
has been developed with extensive procedural refinements to facilitate a high 
surgical survival rate of animals subjected to this model. A detailed surgical protocol 
and an extensive troubleshooting guide are provided in this chapter and aim to 
facilitate subsequent establishment of this model by future operators. 
 
Isoflurane anaesthesia was required to achieve sufficient surgical anaesthesia and 
survival for this model and steps have been taken to ensure any potential 
cardioprotective effects of this regime are reduced by using minimal and consistent 
isoflurane doses between animals. An initial investigation of the potential 
cardioprotective effects of isoflurane demonstrated that there was no significant 
difference in myocardial infarct size between animals subjected to the inhalation 
isoflurane and injectable anaesthetic regimes in this protocol, thereby suggesting 
that any cardioprotective effect of isoflurane in this protocol is minimal. 
 
(2) The mouse in vivo recovery ischaemia-reperfusion model developed here has been 
validated for the evaluation of cardioprotective efficacy in terms of myocardial infarct 
size reduction by the application of two well-described cardioprotective interventions. 
Both ischaemic preconditioning and cyclosporine-A significantly reduced myocardial 
infarct size as expected and thereby demonstrated that the infarct sizes produced by 
this model are amenable to reduction in the presence of a cardioprotective 
intervention. These experiments also confirm that the infarct sizes evoked by this 
model and the quantification methods used are robust and reproducible. 
 
(3) The potential effects of several potentially important variables were investigated in 
this in vivo recovery model of ischaemia-reperfusion thus informing the optimal 
design of future studies in this thesis. An optimal protocol of 30 minutes ischaemia 
and 72 hours reperfusion was shown to elicit an appropriate extent of myocardial 
infarction and was used for all subsequent studies presented in this thesis unless 
otherwise stated. The timing of surgeries during standard operating days had no 
significant effect on infarct size confirming that it is appropriate to utilise full operating 
days to maximise the throughput of this model. Gender did not affect infarct size and 
thus justifies use of mixed gender groups for subsequent studies if required. 
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CHAPTER 5: INVESTIGATION OF CYCLOPHILIN-D 
INHIBITION AS A STRATEGY FOR CARDIOPROTECTION  
 
5.1. Introduction 
Mitochondrial dysfunction and mitochondrial permeability transition pore opening 
account for a significant proportion of cell death upon myocardial ischaemia-reperfusion. 
The mitochondrial proteins involved in these processes represent critical targets for 
interventions to regulate these processes and potentially reduce infarct size and thus 
ultimately improve patient prognosis (reviewed by Gustafsson and Gottlieb, 2008).  
Mitochondrial permeability transition upon mPTP opening is a key effector of cell death 
upon myocardial ischaemia-reperfusion due to its effects on dissipating the inner 
mitochondrial membrane electrochemical gradient and resultant loss of ATP production 
and subsequent necrotic or apoptotic cell death; outlined in chapter 1 (see 1.2.3, Figure 
1.6) (reviewed by Baines, 2009a; Oerlemans et al., 2013). Although the molecular 
composition of the mPTP has been subject to intensive research and conflicting models, 
Cyp-D is accepted as an important regulatory component which confers calcium 
sensitivity to mPTP opening (Connern and Halestrap, 1994; Nicolli et al., 1996).  
Cyp-D inhibition has been identified as an important potential target for reducing mPTP 
opening and thus cell death upon ischaemia-reperfusion. Genetic ablation or 
pharmacological inhibition of Cyp-D renders the mPTP less sensitive to calcium, thereby 
requiring significantly higher calcium concentrations to trigger mPTP opening. Previous 
studies have shown that Cyp-D inhibition reduces cell death following ischaemia-
reperfusion, including in in vivo models of myocardial ischaemia-reperfusion injury 
(Nakagawa et al., 2005; Baines et al., 2005; Gomez et al., 2007); outlined in chapter 1 
(see 1.4.1). Indeed, Gomez et al. (2007) showed that a single intravenous dose of the 
Cyp-D inhibitor, Debio-025, preserved cardiac function and improved survival to 30 days 
in mice subjected to in vivo myocardial ischaemia-reperfusion (Gomez et al., 2007); 
thereby suggesting that Cyp-D represents a target for long-term cardioprotection. 
However, since Debio-025 also inhibits other cyclophilin proteins, the long-term efficacy 
of Cyp-D inhibition for cardioprotection against ischaemia-reperfusion remains unclear. 
The long-term efficacy of Cyp-D inhibition in this setting remains pertinent given the 
suggestion by some studies that long-term Cyp-D inhibition can be detrimental. 
Importantly, Oie et al. (2000) suggested that chronic Cyp-D inhibition by CsA may 
exacerbate cardiac failure and Elrod et al. (2010) showed that Cyp-D knockout mice 
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have a higher predisposition to cardiac hypertrophy and cardiac failure upon 
physiological stress. Although the divergent effects of Cyp-D inhibition in the settings of 
cardiac failure and ischaemia-reperfusion injury may result from the divergent 
pathophysiological processes in these settings, it is crucial to assess the long-term 
efficacy of Cyp-D as a therapeutic target against myocardial ischaemia-reperfusion. This 
is particularly relevant given the complexity of the long-term pathophysiology of 
myocardial ischaemia-reperfusion, including lethal reperfusion injury, inflammation and 
ventricular remodelling, as described in chapter 1 (see 1.2.4).  Indeed, the lack of long-
term trials of cardioprotective efficacy has been identified as a potentially important 
obstacle to the poor translation of therapeutic interventions from basic science research 
to the clinical setting (Hausenloy et al., 2010), as discussed previously. 
 
This chapter aimed to investigate the long-term efficacy of Cyp-D inhibition (by genetic 
ablation of Cyp-D) in conferring cardioprotection against ischaemia-reperfusion injury. 
 
5.2. Research objective and aims 
The main objective of this chapter was to investigate the potential role of Cyp-D 
inhibition (by genetic ablation) as a therapeutic target against the long-term effects of 
myocardial ischaemia-reperfusion injury. The principal aims to achieve this were: 
(1) Investigate the long-term cardioprotective efficacy of Cyp-D inhibition in the 
established model of global genetic ablation of Cyp-D; 
 
(2) Investigate the role of Cyp-D in the heart by establishing and investigating a 
model of cardiac-specific genetic ablation of Cyp-D. 
 
5.3. Aim 1: Investigate long-term cardioprotection of Cyp-D ablation 
5.3.1. Background 
The Cyp-D genetic knockout mouse model is an important experimental tool for 
investigating the roles of Cyp-D and the mPTP in the pathophysiology of ischaemia-
reperfusion. Cyp-D genetic ablation, by deletion of the Ppif gene, allows a more elegant 
elucidation of the roles of Cyp-D without the confounding non-selective effects of many 
of the small molecule inhibitors of Cyp-D described in the literature (detailed in chapter 
1; see 1.4.1). This is particularly important since most of the available pharmacological 
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Cyp-D inhibitors, including CsA and Debio-025, also inhibit the other cyclophilin proteins 
making it difficult isolate the roles of Cyp-D (reviewed by Hausenloy et al., 2012).  
Global genetic ablation of Cyp-D was simultaneously published by three independent 
research groups in 2005 (Basso et al., 2005; Baines et al., 2005; Nakagawa et al., 
2005). This Cyp-D knockout system allowed characterisation of the baseline and 
stressed phenotypes of cells devoid of Cyp-D protein; characterisation of these animals 
is described in detail in chapter 1 (see 1.4.1, Table 1.2). Briefly, mitochondria isolated 
from Cyp-D knockout mice were more resistant to mPTP opening in response to 
simulated triggers of ischaemia-reperfusion including calcium and ROS. Importantly, 
Baines et al. (2005) and Nakagawa et al. (2005) also showed that global genetic 
ablation of Cyp-D significantly reduced myocardial infarct size in vivo in mice subjected 
to ischaemia-reperfusion. These studies confirmed the predicted role of Cyp-D in the 
susceptibility to ischaemia-reperfusion injury and provided a valuable model system in 
which to further examine the potential of Cyp-D as a therapeutic target in this setting.  
However, these studies examined only the relatively short-term cardioprotective efficacy 
of Cyp-D genetic ablation, examining 24 hours reperfusion at most (Baines et al., 2005). 
Our group has shown that Cyp-D knockout mice are resistant to development of cardiac 
failure in response to myocardial ischaemia (by permanent coronary artery ligation) at 
28 days (Lim et al., 2011). However, the long-term efficacy of Cyp-D inhibition by 
genetic ablation in the clinically relevant setting of myocardial ischemia-reperfusion 
injury has not been examined. The main objective of this chapter was to investigate the 
long-term effects of Cyp-D genetic ablation in the setting of myocardial ischaemia-
reperfusion injury using the in vivo model developed in chapter 4. 
 
Aim 1: This first aim of this chapter was to investigate the effect of global Cyp-D genetic 
ablation in mediating long-term cardioprotection against myocardial ischaemia-
reperfusion. The central hypothesis in relation to this research objective was:  
(1) Cyp-D global genetic ablation would significantly reduce myocardial infarct size 
following prolonged periods of reperfusion. 
To investigate the long-term cardioprotective efficacy of Cyp-D genetic ablation it was 
necessary to first determine the expected effect size of myocardial infarct size reduction 
in order to determine the sample sizes required for subsequent long-term studies. This 
section describes the initial evaluation of the effect of Cyp-D global genetic ablation on 
infarct size following myocardial ischaemia-reperfusion injury. 
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5.3.2. Detailed methods 
i Cyp-D global knockout mice 
The Cyp-D global genetic ablation model used in this thesis was obtained from Prof J. 
Molkentin (Cincinnati Children’s Hospital Medical Centre Laboratories, USA) from the 
colony created and published by his laboratory (Baines et al., 2005). Global somatic 
genetic ablation of Cyp-D in this colony was achieved by deletion of the first three 
coding exons of the endogenous Ppif gene according to standard transgenic methods, 
outlined in chapter 3 (see 3.1.2). A targeting vector was designed with homology to the 
non-coding regions of the Ppif locus surrounding the first three coding exons and 
containing the neomycin-resistance gene (neo), which upon insertion into SV129 
derived embryonic stem cells resulted in generation of Ppif null mice (Figure 5.1). Cyp-D 
knockout mice were partially backcrossed onto a C57BL/6 background (approximate 
genetic background 75% C57BL/6 - 25% SV129). 
 
Figure 5.1: Generation of Cyp-D global knockout mice by Baines et al. (2005) 
Global Cyp-D knockout was achieved by standard transgenic methods targeting the Ppif gene 
which encodes Cyp-D. Homologous recombination of the targeting vector and endogenous Ppif 
gene in embryonic derived stem cells resulted in deletion of the first three coding exons and 
insertion of the neomycin-resistance gene. Ppif KO cells were selected by neomycin resistance 
and used to create Cyp-D KO mice. Figure modified from Baines et al. (2005).  
 
Mice provided by Prof J. Molkentin (Cincinnati Children’s Hospital Medical Centre, USA). 
 
Colony maintenance: The Cyp-D global transgenic colony was previously maintained 
as knockout breeding crosses and B6/SV129 mice used as approximate wildtype control 
animals (Figure 5.2 A). For the purposes of this thesis, a more appropriate breeding 
schedule was established to provide true littermate control animals. A series of genetic 
neo
neo
A. Targeting vector
B. Ppif locus 
C. Homologous 
recombination
Negative selectable marker
Exon sequence (exon number in white)
4.4 kb3.0 kb
Intron sequence
1 2 3 4 65
4 65
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backcrossing stages were also undertaken to minimise any potential effects of variations 
in background genetic strain in experiments using this transgenic colony. The breeding 
schedule undertaken in this thesis is summarised in Figure 5.2 and described below.  
 
 
Figure 5.2: Cyp-D global knockout mouse colony backcrossing and maintenance 
A) Original colony: Cyp-D KO mice were originally bred in-house with an approximate genetic 
background of 75% C57BL/6 and 25% SV129. Commercially available B6/SV129 mice were 
used as WT controls. B) Backcrossing stages were completed by initially crossing Cyp-D KO 
mice with C57BL/6 mice to produce Cyp-D HET mice. Cyp-D HET mice were crossed with 
C57BL/6 mice to produce Cyp-D HET (and WT) mice and Cyp-D HET progeny subsequently 
crossed with C57BL/6 mice. Backcrossing was completed for four generations to obtain Cyp-D 
HET mice with an approximate genetic background of 98.4% C57BL/6 and 1.6% SV129. C) Final 
colony was maintained as HET x HET crosses to produce Cyp-D WT, KO and HET progeny. 
 
All breeding stages undertaken in the generation of this colony used a number of 
randomly selected animals from different parents in line with best practice breeding 
guidance (Wolfensohn and Lloyd, 2003). A number of animals from the original Cyp-D 
KO mouse colony maintained within our laboratory were bred with commercially 
obtained C57BL/6 mice (C57BL/6NCrl males and females; Charles River Laboratories, 
UK) to produce Cyp-D HET progeny. Cyp-D HET mice were subsequently bred with 
C57BL/6 animals to produce Cyp-D HET (and Cyp-D WT) progeny. This breeding 
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regime was undertaken for a total of four generations to produce a final colony with a 
genetic background of approximately 98.4% C57BL/6 and 1.6% SV129 (Figure 5.2 B). 
The colony was maintained as Cyp-D HET crosses to produce Cyp-D WT, HET and KO 
progeny for experimental use (Figure 5.2 C). 
ii Genotyping for global genetic ablation of Cyp-D 
All animals from this colony were genotyped prior to use; the genotyping method used 
here was based on that described in chapter 3 (see 3.1.2) with the following 
modifications. DNA samples were prepared from ear biopsies exactly as described 
previously and processed within 7 days of sampling. The PCR reaction mix was based 
on the standard PCR reaction optimised in this thesis and informed by Baines et al. 
(2005). The primers and cycling parameters for this reaction are described in Table 5.1. 
This protocol yielded DNA products of 600 base pairs (bp) (Neo-forward – Exon-4 
reverse product) and 850 bp (Exon-3 forward – Exon-4 reverse product) corresponding 
to the mutant and wildtype DNA products. The genotype of each animal was decoded 
based on the presence or absence of these DNA bands: WT 850 bp only, KO 600 bp 
only and HET both 600 and 850 bp bands (Figure 5.3).  
This PCR protocol was robust and reliably produced clear DNA bands for the 
determination of the genotypes of animals from the Cyp-D transgenic colony. This 
protocol was further confirmed by Western blot analysis of heart samples from Cyp-D 
WT and KO animals (example Western blot is shown subsequently in Figure 5.15).  
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A) Cyp-D PCR primer sequences 
PRIMER SEQUENCE 
PROPERTIES 
Length Tm (ºC) 
Primer 1 / Exon-4 reverse 5'-ATTGTGGTTGGTGAAGTCGCC-3' 21 57.3 
Primer 2 / Exon-3 forward 5'-CTCTTCTGGGCAAGAATTGC-3' 20 59.8 
Primer 3 / Neo forward 5'-GGCTGCTAAAGCGCATGCTCC-3' 21 63.7 
 
B) Cyp-D PCR reaction mix 
REAGENT VOLUME/SAMPLE  (µl) FINAL CONCENTRATION 
Qiagen 10X PCR Buffer 2.0 1X 
10 mM dNTPs 0.4 200 µM 
Primer 1 Exon-4R 100 µM 0.2 1 µM 
Primer 2 Exon-3F 100 µM 0.2 1 µM 
Primer 3 Neo-F 100µM 0.2 1 µM 
Taq polymerase 0.2 - 
Autoclaved distilled water                   15.8 - 
Crude DNA lysate 
†
 1.0 - 
TOTAL VOLUME/SAMPLE (µl)                     20.0 
  
C) Cyp-D PCR thermocycling parameters 
PCR STAGE TEMPERATURE AND DURATION PCR DESCRIPTION 
1  95 ºC for 3 minutes   Hot start 
2  95 ºC for 30 seconds  DNA separation 
3  59 ºC for 30 seconds  Primer annealing 
4  72 ºC for 1 minute  DNA synthesis 
5  95 ºC for 30 seconds  DNA separation 
6  57 ºC for 30 seconds  Primer annealing 
7  72 ºC for 1 minute  DNA synthesis 
8  Go to step 5 for 32 cycles  DNA synthesis 
9  72 ºC for 10 minutes  Final extension 
10  4 ºC for ever  Intermediate storage 
 
Table 5.1: Cyp-D global transgenic colony genotyping protocol 
A) Cyp-D primer sequences and properties. B) A single master mix was made based on Qiagen 
Taq kit (Qiagen, UK) and aliquots taken for each reaction. 
†
 1 µl crude DNA lysate was added to 
each aliquot. C) PCR was performed using a thermal cycler (MJ Research, Canada). 
 
 
Figure 5.3: Cyp-D global transgenic colony representative genotyping result  
The genotype of each animal was determined by the presence or absence of the expected PCR 
products: WT 850 bp band only, KO 600 bp band only and HET both bands (as annotated above 
the gel). A negative control (NEG) was run to ensure there was no external DNA contamination. 
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iii Ischaemia-reperfusion injury in vivo 
Surgical protocol: The susceptibility of Cyp-D knockout and wildtype littermate controls 
was assessed using the in vivo recovery model of ischaemia-reperfusion injury 
developed previously in this thesis using the standard protocol of 30 minutes myocardial 
ischaemia and 72 hours reperfusion (see Figure 3.6). All surgeries were conducted on 
male mice aged 10-16 weeks from the Cyp-D global knockout transgenic colony or 
B6/SV129 mice from Harlan Laboratories, UK, as indicated in the results section below. 
Endpoint 1 – IS/AAR%: The primary endpoint assessed in this study was myocardial 
infarct size by ex vivo histological staining using TTC and Evans blue staining, exactly 
as described previously, to calculate the infarct size as a percentage of AAR. The pre-
defined surgical and AAR exclusion criteria were applied to this dataset (see 3.2.4).  
All infarct size and AAR values are presented as mean ± SEM. Where two groups were 
compared, data were statistically analysed using an unpaired t-test. Where more than 
two groups were compared, data were statistically analysed by one-way ANOVA, 
followed by Bonferroni test comparing relevant columns of data. Where appropriate, 
Deming (Model II) regression analysis was performed to define the relationship between 
infarct size and AAR and reported as: y=mx+c where m is the slope and c is the 
intercept when x=0. All statistical analysis was completed using GraphPad Prism® 
version 5.0 (GraphPad Software, USA). Statistical significance was reported where 
P<0.05 using standard significance coding.  
Statistical power calculations were performed to retrospectively evaluate the power of 
statistical tests undertaken in this chapter to facilitate their interpretation. Where 
sufficient statistical power (80%) was not reached, the effect size and standard deviation 
were used to determine the sample size required to reach sufficient statistical power. 
For all tests, the minimal level of statistical power was judged to be 80%, in accordance 
with published guidelines (Cohen, 1988; Townend, 2002). All power calculations were 
performed using GraphPad StatMate version 2.0 (GraphPad Software, USA).  
Endpoint 2 – Survival: Survival rates of Cyp-D mice were recorded and probable 
cause of death assessed by post-mortem investigation. Kaplan-Meier survival plots were 
plotted using GraphPad Prism® version 5.0 (GraphPad Software, USA). Significance 
was analysed by log-rank tests and significance was reported where P<0.05.  
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5.3.3. Results 
This study first undertook a comprehensive backcrossing breeding schedule to allow 
generation of true wildtype littermate control mice and to theoretically reduce strain 
related variability in future experiments. All experiments using Cyp-D knockout and 
wildtype mice presented in this thesis were performed using true littermate control 
animals with a genetic background of approximately 98.4% C57BL/6 and 1.6% SV129. 
The first stage of this study to investigate the long-term cardioprotective efficacy of Cyp-
D global genetic ablation aimed to characterise the backcrossed Cyp-D knockout colony 
produced here. These experiments are described below and the implications of these 
findings for future studies are discussed in detail subsequently. 
i True littermate controls 
Since previous studies of the Cyp-D global genetic knockout mice within our laboratory 
had utilised B6/SV129 mice as wildtype control animals, it was pertinent to examine 
myocardial infarct size in B6/SV129 mice and Cyp-D wildtype mice (backcrossed to 
98.4% C57BL/6 and 1.6% SV129 genetic background) bred as a part of this thesis.  
B6/SV129 and Cyp-D wildtype mice were subjected to the standard in vivo recovery 
ischaemia-reperfusion model developed in chapter 4 (30 minutes ischaemia and 72 
hours reperfusion). There was no significant difference in myocardial infarct size 
between B6/SV129 and Cyp-D wildtype mice subjected to this standard protocol (Figure 
4.9: IS/AAR% B6/SV129 30.3±3.8 versus Cyp-D WT 35.4±4.3; n≥6/group, NSP>0.05). 
There was no significant difference in AAR (AAR/LV% B6/SV129 56.1±1.9 versus Cyp-
D WT 55.6±2.8; n≥6/group, NSP>0.05) or survival (% survival to 72 hours reperfusion: 
B6/SV129 85.7%, n=7 versus Cyp-D WT 90.0%, n=10) between these groups.  
Although there was a trend towards an increased infarct size in Cyp-D wildtype mice in 
this study, substantially larger sample sizes would be required to detect such a small 
effect size. This was not examined further here since it does not represent a key study 
and would require a large number of animals. However, this experiment highlights the 
importance of using true littermate control animals in the study of myocardial infarction. 
Although this difference is unlikely to be biologically significant, the subsequent effect of 
this could artificially influence the outcome of studies not using correct littermate 
controls. All studies of transgenic animals in this thesis used true littermate animals. 
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Figure 5.4: Infarct size in B6/SV129 and backcrossed Cyp-D WT animals 
Infarct size following 30 minutes ischaemia and 72 hours reperfusion in B6/SV129 and 
backcrossed Cyp-D WT mice (98.4% C57BL/6 and 1.6% SV129); IS/AAR% was not significantly 
different between these mice: IS/AAR% B6/SV129 mice 30.3±3.8 (n=6) versus Cyp-D WT 
35.4±4.3 (n=9). Statistical significance assessed by unpaired t-test,
 NS
P>0.05. 
 
ii Effect size of Cyp-D global genetic ablation 
To assess the effect size of cardioprotection by global Cyp-D genetic ablation, Cyp-D 
knockout and wildtype (true littermate) mice were subjected to the standard in vivo 
ischaemia-reperfusion protocol (30 minutes ischaemia and 72 hours reperfusion). Cyp-D 
knockout mice exhibited significantly smaller infarct sizes as compared to Cyp-D 
wildtype true littermate controls (Figure 5.5: IS/AAR% Cyp-D WT 35.4±4.3 versus Cyp-D 
KO 22.6±2.4; n=9/group, *P<0.05). This corresponds to a relative reduction in infarct 
size of approximately 36.2% (IS/AAR) and an absolute effect size of 12.8% (IS/AAR).  
There was no significant difference in AAR between these groups (AAR/LV% Cyp-D WT 
55.6±2.8 versus Cyp-D KO 62.2±3.0; n=9/group, NSP>0.05), although the mean AAR 
was slightly larger in the Cyp-D KO group, this small difference is unlikely to affect the 
result especially since the infarct sizes presented here are controlled to AAR. This is 
discussed further below in relation to the need to measure AAR (see section iii).  
There was no statistically significant difference in survival between Cyp-D knockout and 
wildtype littermate control mice subjected to this protocol (Figure 5.6: % survival to 72 
hours reperfusion: Cyp-D WT 90.0%, n=10 versus Cyp-D KO 90.0%, n=10).  
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Figure 5.5: Infarct size in Cyp-D knockout mice following ischaemia-reperfusion 
Infarct size following 30 minutes ischaemia and 72 hours reperfusion in Cyp-D KO and Cyp-D 
WT true littermate control animals. Cyp-D KO mice demonstrated significantly smaller infarct 
sizes compared to Cyp-D WT controls: IS/AAR% Cyp-D WT 35.4±4.3 (n=9) versus Cyp-D KO 
22.6±2.4 (n=9). Statistical significance assessed by unpaired t-test,
 
*P<0.05. 
 
 
Figure 5.6: Survival of Cyp-D global knockout mice subjected to ischaemia-reperfusion 
Survival of Cyp-D KO and WT littermates subjected to in vivo recovery ischaemia-reperfusion. 
There was no significant difference in survival to 72 hours between Cyp-D KO and WT control 
mice: survival to 72 hours was 90% for Cyp-D WT (n=10) and KO mice (n=10). No deaths were 
observed 6-72 hours post-surgery. Statistical significance assessed by log-rank test, 
NS
P<0.05. 
 
The high survival of animals subjected to this protocol reflects the low incidence of 
cardiac failure due to the short ischaemic duration examined in this model. This is 
important in order to evaluate the number of animals required to be operated on in 
subsequent studies of long-term cardioprotective efficacy in this thesis. 
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iii Long-term cardioprotective efficacy of global Cyp-D ablation 
The overall objective of this chapter was to investigate the long-term cardioprotective 
efficacy of Cyp-D global genetic ablation in mice subjected to myocardial ischaemia-
reperfusion. Since established cardiac MRI protocols to investigate long-term changes in 
infarct size have been validated to quantify infarct size only and not AAR (as described 
in chapter 1; see 1.5.2), it was important to evaluate whether the effect size of Cyp-D 
global genetic ablation on absolute infarct size observed in this study would allow 
detection of a statistically significant difference between these groups. 
The data obtained in the previous study (presented in Figure 5.5) was re-expressed as 
absolute infarct size: infarct size as a percentage of total left ventricle area (IS/LV%). 
Comparison of IS/LV% was not sufficiently sensitive to detect a statistically significant 
difference between Cyp-D knockout and wildtype animals using this sample size (Figure 
5.7: IS/LV% Cyp-D WT 19.3±2.0 versus Cyp-D KO 14.5±2.0; n=9/group, NSP>0.05). 
 
Figure 5.7: Absolute infarct size in Cyp-D global knockout mice  
Evaluation of effect size of Cyp-D global genetic ablation by comparison of absolute infarct size 
(IS/LV%). The significant difference between Cyp-D WT and KO animals could no longer be seen 
when this data was not controlled to myocardial AAR: IS/LV% Cyp-D WT 19.3±2.0 (n=9) versus 
Cyp-D KO 14.5±2.0 (n=9). Statistical significance assessed by unpaired t-test,
 NS
P>0.05. 
 
Given the smaller effect size of absolute infarct size (IS/LV%) reduction, it is expected 
that substantially larger sample sizes would be required to reach appropriate statistical 
power (80%). Indeed, evaluating the approximate standard deviation (σ≈5.9; based on 
Cyp-D WT σ=5.94 and Cyp-D KO σ=5.89) and the expected effect size (≈4.78 IS/LV%) 
from this study, a prospective statistical power calculation shows that sample sizes of 
approximately 25 animals per group would be required to reach 80% statistical power. 
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Given the substantial samples sizes required for a study of absolute infarct size 
reduction in these animals, it was not feasible to subject these mice to long-term 
investigation of infarct size using cardiac MRI to assess infarct size alone. It is therefore 
not possible to evaluate the long-term cardioprotective efficacy of Cyp-D global genetic 
ablation. Further development of cardiac MRI for this purpose is addressed in chapter 8. 
It is important to note that the low statistical power of examining absolute infarct size in 
this study could potentially be partially overcome by reducing variation in myocardial 
AAR between groups. Comparison of absolute infarct size (IS/LV%) is particularly 
susceptible to variations in AAR, since AAR is an important determinant of infarct size. 
This can be demonstrated by regression analysis of infarct size and AAR where 
increased AAR (AAR/LV%) is positively correlated with increased infarct size (IS/LV%) 
(Figure 5.8: Cyp-D WT r2=0.75 and Cyp-D KO r2=0.71). This analysis illustrates the 
importance of normalising absolute infarct size (IS/LV%) to AAR (AAR/LV%) to increase 
the sensitivity of the comparison of infarction and thus cardioprotective efficacy. 
 
Figure 5.8: Regression analysis of infarct size and AAR in Cyp-D mice 
Regression analysis of myocardial infarct size (Y) and AAR (X) in Cyp-D WT and KO mice. There 
was no significant difference in the slopes of these relationships: Cyp-D WT slope 0.68±0.1 
versus Cyp-D KO slope 0.60±0.1; 
NS
P>0.05. The elevations (intercepts) of these two 
relationships were significantly different: Cyp-D WT intercept -18.3 versus Cyp-D KO -22.7; 
***P<0.001. Regression analysis and statistical significance assessed by Deming regression. 
 
It is also interesting to note that regression analysis of infarct size and AAR of this 
dataset showed that there was no significant difference in the slope (indicative of the 
relationship between infarct size and AAR) between these groups, although the 
elevations (determined by the intercepts) were significantly different, which reflects the 
trend of difference in susceptibility to infarction expected in Cyp-D knockouts. 
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5.4. Aim 2: Further investigate the roles of Cyp-D in the heart 
5.4.1. Background 
The role of Cyp-D in regulating mPTP opening following myocardial ischaemia-
reperfusion injury is widely accepted, as discussed above (see section 5.1). Published in 
vivo studies investigating the role of Cyp-D in cardioprotection against myocardial 
infarction have examined the whole-heart effects of Cyp-D genetic ablation or 
pharmacological inhibition. Results of these studies have been used to infer the role of 
Cyp-D in cardiomyocytes. This conclusion has been supported by in vitro studies of 
isolated cardiomyocytes in which Cyp-D genetic ablation and pharmacological inhibition 
also confer significant cardioprotective effects.  
This section aims to further investigate the roles of Cyp-D in the pathophysiology of 
myocardial ischaemia-reperfusion injury in vivo, with regards to two specific aims: 
(1) Cardiomyocyte-specific roles of Cyp-D: Investigate the contribution of Cyp-D in 
the cardiomyocytes specifically and the cardioprotective efficacy of 
cardiomyocyte-specific Cyp-D genetic ablation. 
 
(2) Temporal roles of Cyp-D: Investigate the time-course of efficacy of Cyp-D 
genetic ablation in conferring cardioprotection against myocardial infarction; 
specifically, investigate the potential for a late-window of cardioprotection by 
Cyp-D genetic ablation following differing durations of reperfusion. 
The development of cardiac-specific inducible transgenic systems provides an 
interesting potential opportunity to investigate these two important aims. Cardiac-specific 
and inducible genetic ablation of Cyp-D in a mouse model may permit investigation of 
these aims in vivo without the non-selective effects of pharmacological Cyp-D inhibitors.  
The second part of this chapter investigates the potential application of an inducible 
cardiomyocyte–specific transgenic model of Cyp-D genetic ablation and its suitability for 
investigating the wider research aims outlined above. 
 
Aim 2: The initial aim of this section was to establish and characterise an in vivo 
transgenic model of inducible cardiac-specific Cyp-D genetic ablation. The central 
hypothesis in relation to this research objective was: 
(1) Generation of an α-MHC-MerCreMer – Cyp-D floxed transgenic mouse would allow 
cardiomyocyte-specific genetic ablation of Cyp-D upon treatment with tamoxifen. 
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5.4.2. Detailed methods 
i Cyp-D cardiac-specific genetic ablation model 
The first stage of this study was to establish a transgenic mouse colony of floxed Cyp-D 
and α-MHC-MerCreMer. The rationale of this inducible cardiac-specific system is 
described in detail in chapter 3 (see 3.1.2 ii). The Cyp-D gene is flanked by loxP sites 
(termed floxed Cyp-D) in all tissues and thus upon activation of MerCreMer activity in 
the cardiomyocytes, Cre-recombination of loxP sites excises the Cyp-D gene. Upon 
degradation of the existing Cyp-D protein, the cardiomyocytes of these animals 
theoretically become Cyp-D null; this genetic system is summarised in Figure 5.9. 
The individual transgenic strains required for this model were imported into our 
laboratory and an extensive breeding schedule undertaken to obtain Cyp-D floxed – α-
MHC MerCreMer mice; this breeding protocol is summarised in Figure 5.10.  
Cyp-D floxed: The Cyp-D floxed mouse was originally created by Schinzel et al. (2005) 
by insertion of loxP sites using standard transgenic methods (see section 3.1.2 ii). A 
targeting vector containing loxP sites and the neomycin-resistance gene (neo) was 
inserted into 129/SvJ RW4 derived embryonic stem cells and transgenic stem cells used 
to create Cyp-D floxed mice (Cyp-Dflox) in a C57BL/6 strain. The loxP sites were placed 
to surround exons 3, 4 and 5 of the Ppif gene to allow excision of these exons upon Cre-
driven recombination (Schinzel et al., 2005). These transgenic mice were then bred with 
C57BL/6 mice for two generations to give an approximate genetic background of 87.5% 
C57BL/6 and 12.5% 129/SvJ. The Cyp-D floxed mice were obtained from Jackson 
Laboratories, USA (strain Ppiftm1Mmos/J; stock 005737) and imported into our facility. 
The breeding schedule used to create the colony is summarised in Figure 5.10 A. 
Standard terminology is used for floxed genotypes throughout this thesis: wildtype 
(WT/WT), heterozygote floxed (WT/FL) and homozygous floxed (FL/FL) (Figure 5.10 A). 
α-MHC-MerCreMer: The cardiac-specific MerCreMer (α-MHC-MerCreMer) transgenic 
construct used here was exactly as described previously (see 3.1.2 ii). The α-MHC-
MerCreMer transgene was expressed in FVB/N embryos using standard methods. The 
resulting transgenic animals were bred with C57BL/6 mice for a total of 15 generations 
to a genetic background of B6/SV129 and subsequently onto a C57BL/6 genetic 
background. The α-MHC-MerCreMer transgenic mice used in this study are considered 
to be fully backcrossed on to a C57BL/6 genetic background. This cardiac-specific 
MerCreMer transgenic strain was provided as a kind gift from a collaborator (Dr R. 
Breckenridge, University College London, UK) which was originally from Jackson 
Laboratories, USA (strain B6.FVB[129]-Tg[Myh6-cre/Esr1*]1Jmk/J; stock 005657).  
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Figure 5.9: Generation of inducible cardiac-specific Cyp-D genetic ablation  
Cardiac-specific genetic ablation of Cyp-D was achieved using a loxP and Cre-recombinase 
system. A) Cyp-D was flanked by loxP sites surrounding exons 3-5. B) MerCreMer double fusion 
construct was inserted under regulation of the α-MHC cardiac-specific promoter. C) Genetic 
recombination occurs upon activation of MerCreMer by tamoxifen to delete Ppif exons 3-5. 
 
Standard terminology is used for genotypes of α-MHC-MerCreMer transgenic animals: 
wildtype (WT/WT) and MerCreMer heterozygote (WT/Cre). The established genotyping 
protocol for these animals did not permit the distinction between the heterozygous and 
homozygous introduction of MerCreMer and so the breeding schedule was designed to 
ensure that animals were either wildtype (WT/WT) or heterozygous (WT/Cre) (see 
Figure 5.10); this is described further below. 
Colony maintenance: An intermediate cross between the Cyp-D FL/FL and MerCreMer 
heterozygous mice (MCM +/-) was undertaken to obtain animals transgenic for both 
Cyp-D floxing and MerCreMer (Figure 5.10 B). This breeding strategy was designed 
such that it never produced MerCreMer homozygous animals (Cre/Cre) given the 
difficulties associated with distinguishing between single or double insertion of the 
MerCreMer gene (i.e. WT/Cre and Cre/Cre) (as discussed by Davis et al., 2012). The 
final Cyp-D floxed – MerCreMer colony was maintained by crossing Cyp-D WT/FL mice 
with MerCreMer wildtype and heterozygous animals (Figure 5.10 C).  
A. Cyp-D locus
B. αMHC locus
C. Cre-driven 
recombination
1 2 3 4 65
α-MHC promoter Mer MerCre
lox lox
1 2 6lox
Mer MerCre + Tamoxifen
MerCreMer fusion construct
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195 
 
Figure 5.10: Cyp-D flox – α-MHC-MerCreMer transgenic colony and maintenance 
A) Original colony: Cyp-D heterozygous floxed (WT/FL) and MerCreMer mice. Cyp-D 
heterozygous floxed mice were bred to produce Cyp-D FL/FL mice. B) Intermediate cross: Cyp-D 
FL/FL mice and MerCreMer heterozygous mice were bred to produce progeny containing the 
Cyp-D floxed gene and MerCreMer. C) Final colony: maintained as Cyp-D WT/FL Cre WT/WT 
with Cyp-D WT/FL Cre WT/CRE to produce the required transgenic animals. 
 
ii Genotyping for floxed Cyp-D 
All animals from this transgenic colony were genotyped for the presence of floxed Cyp-D 
using a standard PCR method based on that described earlier (see 3.1.2 iii). DNA 
samples were prepared from ear biopsies exactly as described previously and 
processed within a maximum of 7 days but ideally within 6 hours. The PCR reaction for 
floxed Cyp-D was based on the standard protocol optimised in this thesis. The PCR 
primers and cycling parameters used here were informed by the protocol provided by 
Jackson Laboratories, USA, who originally supplied these animals (Table 5.2). These 
PCR primers were designed to bind either side of the loxP insertion sites meaning that 
presence of loxP sites produces a larger PCR product (400 bp) compared to the 
wildtype (250 bp). The genotype of each animal was decoded based on these DNA 
bands: WT 250 bp only, homozygous (FL/FL) 400 bp only and heterozygous floxed 
(WT/FL) 400 and 250 bp bands (Figure 5.11). This protocol was robust and reliable. 
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A) Cyp-D floxed PCR primer sequences 
PRIMER SEQUENCE 
PROPERTIES 
Length Tm (ºC) 
Primer 1 / Cyp-D reverse 5'-TCTCACCAGTGCATAGGGCTCTG-3' 23 64.2 
Primer 2 / Cyp-D forward 5'-GCTTTGTTATCCCAGCTGGCGC-3' 22 64.0 
 
B) Cyp-D floxed PCR reaction mix 
REAGENT VOLUME/SAMPLE  (µl) FINAL CONCENTRATION 
Qiagen 10X PCR Buffer 2.0 1X 
10 mM dNTPs 0.4 200 µM 
Primer 1 100 µM 0.2 1 µM 
Primer 2 100 µM 0.2 1 µM 
Taq polymerase 0.2 - 
Autoclaved distilled water                   16.0 - 
Crude DNA lysate 
†
 1.0 - 
TOTAL VOLUME/SAMPLE (µl)                     20.0 
  
C) Cyp-D floxed PCR thermocycling parameters 
PCR STAGE TEMPERATURE AND DURATION PCR DESCRIPTION 
1  94 ºC for 3 minutes   Hot start 
2  94 ºC for 30 seconds  DNA separation 
3  62 ºC for 30 seconds  Primer annealing 
4  72 ºC for 1 minute  DNA synthesis 
5  Go to step 2 for 35 cycles  DNA synthesis 
6  72 ºC for 10 minutes  Final extension 
7  4 ºC for ever  Intermediate storage 
 
Table 5.2: Cyp-D floxed genotyping protocol 
A) Cyp-D floxed primer sequences and properties. B) A single master mix was made based on 
Qiagen Taq kit (Qiagen, UK) and aliquots taken for each reaction. 
†
 1 µl crude DNA lysate was 
added to each reaction. C) PCR was undertaken by a thermal cycler (MJ Research, Canada). 
 
 
 
Figure 5.11: Cyp-D floxed representative genotyping result 
The genotype of each animal was determined by the presence or absence of the expected PCR 
products: 250 bp wildtype band and 400 bp mutant band. Genotypes were determined by the 
presence or absence of these bands: WT 250 bp, homozygous floxed 400 bp and heterozygous 
floxed both bands. A negative control (NEG) was run to ensure there was no DNA contamination. 
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iii Genotyping for α-MHC-MerCreMer 
These animals were also genotyped for the α-MHC-MerCreMer construct. The 
genotyping protocol was based on the standard protocol described in chapter 3 (see 
3.1.2 iii). As detailed above, lysis of DNA samples for this PCR reaction was ideally 
undertaken within 6 hours of the biopsies being taken. Delayed sample lysis resulted in 
poor definition of the PCR DNA bands (particularly the internal control DNA band), which 
in some cases required re-sampling of ear biopsies. The PCR reaction for MerCreMer 
was based on the standard reaction optimised in this thesis and is detailed in Table 5.3. 
This PCR protocol yielded DNA products of 440 and 324 bp corresponding to the mutant 
(MerCreMer) and wildtype DNA products respectively. The internal control band was 
expected to be present in every reaction and the transgenic band only in samples 
heterozygous for Cre. The genotype of each animal was decoded based on the 
presence of the transgenic DNA band: WT 324 bp control band only and heterozygous 
MerCreMer (WT/Cre) both 324 bp control and 440 bp transgenic bands (Figure 5.12).  
This PCR was generally robust, however, on some occasions the internal control bands 
were difficult to obtain and additional PCR attempts were required. The success of this 
PCR was improved by increasing the DNA concentration (final reaction detailed in Table 
5.3) and ensuring that samples were lysed immediately upon biopsy (maximum 6 hour 
delay). For samples where the internal control product was not present, repeat reactions 
were run and fresh ear biopsies taken where clear PCR products could not be obtained.  
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A) MerCreMer PCR primer sequences 
PRIMER SEQUENCE 
PROPERTIES 
Length 
Tm 
(ºC) 
Primer 1 / Control forward 5'-CTAGGCCACAGAATTGAAAGATCT-3' 24 59.3 
Primer 2 / Control reverse 5'-GTAGGTGGAAATTCTAGCATCATCC-3' 25 61.3 
Primer 4 / TC forward 
Primer 3 / TG reverse 
5'-ATACCGGAGATCATGCAAGC-3’ 
5'-AGGTGGACCTGATCATGGAG-3' 
20 
20 
57.3 
59.4 
 
B) MerCreMer PCR reaction mix 
REAGENT VOLUME/SAMPLE  (µl) FINAL CONCENTRATION 
Qiagen 10X PCR Buffer 2.0 1X 
MgCl2 25 mM 0.8 2.5 mM 
‡
 
10 mM dNTPs 0.4 20 µM 
Primer 1 100 µM 0.1 0.5 µM 
Primer 2 100 µM 0.1 0.5 µM 
Primer 3 100 µM 0.2 1 µM 
Primer 4 100 µM 0.2 1 µM 
Taq polymerase  0.12 - 
Autoclaved distilled water                   12.78 - 
Crude DNA lysate 
†
 3.3 - 
TOTAL VOLUME/SAMPLE (µl)                     20.0 
  
C) MerCreMer PCR thermocycling parameters 
PCR STAGE TEMPERATURE AND DURATION PCR DESCRIPTION 
1  94 ºC for 3 minutes  Hot start 
2  94 ºC for 30 seconds  DNA separation 
3  70 ºC for 45 seconds  Primer annealing 
4  72 ºC for 45 seconds  DNA synthesis 
5  Go to step 2 for 35 cycles  DNA synthesis 
6  72 ºC for 2 minutes  Final extension 
7  4 ºC for ever  Intermediate storage 
 
Table 5.3: α-MHC MerCreMer genotyping protocol 
A) MerCreMer genotyping primer sequences and properties. B) A single master mix was made 
(Qiagen, UK). 
†
 3.3 µl crude DNA lysate was added to each master mix aliquot; 
‡
 MgCl2 
concentration was based on addition of MgCl2 and existing MgCl2 in standard Qiagen 10X buffer 
solution (15 mM MgCl2). C) PCR was performed by a thermal cycler (MJ Research, Canada). 
 
 
Figure 5.12: α-MHC-MerCreMer representative genotyping result 
Two PCR bands were expected: 440 bp transgenic band and 324 bp internal control band. 
Genotypes of animals were determined by the presence or absence of the transgenic band: WT 
324 internal control band only and heterozygous MerCreMer 440 and 324 bp.  
 
500
200
300
(bp)
Control band (324 bp)
Mutant band (440 bp)400
M
W
W
T
/C
re
W
T
/C
re
W
T
/C
re
W
T
/W
T
W
T
/C
re
W
T
/W
T
W
T
/W
T
N
E
G
199 
iv Tamoxifen treatment of Cyp-D cardiac-specific mice 
To achieve genetic ablation of Cyp-D in cardiomyocytes it was necessary to treat these 
animals with tamoxifen to allow entry of the MerCreMer protein into the nucleus where 
its Cre-recombinase activity drives homologous genetic recombination of the loxP sites 
flanking Cyp-D. An overview of the refinement of the tamoxifen dosing protocol is 
provided below and the final dosing regime is detailed subsequently.  
Refinement of tamoxifen dosing regime: Refinement of the tamoxifen protocol was 
undertaken in collaboration with Dr A. Hall within our laboratory, as detailed below. 
In accordance with a previous tamoxifen dosing regime used within our laboratory, 
tamoxifen (Sigma-Aldrich, UK) was dissolved in vehicle comprising ethanol-100% and 
corn oil (1 part ethanol to 9 parts corn oil) to give a final dosing concentration of 20 
mg/kg (administration of 100 µl of 5 mg/ml tamoxifen per 25 g mouse). However, 
tamoxifen has a very low solubility even in this vehicle and so required sonication or 
agitation at 37ºC to achieve complete tamoxifen dissolution. The previous method within 
our laboratory had used sonication to achieve rapid and total tamoxifen dissolution. 
However, initial trials of this regime showed no significant difference in Cyp-D protein 
levels following 5 days tamoxifen treatment or 5 days treatment with 7 days washout. 
Investigation of tamoxifen dosing protocol by Dr A. Hall: This dosing regime was 
concurrently applied to a different tamoxifen-inducible α-MHC-MerCreMer cardiac 
genetic ablation model within our laboratory and showed a very large degree of variation 
in final protein levels between experiments. This suggested that there may be a problem 
with the method used to prepare the tamoxifen solutions. It was observed that the 
sonication durations used in these studies may have varied between preparations and 
that sonication resulted in significant heating of the solution dependent upon the 
duration of sonication. This was investigated in this separate tamoxifen-inducible genetic 
model due to the low number of Cyp-D floxed – MerCreMer animals available. 
Subsequent investigations used gentle agitation of the tamoxifen-vehicle mix at 37ºC for 
4 hours to dissolve the tamoxifen. Administration of this tamoxifen solution (20 mg/kg) 
resulted in death of a number of animals following 3-5 days tamoxifen. This suggested 
that the method of preparing the tamoxifen solution here did not significantly affect the 
activity of tamoxifen, hence its increased toxicity. The tamoxifen dose was reduced to 18 
mg/kg and showed improved survival of treated animals. Application of the refined 
tamoxifen protocol (18 mg/kg tamoxifen, solution prepared by warmed agitation) showed 
significant and consistent target gene ablation (reported by Dr A. Hall).  
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These preliminary studies demonstrated that the refined tamoxifen dosing protocol was 
effective at inducing MerCreMer recombination of loxP sites and this was employed in 
all subsequent experiments of the inducible genetic ablation system presented here. 
Final tamoxifen dosing regime: The final tamoxifen dosing protocol used in this thesis 
was 18 mg/kg tamoxifen administered daily as an intraperitoneal bolus for 5 days. All 
mice used in this study weighed approximately 25 g and animals were administered 
approximately 100 µl of this 4.5 mg/ml tamoxifen solution, where the exact volume was 
calculated for each animal based on its weight to give a final dose of 18 mg/kg. The 
tamoxifen dosing solution was prepared to a concentration of 4.5 mg/ml by dissolution in 
ethanol-100% and corn oil vehicle (1 part ethanol to 9 parts corn oil) incubated at 37ºC 
with gentle agitation for 4 hours until total dissolution of tamoxifen. Tamoxifen solutions 
were freshly prepared for each study and stored for a maximum of 6 days at 4ºC.  
Animals were dosed daily between 09:00 and 10:00 and monitored closely for the 
duration of the dosing protocol. Consistent timing of tamoxifen dosing was observed 
throughout to ensure that the effects of tamoxifen were closely matched between 
groups. Control animals were administered matched volumes of ethanol / corn oil 
vehicle. Animals were dosed for 5 consecutive days and hearts extracted at baseline 
(prior to dosing), following 5 days treatment (on day 6), following 5 days treatment and 7 
days washout and following 5 days treatment and 14 days washout; this dosing protocol 
is summarised in Figure 4.15. The extraction protocol is described below (see section v).  
 
Figure 5.13: Tamoxifen dosing protocol for investigating inducible Cyp-D genetic ablation 
Schematic of tamoxifen dosing protocol for investigating genetic ablation of Cyp-D in Cyp-D 
floxed α-MHC-MerCreMer model. Tamoxifen was administered at 18 mg/kg (100 µl of 4.5 mg/ml 
tamoxifen solution per 25 g mouse) as an I.P. bolus daily for 5 consecutive days (dashed 
arrows). Control animals were administered a matched volume of ethanol / corn oil vehicle. At the 
pre-defined time-point, the ventricles were removed and frozen for analysis of Cyp-D protein 
levels by Western blot. Mice were randomised to the 4 groups indicated (solid arrows). 
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v Assessment of Cyp-D protein levels by Western blot 
To assess the efficacy of Cyp-D genetic ablation in the cardiomyocytes using this 
genetic model and tamoxifen dosing regime, a preliminary study to assess total heart 
levels of Cyp-D was undertaken using Western blot analysis. The Western blot protocol 
is described in chapter 3 (see 3.4.2) and the precise details provided below. 
Preparation of heart samples: Hearts were extracted from anaesthetised mice and 
cannulated for manual perfusion exactly as described previously. The atria were 
removed and discarded and the left and right ventricular tissue immediately frozen in 
liquid nitrogen and stored at -80ºC until further processing. Tissues were homogenised 
using a glass pestle and mortar in standard homogenisation buffer (described in 3.4.1 i). 
Immediately prior to use for Western blot analysis, the protein concentration of the 
ventricular tissue samples was assessed using a standard BCA protein assay exactly as 
described previously (see 3.4.1 iii). Tissue samples were diluted to a set protein 
concentration informed by the most dilute tissue sample by addition of homogenisation 
buffer detailed above. Tissue samples were stored on ice for the duration of processing 
(maximum 2 hours) to avoid multiple freeze-thaw cycles. 
Western blotting protocol: Western blot analysis was performed by standard SDS-
PAGE of protein samples performed exactly as described in chapter 3 (see 3.4.2).  
Primary antibodies (detailed in Table 5.4 A) were diluted 1:1000 (final concentration of 1 
µg/ml) in 5% milk / PBS + Tween solution and incubated with the membrane for 45-60 
minutes at room temperature with agitation. Since the expected molecular weights of the 
two proteins of interest (Cyp-D and α-tubulin) are sufficiently different it was possible to 
probe membranes for these proteins simultaneously without the need for stripping 
antibodies. Following incubation of primary antibodies, excess unbound antibody was 
removed by washing the membrane six times for 10 minutes each in PBS + Tween.  
An anti-mouse secondary antibody (detailed in Table 5.4 B) was diluted 1:2000 (final 
concentration of 0.5 µg/ml) in 5% milk PBS + Tween and incubated with the membrane 
for 1 hour at room temperature with agitation. This secondary antibody was conjugated 
to the HRP enzyme to allow subsequent visualisation of antibody binding using the 
standard chemiluminescence reaction described below. Following incubation of the 
secondary antibody, membranes underwent six 10 minute washes with PBS + Tween to 
remove unbound secondary antibody prior to chemiluminescence detection. 
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A) Primary antibodies: 
ANTIBODY ANTIBODY DETAILS 
Cyp-D Anti-cyclophilin-D mouse monoclonal antibody to Cyp-D (also termed Cyp-F) 
Purchased from Abcam Mitosciences® UK (catalogue number: ab110324) 
Stock 1 mg/ml; diluted 1:1000 to give working concentration 1 µg/ml  
Predicted molecular weight 22 kDa 
α-tubulin Anti-α-tubulin monoclonal antibody to α-tubulin 
Purchased from Abcam® UK (catalogue number: ab7291)  
Stock 1 mg/ml; diluted 1:1000 to give working concentration 1 µg/ml  
Predicted molecular weight 50 kDa 
 
B) Secondary antibody: 
ANTIBODY ANTIBODY DETAILS 
Anti-mouse Horse anti-mouse IgG HRP-linked polyclonal antibody 
Purchased from Cell Signalling, USA (catalogue number: 7076S).  
Stock 1 mg/ml; diluted 1:2000 to give working concentration 0.5 µg/ml  
 
Table 5.4: Antibodies for Western blot analysis of Cyp-D protein levels 
A) Primary antibodies anti-Cyp-D and anti-α-tubulin. B) Secondary antibody was an anti-mouse 
IgG polyclonal antibody conjugated to HRP to allow subsequent detection by standard ECL. 
Antibodies were purchased from Abcam® (UK) or Cell Signalling Technology (USA) as detailed. 
 
 
Protein bands were visualised using a standard HRP chemiluminescence reaction 
exactly as described previously (see 3.4.2 iv). Protein band intensity from these 
photographic films was quantified by densitometry performed using ImageJ software 
(version 1.45s, National Institutes of Health, USA) as described in chapter 3 (see 3.4.2 
iv). Protein levels were quantified and normalised to the α-tubulin loading control for 
each sample and expressed in arbitrary units (A.U.). All values are presented as mean 
A.U. ± SEM. Data were analysed by one-way ANOVA followed by Bonferroni test using 
GraphPad Prism® version 5.0 (GraphPad Software, USA). Statistical significance was 
reported where P<0.05. Representative protein bands are shown alongside average 
densitometry quantifications presented in this chapter. 
 
  
203 
5.4.3. Results 
The Cyp-D floxed – α-MHC-MerCreMer transgenic colony was established by series of 
genetic crosses of previously generated separate colonies. The breeding schedule 
undertaken to achieve this was complex and was further complicated by very poor 
breeding of these animals. There was no known reason for the poor pregnancy rate of 
these animals; however, this hindered experimental investigation of these animals. 
i Investigation of tamoxifen dosing protocol 
The first stage to investigate the use of this genetic ablation model for subsequent 
ischaemia-reperfusion experiments was to characterise an appropriate tamoxifen dosing 
regime and the resulting extent of reduction in Cyp-D protein levels in the heart.  
Initial experiments used a tamoxifen dose of 20 mg/kg prepared by sonication; however, 
this showed no appreciable reduction in Cyp-D protein levels in whole heart 
homogenates; this data is not presented in this thesis since the dosing regime was 
subsequently suggested to be unreliable. Further experiments by Dr A. Hall within our 
laboratory using this dosing regime in a separate tamoxifen inducible α-MHC-
MerCreMer genetic ablation model indicated that the sonication method for preparation 
of the tamoxifen solution was likely to be adversely affecting tamoxifen activity. The 
optimisation of a refined dosing protocol used for the experiments presented in this 
chapter is described above (see 5.4.2 v). Initial experiments using this potentially 
variable dose of tamoxifen were therefore discarded and all data presented in this thesis 
used the refined protocol described thereafter (18 mg/kg; prepared in 1 part ethanol-
100% and 9 parts corn oil by agitation at 37ºC). 
ii Investigation of Cyp-D genetic ablation – Cyp-D protein levels 
Analysis of Cyp-D protein levels at baseline in Cyp-D floxed (FL/FL) – MerCreMer 
(WT/Cre) and Cyp-D (WT/WT) – MerCreMer (WT/Cre) showed a significance difference 
in Cyp-D protein levels between these genotypes (Figure 5.14). Although it should be 
noted that this analysis was based on a relatively small number of animals (n=2/group) 
and should be repeated for further investigation of this genetic ablation model. 
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Figure 5.14: Cyp-D levels at baseline in wildtype and floxed animals 
Western blot analysis to quantify Cyp-D protein levels in ventricular tissue at baseline. A) 
Representative protein bands from Western blot. B) Densitometry of Western blot to calculate 
Cyp-D protein levels normalised to α-tubulin protein levels. Statistical significance was assessed 
by one-way ANOVA comparing to Cyp-D (+/+) MerCreMer (+/-); Cyp-D levels were significantly 
increased in Cyp-D floxed mice compared to WT littermates (*P<0.05). Ventricular tissue 
samples from Cyp-D global KO mice were included as a negative control for Cyp-D protein 
levels. (n=2/group). 
 
This suggests that insertion of the loxP sites flanking Cyp-D has affected Cyp-D protein 
expression. This presents an important consideration for future investigation of these 
animals since Cyp-D (+/+) MerCreMer treated animals would ordinarily be used as a 
tamoxifen treated control group to evaluate any effects of Cre-toxicity. However, given 
that Cyp-D baseline expression differed between these genotypes, this may affect 
susceptibility to myocardial infarction. This did not affect the interpretation of the data 
presented below in Figure 5.15 since all animals in this experiment were Cyp-D FL/FL.  
Cyp-D protein levels were examined in Cyp-D floxed (FL/FL) – MerCreMer (WT/Cre) 
mice before tamoxifen treatment and at various time-points following 5 days tamoxifen 
treatment (see Figure 5.13 for protocol timings). There was no statistically significant 
difference in Cyp-D protein levels in ventricular tissue extracted from these animals 
(Figure 5.15; comparing white and blue bars, P>0.05, n=3/group), although there 
appeared to be a trend towards decreased Cyp-D protein levels following 7 and 14 days 
washout of tamoxifen treatment. This should now be investigated further. 
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Figure 5.15: Cyp-D levels in tamoxifen treated animals 
Western blot analysis of Cyp-D protein levels in ventricular tissue of Cyp-D floxed (FL/FL) 
MerCreMer (WT/Cre) animals at baseline and following 5 days tamoxifen treatment with varied 
washout periods. A) Representative protein bands from Western blot. B) Densitometry to 
calculate Cyp-D protein levels normalised to α-tubulin. Statistical significance assessed by one-
way ANOVA comparing treated animals (blue bars; n=3/group) with baseline (white bar; n=3); no 
significant difference in Cyp-D protein levels (P>0.05). Ventricular tissue samples from Cyp-D KO 
mice were included as a negative control for Cyp-D protein (significantly different compared to 
other groups; ***P<0.001, n=2).  
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5.5. Discussion 
The overall research objective of this chapter was to investigate the long-term efficacy of 
Cyp-D genetic ablation in protecting against myocardial ischaemia-reperfusion. The 
initial stage of this was to investigate the effect of global and cardiac-specific genetic 
ablation of Cyp-D on the susceptibility to myocardial infarction in the in vivo recovery 
model of ischaemia-reperfusion injury developed here. This chapter describes the 
experiments undertaken towards this aim and the obstacles to further investigation.  
5.5.1. Aim 1: Investigate long-term cardioprotection by Cyp-D ablation  
This first section of this chapter aimed to investigate the use of the well-established Cyp-
D global genetic knockout model to examine the long-term efficacy of Cyp-D inhibition in 
the setting of myocardial ischaemia-reperfusion injury. This is an important outstanding 
research question since although several studies have shown that genetic ablation of 
Cyp-D reduces myocardial infarct size following ischaemia-reperfusion when assessed 
following short reperfusion durations (Baines et al., 2005; Nakagawa et al., 2005; Lim et 
al., 2007), it is not known whether this would confer long-term cardioprotective effects.  
Given recent reports that Cyp-D knockout mice are more susceptible to cardiac failure 
upon physiological stress (Elrod et al., 2010), it is ever more pertinent to determine 
whether Cyp-D knockout mice remain cardioprotected at extended periods of myocardial 
reperfusion. This has been suggested by Gomez et al. (2007) who reported that 
administration of the Cyp-D inhibitor, Debio-025, improved cardiac function and survival 
30 days following ischaemia-reperfusion (Gomez et al., 2007). However, this study did 
not examine infarct size at this extended time-point and furthermore cannot exclude the 
influence of non-selective effects of Debio-025 on the other cyclophilin proteins. 
Although pharmacological inhibition of Cyp-D would be more clinically relevant, selective 
inhibitors of Cyp-D are not yet available (as reviewed in chapter 1; see 1.4.1) and 
therefore models of Cyp-D genetic ablation provide a more selective and elegant system 
in which to investigate the roles of Cyp-D. The Cyp-D global genetic knockout mouse 
colony is an important model for the proof-of-concept study proposed here. 
Before embarking on this large-scale and costly long-term study of the cardioprotective 
efficacy of Cyp-D genetic ablation, a pilot study was undertaken to assess the expected 
effect size and variability of myocardial infarct size reduction in these animals.  
Effect of using true littermate control animals: This study first sought to improve the 
breeding strategy of the existing Cyp-D global genetic knockout mouse colony within our 
laboratory to allow investigation of true littermate control mice. Myocardial infarct size in 
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commercially available B6/SV129 and Cyp-D wildtype mice was assessed to evaluate 
whether this subtle difference in genetic background influenced myocardial infarct size. 
This was important to allow interpretation of future experimental results obtained using 
this backcrossed colony in the context of previous studies of non-backcrossed animals. 
It is important to note that infarct sizes resulting from this model are subject to inherent 
variation due to the in vivo nature of this myocardial insult and the relatively basic 
quantification method. This model is therefore not sufficiently sensitive to detect very 
small differences in infarct size, whereby very large and unfeasible sample sizes would 
be required to reach the required level of statistical power. As such, this study was not 
expected to discern a statistically significant difference between these groups but was 
instead intended to permit a qualitative comparison of the potential influence of subtle 
strain differences in the susceptibility to myocardial infarction. There was a slight but 
non-significant trend to increased infarct size in Cyp-D wildtype mice (98.4% C57BL/6 
and 1.6% SV129 genetic background) compared to B6/SV129 mice (Figure 5.4). 
Although this small difference in infarct size (approximately 5.1% IS/AAR) is unlikely to 
be biologically significant with regards to outcomes of myocardial ischaemia-reperfusion 
injury, this study highlights the importance of using appropriate littermate control 
animals. The small difference in infarct size between these genetic backgrounds could 
adversely affect the outcome of studies using inappropriate genetic controls. For 
example, this study suggests that comparison of infarct size between B6/SV129 and 
Cyp-D knockout mice would result in a smaller effect size and thus a possibly increased 
probability of concluding a false negative result (type II error). 
Indeed, published studies have identified variations in cardiovascular traits between 
strains of inbred mice, including differences in LV function, heart rate and susceptibility 
to cardiac rupture in response to myocardial infarction (Hoit et al., 2002; Gao et al., 
2005). Notably, Gorog et al. (2003) showed statistically significant differences in 
myocardial infarct size between sub-strains of C57BL/6 mice bred within their laboratory 
(Gorog et al., 2003). These studies confirm the assertion that all experiments using 
transgenic animals should ensure that correct true littermate control animals are 
investigated. All studies of transgenic mice in this thesis used true littermate controls in 
accordance with best practice (as evaluated and recommended by Davis et al., 2012). 
Effect of global genetic ablation of Cyp-D: The effect of global knockout of Cyp-D on 
the susceptibility to myocardial infarct size was examined in animals subjected to the 
standard in vivo recovery model of ischaemia-reperfusion developed in this thesis. Cyp-
D knockout mice exhibited significantly smaller infarct sizes compared to true wildtype 
littermate controls (Figure 5.5). This is in agreement with previous studies showing that 
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Cyp-D knockout mice are protected against ischaemia-reperfusion at shorter reperfusion 
durations (Nakagawa et al., 2005; Baines et al., 2005; Lim et al., 2007). 
This study did not show any effect of Cyp-D genetic ablation on survival following 
ischaemia-reperfusion (Figure 4.). Given the profound reduction in myocardial infarct 
size in Cyp-D knockout mice it could perhaps be expected that this would correlate with 
improved survival. Indeed, a previous study by our laboratory showed that Cyp-D 
knockout mice exhibited improved survival following permanent coronary artery ligation 
(Lim et al., 2011). However, this model of cardiac failure examined a greater ischaemic 
insult and longer term prognosis (to 28 days) of these animals which showed a higher 
control mortality rate. Interestingly, Lim et al. (2011) showed that all deaths occurred 3-5 
days following the onset of ischaemia. This may suggest that the ischaemia-reperfusion 
model here could cause increased mortality at further extended reperfusion periods; 
however, the pathophysiology of this model is different due to the effects of reperfusion. 
The ischaemia-reperfusion model presented here was not optimised to detect 
differences in mortality and further characterisation studies at extended reperfusion 
durations would be required to investigate this further. 
This study provides the first demonstration, to our knowledge, that Cyp-D knockout mice 
remain cardioprotected in terms of reduced myocardial infarct size at an extended 
duration of reperfusion. This provides further support that Cyp-D inhibition is likely to 
confer long-term cardioprotective benefits and thus represents an important target.  
It is expected that the cardioprotective effect exerted by genetic ablation of Cyp-D 
observed here is mediated by reduced mPTP opening. Although reduced mPTP 
opening in these animals has not been directly implicated here, this is strongly 
supported by previous studies investigating mPTP opening in these animals. Indeed, the 
initial generation of Cyp-D global knockout mice showed that mitochondria devoid of 
Cyp-D protein exhibited resistance to mPTP opening, mitochondrial swelling and loss of 
mitochondrial membrane potential in response to calcium and ROS triggers of mPTP 
opening (Nakagawa et al., 2005; Baines et al., 2005; Basso et al., 2005; Schinzel et al., 
2005). Although only Baines et al. (2005) directly investigated this in cardiac 
mitochondria, it is widely accepted that the phenotypes observed in Cyp-D knockout 
mice are likely to result from reduced mPTP opening (reviewed by Bernardi, 2013; Elrod 
and Molkentin, 2013; Javadov and Kuznetsov, 2013). 
However, Cyp-D genetic ablation may confer further biological effects due to reduced 
mPTP opening. The seminal study by Elrod et al. (2010) alluded to the potential 
physiological role of Cyp-D in calcium regulation, whereby reduced mPTP opening in 
mitochondria devoid of Cyp-D resulted in increased mitochondrial matrix calcium levels 
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and in turn altered metabolic flexibility. Specifically, increased mitochondrial calcium in 
these animals resulted in increased activation of mitochondrial dehydrogenase 
enzymes, increased glucose oxidation and decreased fatty acid metabolism (Elrod et al., 
2010). This study demonstrates the wider role of Cyp-D and mPTP opening in cellular 
homeostasis and metabolism and is suggestive of some of the likely pathways indirectly 
influenced by Cyp-D. It is therefore important to consider these wider effects when 
interpreting the phenotypes of Cyp-D knockout mice. 
In addition to the consequences of Cyp-D genetic ablation on metabolic flexibility, it is 
also important to consider the potential interference of these indirect effects for the 
interpretation of the phenotypes of Cyp-D knockout mice. Indeed, a recent study by 
Murphy’s group (Menazza et al., 2013) showed that genetic ablation of Cyp-D caused 
altered expression of a number of mitochondrial proteins, including several important 
metabolic proteins involved in pyruvate and fatty acid oxidation (Menazza et al., 2013). 
This is particularly important given the essential roles of mitochondrial function and 
respiration in determining cell survival upon myocardial ischaemia-reperfusion (reviewed 
in chapter 1; see 1.2.3). However, it should be noted that this study did not detect any 
resulting difference in mitochondrial respiration in Cyp-D knockout hearts (Menazza et 
al., 2013). The importance of Cyp-D in metabolic regulation is also shown by the 
manifestation of adult-onset obesity in Cyp-D knockout mice (Luvisetto et al., 2008). It is 
therefore important to consider the effects of Cyp-D on metabolism when interpreting the 
susceptibility of these mice to myocardial infarction. 
Further to this, a very recent study by Murphy’s group (Nguyen et al., 2013) showed that 
the acetylation of a number of mitochondrial proteins was altered in Cyp-D knockout 
hearts. Although this study did not show direct regulation of acetylation and 
deacetylation by Cyp-D, it was proposed that increased mitochondrial calcium in the 
absence of transient mPTP opening in Cyp-D knockout mitochondria causes increases 
mitochondrial dehydrogenase enzyme activity, thereby increasing NADH / NAD+ levels 
(by approximately 80%). This was predicted to reduce deacetylase enzyme activity. 
Interestingly, despite the previously asserted role of Sirt-3 as the major mitochondrial 
deacetylase protein, this study provided some evidence that the increased acetylation 
here was not the result of decreased Sirt-3 activity. Since this reduced deacetylase 
activity appeared to be linked to NADH / NAD+ levels (Nguyen et al., 2013), this appears 
to implicate one or more Sirt proteins, since these are the only known KDAC proteins 
with NAD+ sensitivity. This study therefore poses the intriguing possibility that the other 
mitochondrial Sirt proteins (Sirt-4 and -5) may be exerting modified deacetylase activity 
in the absence of Cyp-D, although this was not investigated by this study. However, 
since previous studies have suggested that Sirt-4 and -5 mediate only modest 
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deacetylase activity (Lombard et al., 2007), the involvement of these proteins in the 
altered acetylome of Cyp-D knockout mice remains speculative. It is possible that 
altered mitochondrial protein acetylation in Cyp-D knockout hearts may instead indicate 
increased activity of acetylation proteins, although this was not examined in this study. 
The role of acetyl-regulation of mitochondrial proteins is discussed in detail in chapter 6. 
The role of Cyp-D in metabolic regulation is perhaps likely to become an increasing area 
of research interest given the recent implication of the ATP synthase enzyme (complex 
V) as the constituent protein of the mPTP (Bonora et al., 2013; Giorgio et al., 2013). The 
role of metabolic regulation in the pathophysiology of myocardial ischaemia-reperfusion 
injury is discussed in detail in relation to Sirt-3 in chapter 6. 
Since the effects of Cyp-D on metabolic regulation are likely to become more profound 
following prolonged inhibition, temporal regulation of Cyp-D expression may provide a 
more elegant genetic model to investigate its role in cardioprotection and as a potential 
therapeutic target for long-term cardioprotection. Importantly, genetic ablation of Cyp-D 
following the onset of myocardial reperfusion would remove the potential confounding 
influences of these wider phenotypes exerted by Cyp-D knockout during ischaemia. 
Temporal regulation of Cyp-D genetic ablation is discussed subsequently (see 5.5.2). 
Long-term cardioprotective efficacy of global Cyp-D ablation: The long-term 
efficacy of Cyp-D genetic ablation was not investigated here at further extended 
reperfusion durations due to the limitations of infarct size and AAR quantification using 
ex vivo histological endpoints; discussed in detail in chapter 4 (see 4.6.3; Reperfusion 
duration). Briefly, it is unclear whether histological staining provides accurate 
quantification of myocardial salvage at extended reperfusion durations due to the 
possible effects of inflammatory cell infiltration which may mask the true extent of 
infarction assessed by TTC staining and myocardial remodelling which may affect AAR 
measurement. The aim of this thesis was to investigate the long-term cardioprotective 
efficacy of modulating mitochondrial targets, however, this required development and 
validation of in vivo methods for quantifying infarct size and AAR in vivo; cardiac MRI 
methods for quantification of infarct size and AAR forms the focus of chapter 8. 
With regards to the future investigation of the long-term cardioprotective efficacy of Cyp-
D genetic ablation, the experiments presented here provide a valuable insight into the 
effect of Cyp-D knockout to inform the experimental design of future studies. Cyp-D 
knockout reduced absolute infarct size (IS/AAR%) by approximately 12.8% which 
corresponded to a relative reduction of approximately 36% (IS/AAR). The effect size and 
standard deviation of IS/AAR% and IS/LV% in this study can be used to inform the 
expected sample sizes required for future studies using cardiac MRI, discussed below.  
211 
To evaluate the possibility of using currently established cardiac MRI methods to assess 
myocardial infarct size over extended durations of reperfusion, this same dataset was 
re-expressed as infarct size as a percentage of left ventricle area (IS/LV%). As 
expected, not normalising infarct size to AAR reduced the statistical power of this 
comparison by increasing the relative error (standard deviation; σ) and reducing the 
absolute effect size. This reduction in statistical power meant that a significant difference 
could no longer be detected between these groups (Figure 5.7). Indeed, a prospective 
sample size calculation showed a predicted sample size of approximately 25 per group 
would be required to reach sufficient statistical power. This confirms that it would not be 
appropriate to investigate the long-term effect of Cyp-D genetic ablation on infarct size 
using current cardiac MRI protocols which have not been validated to quantify AAR. 
It should however, be noted that the sensitivity of cardiac MRI quantification of infarct 
size using late-gadolinium enhancement imaging to detect cardioprotective efficacy has 
not been tested here. It is possible that this MRI method may have been sufficient to 
detect this cardioprotective effect given its increased sampling of the myocardium (due 
to it’s three-dimensional nature). This was not tested in this thesis due to the practical 
and financial constrainsts of undertaking such a speculative study. 
The long-term cardioprotective efficacy of Cyp-D genetic ablation was therefore not 
investigated further here. This study highlights the importance analysing myocardial 
AAR to assess cardioprotective efficacy and provides the impetus for investigation of 
cardiac MRI for determining AAR in vivo in the reperfused mouse heart. This is 
addressed in chapter 8 of this thesis. 
5.5.2. Aim 2: Further investigate the roles of Cyp-D in the heart  
The role of Cyp-D in regulating calcium sensitivity to mPTP opening upon myocardial 
reperfusion is widely accepted, however, the effect role of Cyp-D inhibition for long-term 
cardioprotection has not been confirmed in vivo, as discussed above. A further caveat to 
the use of the Cyp-D global genetic knockout mouse is the potential confounding effects 
of the timing of Cyp-D inhibition, whereby it is not possible to determine whether Cyp-D 
inhibition at the time of myocardial reperfusion or thereafter, as would occur in the 
clinical setting of acute myocardial infarction, would confer cardioprotection. Although 
pharmacological inhibition of Cyp-D would arguably represent the most immediately 
clinically translatable therapy, the lack of selective Cyp-D pharmacological inhibitors 
(see 1.4.1) complicates this. It is pertinent to determine whether specific inhibition of 
Cyp-D (i.e. by genetic ablation) at reperfusion reduces the susceptibility to infarction. 
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Development of inducible Cyp-D genetic ablation model: Development of inducible 
genetic ablation systems that allow regulation of the timing of genetic knockout of the 
target gene represent emerging and important models for proof-of-concept studies to 
dissect the role of proteins in pathophysiological processes. The second section of this 
chapter attempted to investigate the use of a floxed-MerCreMer system to knockout 
Cyp-D specifically in the cardiac muscle (i.e. only in cardiomyocytes) without the 
confounding non-selective effects of pharmacological Cyp-D inhibitors. The overall 
objective of this section was ultimately to investigate the role of Cyp-D specifically in the 
cardiomyocytes and importantly, investigate the time-course of Cyp-D involvement in the 
development of myocardial infarction; as discussed previously (see 5.4.1). 
The Cyp-D floxed mouse line was developed by Schinzel et al. (2005) and crossed with 
the EIIa transgenic Cre mouse in which Cre-recombinase is expressed during early 
development (created by Lakso et al., 1996), to generate Cyp-D genetic knockout mice 
(Schinzel et al., 2005); described previously in chapter 1 (see 1.4.1). To examine the 
potential use of a Cyp-D floxed-MerCreMer cardiac-specific inducible genetic knockout 
model, the experiments presented in this chapter aimed to produce a more sophisticated 
transgenic colony to allow temporal and spatial regulation of Cyp-D genetic ablation. 
Intensive efforts were required to establish this final colony from the existing separate 
transgenic animals given the very poor breeding success encountered.  
Efficacy of temporal genetic ablation of Cyp-D: Given the low number of animals 
produced by this Cyp-D floxed-MerCreMer colony, the tamoxifen dosing regime to drive 
MerCreMer-mediated recombination was optimised in a different transgenic system. 
Since this genetic system used the same MerCreMer strain, it was expected that the 
resulting Cre-recombinase activity of this tamoxifen regime would be consistent between 
these models. Optimisation of this tamoxifen dosing protocol considered the resulting 
animal mortality, off-target tamoxifen toxicity and genetic recombination efficacy  
A refined tamoxifen dosing protocol was applied to Cyp-D floxed-α-MHC-MerCreMer 
(FL/FL; WT/Cre) mice. Investigation of ventricular Cyp-D protein levels showed no 
significant difference between any of the time-points tested up to 5 days tamoxifen 
treatment and 14 days protein washout (Figure 5.15). The greatest reduction in Cyp-D 
protein level compared to baseline was detected in tissues harvested 14 days following 
washout of tamoxifen treatment; however, this only corresponded to a 26.8% reduction 
in Cyp-D protein compared to baseline and was not statistically significant (Figure 5.15).  
It is important to note that this experiment examined total ventricular tissue and since 
this model is expected to knockout the Cyp-D gene only in the cardiomyocytes, a 
residual level of Cyp-D protein was expected from other cell types within the heart 
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(namely fibroblasts). However, given that cardiomyocytes are highly mitochondria-
enriched, it was expected that the majority of mitochondria (and thus Cyp-D protein) 
investigated by this protocol was from cardiomyocytes. It is therefore unlikely that the 
high level of Cyp-D protein remaining in these samples following this tamoxifen-
treatment regime corresponded to non-muscle cells. This protocol was concluded to 
induce an unacceptably low knockout of Cyp-D protein to warrant investigation of the 
susceptibility to myocardial infarction in these animals. It is now important to investigate 
this further by examining Cyp-D protein levels in cardiomyocytes isolated from tamoxifen 
treated animals to confirm the level of Cyp-D protein remaining in the cardiomyocytes.  
In addition, examination of Cyp-D mRNA levels in isolated cardiomyocytes would allow 
assessment of the efficacy of genetic ablation induced by this system. The tamoxifen 
dose used in this study (18 mg/kg) was slightly lower than that used in published studies 
(including Sohal et al., 2001 who originally published the protocol using 20 mg/kg 
tamoxifen) and thus may not induce sufficient activation of Cre-recombination. It may be 
interesting to examine the use of tamoxifen-containing chow since this has been 
suggested to result in increased MerCreMer activation and lower tamoxifen toxicity due 
to its more steady intake (Davis et al., 2012). However, since a concurrent study within 
our laboratory using this same MerCreMer strain and tamoxifen dosing regime provided 
genetic ablation of a different target gene, it is unlikely that this was a problem. 
Although further investigation of Cyp-D mRNA and protein levels in cardiomyocytes is 
critical to evaluate the use of this genetic model for further studies, this was not 
undertaken here due to the poor availability of animals and low cardiomyocyte yield 
using the established primary isolation technique within our laboratory. This poor 
cardiomyocyte yield would have necessitated investigation of a large number of hearts; 
however, recent improvements to this protocol improve the feasibility of this study upon 
availability of animals. These experiments should be undertaken to continue the project. 
Importantly, the time-course of the reduction in Cyp-D protein levels suggested by this 
study may potentially restrict the application of this model for the investigation of Cyp-D 
genetic ablation upon myocardial reperfusion. Since there was no appreciable reduction 
in Cyp-D levels following 5 days tamoxifen treatment (Figure 5.15), the effect of Cyp-D 
genetic ablation after myocardial ischaemia and during early reperfusion may not be 
possible. Future experiments should investigate a more detailed time-course of the 
reduction in Cyp-D levels within the first 7 days following tamoxifen treatment. Since the 
time-course of protein level reduction in this system depends on the time for genetic 
ablation and the rate of protein turnover, it would be important to examine mRNA and 
protein levels for further optimisation of this system. The turnover rate of Cyp-D is not 
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known and it may be that it is not sufficiently rapid to allow elegant knockout of Cyp-D in 
the early reperfusion period. Further studies should be undertaken to address this. 
Limitations of Cre-loxP genetic ablation systems: It is also important to note that 
there was a significant difference in Cyp-D protein levels in Cyp-D floxed (FL/FL) mice 
compared to non-floxed wildtype controls (Figure 5.14). Although this was not 
investigated further in this study, this may present an important consideration for the 
future use of this genetic ablation system since these mice would ordinarily be used to 
control for any non-specific effects of tamoxifen (see 3.1.2 ii). This suggests that 
insertion of the loxP sites flanking the Cyp-D gene has changed Cyp-D gene expression, 
which is an unusual although important potential consequence of this system. Further 
examination of Cyp-D protein levels in the control mice outlined previously should be 
undertaken prior to use of these mice to investigate the susceptibility to infarction. 
In addition to the potential effect of loxP site insertion, further confounding effects 
resulting from tamoxifen and / or Cre toxicity have been reported in previous studies 
utilising this method of genetic modification. These potential confounding effects have 
been discussed extensively in the literature (reviewed by Davis et al., 2012) and are 
summarised in chapter 3. These effects represent important considerations for the use 
of the tamoxifen-inducible genetic model presented here. Although this thesis describes 
only the early stages of development of this system, it is crucial to appreciate that this 
model will, in itself, impart some limitations and careful consideration of these limitations 
is required for subsequent interpretation of this model for studies of the role of Cyp-D. 
The cardiac-specific inducible Cyp-D knockout model created here remains a potentially 
important tool for investigating the precise roles of Cyp-D in myocardial ischaemia-
reperfusion injury with regards to tissue specificity and the timing of its involvement. The 
further experiments described above will be important for evaluating the future use of 
this model for dissecting the roles of Cyp-D in myocardial infarction. 
5.5.3. Summary of potential limitations 
The specific experimental limitations of this study have been discussed throughout this 
section. The main limitation with regards to the overall objective of this chapter to 
investigate the long-term cardioprotective efficacy of Cyp-D genetic ablation was the 
relatively small absolute effect size of Cyp-D global genetic ablation when assessing 
infarct size alone (IS/LV%), which precluded the further investigation of these mice using 
current MRI techniques. Given the financial costs of cardiac MRI, it was not feasible to 
undertake a pilot cardiac MRI study in these Cyp-D global knockout animals when this 
preliminary study suggests that substantial sample sizes would be required. This is 
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addressed in chapter 8 of this thesis which examines the importance of controlling 
infarct size measurements to AAR and investigates novel cardiac MRI methods to 
quantify AAR in vivo to enable this in future studies of cardioprotection. 
 
5.5.4. Summary 
The main research objective of this chapter was to investigate the long-term 
cardioprotective efficacy of Cyp-D genetic ablation in reducing myocardial infarct size. 
(1) The Cyp-D global knockout mouse colony has been genetically backcrossed onto a 
C57BL/6 background to allow investigation of true littermate control animals. 
Although this study was not sufficiently statistically powered to detect such a small 
effect size, there was a slight trend towards increased myocardial infarct size in Cyp-
D WT mice compared to the commercial B6/SV129 mice previously used as 
controls. This highlights the importance of using true littermate controls for the study 
of transgenic animals; this gold-standard practice was adhered to in all experiments. 
 
(2) Global genetic ablation of Cyp-D significantly reduced myocardial infarct size in mice 
subjected to in vivo ischaemia-reperfusion injury investigated at 3 days reperfusion. 
Although Cyp-D genetic ablation did not affect survival of animals subjected to this 
model, the protocol used here did not elicit significant mortality of control (wildtype) 
mice and therefore was not sufficiently powered to detect differences in survival.  
 
This study provides the first demonstration of sustained cardioprotection in Cyp-D 
knockout mice following an extended reperfusion period and further supports the role 
of Cyp-D as a target for cardioprotection against ischaemia-reperfusion injury. 
 
(3) To further investigate the specific role of Cyp-D in the development of myocardial 
infarction, a more elegant cardiac-specific transgenic model of Cyp-D genetic 
ablation was investigated. This thesis describes the establishment of a Cyp-D floxed 
– α-MHC MerCreMer colony from previous transgenic strains and the initial 
experiments to characterise its future use. Although the poor breeding success of 
this colony posed significant obstacles to this study, an initial tamoxifen dosing 
protocol showed only a modest and non-significant decrease in ventricular Cyp-D. 
Future experiments are required to further refine this tamoxifen inducible genetic 
ablation model to determine: (1) Cyp-D expression levels in isolated cardiomyocytes 
and (2) a more detailed time-course of the reduction in Cyp-D protein levels. These 
experiments were not completed here due to the restraints of poor breeding of this 
colony and the need to refine the cardiomyocyte isolation protocol. 
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CHAPTER 6: INVESTIGATION OF THE ROLE SIRTUIN-3 IN 
THE PATHOPHYSIOLOGY OF ISCHAEMIA-REPERFUSION  
 
6.1. Introduction 
The previous chapter of this thesis has highlighted the importance of mitochondria in the 
pathophysiological processes that occur upon myocardial ischaemia-reperfusion and the 
possibility for modulation of an important mitochondrial protein to elicit cardioprotective 
benefit. Sirt-3 has been identified as an important regulator of mitochondrial biology and 
may therefore be important in the pathophysiology of ischaemia-reperfusion injury. This 
chapter aimed to investigate the effects of modulating Sirt-3 activity to indirectly affect 
mitochondrial function and survival upon ischaemia-reperfusion. The overall objective of 
this chapter was to determine whether Sirt-3 is a feasible target for cardioprotection. 
Sirt-3 is a key mitochondrial deacetylase protein which regulates the activity of a number 
of mitochondrial proteins involved in cell survival and energy production; as discussed in 
chapter 1 (see 1.4.2 ii). Amongst its numerous targets, Sirt-3 is known to deacetylate 
Cyp-D to reduce its PPIase activity, which is central to its regulation of mPTP opening. 
Indeed, genetic ablation of Sirt-3 results in hyper-acetylation of Cyp-D and increased 
PPIase activity, manifesting in increased mPTP opening in response to high calcium 
stresses (Hafner et al., 2010; Shulga et al., 2010). Although Sirt-3 appears to regulate 
the activity of a diverse array of mitochondrial proteins, its cumulative predicted actions 
in reducing mPTP opening, cellular acidosis and ROS levels and increasing oxidative 
phosphorylation, suggest that Sirt-3 activity may be beneficial for mitochondrial function 
and survival; as summarised in chapter 1 (see 1.4.2 iv, Figure 1.15). 
Myocardial ischaemia-reperfusion is recognised to evoke substantial cellular metabolic 
stress and injury in which mPTP opening has been implicated as a major end-effector 
(see chapter 1; also reviewed by Yellon and Hausenloy, 2007). Given the importance of 
Sirt-3 deacetylation in reducing mPTP opening and potentially reducing extrinsic 
apoptotic cell death (summarised in Figure 1.15), it is expected that increased Sirt-3 
activity may promote cell survival upon myocardial ischaemia-reperfusion. This chapter 
investigates modulation of Sirt-3 activity as a potential cardioprotective strategy. 
This chapter aimed to investigate the effects of Sirt-3 genetic ablation and 
overexpression on the development of infarction upon ischaemia-reperfusion. 
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Investigation of the roles of Sirt-3 in myocardial ischaemia-reperfusion injury presented 
in this chapter was undertaken as a separate study to complement the in vitro 
investigation of Sirt-3 by Dr A. Hall and Dr S. Kumar; all in vivo data presented here was 
conducted independently and all references to the existing data are duly noted below. 
 
6.2. Research objective and aims 
The main objective of this chapter was to investigate modulation of Sirt-3 as a potential 
therapeutic target to protect against in vivo myocardial ischaemia-reperfusion injury. The 
principal research aims to achieve this objective were: 
(1) Investigate the effect of Sirt-3 genetic ablation on the development of myocardial 
infarction in response to in vivo ischaemia-reperfusion; 
 
(2) Investigate the effect of fasting-induced Sirt-3 overexpression on the 
development of myocardial infarction upon in vivo ischaemia-reperfusion. 
 
6.3. Aim 1: Investigate Sirt-3 genetic ablation in myocardial 
infarction 
6.3.1. Background and preliminary data 
The overall aim of this chapter was to investigate the role of Sirt-3 in mediating the 
response to myocardial ischaemia-reperfusion injury in vivo. Sirt-3 is known to 
deacetylate a number of mitochondrial proteins including important proteins regulating 
mitochondrial function and cell survival (as described above and detailed in chapter 1; 
see 1.4.2). These roles of Sirt-3 led to the initial hypothesis investigated here. 
 
Original hypothesis: 
Ischaemia-reperfusion increases Sirt-3 mediated deacetylation of mitochondrial proteins 
to promote mitochondrial function and cell survival. 
 
Initial preliminary studies within our laboratory aimed to investigate the potential roles of 
Sirt-3 in myocardial ischaemia-reperfusion injury using a number of well-established in 
vitro models using the HL-1 cardiac cell line. This cardiac cell line is a widely used and 
important in vitro model system, which has been reported to retain many cardiac 
phenotypes including cellular morphology, biochemistry and electrophysiology 
(developed by Claycomb et al., 1998). These studies of cell death, mPTP opening and 
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mitochondrial morphology provide an important initial stage of investigation to determine 
whether a protein of interest exerts significant effects in ischaemia-reperfusion injury. 
These in vitro studies showed that Sirt-3 overexpression conferred a number of 
beneficial effects: reduced cell death in response to simulated ischaemia-reperfusion, 
delayed mPTP opening and increased mitochondrial fusion (Figure 6.1, blue bars; 
Experiments performed by Dr A. Hall and Dr S. Kumar). Importantly, overexpression of a 
mutated Sirt-3 protein with no deacetylase activity did not confer these beneficial effects 
to cell survival and indicators of mitochondrial health (Figure 6.1, black bars), therefore 
confirming the importance of Sirt-3 deacetylase activity in promoting these beneficial 
outcomes. The main results of these in vitro experiments are summarised in Figure 6.1 
(experiments undertaken by Dr A. Hall and Dr S. Kumar) and discussed below in the 
context of the hypothesis investigated in the first part of this chapter. 
 
 
 
 
 
 
Figure 6.1: Pilot in vitro studies investigating the role of Sirt-3  
Preliminary studies to investigate the roles of Sirt-3 in ischaemia-reperfusion injury using well-
established in vitro models. HL-1 cells were transfected with control empty plasmid (white bars), 
functional Sirt-3 (blue bars) and mutant Sirt-3 with no deacetylase activity (black bars). 
A) Cell death: Susceptibility of HL-1 cells to cell death following simulated ischaemia-reperfusion 
(12 hours hypoxia and 1 hour re-oxygenation) was assessed as the percentage of transfected 
cells exhibiting propidium iodide (PI) staining (dead cells) using fluorescence microscopy. Cell 
death was significantly reduced by overexpression of Sirt-3. Statistical significance was assessed 
by one-way ANOVA, *P<0.05; n=4 group (30 random fields per sample).  
B) Time to mPTP opening: Mitochondria were loaded with tetramethyl rhodaminemethyl ester 
(TMRM) dye which accumulates into the mitochondria where its fluorescence is quenched; 
confocal laser stimulation of TMRM generates ROS which induces mPTP opening allowing 
diffusion of TMRM into the cytosol where auto-quenching of its fluorescent signal is relieved. 
Time to mPTP opening was measured as the time to half maximum cytosolic TMRM signal. Time 
to mPTP opening was significantly delayed by Sirt-3 overexpression and there was mutant Sirt-3 
had no effect. Statistical significance assessed by one-way ANOVA, n≥8/group.  
C) Mitochondrial morphology: Representative images of mitochondrial morphology assessed by 
transfection of mitochondria with mitochondrial yellow fluorescent protein (mtYFP) to allow 
visualisation of mitochondria: i) Empty vector: baseline morphology; ii) Sirt-3 overexpression: 
predominantly fused mitochondria, iii) Mutant Sirt-3: largely normal morphology.  
D) Quantification of mitochondrial morphology: Mitochondria were significantly more fused upon 
Sirt-3 overexpression. Statistical significance assessed by one-way ANOVA, *P<0.05; n≥6/group.  
 
Experiments presented in this figure were performed by Dr A. Hall and Dr S. Kumar. Detailed 
methods for these experiments are outlined in a previous publication by our laboratory describing 
the application of these in vitro models (Ong et al., 2010). (Figure overleaf) 
  
 
Figure 6.1: Sirt-3 in vitro pilot studies – constructed from data provided by Dr A. Hall and Dr S. Kumar – Full legend provided on the preceding page. 
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These studies appear to confirm the predicted role of Sirt-3 deacetylase activity in 
promoting mitochondrial and cellular survival upon stress stimuli. This suggests that 
increased Sirt-3 deacetylase activity may provide a viable therapeutic target for 
protecting against myocardial ischaemia-reperfusion. 
This chapter aimed to investigate the effects of modulating Sirt-3 activity on the 
susceptibility to myocardial infarction in vivo. Since our laboratory did not have access to 
a Sirt-3 genetic overexpression model, an established Sirt-3 genetic ablation model 
(described in detail below) was used to investigate the roles of Sirt-3 in the development 
of myocardial infarction upon ischaemia-reperfusion. Silencing of Sirt-3 in an in vitro cell 
line model has been shown to result in increased cell death upon hypoxia (Pellegrini et 
al., 2012). Given the results of these in vitro studies, it was hypothesised that Sirt-3 
genetic knockout mice would exhibit more rapid mPTP opening and increased cell death 
upon myocardial ischaemia-reperfusion. 
 
Aim 1: The first aim of this chapter was to investigate the effect of global genetic 
ablation of Sirt-3 on the development of myocardial infarction following in vivo 
ischaemia-reperfusion injury. The central hypothesis in relation to this objective was:  
(1) Sirt-3 genetic ablation would significantly increase myocardial infarct size upon in 
vivo ischaemia-reperfusion. 
 
6.3.2. Detailed methods 
i Sirt-3 global knockout mice 
A Sirt-3 global genetic knockout mouse model was obtained from Dr D. Gius (Vanderbilt 
University Medical Centre, USA) from the colony originally created by Ahn et al. (2008). 
Genetic ablation of Sirt-3 was achieved by deletion of exons 2, 3 and 4 of the 
endogenous Sirt-3 gene by insertion of loxP sites flanking these exons and crossing of 
Sirt-3 floxed mice with EIIa transgenic Cre-recombinase mice (developed by Lakso et 
al., 1996) to drive loxP site recombination to delete these exons (summarised in Figure 
6.2). Mice were backcrossed onto a C57BL/6 background (Ahn et al., 2008). 
Colony maintenance: Sirt-3 global knockout mice were obtained from Dr D. Gius 
(Vanderbilt University Medical Centre, USA) and a number of Sirt-3 knockout and 
heterozygous animals imported into our laboratory. A Sirt-3 transgenic colony was 
established from these original animals as outlined in Figure 5.2.  
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Figure 6.2: Generation of Sirt-3 global knockout mice by Ahn et al. (2008) 
Global genetic knockout of Sirt-3 was achieved by insertion of loxP sites flanking exons 2-4 of the 
Sirt-3 gene using standard transgenic methods. Sirt-3 floxed mice were crossed with transgenic 
EIIa Cre-recombinase mice to cause Cre-driven recombination of Sirt-3 loxP sites to delete exons 
2-4 of the Sirt-3 gene. Sirt-3 KO mice were bred with C57BL/6 mice to generate the colony and 
backcrossed onto a C57BL/6 genetic background. Figure modified from Ahn et al. (2008).  
 
Mice were provided by Dr D. Gius (Vanderbilt University Medical Centre, USA). 
 
 
 
 
Figure 6.3: Sirt-3 colony establishment and maintenance 
A) Original colony: Sirt-3 KO mice were crossed with Sirt-3 HET mice to create a stock of Sirt-3 
HET animals. B) Final colony: maintained as Sirt-3 HET x HET crosses to produce progeny of 
Sirt-3 WT, KO and HET (in accordance with expected Mendelian ratios indicated in brackets). 
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ii Genotyping for Sirt-3 genetic ablation 
The genotyping method used for these animals was based on the standard protocol 
described in chapter 3 (see 3.1.2 iii) with the following modifications. DNA samples were 
prepared from ear biopsies and processed within 6 hours, exactly as described 
previously. The PCR reaction mix was based on a standard reaction optimised in this 
thesis where the precise primers and sampling parameters are described in Table 6.1. 
The PCR primers and thermocycling conditions used in this reaction were informed by 
Dr D. Gius (personal communication) with further optimisation undertaken in this thesis.  
The final PCR protocol developed here required the wildtype and mutant PCR product 
bands to be amplified in separate reactions to give optimal amplification of the required 
DNA bands. This protocol yielded DNA products with expected sizes of 499 bp (reaction 
A; KO) and 336 bp (reaction B; WT). The genotype of each animal was decoded based 
on the presence or absence of these DNA bands between the two separate reactions: 
KO 499 bp only, WT 336 bp only and HET both 499 and 336 bp bands (Figure 6.4). 
When run separately these PCR reactions were robust and reliably produced clear DNA 
bands for genotyping. The success of these PCR reactions relied on immediate 
processing of ear biopsies, ideally within 2 hours of sampling (up to a maximum delay of 
6 hours). Replacement ear samples were required where a clear PCR genotyping 
results could not be obtained after two attempts.  
Given that PCR amplification of the wildtype and knockout DNA bands for these 
samples had to be separated to give optimal DNA amplification, it was vital that these 
reactions were as robust and reliable as possible. Particular care was taken to ensure 
successful and accurate addition of the crude DNA lysate samples to each sample to 
reduce the possibility of false negative results for the DNA bands. If there was any 
uncertainty regarding the presence or absence of a PCR band then the reactions for that 
animal were repeated to ensure accurate genotyping of all animals used in these 
studies. This genotyping protocol was confirmed by Western blot interrogation of Sirt-3 
protein levels in samples from randomly selected Sirt-3 wildtype and knockout animals. 
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A) Sirt-3 PCR primer sequences 
PRIMER  SEQUENCE 
PROPERTIES 
Length Tm (ºC) 
PCR REACTION A (KO):    
Primer 1: KO forward 5’-AACGATGAAATCTCCCGGTTTGGC-3’  24 62.7 
Primer 2: KO reverse 5’-TCTTGCAGTTGCATCCGACTTGTG-3’ 24 62.7 
PCR REACTION B (WT):    
Primer 3: WT forward 5'-ATCTCGCAGATAGGCTATCAGC-3’ 22 60.3 
Primer 4: WT reverse 5’-AACCACGTAACCTTACCCAAGG-3’ 22 60.3 
 
B) Sirt-3 PCR reaction mix 
REAGENT VOLUME/SAMPLE  (µl) FINAL CONCENTRATION 
Qiagen 10X PCR Buffer 2.0 1X 
10 mM dNTPs 0.4 200 µM 
Primer forward 100 µM 0.2 1 µM 
Primer reverse 100 µM 0.2 1 µM 
Taq polymerase 0.2 - 
Autoclaved distilled water                     15.5 - 
Crude DNA lysate 
†
 1.5 - 
TOTAL VOLUME/SAMPLE (µl)                     20.0 
  
C) Sirt-3 PCR thermocycling parameters 
PCR STAGE TEMPERATURE AND DURATION PCR DESCRIPTION 
1  95 ºC for 15 minutes   Hot start 
2  94 ºC for 1 minute  DNA separation 
3  60 ºC for 1minute  Primer annealing 
4  68 ºC for 1 minute  DNA synthesis 
5  Go to step 2 for 34 cycles  DNA separation 
6  68 ºC for 7 minutes  Final extension 
7  4 ºC for ever  Intermediate storage 
 
Table 6.1: Sirt-3 global transgenic colony genotyping protocol 
A) Sirt-3 primer sequences for reaction A (KO) and reaction B (WT). B) PCR was run as two 
separate reactions – reaction A for KO and reaction B for WT where a master mix for each 
reaction was made based on Qiagen Taq kit (Qiagen, UK) with addition of primers A or primers 
B. 
†
 1.5 µl DNA lysate. C) PCR was undertaken by a thermal cycler (MJ Research, Canada). 
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Figure 6.4: Sirt-3 transgenic colony representative genotyping result  
The genotype of each animal was determined by the presence or absence of the expected PCR 
bands by comparison to the molecular weight ladder (lane 1) for reaction A KO 499 bp and 
reaction B WT 336 bp where HET animals were positive for both bands (as annotated). A 
negative control (NEG) was run to ensure there was no external DNA contamination. 
 
iii Ischaemia-reperfusion injury in vivo 
Surgical protocol: The susceptibility of Sirt-3 knockout and wildtype littermate controls 
was assessed using the in vivo recovery model of myocardial ischaemia-reperfusion 
injury developed previously in this thesis. Mice were subjected to either 30 or 45 minutes 
ischaemia followed by 24 hours reperfusion (Figure 4.10 B-C; overleaf). All surgeries 
were conducted on male mice aged 8-12 weeks from the Sirt-3 transgenic colony or 
C57BL/6 mice (Charles River Laboratories, UK) as indicated in the results section. 
Endpoint 1 – IS/AAR%: The primary endpoint assessed in this study was infarct size by 
ex vivo histological staining using TTC and Evans blue staining exactly as described 
previously to calculate the infarct size as a percentage of AAR. The pre-defined surgical 
and myocardial AAR exclusion criteria were applied to this dataset (see 3.2.4).  
All infarct size and AAR values are presented as mean ± SEM. All analysis was 
completed using GraphPad Prism® version 5.0 (GraphPad Software, USA) where the 
statistical tests and parameters were exactly as described in chapter 3 (see 3.2.4). 
Details of sample sizes and statistical tests are provided alongside results. 
Endpoint 2 – Survival: Survival of Sirt-3 mice subjected to this protocol was analysed 
by Kaplan-Meier survival plots and long-rank tests using GraphPad Prism® version 5.0 
(GraphPad Software, USA), exactly as described in chapter 3 (see 3.2.3). There was no 
statistical significance in survival between groups presented in this chapter. 
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Figure 6.5: Sirt-3 ischaemia-reperfusion in vivo recovery protocol 
Sirt-3 KO and WT littermate mice underwent the in vivo ischaemia-reperfusion protocol for either 
B) 30 minutes ischaemia or C) 45 minutes ischaemia. Sham operated animals underwent 45 
minutes stabilisation (A). Hearts were extracted for staining for infarction at 24 hours reperfusion. 
 
iv Assessment of Sirt-3 protein levels by Western blot 
Sirt-3 protein levels were examined in C57BL/6 mice subjected to this surgical protocol 
to assess the effect of ischaemia and reperfusion on Sirt-3 protein levels. Western blot 
analysis was performed as previously (see 3.4.2) with the modifications below. 
Preparation of heart samples: C57BL/6 mice underwent in vivo myocardial ischaemia-
reperfusion surgery where hearts were extracted for analysis immediately following 30 
minutes ischaemia or 30 minutes ischaemia and 16 hours reperfusion (Figure 6.6).  
Processing of heart tissue was completed by Dr A. Hall within our laboratory:  
Immediately following extraction, hearts were processed to isolate mitochondria for 
Western blot analysis. Hearts were extracted exactly as described previously and left 
and right ventricular tissue immediately homogenised using a glass pestle and mortar in 
standard homogenisation buffer. Mitochondrial proteins were isolated using a 
commercial kit (Qproteome mitochondria isolation kit, Qiagen, UK) according to the 
manufacturer’s instructions (see 3.4.1 ii). Mitochondria were washed and re-suspended 
for Western blot analysis. The protein concentration of mitochondrial samples was 
assessed using a standard BCA protein assay. Samples were diluted to a set protein 
concentration by addition of the standard homogenisation buffer. 
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Stab
15 min
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30 min
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45 min
Extract
Extract
24 hrsAnaesthetic Duration 50 550 5 20
24 hrsAnaesthetic Duration 50 550 5
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Extract
24 hrsAnaesthetic Duration 50 550 5
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Figure 6.6: Surgical protocol to examine Sirt-3 expression levels 
C57BL/6 mice underwent in vivo ischaemia with or without reperfusion. A) Sham: hearts were 
extracted following stabilisation or 16 hours recovery. B) Ischaemia / Reperfusion: hearts were 
extracted following 30 minutes ischaemia or 30 minutes ischaemia and 16 hours reperfusion. 
 
Western blotting protocol: Western blot analysis was performed by SDS-PAGE of 
protein samples exactly as described in chapter 3 (see 3.4.2). Since Sirt-3 and VDAC 
(the intended control for protein loading) have very similar molecular weights (28 and 32 
kDa respectively) and are detected using antibodies raised in the same species (rabbit; 
see Table 6.2) it was necessary to run two separate gels to assess the levels of these 
proteins. Previous attempts at stripping the membrane of bound antibody indicated that 
some primary antibody remained thereby precluding the use a single membrane for 
interrogation of both of these proteins. Particular care was taken to ensure protein 
loading was consistent between all samples. Normalisation of Sirt-3 protein levels to 
VDAC is discussed below in section 6.3.3. 
Antibody interrogation of proteins: Primary antibodies (detailed in Table 6.2 A) were 
diluted 1:1000 (final concentration of 1 µg/ml) and incubated with the membrane for 45-
60 minutes at room temperature with agitation. An anti-horse secondary antibody was 
used to detect primary antibody binding (detailed in Table 6.2 B).  
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A) Primary antibodies: 
ANTIBODY ANTIBODY DETAILS 
Sirt-3 Anti-Sirt-3 rabbit monoclonal antibody to Sirt-3 
Purchased from Cell Signalling, USA (catalogue number: 5490) 
Stock 1 mg/ml; diluted 1:1000 to give working concentration 1 µg/ml  
Predicted molecular weight 28 kDa 
VDAC Anti-VDAC rabbit monoclonal antibody to VDAC 
Purchased from Cell Signalling, USA (catalogue number: 4661) 
Stock 1 mg/ml; diluted 1:1000 to give working concentration 1 µg/ml  
Predicted molecular weight 32 kDa 
 
B) Secondary antibody: 
ANTIBODY ANTIBODY DETAILS 
Anti-rabbit Horse anti-rabbit IgG HRP-linked polyclonal antibody 
Purchased from Cell Signalling, USA (catalogue number: 7074S).  
Stock 1 mg/ml; diluted 1:2000 to give working concentration 0.5 µg/ml  
 
Table 6.2: Antibodies for Western blot analysis of Sirt-3 protein levels 
A) Primary antibodies were anti-Sirt-3 and anti-VDAC. B) Secondary antibody was an anti-rabbit 
IgG polyclonal antibody conjugated to HRP to allow detection by a standard chemiluminescence 
reaction. All antibodies were purchased from Cell Signalling Technology (USA) as detailed here. 
 
Chemiluminescence detection of antibody binding: Protein bands were visualised 
using a standard HRP chemiluminescence reaction as described previously (see 3.4.2). 
Protein levels were quantified and expressed as arbitrary units (A.U.) from densitometry 
analysis. Normalisation of Sirt-3 protein levels to VDAC as a control for protein loading 
was not undertaken here since VDAC expression appeared to vary between groups 
(see 6.3.3 for details). The potential effects of this are discussed in detail below. All 
values are presented as mean A.U. ± SEM. Data were analysed by one-way ANOVA 
and Bonferroni test using GraphPad Prism® version 5.0 (GraphPad Software, USA). 
Statistical significance was reported where P<0.05 using standard significance coding. 
Representative protein bands are shown alongside densitometry quantifications. 
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6.3.3. Results 
To investigate the effect of global genetic ablation of Sirt-3 on myocardial infarct size 
following ischaemia-reperfusion injury, Sirt-3 knockout and wildtype (true littermate) 
mice were subjected to in vivo ischaemia and reperfusion. The standard 30 minute 
ischaemic protocol evoked an infarct size in Sirt-3 wildtype mice in accordance with that 
expected in previous studies of wildtype animals (Figure 5.5 A; WT). Importantly, there 
was no significant difference in infarct size between Sirt-3 knockout and wildtype 
animals (Figure 5.5 A: IS/AAR% Sirt-3 WT 36.3±2.0 versus Sirt-3 KO 33.3±4.1; 
n≥7/group, NSP>0.05). There was no significant difference in AAR (AAR/LV% Sirt-3 WT 
60.2±1.8 versus Sirt-3 KO 56.3±2.1; n≥7/group, NSP>0.05) or survival (survival % to 24 
hours reperfusion: Sirt-3 WT 87.5%, n=8 versus 88.9%, n=9) between these groups. 
To investigate the potential role of Sirt-3 under more severe stress conditions, Sirt-3 
mice were subjected to a longer ischaemic insult of 45 minutes; however, this also 
showed no significant difference in infarct size between Sirt-3 knockout and wildtype 
animals (Figure 5.5 B: IS/AAR% Sirt-3 WT 46.9±3.7 versus Sirt-3 KO 44.4±4.8; 
n=5/group, NSP>0.05). There was no significant difference in AAR (AAR/LV%: Sirt-3 WT 
63.5±7.3 versus Sirt-3 KO 63.5±3.4; n=5/group, NSP>0.05) or survival (survival % to 24 
hours reperfusion: Sirt-3 WT 71.4%, n=7 versus Sirt-3 KO 83.3%, n=6).  
 
Figure 6.7: Infarct size in Sirt3 wildtype and knockout mice 
Infarct size in Sirt-3 KO and WT littermate mice. A) 30 minutes ischaemia and 24 hours 
reperfusion: no significant difference in infarct size between Sirt-3 KO and WT mice: IS/AAR% 
Sirt-3 WT 36.3±2.0 (n=7) versus Sirt-3 KO 33.3±4.1 (n=8); 
NS
P>0.05. B) 45 minutes ischaemia 
and 24 hours reperfusion: no significant difference in infarct size between Sirt-3 KO and WT 
mice: IS/AAR% Sirt-3 WT 46.9±3.7 (n=5) versus Sirt-3 KO 44.4±4.8 (n=5), 
NS
P>0.05. 
Significance assessed by unpaired t-test. 
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Since genetic ablation of Sirt-3 did not appear to affect myocardial infarct size, these 
results suggest that Sirt-3 may not play an important role in the pathophysiology of 
myocardial ischaemia-reperfusion. This is unexpected given that Sirt-3 silenced cells 
were shown to exhibit increased cell death upon hypoxia in an in vitro model (Pellegrini 
et al., 2012; as discussed above); this is discussed in detail subsequently (see 6.5.1). 
To investigate the effect of myocardial ischaemia and reperfusion on Sirt-3 expression 
levels, C57BL/6 were subjected to this surgical procedure and mitochondrial Sirt-3 
protein levels examined immediately following ischaemia and after ischaemia and 
reperfusion.  Analysis of Sirt-3 and VDAC protein levels in these samples showed 
increased levels of Sirt-3 protein in ischaemic samples compared to equivalent control 
operated animals. However, there was a large variation in VDAC protein levels between 
these samples, where it appeared that increased Sirt-3 levels appeared alongside 
decreased VDAC levels (Figure 5.14 A). Although there was no statistically significant 
difference in VDAC levels between these groups, absolute Sirt-3 levels were quantified 
without normalisation to VDAC to avoid any confounding effects of altered VDAC 
expression (quantification of absolute Sirt-3 protein levels is shown in Figure 5.14 B). 
This analysis of mitochondrial Sirt-3 protein levels showed that myocardial ischaemia 
significantly increased Sirt-3 protein by approximately 3.0 fold compared to equivalent 
sham operated mice (Figure 5.14 B: white compared to white hashed bars, n=3/group, 
**P<0.01). Interestingly, animals subjected to the 16 hour sham procedure also showed 
a significant increase in mitochondrial Sirt-3 protein levels compared to 30 minute sham 
operated mice (Figure 5.14 B: white hashed compared to black hashed bars, n=3/group, 
*P<0.05). However, it should be noted that there was no significant difference in Sirt-3 
protein levels following ischaemia-reperfusion compared to sham operated animals 
(Figure 5.14 B: black compared to black hashed bars, n=3/group, NSP>0.05).  
 
230 
 
Figure 6.8: Sirt-3 protein levels following ischaemia and ischaemia-reperfusion 
Western blot analysis to quantify Sirt-3 protein levels in mitochondria isolated from C57BL/6 mice 
immediately following ischaemia (white bar) and following ischaemia and reperfusion (black bar). 
Sirt-3 levels were also examined in equivalent sham operated animals (hashed bars); n=3/group. 
A) Representative protein bands from Western blot for Sirt-3 and VDAC. Since VDAC protein 
levels appeared to be variable between groups, this was not used as a loading control for 
normalisation of Sirt-3 levels. B) Densitometry of Western blot analysis to calculate Sirt-3 protein 
levels (absolute A.U. not normalised to VDAC). Statistical significance assessed by one-way 
ANOVA; mitochondrial Sirt-3 protein levels were significantly increased by ischaemia 
(comparison of white hashed and white bars; **P<0.01).There was no significant difference in 
mitochondrial Sirt-3 levels following ischaemia-reperfusion compared to sham (
NS
P>0.05). 
 
 
This study suggests that the surgical procedure used to induce myocardial ischaemia-
reperfusion elicits a significant stress response. The potential implications of this are 
discussed in detail subsequently in this chapter (see 6.5.1).  
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6.4. Aim 2: Investigate Sirt-3 overexpression in myocardial 
infarction 
6.4.1. Background 
The demonstration that genetic ablation of Sirt-3 does not affect the susceptibility to 
myocardial infarction appears to suggest that Sirt-3 may not play a fundamental role in 
the pathophysiology of myocardial ischaemia-reperfusion injury. However, given the 
convincing in vitro data previously generated within our laboratory showing that Sirt-3 
overexpression reduced cell death upon simulated ischaemia-reperfusion, delayed 
ROS-induced mPTP opening and promoted mitochondrial elongation (see pilot data by 
Dr A. Hall and Dr S. Kumar; Figure 6.1), the second part of this chapter sought to 
investigate the effects of Sirt-3 overexpression on the susceptibility to infarction in vivo.  
Since our laboratory did not have access to a genetic model of Sirt-3 overexpression, a 
fasting protocol was utilised to increase Sirt-3 protein levels. Fasting has previously 
been shown to increase Sirt-3 expression in the liver and brown adipose tissue, where 
Hirschey et al. (2010) demonstrated maximal Sirt-3 protein levels were obtained 
following 18 hours fasting (Hirschey et al., 2010). A similar approach to induce Sirt-3 
overexpression was undertaken by Lu et al. (2011), where fasting (24 hours but not 8 
hours) was required to reveal a statistically significant difference in acetaminophen-
induced liver injury between Sirt-3 knockout and wildtype mice, although this study did 
not report the extent of Sirt-3 overexpression induced by these fasting durations (Lu et 
al., 2011). The mechanism of increased Sirt-3 expression is expected to result from 
increased mitochondrial NAD+ levels in response to fasting, since Sirt-3 activity is 
regulated by NAD+ levels. Indeed, Yang et al. (2007a) showed that 48 hours fasting of 
rats resulted in an approximate 2.5-fold increase in NAD+ levels (Yang et al., 2007a). 
These findings are in agreement with the well-defined role of the sirtuin proteins as a 
metabolic sensors (reviewed by Shinmura, 2013). The second part of this chapter aims 
to investigate the role of Sirt-3 in the pathophysiology of myocardial ischaemia-
reperfusion injury using this model of increased Sirt-3 expression.  
 
Aim 2: The second aim of this chapter was to investigate the effect of fasting-induced 
Sirt-3 overexpression on susceptibility to myocardial infarction. The central hypothesis in 
relation to this research objective was as described above, based on the in vitro data:  
(1) Sirt-3 overexpression induced by fasting would significantly reduce myocardial 
infarct size upon in vivo ischaemia-reperfusion. 
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6.4.2. Detailed methods 
The methods used in this section were largely based on those described in part 1 of this 
chapter (section 6.3.2) with additional experimental details provided here. 
i Fasting protocol 
Use of animals in this study was in accordance with the United Kingdom Animal 
(Scientific Procedures) Act of 1986. Fasting for a maximum of 16 hours is permitted 
without a specific Home Office protocol since it is not considered to be a procedure; the 
fasting protocol used here did not exceed 16 hours fasting. Fasting was initiated by 
removal of food from the housing cage, where animals were provided with water ad 
libitum. It was essential to ensure that all traces of food were removed from the floor of 
the cage. Animals were closely monitored during fasting to ensure maintained welfare. 
ii Ischaemia-reperfusion injury in vivo 
Following 16 hours fasting, animals were subjected to the in vivo ischaemia-reperfusion 
protocol developed in chapter 4 of this thesis, using a protocol of 30 minutes ischaemia 
and 24 hours reperfusion exactly as described above (see 6.3.2 iii, Figure 4.10 B). 
Particular care was taken to ensure that all animals were in good health prior to 
commencing surgery. The time-course of recovery and the observed activity of fasted 
animals (both Sirt-3 knockout and wildtype mice) following this surgical protocol was 
noticeably slower than expected from fed counterparts (although this was not formally 
assessed or quantified). There was no statistical difference in the survival of fasted 
versus fed wildtype mice. Animals were closely monitored by experienced technical staff 
to ensure that the severity limit of the procedural licence was not exceeded and that 
animals were in good health throughout this protocol. 
Following 24 hours reperfusion, mice were anaesthetised and hearts extracted for ex 
vivo histological staining using TTC and Evans blue exactly as described above (see 
section 6.3.2 iii). The standard surgical and AAR exclusion criteria were applied. 
This fasting study was undertaken in both Sirt-3 knockout and wildtype mice, since 
although it was only expected to increase Sirt-3 expression in the wildtype animals, it 
was important to include the Sirt-3 knockout control group to assess the involvement of 
Sirt-3 in any effect observed. For this same reason, additional surgeries of fed Sirt-3 
knockout and wildtype mice were also performed during this study to permit inclusion of 
these groups in the final analysis of the effect of fasting on susceptibility to infarction. 
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6.4.3. Results 
i Susceptibility to ischaemia-reperfusion injury 
Although analysis of the time-course of Sirt-3 expression with incremental durations of 
fasting was not undertaken here, 16 hours fasting was shown to evoke Sirt-3 
overexpression (Figure 6.9 A; corresponding to approximately a 1.5 fold increase in 
ventricular Sirt-3 protein level). This should be formally investigated in a larger sample. 
To investigate the effect of fasting-induced Sirt-3 overexpression on the susceptibility to 
myocardial infarction, fasted Sirt-3 knockout and wildtype (true littermate) mice were 
subjected to 30 minutes ischaemia and 24 hours reperfusion. This study was 
undertaken with randomised additional surgeries for Sirt-3 knockout and wildtype fed 
mice to allow a comparison of the effect of fasting with fed control animals. Fasted 
wildtype animals exhibited significantly larger infarct sizes compared to fasted Sirt-3 
knockout mice (Figure 6.9: IS/AAR% fasted Sirt-3 WT 52.8±4.7 versus fasted Sirt-3 KO 
26.9±4.3; n=6/group, **P<0.01). There was no significant difference in AAR or survival. 
The lack of any effect of fasting on myocardial infarct size in Sirt-3 knockout mice 
confirms that the increased susceptibility to infarction in fasted wildtype mice results 
from Sirt-3 since there is no significant effect of fasting in Sirt-3 knockout mice. 
 
Figure 6.9: Infarct size in Sirt-3 fasted wildtype and knockout mice 
A) Representative Western blot analysis of ventricular Sirt-3 protein levels in Sirt-3 WT fed and 
fasted mice. B) Infarct size in fasted Sirt-3 KO and WT littermate animals subjected to 30 minutes 
ischaemia and 24 hours reperfusion compared against fed controls. Infarct size in fasted Sirt-3 
WT mice was significantly larger than in fasted Sirt-3 KO mice: IS/AAR% Sirt-3 WT fasted 
52.8±4.7 (white hashed bar; n=6) versus Sirt-3 KO 26.9±4.3 (black hashed bar; n=6). Statistical 
significance was assessed by one-way ANOVA comparing relevant groups,
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6.5. Discussion 
The overall research objective of this chapter was to investigate the potential modulation 
of Sirt-3 as a cardioprotective intervention to reduce myocardial infarction upon 
ischaemia-reperfusion. The initial in vitro studies within our laboratory indicated that Sirt-
3 overexpression conferred a number of beneficial effects, notably increased cell 
survival upon simulated ischaemia-reperfusion injury. This chapter describes further 
investigation of the role of Sirt-3 in in vivo ischaemia-reperfusion injury. 
6.5.1. Aim 1: Investigate the effect of Sirt-3 genetic ablation on 
susceptibility to myocardial infarction 
Original research hypothesis and pilot data: Sirt-3 has been shown to mediate 
deacetylation of a number of key mitochondrial proteins, including proteins known to be 
important in controlling cell survival (summarised in chapter 1; see Table 1.3). Notably, 
Sirt-3 deacetylation of Cyp-D reduces its PPIase activity resulting in reduced mPTP 
opening (Shulga et al., 2010; Hafner et al., 2010). Further to this, Sirt-3 deacetylation 
increases the activity of the ROS scavenger enzyme, MnSOD (Jacobs et al., 2008; 
Chen et al., 2011), intracellular anhydrase (CA) (Pellegrini et al., 2012) and the Bax-
binding protein, Ku70 (Sundaresan et al., 2008). It was, therefore, hypothesised that the 
cumulative actions of Sirt-3 on these important mitochondrial proteins would reduce 
mPTP opening directly by reducing Cyp-D activity and indirectly by reduced ROS levels. 
This would therefore be expected to reduce cell death upon myocardial ischaemia-
reperfusion (summarised in chapter 1, Figure 1.15). 
The in vitro pilot data from our laboratory showed that overexpression of Sirt-3 in the HL-
1 cardiac cell line conferred several beneficial effects including reduced cell death 
following simulated ischaemia-reperfusion injury, delayed mPTP opening and increased 
mitochondrial fusion. Importantly, these beneficial effects were not observed following 
expression of mutated Sirt-3 lacking deacetylase activity, thereby confirming that Sirt-3 
deacetylation mediates several beneficial effects which are expected to promote cell 
survival (summarised in Figure 6.1; experiments undertaken by Dr A. Hall and Dr S. 
Kumar). These studies provided initial evidence that Sirt-3 mediated deactylation may 
play an important role in the response to myocardial ischaemia-reperfusion injury and 
suggested that overexpression or increased activity of Sirt-3 may protect against the 
injurious effects of ischaemia-reperfusion in vivo.  
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Susceptibility of Sirt-3 knockout mice to myocardial infarction: The first section of 
this chapter investigated this original hypothesis using a model of global genetic ablation 
of Sirt-3. Given the apparent protective role of Sirt-3 overexpression in vitro in the HL-1 
cardiac cell line, it was expected that genetic ablation of Sirt-3 would render the 
myocardium more susceptible to infarction from in vivo ischaemia-reperfusion. This was 
based on the assumed opposing effects of ablation and overexpression of this gene. 
However, these experiments demonstrated that there was no difference in infarct size 
between Sirt-3 knockout and wildtype mice subjected to 30 minutes ischaemia (Figure 
6.6 A). Since Sirt-3 activity is known to be upregulated by cellular stress, a more severe 
ischaemic insult (45 minutes myocardial ischaemia) was investigated, however, this also 
showed that Sirt-3 genetic knockout did not affect the susceptibility to infarction (Figure 
6.6 B). This was unexpected based on the role of Sirt-3 overexpression previously 
demonstrated by our laboratory in vitro in the HL-1 cardiac cell line (Figure 6.1). 
There are numerous potential explanations for this discrepancy between the in vitro and 
in vivo studies. The most obvious potential variable is the difference between the 
knockout and overexpression models investigated here. Genetic ablation of Sirt-3 may 
trigger some compensatory mechanism that is abrogating the effect of the knockout of 
Sirt-3. This was not expected given that the other sirtuin deacetylase proteins are not 
located in the mitochondria. It is possible however, that the other mitochondrial Sirt 
proteins, -4 and -5, exert deacetylase activities in the absence of Sirt-3. It should be 
noted however that these proteins have been shown to possess little deacetylase 
activity at baseline (Lombard et al., 2007). Further studies could investigate this by 
analysis of expression and activity of other Sirt proteins (potentially including normally 
cytosolic Sirt-1) in mitochondria isolated from Sirt-3 knockout hearts.  
However, overexpression of Sirt-3 in the in vitro HL-1 cell model presented here may 
also introduce some artificial effects of Sirt-3 protein function. A potential pitfall of such 
transfection approaches is the potential for artificial localisation of the protein of interest. 
For example, overexpression of Sirt-3 may result in accumulation and activity of 
exogenous Sirt-3 protein in the cytosol. The precise localisation of Sirt-3 in the HL-1 cell 
system summarised here was not investigated in these experiments. In addition, further 
in vitro artefacts may derive from inherent differences in immortalised cells compared to 
ex vivo and in vivo cell preparations; this is discussed in more detail subsequently. 
The potential influence of the difference between genetic overexpression and knockout 
was investigated further in part two of this chapter and is discussed in detail below. 
Additional potential reasons for the apparent discrepancy between these studies are 
discussed at the end of this chapter (see 6.5.3). 
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Increased Sirt-3 protein levels in response to stress: Since Sirt-3 is a stress protein 
known to be upregulated in response to stress stimuli, including calorie restriction and 
fasting (Sundaresan et al., 2008; Lu et al., 2011), mitochondrial Sirt-3 protein levels 
were examined in hearts extracted immediately following myocardial ischaemia and 
following ischaemia and reperfusion. This study did not examine total cell or cytosolic 
fractions and therefore provides an indication only of mitochondrial Sirt-3 protein levels. 
It is important to note that there appeared to be a trend towards decreased VDAC 
protein levels in the mitochondrial samples with higher Sirt-3 protein levels. Although this 
procedure was not expected to affect VDAC levels, to avoid any confounding effects of 
this for the normalisation of Sirt-3 protein levels, analysis of Sirt-3 protein was computed 
as absolute band intensity and not normalised to VDAC levels. Since Sirt-3 protein 
levels have not been normalised to a loading control, the protein levels observed here 
are likely to be subject to slightly larger errors than would otherwise be expected. This 
Western blot analysis could be repeated using a different mitochondrial loading control, 
such as prohibitin, which has been suggested to be more stably expressed (Merkwirth 
and Langer, 2009; Verweij et al., 2013). However, this was not required since analysis of 
absolute Sirt-3 protein was sufficiently sensitive to detect significant changes. 
This study showed that myocardial ischaemia significantly increased mitochondrial Sirt-3 
protein levels by approximately 3.0-fold compared to sham operated animals (Figure 
5.14 B). The short experimental protocol investigated here suggests that this increase in 
mitochondrial Sirt-3 protein results from either post-translational regulation (for example 
reduced Sirt-3 degradation) or intracellular targeting of the Sirt-3 protein and not de novo 
synthesis of Sirt-3. Sirt-3 is known to be targeted to the mitochondria by an N-terminal 
sequence which is subsequently cleaved within the mitochondrial matrix to form the 
functional Sirt-3 protein (Frye, 2000; Schwer et al., 2002). It is therefore possible that 
under baseline conditions there is a pool of inactive cytosolic Sirt-3 protein which is 
translocated to the mitochondria upon myocardial stress, as discussed further below. 
To further investigate the effect of myocardial ischaemia and reperfusion on Sirt-3 
protein levels it would be of interest to examine mitochondrial, nuclear and cytosolic 
cellular fractions to examine the subcellular localisation of Sirt-3. This would be 
particularly interesting given the potential nuclear role of Sirt-3 upon stress suggested by 
Sundaresan et al. (2008), where stress stimuli causeed nuclear-enrichment of Sirt-3 
(Sundaresan et al., 2008). However, attempts at precise cellular fractionation within our 
laboratory showed notable contamination of these fractions and so this was not 
investigated further in this thesis. The mitochondrial fractions examined in this chapter 
were processed using a well-characterised commercial mitochondrial isolation kit proven 
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to provide an uncontaminated preparation. The precise mechanism of increased Sirt-3 
protein levels following ischaemia therefore remains speculative and is an important 
direction for future experiments investigating the role of Sirt-3 in ischaemia-reperfusion. 
Interestingly, the sham recovery procedure also evoked a significant increase in 
mitochondrial Sirt-3 protein levels (Figure 5.14 B), which was not further increased upon 
ischaemia-reperfusion. This suggests that the surgical protocol employed here evokes a 
significant stress response, as discussed briefly in chapter 4 (see 4.6.4). This increase 
in mitochondrial Sirt-3 protein levels may result from the potentially reduced calorie 
intake of these animals in the immediate post-operative period. Recovering mice (both 
sham and ischaemia-reperfusion operated) display reduced activity during recovery and 
appear to show reduced food and water intake during this period (however, it should be 
noted that activity levels and food intake have not been formally quantified). Once could 
speculate that the potentially reduced calorie intake or mild fasting of recovering animals 
may therefore evoke increased mitochondrial Sirt-3 protein levels; the effects of fasting 
on Sirt-3 protein expression are discussed in detail below. This also offers a possible 
reason for the absence of increased mitochondrial Sirt-3 protein levels in animals 
subjected to the 30 minute sham procedure. Given the extended time-course examined 
here (16 hours recovery), the increased mitochondrial Sirt-3 protein observed may result 
from de novo protein synthesis, although this has not been directly investigated here. 
It is important to note that although the studies presented here have demonstrated 
increased Sirt-3 protein levels following ischaemia; increased Sirt-3 activity has not been 
investigated. Myocardial ischaemia is expected to increase NAD+ levels (confirmed by 
Yang et al., 2007a) and is therefore expected to result in increased Sirt-3 activity. Sirt-3 
deacetylase activity can be quantified using a radiolabelled acetyl-lysine assay or using 
more recently developed fluorescence labelling methods. A commercial assay kit from 
Cyclex (MBL International, USA) has been shown to provide a convenient and accurate 
method to quantify Sirt-3 deacetylase activity (as used by Shulga et al., 2010). This 
assay may serve as a useful tool for further investigation of the role of Sirt-3 in the 
experiments presented in this chapter, to confirm concomitant increased Sirt-3 activity. 
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6.5.2. Aim 2: Investigate fasting-induced Sirt-3 overexpression on the 
susceptibility to myocardial infarction 
Given the role of Sirt-3 as a metabolic sensor, a fasting-induced model of Sirt-3 
overexpression was examined in this thesis. This was particularly important given that 
under baseline (fed) conditions, Sirt-3 did not appear to be mediating a critical role in the 
pathophysiology of myocardial ischaemia-reperfusion and the development of infarction.  
Hirschey et al. (2010) showed that fasting increases Sirt-3 protein levels which in turn 
reduces mitochondrial protein acetylation (confirming increased Sirt-3 activity) in liver 
and brown adipose tissue. A time-course study of these animals showed that Sirt-3 
protein levels increased with the duration of fasting and maximal Sirt-3 levels were 
reached after 18 hours fasting (Hirschey et al., 2010). Importantly, Lu et al. (2011) 
demonstrated that following 24 hours (and not 8 hours) fasting there was a significant 
difference in the susceptibility of Sirt-3 fed and fasted mice to acetaminophen-induced 
liver toxicity (Lu et al., 2011). This illustrates that moderate durations of fasting (18-24 
hours) can serve as an ‘agonist’ for identifying the pathophysiological roles of Sirt-3. 
Fasting-induced increases in Sirt-3 expression were therefore investigated to provide a 
potentially more appropriate comparison with the previous in vitro studies that revealed 
an important role of Sirt-3 in cardiac cells. The second part of this chapter investigated 
the susceptibility to myocardial infarction of fed and fasted animals. This thesis used a 
16 hour fasting protocol since this was permitted by the UK Home Office without 
requirement for a specific procedural licence. This 16 hour fasting protocol was 
expected to significantly increase Sirt-3 protein levels, based on the approximate time-
course of Sirt-3 overexpression demonstrated by Hirschey et al. (2010).  
Based on the pilot in vitro data (summarised in Figure 6.1), it was hypothesised that 
fasting-induced overexpression of Sirt-3 would protect against myocardial ischaemia-
reperfusion, resulting in reduced myocardial infarct size in fasted wildtype mice. 
Interestingly, 3 days pre-operative fasting protects against renal and hepatic ischaemia-
reperfusion, termed ‘fasting induced preconditioning’ (Mitchell et al., 2010). This group 
subsequently showed that 3 days fasting also reduced complex II driven mitochondrial 
respiration and mPTP opening (Mitchell et al., 2010; Verweij et al., 2013).  
However, the 16 hour fasting protocol used here resulted in increased susceptibility to 
myocardial infarction in Sirt-3 wildtype animals (Figure 6.9). Since there was no 
equivalent increase in myocardial infarct size in fasted Sirt-3 knockout mice, it appears 
that this increased injury is mediated by the actions of Sirt-3. This fasting protocol was 
shown to increase myocardial Sirt-3 protein levels; however, the localisation and activity 
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of Sirt-3 should also be investigated in these animals, as discussed above. This 
detrimental effect of fasting in wildtype mice is apparently in conflict with the effect of 
fasting-mediated protection against renal and hepatic ischaemia-reperfusion (Mitchell et 
al., 2010; Verweij et al., 2013). This may result from the more severe fasting protocol 
used by these published studies (3 days fasting) or some organ-specific effects. 
Indeed, the higher metabolic demand of the heart compared to the liver may account for 
some of this difference since fasting has been shown to cause downregulation of 
complexes I, IV and V and reduced oxidative phosphorylation (Verweij et al., 2013). It 
could be speculated that the heart may be less able to compensate for these changes 
induced by fasting. It would be pertinent to further investigate the metabolic changes in 
Sirt-3 wildtype and knockout hearts under fed and fasted conditions. Interestingly, Sirt-3 
knockout (under fed conditions) significantly reduces ATP levels in mouse embryonic 
cells (Ahn et al., 2008) but not in the liver (Hirschey et al., 2010). Further studies should 
examine myocardial ATP levels in fed and fasted Sirt-3 wildtype and knockout mice.  
The increased susceptibility to myocardial infarction in fasted Sirt-3 wildtype animals 
compared to Sirt-3 knockout mice (Figure 6.9) appears to conflict with the beneficial 
effect of Sirt-3 overexpression in vitro (summarised in Figure 6.1; experiments by Dr A. 
Hall and Dr S. Kumar) and appears to disprove our original hypothesis. However, a 
similar protective effect of Sirt-3 genetic ablation in fasted animals compared to wildtype 
fasted mice was observed in a model of liver toxicity discussed above (Hirschey et al., 
2010). These studies appear to suggest that Sirt-3 may be associated with increased 
cell death under certain triggers of cell stress following fasting. 
It is important to note that there are notable differences between the in vitro and in vivo 
model systems investigated here. A potential confounding factor influencing the 
interpretation of the in vitro data described here is the highly glycolytic metabolism of 
immortalised cell lines, including the HL-1 cell line, compared to the physiological 
metabolic state in vivo, where the heart is highly dependent on fatty acid oxidation (see 
chapter 1; 1.2.1). Indeed, the reduction in oxidative phosphorylation in HeLa cells has 
been shown to be manifested by a decrease in mitochondrial respiration (Rossignol et 
al., 2004), which could potentially influence the roles of metabolic sensor proteins, such 
as Sirt-3. The importance of the changed metabolic status of HeLa cells was shown by 
Shulga et al. (2010) where incubation of these cells in galactose-containing medium, 
which has been shown to stimulate a metabolic switch to oxidative phosphorylation, was 
required to detect a difference in Sirt-3 activity (Shulga et al., 2010). The altered 
changed metabolic state of HL-1 cells investigated in the in vitro experiments here may 
therefore influence the interpretation of the role of Sirt-3 from this study. 
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The relative merits and importance of these studies must now be evaluated to interpret 
the role of Sirt-3 in the pathophysiology of myocardial ischaemia-reperfusion injury. 
6.5.3. Evaluation of the role of Sirt-3 as a potential cardioprotective target 
It is important to note that this chapter of the thesis has not demonstrated a clear effect 
of Sirt-3 in ischaemia reperfusion injury in the normal physiological fed state. This poses 
the question as to whether Sirt-3 is an important mediator of ischaemia-reperfusion 
injury. The further studies discussed above would be necessary to address the revised 
working hypothesis of this research project; that Sirt-3 is detrimental in the setting of 
ischaemia-reperfusion injury. Investigation of the effect of Sirt-3 inhibition using a 
pharmacological inhibitor would provide an additional valuable insight into the potential 
for modulation of Sirt-3 activity as a therapeutic approach to reduce the susceptibility to 
myocardial infarction. Specifically, it would be important to investigate whether Sirt-3 
inhibition at reperfusion could mediate a cardioprotective effect. 
It remains interesting that there was no effect of Sirt-3 genetic ablation on the 
susceptibility to myocardial infarction in fed animals and this questions whether Sirt-3 
represents a relevant target for cardioprotection against ischaemia-reperfusion. Given 
that it is evident that fasting-induced Sirt-3 overexpression elicits an increased infarct 
size, it would usually be suggested that inhibition of Sirt-3 as a therapeutic strategy may 
reduce infarct size. However, the data presented in the first part of this chapter suggests 
that this may not be the case. It is possible that this lack of reduction of infarct size in 
Sirt-3 knockout mice results from a compensatory mechanism in response to the 
absence of Sirt-3, especially since this is a global genetic knockout model. This could be 
addressed using inducible Sirt-3 knockout or a pharmacological inhibitor since this 
would more appropriately model the target of temporal Sirt-3inhibition. Unfortunately, 
inducible Sirt-3 knockout mice are not currently available. Although Galli et al. (2012) 
recently reported a pharmacological inhibitor with increased selectivity for Sirt-3 over 
Sirt-1 and -2, potential inhibition of other mitochondrial Sirt proteins (-4 and -5) has not 
be examined (Galli et al., 2012). A pharmacological approach may provide an important 
tool to investigate the role of Sirt-3 in myocardial ischaemia-reperfusion in vivo. 
The precise role of Sirt-3 in the pathophysiology of myocardial ischaemia-reperfusion 
injury remains unclear; however, it appears that the metabolic status of the cells upon 
the onset of the ischaemia-reperfusion insult may influence the roles of this protein. 
Although Sirt-3 deacetylation has been linked with many beneficial effects for 
mitochondrial function and cell survival (as summarised in chapter 1; see Figure 1.15), 
there remains some controversy over the precise outcomes for cell death. The role of 
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Sirt-3 regulation of Bax-mediated cell death may be important in this setting, where Sirt-
3 deacetylation of Cyp-D has been shown to result in hexokinase II (HKII) dissociation 
from the outer mitochondrial membrane (Shulga et al., 2010; Verma et al., 2013). 
Shulga et al. (2010) have provided some evidence that Cyp-D mediated dissociation of 
HKII is regulated by a conformational change in ANT, which has been shown to be 
influenced by the cellular metabolic status. It is therefore possible that the metabolic 
status of the cell upon the insult directs the balance of cell survival and death pathways 
(Shulga et al., 2010). Further investigation of prevalence of these cell survival and death 
signalling pathways in response to differential stress insults is required. 
The effect of fasting on myocardial Sirt-3 expression levels and the resulting increased 
susceptibility to myocardial infarction is a particularly exciting finding. The biological 
basis of this is discussed above in relation to the pathophysiological roles of Sirt-3; 
however, this also represents a potentially important consideration clinically, where 
fasting prior to major surgeries is common practice. Experiments in this chapter suggest 
that fasting could actually increase injury resulting from myocardial ischaemia-
reperfusion. This may be relevant for surgical procedures such as coronary artery 
bypass graft, where patients would be fasted prior to surgery and where the myocardium 
would be subjected to a degree of ischaemia-reperfusion. Although this has not been 
specifically investigated here, the initial data presented here would be useful to 
investigate in future studies. In particular, it would now be interesting to examine 
whether this increased susceptibility to myocardial infarction could be ameliorated by 
treatment with a pharmacological Sirt-3 inhibitor, such as that described by Galli et al. 
(2012). Finally, this study also highlights the importance of ensuring a constant supply of 
food for all experimental animals immediately prior to surgery. 
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6.5.4. Summary 
The overall research objective of this chapter was to investigate the potential modulation 
of Sirt-3 as a cardioprotective intervention to reduce myocardial infarction upon 
ischaemia-reperfusion. The initial in vitro pilot studies undertaken within our laboratory 
using the cardiac HL-1 cell line showed that overexpression of Sirt-3 conferred several 
beneficial effects that may ultimately protect against ischaemia-reperfusion injury. This 
chapter aimed to further examine the potential therapeutic effects of modulation of Sirt-3 
activity in vivo. The key findings of this chapter are summarised below: 
(1) Genetic ablation of Sirt-3 did not affect the susceptibility of mice to myocardial 
infarction upon ischaemia-reperfusion. This was investigated following a standard in 
vivo ischaemic insult (30 minutes), widely used in this thesis, and also following an 
extended ischaemic insult (45 minutes). Since Sirt-3 genetic ablation did not affect 
infarct size, this study appears to suggest that Sirt-3 does not mediate a critical role 
in the pathophysiology of myocardial ischaemia-reperfusion injury. 
 
(2) The in vivo recovery surgical protocol employed here evoked a significant increase 
in mitochondrial Sirt-3 protein levels. Since this increase was seen following only 30 
minutes of myocardial ischaemia, it suggests that post-translational processing or 
cellular translocation provides a means by which mitochondrial Sirt-3 protein levels 
can be rapidly regulated in response to stress. 
 
The sham recovery surgical procedure with no myocardial ischaemia-reperfusion 
also significantly increased mitochondrial Sirt-3 protein levels, indicating that some 
element of this procedure elicits a significant stress response. This was not 
specifically investigated here; however, this provides an important consideration for 
the interpretation of future studies using this in vivo model. 
 
(3) Fasting of wildtype mice increased Sirt-3 protein expression in the heart. 
Interestingly, wildtype fasted mice were more susceptible to myocardial infarction 
than fed animals, where this effect is confirmed to be the result of Sirt-3 activity since 
fasting did not affect infarct size in Sirt-3 knockout mice.  
 
This study suggests that under certain conditions, Sirt-3 may mediate a detrimental 
response to myocardial ischaemia-reperfusion, whereby Sirt-3 inhibition may provide 
a potential therapeutic target for cardioprotective benefit in this setting. 
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CHAPTER 7: INVESTIGATION OF THE ROLE OF DJ-1 IN THE 
PATHOPHYSIOLOGY OF ISCHAEMIA-REPERFUSION INJURY 
 
7.1. Introduction 
DJ-1 is another potentially important protein associated with the preservation of 
mitochondrial function. DJ-1 (also known as PARK7) is a highly conserved and widely 
expressed mitochondrial protein that has been implicated in numerous pathologies, 
notably in neurodegeneration where mutations in DJ-1 cause an early-onset heritable 
form of Parkinson’s disease (Bonifati et al., 2003). Several studies have elucidated 
important roles for DJ-1 in the brain including sensing oxidative stress, scavenging ROS 
(Kinumi et al., 2004; Taira et al., 2004; Zhang et al., 2005) and preserving mitochondrial 
function (Canet-Aviles et al., 2004; Zhang et al., 2005; Krebiehl et al., 2010).  
Given these crucial roles of DJ-1 in maintaining physiological mitochondrial function, 
modulation of DJ-1 represents a potential therapeutic target for pathological conditions 
involving mitochondrial dysfunction, including ischaemia-reperfusion injury (as detailed 
in chapter 1; see 1.4.3). Indeed, DJ-1 genetic ablation has been shown to render the 
brain more susceptible to ischaemia-reperfusion in an in vivo model of stroke (Aleyasin 
et al., 2007). Although DJ-1 protein is expressed in the heart (Bonifati et al., 2003), its 
roles in normal cardiomyocyte mitochondrial function and its potential importance in the 
pathophysiology of myocardial ischaemia-reperfusion are not well understood. The 
studies presented in this chapter aimed to examine the role of DJ-1 in myocardial 
infarction upon ischaemia-reperfusion to evaluate the potential future modulation of DJ-1 
as a therapeutic target for cardioprotective in this setting. 
 
Investigation of DJ-1 in myocardial ischaemia-reperfusion presented in this chapter was 
undertaken as a separate study to complement the in vitro investigation of DJ-1 by Ms 
U. Mukherjee within our laboratory; all in vivo data presented here was conducted 
independently and all references to existing data and technical assistance are duly 
acknowledged. The in vitro data presented in the introductory sections was prepared 
from the manuscript of this publication (Dongworth and Mukherjee et al.; in submission). 
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7.2. Research objective and aims 
The main objective of this chapter was to investigate the role of mitochondrial DJ-1 in 
the heart, specifically its potential role in the pathophysiology of ischaemia-reperfusion. 
The principal research aims to achieve this objective were: 
(1) Investigate the role of DJ-1 in normal cardiac physiology and function; 
 
(2) Investigate the role of DJ-1 in the pathophysiology of myocardial ischaemia-
reperfusion. 
 
7.3. Aim 1: Investigate role of DJ-1 in cardiac physiology  
7.3.1. Background and preliminary data 
Previous studies investigating the role of DJ-1 have primarily examined its role in the 
brain; specifically in the development of Parkinson’s disease upon mutation of the DJ-1 
gene resulting in non-functional forms of the DJ-1 protein (Bonifati et al., 2003). As such, 
previous evaluations of the effects of global genetic ablation of DJ-1 have focused on 
the brain and the neurological symptoms displayed by these animals. DJ-1 knockout 
animals display no morphological differences in nervous system structure, including the 
brain itself (Yamaguchi and Shen, 2007). Furthermore, despite the reported roles of DJ-
1 as an important sensor of oxidative stress and ROS scavenger, mitochondrial 
antioxidant protein levels are normal in young DJ-1 knockout mice (12-16 weeks); 
although it should be noted that mitochondrial MnSOD and glutathione peroxidase were 
upregulated in aged DJ-1 knockout animals (Andres-Mateos et al., 2007). Given the 
apparently normal neurological phenotype of DJ-1 knockout mice, it is pertinent to 
evaluate the role of DJ-1 in the heart, in which this protein is also highly expressed, to 
determine its roles in cardiac physiology and pathophysiology. 
Initial studies undertaken within our laboratory investigated the role of DJ-1 in our well-
established in vitro models of ischaemia-reperfusion injury using the HL-1 cardiac cell 
line. These studies demonstrated that at baseline, overexpression of DJ-1 increased the 
extent of mitochondrial fusion (Figure 6.1; experiment performed by Ms U. Mukherjee). 
Importantly, overexpression of mutant inactive forms of DJ-1 protein, DJ-1 L166P (which 
is unable to dimerise) and DJ-1 C106A (in which Cys106 is resistant to oxidation) did not 
confer this improved mitochondrial phenotype, thereby confirming that this beneficial 
phenotype is mediated by DJ-1 (Figure 6.1; experiment performed by Ms U. Mukherjee).  
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Figure 7.1: Initial in vitro investigation of the role of DJ-1 
Initial in vitro studies performed by Ms U. Mukherjee to investigate the role of DJ-1 in the basal 
mitochondrial phenotype in the HL-1 cell model of mitochondrial morphology. HL-1 cells were 
transfected with the control empty plasmid (white bar), functional DJ-1 (blue bar) and mutant 
forms of DJ-1: L166P and C106A (black bars). A) Representative images of mitochondrial 
morphology assessed by transfection of mitochondria with mitochondrial red fluorescent protein 
(mtRFP): i) Empty vector: baseline morphology; ii) DJ-1 overexpression: predominantly fused 
mitochondria, iii) L166P mutant DJ-1: largely normal morphology and iv) C106A mutant DJ-1: 
largely normal morphology. D) Quantification of mitochondrial morphology. Statistical significance 
was assessed by one-way ANOVA, *P<0.05; n=6/group. 
 
Experiments performed by Ms U. Mukherjee. Detailed methods are presented by a previous 
publication by our laboratory (Ong et al., 2010).  
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This study suggests that DJ-1 mediates an important regulatory role affecting 
mitochondrial morphology at baseline in this cardiac cell line; therefore suggesting that 
DJ-1 may confer a similar beneficial role in vivo. Unfortunately, attempts to develop an in 
vitro model of genetic knockdown of DJ-1 using lentiviral transfection of short-hairpin 
(sh) RNA did not sufficiently reduce DJ-1 protein levels to warrant further investigation 
for comparison with the in vivo knockout model; discussed subsequently (see 7.4).  
The first section of this chapter aimed to investigate whether genetic ablation of DJ-1 
resulted in any overt cardiac phenotype at baseline, whereby the in vitro data above led 
us to suggest that DJ-1 knockout mice would have some impairment of cardiac function.  
 
Aim 1: This section aimed to investigate the effect of DJ-1 genetic ablation on cardiac 
physiology and function. It was hypothesised that DJ-1 knockout mice would display: 
(1) Cardiac function: Unaffected baseline cardiac function but impaired stress response; 
 
(2) Mitochondrial morphology: More fragmented mitochondria at baseline; 
 
(3) Myocardial ATP levels: Lowered myocardial ATP levels at baseline. 
 
 
7.3.2. Detailed methods 
i DJ-1 global knockout mice 
The DJ-1 global genetic knockout mouse model used here was obtained from Dr F 
Giorgini and Dr M Repici (University of Leicester, UK) from the initial colony created by 
Goldberg et al. (2005). Genetic ablation of DJ-1 was achieved by deletion of exon-2 of 
the endogenous PARK7 gene using standard transgenic methods described in chapter 
3 (see 3.1.2). The resulting DJ-1 knockout mice were backcrossed onto a C57BL/6 
genetic background (Goldberg et al., 2005). DJ-1 knockout mice are also commercially 
available from Jackson Laboratories, USA (strain Cg-Park7tm/Shn/J; stock 006577). 
Colony maintenance: DJ-1 global knockout mice obtained from Dr F Giorgini and Dr M 
Repici (University of Leicester, UK) were used to establish a transgenic colony within 
our laboratory. Establishment and breeding of the DJ-1 knockout mouse colony was 
undertaken in collaboration with Ms U. Mukherjee and technical staff at University 
College London. DJ-1 knockout mice were crossed with commercially available C57BL/6 
mice (Charles River Laboratories, UK) to generate a stock of DJ-1 heterozygous mice 
that were used to maintain the DJ-1 colony (Figure 5.2 B). The final colony was 
maintained as crosses of DJ-1 heterozygotes to produce DJ-1 WT, HET and KO mice. 
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All experiments were performed on DJ-1 knockout and wildtype true littermate controls. 
Due to time restraints and the poor breeding of these mice, experiments were conducted 
on mixed groups of male and female mice with equal numbers of males and females 
within and between all groups. It was not expected that there would be any confounding 
effects of sex on the data presented here since it was previously shown in this thesis 
that gender did not significantly affect the infarct sizes observed in this model (see 
chapter 4; see 4.5.3 iv). All mice used in these experiments were aged 12-16 weeks. 
  
 
Figure 7.2: DJ-1 colony establishment and maintenance 
Establishment and breeding of the DJ-1 KO mouse colony. A) Original colony: DJ-1 KO mice 
were crossed with commercially available C57BL/6 mice to create a stock of DJ-1 HETs. B) Final 
colony: was maintained as DJ-1 HET x HET crosses to produce progeny of DJ-1 WT, KO and 
HET (in accordance with expected Mendelian ratios indicated in brackets). 
 
Establishment and initial breeding of this colony was undertaken in collaboration with Ms U. 
Mukherjee and technical staff at University College London, UK. 
  
ii Genotyping for DJ-1 genetic ablation 
The genotyping method used for these animals was based on that described in chapter 
3 (see 3.1.2 iii). DNA samples were prepared from ear biopsies processed within 7 days 
exactly as described previously. The PCR reaction mix was based on the standard 
reaction optimised in this thesis. The PCR primers and thermocycling conditions used in 
this reaction were informed by Dr F Giorgini and Dr M Repici (personal communication) 
and are described in Table 7.1. This reaction yielded DNA products of 500 bp and 250 
bp corresponding to knockout and wildtype bands respectively (Figure 7.3). 
DJ-1 KO
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A) DJ-1 PCR primer sequences 
PRIMER SEQUENCE 
PROPERTIES 
Length 
Tm 
(ºC) 
Primer 1 / WT forward 5'-GATCCAGTGCTCTTAGCCACAGACTA-3’ 26 64.8 
Primer 2 / WT reverse 5’-GCATGACATCCACAGGAATCACT-3’ 23 60.6 
Primer 3 / KO reverse 5’-GGATCAATTCTCTAGAGCTCGCTGATCA-3’ 28 65.1 
 
B) DJ-1 PCR reaction mix 
REAGENT VOLUME/SAMPLE  (µl) FINAL CONCENTRATION 
Qiagen 10X PCR Buffer 2.0 1X 
10 mM dNTPs 0.8 400 µM 
Primer 1 100 µM 1 5 µM 
Primer 2 100 µM 1 5 µM 
Primer 3 100µM 1 5 µM 
Taq polymerase 0.3 - 
Autoclaved distilled water                   12.9 - 
Crude DNA lysate 
†
 1.0 - 
TOTAL VOLUME/SAMPLE (µl)                     20.0 
  
C) DJ-1 PCR thermocycling parameters 
PCR STAGE TEMPERATURE AND DURATION PCR DESCRIPTION 
1  94 ºC for 4 minutes   Hot start 
2  94 ºC for 1 minute  DNA separation 
3  65 ºC for 1minute  Primer annealing 
4  72 ºC for 1 minute  DNA synthesis 
5  Go to step 2 for 35 cycles  DNA synthesis 
6  72 ºC for 7 minutes  Final extension 
7  4 ºC for ever  Intermediate storage 
 
Table 7.1: DJ-1 global knockout mouse genotyping protocol 
A) DJ-1 primer sequences and properties. B) A single master mix was made based on the 
Qiagen Taq kit (Qiagen, UK) and aliquots taken for each reaction. 
†
 1 µl crude DNA lysate was 
added. C) PCR was undertaken by a thermal cycler (MJ Research, Canada). 
 
 
 
Figure 7.3: DJ-1 global transgenic colony representative genotyping result  
The genotype of each animal was determined by the presence or absence of the expected PCR 
products by comparison to molecular weight ladder (lane 1): WT 250 bp band only, KO 500 bp 
band only and HET both bands (as annotated above the gel). A negative control (NEG) was run 
to ensure there was no external DNA contamination. 
  
MW WT  HET KO  HET  WT  KO  KO NEG
800
200
500
(bp)
300
Mutant band (500 bp)
Wildtype band (250 bp)
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iii Cardiac phenotyping by echocardiography 
Echocardiography evaluation of animals was undertaken in collaboration with Dr A. 
Dyson (Department of Medicine, University College London, UK). 
 
Cardiac function of DJ-1 knockout and wildtype control mice was assessed using a 
standard small animal echocardiography setup as described in chapter 3 (see 3.7). 
Echocardiography setup: The echocardiography setup was exactly as described 
previously in section 3.7. Echocardiography measurements were taken according to the 
parameters detailed previously and summarised in Table 7.2.  
 
ENDPOINT ECHOCARDIOGRAPHIC CALCULATION 
Anatomical 
measurements  
Left ventricle internal dimension and thickness of anterior and posterior 
walls; determined from parasternal short-axis view at papillary muscle. 
Peak aortic blood 
flow velocity 
Determined by pulsed-wave Doppler in the aortic arch where the 
direction of blow flow was confirmed by colour Doppler imaging. 
Peak velocity calculated as mean maximum of 6 velocity-time traces. 
 
Heart rate (BPM) Calculated as mean time between 6 Doppler velocity-time traces. 
Stoke volume (µl) Calculated as: (Velocity time integral * vessel cross section area). 
Vessel cross sectional area calculated as: (π x [0.5 x diameter]
2
);  
where vessel diameter was assumed to be 1.34mm 
†
  
 
Cardiac output 
(ml/min) 
Calculated as: (Heart rate * stroke volume) 
Fractional 
shortening (%) 
Calculated as: [(LV end diastolic diameter - LV end systolic 
diameter)/(LV end diastolic volume)]*100 
 
Table 7.2: Echocardiographic measurements of cardiac structure and function 
Summary of echocardiographic measurements of left ventricular ED and ES dimensions and 
measurements to assess principal features of cardiac function. 
† 
Based on previous studies.  
 
Echocardiographic images and raw data analysis were performed by Dr A. Dyson. 
 
Isoproterenol challenge: An isoproterenol cardiac stress protocol was investigated to 
induce inotropic and chronotropic stimulation of the heart to evaluate potential 
differences in cardiac function that may not be evident at baseline. 
Optimisation of isoproterenol protocol – The isoproterenol dosing protocol used here 
was optimised to determine the time-course and magnitude of heart rate increase in 
response to different isoproterenol doses. C57BL/6 mice were anaesthetised with 1.8-
2.0% isoflurane vaporised in oxygen (1.5 L/minute) and placed in the supine position. 
Heart rate was continually recorded using the standard ECG setup described previously 
(Powerlab coupled to Chart 7 software, AD Instruments, UK) with automated calculation 
of heart rate. Upon a steady state of anaesthesia using a consistent and minimal dose of 
isoflurane, isoproterenol was given as an intraperitoneal bolus and heart rate monitored. 
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This preliminary study showed that in the small sample size tested, 1 ng/g and 2 ng/g 
isoproterenol initiated only a moderate heart rate increase assessed at 4 minutes post-
administration. An optimal dose of 4ng/g elicited a significant heart rate increase that 
reached its maximum within approximately 4 minutes of dosing and plateaued for 
approximately 20 minutes. An example of the heart rate increase evoked by this 
isoproterenol dose is shown in Figure 7.4. It should however, be noted that the starting 
heart rates in the pilot investigations of the effect of isoproterenol were slightly lower 
than expected using isoflurane anaesthesia. An increased dose of 8 ng/g isoproterenol 
caused immediate death of 2 animals and was therefore not investigated further. 
 
 
Figure 7.4: Representative heart rate increase in response to 4 ng/g isoproterenol 
Example increase in heart rate following administration of 4 ng/g isoproterenol as a single 
intraperitoneal bolus at (i). Maximal increase in heart rate approximately 4 minutes post-
administration. (ii) Plateau of increased heart rate continued for approximately 20 minutes (up to 
8 minutes shown here). Heart rate increased from approximately 470 BPM to 600 BPM. 
 
The final isoproterenol protocol using 4 ng/g was applied to all subsequent cardiac 
stress echocardiography measurements in this chapter. Isoproterenol (Sigma, UK) was 
dissolved in saline and 4 ng/g administered as a single intraperitoneal bolus (stock 
isoproterenol 1 µg/ml; administered 100 µl per 25 g mouse). Repeat echocardiographic 
measurements were started 4 minutes after administration of the isoproterenol bolus. 
Statistical analysis: All values were calculated exactly as described in Table 7.2 and 
were reported as mean ± SEM. Data were analysed by one-way ANOVA and Bonferroni 
test using GraphPad Prism® version 5.0 (GraphPad Software, USA). Significance was 
reported where P<0.05 using standard coding. 
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iv Electron microscopy analysis of mitochondrial morphology 
Preparation of heart samples: Hearts were prepared exactly as described in chapter 3 
(see 3.6.1) using the non-recovery in vivo protocol. To assess baseline mitochondrial 
morphology, hearts were extracted from DJ-1 knockout and wildtype littermate control 
mice following 25 minutes in vivo stabilisation. Heart samples were processed for EM 
using a series of fixation and staining steps (described in chapter 3; see 3.6.2).  
EM processing and imaging was undertaken by Mr M. Turmaine (Electron Microscopy 
Services Facility, University College London, UK). 
Assessment of mitochondrial morphology: Mitochondrial morphology was evaluated 
by assessment of interfibrillar mitochondrial length compared to sarcomere length where 
normal mitochondrial length was considered to be approximately 1 sarcomere length. 
Mitochondria were defined as less than 1 sarcomere (fragmented), equal to 1 sarcomere 
(normal) or greater than 1 sarcomere (fused) as validated by Ong et al. (2010). 
Analysis of images was performed by Dr S.B. Ong who was blinded to treatment groups. 
The proportion of mitochondrial defined as normal, fragmented and fused was 
calculated for each heart (total of 500-600 mitochondria per heart) and expressed as 
mean percentage of mitochondria ± SEM. GraphPad Prism® version 5.0 (GraphPad 
Software, USA) was used to perform one-way ANOVA analysis and Bonferroni test 
comparing relevant groups. Statistical significance was reported where P<0.05. 
v Myocardial ATP Assay 
Baseline myocardial ATP levels were measured in left ventricle tissue samples from DJ-
1 knockout and wildtype hearts using a standard commercial ATP assay kit. 
Langendorff preparation of heart samples: Heart samples were prepared using 
Langendorff perfusion exactly as described previously (see 3.5.1); the total time from 
extraction to perfusion did not exceed 2 minutes 30 seconds for any heart preparation. 
ATP luminescence assay: Myocardial ATP levels were measured using a commercial 
ATP assay kit (ATP Bioluminescent Assay Kit, Sigma, UK) in accordance with the 
manufacturer’s instructions as detailed previously (see 3.5.2). Luminescence values 
were normalised to the average value recorded for wildtype control samples and 
expressed as a percentage of control ± SEM. All statistical analyses were completed 
using GraphPad Prism® version 5.0 (GraphPad Software, USA). Data were analysed by 
one-way ANOVA, followed by Bonferroni test comparing relevant groups. Statistical 
significance was reported where P<0.05. 
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7.3.3. Results 
Following establishment of the DJ-1 colony within our laboratory, it was pertinent to 
investigate whether DJ-1 genetic ablation caused any overt cardiac phenotype.  
 
i Cardiac phenotyping by echocardiography 
Echocardiography of DJ-1 knockout and wildtype littermate control mice demonstrated 
no significant differences in anterior and posterior LV wall dimensions during systole or 
diastole. There were no significant differences in heart rate, fractional shortening cardiac 
output or stroke volume between DJ-1 knockout and wildtype littermates at baseline or 
following isoproterenol stress; representative M-mode echocardiography images are 
provided in Figure 7.5 and quantification of these endpoints summarised in Figure 7.6  
Isoproterenol stress yielded a significant increase in heart rate in both DJ-1 knockout 
and wildtype mice (Figure 7.6 A: heart rate in BPM: DJ-1 WT baseline 498.5±19.9 and 
isoproterenol 620.2±10.2, n=6, P<0.05; DJ-1 KO baseline 505±25.9 and isoproterenol 
628.8±17.0, n=5, P<0.05) and fractional shortening (Figure 7.6 B: fractional shortening 
% DJ-1 WT baseline 34.7±3.1 and isoproterenol 63.0±1.2, n=6, P<0.05; DJ-1 KO 
baseline 41.2±4.1 and isoproterenol 65.4±3.2, n=5, P<0.05). This demonstrated that this 
isoproterenol stress protocol evoked a sufficient cardiac stress response. There were no 
differences in stroke volume or cardiac output between DJ-1 knockout and wildtype mice 
at baseline or following isoproterenol challenge (Figure 7.6 C and D respectively). 
 
 
Figure 7.5: Representative echocardiographic phenotyping of DJ-1 knockout animals 
Representative images from echocardiography of DJ-1 KO and WT littermate control mice at 
baseline and following isoproterenol treatment (4 ng/g, 4 minutes). A-B. Representative images 
of DJ-1 WT (A) and KO (B) at baseline (i) and following isoproterenol (ii). 
 
Echocardiographic images and raw data analysis were performed by Dr A. Dyson. 
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Figure 7.6: Echocardiographic phenotyping of DJ-1 knockout animals performed with Dr A. Dyson – Full legend is provided on the following page. 
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Figure 7.6: Echocardiographic phenotyping of DJ-1 knockout animals 
A-D. Isoproterenol (4ng/g) treatment increased the heart rate and fractional shortening in DJ-1 
knockout and wildtype mice (n≥5/group). Significance assessed by one-way ANOVA comparing 
WT Basal with WT ISO and KO Basal with KO ISO, P<0.05. (Figure on preceding page) 
 
Echocardiographic images and raw data analysis were performed by Dr A. Dyson. 
 
 
ii Mitochondrial morphology 
Evaluation of the baseline mitochondrial morphology in DJ-1 knockout and wildtype 
littermate control hearts was performed using electron microscopy imaging of ex vivo 
prepared hearts. Classification of mitochondrial morphology in comparison to sarcomere 
length according to a protocol previously validated by our laboratory (Ong et al., 2010), 
demonstrated that there was a significant increase in the proportion of fragmented 
mitochondria in DJ-1 knockout hearts at baseline compared to wildtypes (Figure 7.7). 
 
Figure 7.7: Baseline mitochondrial morphology in DJ-1 knockout hearts 
Mitochondrial morphology at baseline in DJ-1 KO (n=5) and WT (n=3) hearts. A) Representative 
EM images showing mitochondrial morphology in i) DJ-1 WT and ii) DJ-1 KO heart samples. 
Mitochondrial morphology was evaluated against sarcomere length. There was a significant 
increase in the proportion of fragmented mitochondria in DJ-1 KO hearts compared to WT. 
Statistical significance assessed by one-way ANOVA comparing relevant groups; significance 
indicated for comparison of DJ-1 WT (white bar) and KO (black bar) for each classification. 
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iii Myocardial ATP levels 
Assessment of myocardial ATP levels in Langendorff prepared hearts from DJ-1 
knockout and wildtype littermate mice showed no significant difference between DJ-1 
knockout and wildtype mice at baseline (Figure 4.19: n≥5/group, NSP>0.05).  
 
Figure 7.8: Myocardial ATP levels in DJ-1 knockout hearts 
Hearts were extracted from DJ-1 KO (n=5/group) and WT littermate control (n=6/group) hearts 
and subjected to control or ischaemia on the Langendorff. ATP levels were measured using a 
luminescence kit and raw luminescence values normalised to DJ-1 WT control levels. There was 
no difference in ATP levels between DJ-1 KO and WT mice following control or ischaemic 
conditions. However, this ischaemic stimulus did not elicit a significant decrease in ATP levels. 
Statistical significance assessed by one-way ANOVA comparing all groups; n≥5/group, 
NS
P>0.05. 
(Extract from analysis presented in Figure 7.12 of all groups, hence the use of ANOVA test here) 
 
These experiments appear to suggest that although DJ-1 affects cardiac mitochondrial 
morphology at baseline, it does not exert any substantial effect on myocardial phenotype 
with regards to mitochondrial function (inferred by ATP levels) or cardiac function. 
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7.4. Aim 2: Investigate role of DJ-1 in ischaemia-reperfusion injury 
7.4.1. Background and preliminary data 
The first section of this chapter demonstrated that although DJ-1 genetic ablation in vivo 
increased mitochondrial fragmentation, these animals did not display any overt cardiac 
phenotype at baseline. This next section aims to investigate the effect of DJ-1 knockout 
on the susceptibility of these animals to myocardial ischaemia-reperfusion. 
As discussed above, DJ-1 has been implicated in the pathophysiology of neuronal 
ischaemia-reperfusion injury, where genetic ablation of DJ-1 rendered the brain more 
susceptible to infarction in an in vivo model of stroke (Aleyasin et al., 2007). This 
suggests that if DJ-1 plays a similar role in the heart, DJ-1 may represent a potential 
therapeutic target for protecting the heart against ischaemia-reperfusion injury.  
Initial in vitro studies in our laboratory investigated the potential role of DJ-1 in cardiac 
ischaemia-reperfusion injury using a well-established model of HL-1 cardiac cell 
simulated ischaemia-reperfusion. This demonstrated a clear role of DJ-1 in the 
pathophysiology of cell survival, where overexpression of DJ-1 significantly increased 
cell survival (Figure 7.9 A; experiment performed by Ms U. Mukherjee). Interestingly, 
assessment of mitochondrial permeability transition in vitro in response to ROS-induced 
stress in HL-1 cells showed that overexpression of DJ-1 resulted in delayed mPTP 
opening (Figure 7.9 B; experiment performed by Ms U. Mukherjee). These in vitro 
studies provided an initial suggestion that DJ-1 mediates a similarly protective role 
against ischaemia-reperfusion in the heart as previously demonstrated in the brain.  
To further investigate the cardioprotective role of DJ-1, additional studies were 
undertaken to examine the effect of DJ-1 knockout in native heart tissue. 
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Figure 7.9: Initial in vitro investigation of the role of DJ-1 in ischaemia-reperfusion  
Initial in vitro studies performed by Ms U. Mukherjee to investigate the role of DJ-1 in ischaemia-
reperfusion in HL-1 cardiac cells. HL-1 cells were transfected with the control empty plasmid 
(white bars), functional DJ-1 (blue bars) and mutant DJ-1 (black bars): L116P and C106A.  
A) Cell death: susceptibility of HL-1 cells to cell death following simulated ischaemia-reperfusion 
(12 hours hypoxia followed by 1 hour re-oxygenation) assessed as the percentage of transfected 
cells (taken a total cell number) exhibiting propidium iodide (PI) staining using fluorescence 
microscopy. Cell death is significantly reduced by overexpression of DJ-1. Statistical significance 
assessed by one-way ANOVA, **p<0.01; n=5/group (30 random fields per sample).  
B) Time to mPTP opening: assessed using the TMRM laser-induced ROS model of mPTP 
opening; described briefly in chapter 6 (see 6.3.1). Time to mPTP opening was measured as the 
time to half maximum cytosolic TMRM fluorescence in seconds. mPTP opening was delayed by 
overexpression of DJ-1. Significance was assessed by one-way ANOVA, n=6/group. 
 
Experiments presented in this figure were performed by Ms U. Mukherjee. Detailed methods are 
presented by a previous publication by our laboratory (Ong et al., 2010).  
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Aim 2: The second part of this chapter investigated the effect of global genetic ablation 
of DJ-1 on the susceptibility to myocardial infarction upon ischaemia-reperfusion. The 
central hypothesis in relation to this research objective was:  
(1) DJ-1 genetic ablation would significantly increase the susceptibility to myocardial 
ischaemia-reperfusion injury. 
 
It was hypothesised that upon myocardial ischaemia, DJ-1 knockout mice would display: 
(1) Mitochondrial morphology: Increased mitochondrial fragmentation upon ischaemia; 
 
(2) Myocardial ATP levels: Further lowered myocardial ATP levels upon ischaemia; 
 
(3) Infarct size: Increased myocardial infarct size following ischaemia-reperfusion. 
 
7.4.2. Detailed methods 
The methods used in this section were largely based on those described in the 
preceding section (section 7.3.2) with additional experimental details provided here. 
i Electron microscopy analysis of mitochondrial morphology 
Preparation of heart samples: Hearts were prepared exactly as described above (see 
7.3.2 iv). To assess mitochondrial morphology following myocardial ischaemia, animals 
were subjected to 20 minutes in vivo myocardial ischaemia by occlusion of the LAD; a 
summary of the non-recovery in vivo procedure used here is provided in chapter 3 (see 
3.6.1; Figure 3.12). Hearts were extracted at the end of the defined ischaemia period 
with the occluding snare system still in place. Immediately following cannulation of the 
aorta, the snare system was released to allow complete perfusion and washout of the 
heart. Processing and EM analysis was exactly as described above (see 7.3.2 iv).  
EM imaging was undertaken by Mr M. Turmaine (Electron Microscopy Services Facility, 
University College London, UK) and analysis of EM images was performed by Dr S.B. 
Ong (formerly of Hatter Cardiovascular Institute, University College London, UK). 
ii Myocardial ATP Assay 
Myocardial ATP levels were measured in left ventricle tissue samples isolated from DJ-1 
knockout and wildtype hearts following a sublethal ischaemic insult. 
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Langendorff preparation of heart samples: Hearts were extracted from DJ-1 
knockout and wildtype littermates and perfused on the Langendorff apparatus exactly as 
described above. Following 10 minutes stabilisation perfusion, myocardial ischaemia 
was simulated by closure of the flow regulator tap to stop perfusion for 20 minutes (see 
3.5.1, Figure 3.16). Successful ischaemia was confirmed by lack of effluent from the 
heart and impaired contractile function. Processing of heart samples and the ATP assay 
were performed and analysed exactly as described above (see 7.3.2 v). 
iii Myocardial ischaemia-reperfusion injury 
Assessment of the susceptibility to myocardial infarction following ischaemia-reperfusion 
was performed in DJ-1 knockout and wildtype animals subjected to the in vivo recovery 
model of ischaemia-reperfusion injury developed in chapter 4 of this thesis.  
Surgical protocol: The susceptibility of DJ-1 knockout and wildtype littermate control 
animals was assessed following 45 minutes ischaemia and 24 hours reperfusion (Figure 
7.10 A). A standard IPC protocol of one cycle of 5 minutes ischaemia and 5 minutes 
reperfusion was also investigated (Figure 7.10 B). The increased ischaemic duration 
used in this study meant that the total anaesthetic duration of this surgical protocol was 
slightly extended in comparison to the standard protocol investigated previously (70 
minutes duration compared to standard 55 minute duration). 
 
Figure 7.10: DJ-1 ischaemia-reperfusion in vivo recovery protocol 
DJ-1 KO mice and true WT littermate controls were randomised to control or IPC protocols. A) 
Control: 15 minutes stabilisation, 45 minute ischaemia and 24 hours reperfusion. B) IPC: 5 
minutes stabilisation, one cycle IPC consisting of 5 minutes ischaemia and 5 minutes reperfusion 
prior to the main ischaemic insult of 45 minutes followed by 24 hours reperfusion. 
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Endpoint 1 – IS/AAR%: The primary endpoint assessed in this study was infarct size by 
ex vivo histological staining using TTC and Evans blue staining, exactly as described 
previously, to calculate the infarct size as a percentage of AAR. The pre-defined surgical 
and myocardial AAR exclusion criteria were applied to this dataset (see 3.2.4). 
All infarct size and AAR values are presented as mean ± SEM. All statistical analysis 
was completed using GraphPad Prism® version 5.0 (GraphPad Software, USA). Where 
two groups were compared, data were analysed using an unpaired t-test. Where more 
than two groups were compared, data were analysed by one-way ANOVA, followed by 
Bonferroni test comparing relevant columns of data. Statistical significance was reported 
where P<0.05 using standard significance coding.  
Endpoint 2 – Survival: Survival rates of DJ-1 mice subjected to this surgical protocol 
were recorded and probable cause of death determined by post-mortem analysis. 
Kaplan-Meier survival plots were plotted using GraphPad Prism® version 5.0 (GraphPad 
Software, USA). Statistical significance was analysed by log-rank tests. There was no 
statistical significance in survival between groups presented in this chapter.  
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7.4.3. Results 
Given the suggestion that DJ-1 overexpression in vitro in HL-1 cardiac cells protected 
against simulated ischaemia-reperfusion and delayed ROS-induced mPTP opening 
(summarised in Figure 7.9), the effect of DJ-1 genetic ablation was investigated in vivo. 
 
i Mitochondrial morphology 
Evaluation of the mitochondrial morphology in DJ-1 knockout and wildtype control mice 
following 20 minutes of in vivo ischaemia showed that there was no longer any 
significant difference in mitochondrial morphology between these animals (Figure 7.11). 
 
Figure 7.11: Mitochondrial morphology in DJ-1 knockout hearts following ischaemia 
Assessment of mitochondrial morphology following 20 minutes in vivo myocardial ischaemia in 
heart samples from DJ-1 KO (n=5) and WT littermate controls (n=3). A) Representative EM 
images showing mitochondrial morphology in i) DJ-1 WT and ii) DJ-1 KO hearts following 
ischaemia. B) Mitochondrial morphology was determined by EM analysis for comparison of 
mitochondrial length against sarcomere length. There was no significant difference in 
mitochondrial morphology between DJ-1 KO and WT hearts following ischaemia; significance 
indicated for comparison of DJ-1 WT (white bar) and KO (black bar) for each classification. 
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ii Myocardial ATP levels 
To assess the effect of ischaemia on myocardial ATP levels, Langendorff prepared 
hearts were subjected to 20 minutes global ischaemia and the resulting ATP levels 
assessed in left ventricle samples. However, this ischaemic protocol did not significantly 
reduce ATP levels in wildtype hearts (Figure 7.12: n≥5/group, NSP>0.05) meaning that 
any comparison of DJ-1 knockout and wildtype hearts after ischaemia would be of 
limited value for assessing the effect of DJ-1 genetic ablation on myocardial ATP levels. 
 
Figure 7.12: Myocardial ATP levels in DJ-1 knockout hearts 
Hearts were extracted from DJ-1 KO (n=5/group) and wildtype littermates (n=6/group) and 
subjected to control or ischaemia on the Langendorff. ATP levels were measured using an ATP 
kit and raw luminescence values normalised to DJ-1 WT control levels. There was no difference 
in ATP levels between DJ-1 KO and WT mice following control or ischaemic conditions. However, 
this ischaemic stimulus did not elicit a significant decrease in ATP levels. Statistical significance 
assessed by one-way ANOVA comparing all groups; n≥5/group, 
NS
P>0.05. 
 
The effect of myocardial ischaemia on ATP levels was not investigated further since an 
extended duration of ischaemia would be expected to induce a differential degree of cell 
death (based on the preliminary role of DJ-1 from the previous in vitro studies and 
subsequently confirmed below in section iii). Given the potential difference in cell death 
in DJ-1 wildtype and knockout hearts subjected to an extended ischaemic insult, it would 
not have been valid to evaluate mitochondrial function following a long ischaemic insult. 
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iii Susceptibility to ischaemia-reperfusion injury 
The effect of DJ-1 knockout on the susceptibility to myocardial infarction upon 
ischaemia-reperfusion had not previously been investigated in vivo. DJ-1 wildtype and 
knockout mice were subjected to a modified protocol of 45 minutes ischaemia and 24 
hours reperfusion. DJ-1 knockout mice exhibited significantly larger infarct sizes as 
compared to DJ-1 wildtype littermate controls (Figure 5.5: IS/AAR% DJ-1 WT 37.7±4.0 
versus DJ-1 KO 50.9±3.5; n=8/group, *P<0.05). There was no significant difference in 
AAR (AAR/LV% DJ-1 WT 54.0±3.2 versus DJ-1 KO 48.2±1.9; n=8/group, NSP>0.05) or 
survival (% survival to 24 hours: DJ-1 WT 80%, n=10 versus DJ-1 WT 72.7%, n=11). 
 
Figure 7.13: Infarct size in DJ-1 wildtype and knockout mice 
Infarct size following 45 minutes ischaemia and 24 hours reperfusion in DJ-1 KO and WT 
littermate control animals. DJ-1 KO mice demonstrated significantly larger infarct sizes compared 
to DJ-1 WT controls: IS/AAR% DJ-1 WT 37.7±4.0 versus DJ-1 KO 50.9±3.5, n=8/group. 
Statistical significance assessed by unpaired t-test,
 
*P<0.05. 
 
Further to this, the susceptibility to cardioprotection by a standard IPC protocol was 
investigated in these animals. As expected, IPC significantly reduced myocardial infarct 
size in DJ-1 wildtype mice (Figure 4.12 A: IS/AAR% DJ-1 WT control 37.7±4.0 versus 
IPC 21.8±2.3, n=8/group, *P<0.05), thereby serving as a positive control for 
cardioprotection in this model. There was no significant difference in AAR (AAR/LV% 
DJ-1 WT control 54.0±3.2 versus DJ WT IPC 50.5±3.1, n=8/group, NSP>0.05) or survival 
(% survival to 24 hours: DJ-1 WT control 80%, n=10 versus DJ-1 WT IPC 80%, n=10). 
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Interestingly, IPC did not significantly reduce myocardial infarct size in DJ-1 knockout 
mice, where only a small trend towards decreased infarct size was observed in these 
animals (Figure 4.12 B: IS/AAR% DJ-1 KO control 50.9±3.5 versus IPC 39.4±4.1, 
n=8/group, NSP>0.05). There was no significant difference in AAR (AAR/LV% DJ-1 KO 
control 48.2±1.9 versus DJ KO IPC 54.3±3.8, n=8/group, NSP>0.05) or survival (% 
survival to 24 hours: DJ-1 KO control 72.7%, n=11 versus DJ-1 KO IPC 80%, n=10). 
 
Figure 7.14: Susceptibility of DJ-1 knockout mice to cardioprotection by IPC 
Cardioprotection by one cycle of IPC (5 minutes ischaemia and 5 minutes reperfusion) prior to 
the main ischaemic insult of 45 minutes and 24 hours reperfusion in DJ-1 KO and WT littermate 
controls. A) Significant reduction in infarct size by IPC in DJ-1 WT mice: IS/AAR% control 
36.9±4.6 versus IPC 21.9±2.7, n=7/group, *P<0.05. B) No significant reduction in infarct size by 
IPC in DJ-1 KO mice: IS/AAR% control 51.3±4.0 versus 41.9±3.9, n=7 group, 
NS
P>0.05. 
Statistical significance assessed by unpaired t-test. 
  
This study suggests that DJ-1 may be involved in the cardioprotective pathway elicited 
by IPC. However, this apparent resistance to IPC was not investigated using additional 
cycles of preconditioning to assess whether this could be overcome with a higher IPC 
stimulus. The potential involvement of DJ-1 in IPC is discussed in detail below. 
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7.5. Discussion 
The overall objective of this chapter was to investigate whether DJ-1 plays a role in the 
heart. Previous investigations have demonstrated a convincing role for DJ-1 in 
maintaining mitochondrial function in the brain at baseline in aged animals and in the 
pathophysiological response to neuronal ischaemia-reperfusion injury (Bonifati et al., 
2003; Aleyasin et al., 2007). Indeed, DJ-1 knockout mice displayed increased cerebral 
infarct size in an in vivo stroke model (Aleyasin et al., 2007). Cumulatively these findings 
suggest the intriguing possibility that DJ-1 in the heart may be exhibiting a similar role in 
maintaining mitochondrial function and protecting against ischaemia-reperfusion injury. 
The initial in vitro studies undertaken within our laboratory investigated the effect of 
overexpression of wildtype and mutant forms of DJ-1 in important models of 
mitochondrial and cell survival. These studies demonstrated a convincing role for DJ-1 
in this cardiac cell line, where it was shown that overexpression of DJ-1 conferred 
beneficial outcomes of increased mitochondrial elongation and delayed mPTP opening. 
Our laboratory has previously shown that these mitochondrial phenotypes correlate with 
improved cell survival in response to simulated ischaemia-reperfusion injury in this cell 
line (Ong et al., 2010).  Indeed, DJ-1 overexpression in this cell line reduced cell death 
upon simulated ischaemia-reperfusion (Dongworth and Mukherjee et al., in submission). 
To extend the findings of this initial research and to confirm an in vivo role for DJ-1 in the 
pathophysiology of myocardial ischaemia-reperfusion, further studies were undertaken 
to investigate the effect of genetic ablation of DJ-1 on cardiac phenotype and 
susceptibility to infarction from ischaemia-reperfusion. Unfortunately it was not possible 
to directly compare the in vitro and in vivo systems since we did not have access to a 
DJ-1 overexpressing transgenic mouse line and attempts to create a DJ-1 knockdown in 
vitro system did not produce a sufficient reduction in DJ-1 protein levels (experiment 
conducted by Ms U. Mukherjee; data of DJ-1 knockdown not included here). 
7.5.1. Role of mitochondrial DJ-1 in cardiac function  
Cardiac phenotype: Given the known role of DJ-1 in maintaining mitochondrial function 
in the brain, it was hypothesised that this would result in impaired cardiac function at 
baseline and in response to isoproterenol stress in hearts devoid of DJ-1. However, this 
study showed that adult DJ-1 knockout mice display no overt cardiac phenotype at 
baseline or following isoproterenol stress (Figure 7.6), thereby suggesting that DJ-1 
does not mediate a critical role in cardiac function under physiological conditions. 
Importantly since these DJ-1 knockout mice do not display any overt cardiac phenotype 
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such as LV hypertrophy, it was possible to examine the effect of DJ-1 knockout on 
susceptibility to ischaemia-reperfusion without any confounding myocardial pathology. 
It is possible that the lack of any overt cardiac phenotype in DJ-1 knockout animals 
could be due to the relatively young age at which these animals were characterised (12-
16 weeks old). Importantly, previous studies have shown that mitochondrial antioxidant 
protein expression is normal in young brain mitochondria from DJ-1 knockout animals 
and only exacerbated upon ageing (Andres-Mateos et al., 2007). It is possible that aged 
DJ-1 knockout animals may display an overt cardiac phenotype; however, investigation 
of aging was outside of the remit of this thesis. Additionally, it was advantageous to 
study the effect of DJ-1 without any confounding myocardial pathology, as discussed 
above, meaning that the effects demonstrated in the subsequent studies can be firmly 
concluded to result from the stress tested. 
It would be interesting to examine the effect of DJ-1 genetic ablation on cardiac function 
following ischaemia-reperfusion. This could be undertaken in using cardiac MRI to 
assess cardiac function and infarct size at baseline and following ischaemia-reperfusion 
injury, which would provide a comprehensive investigation of the role of DJ-1 in the long-
term pathophysiology of myocardial ischaemia-reperfusion; as discussed further below. 
Mitochondrial morphology: Given that overexpression of DJ-1 resulted in increased 
mitochondrial elongation in the initial in vitro studies, it was expected that DJ-1 genetic 
ablation would cause increased mitochondrial fragmentation. Indeed, assessment of 
mitochondrial morphology at baseline showed an increased proportion of shorter 
mitochondria in DJ-1 knockout hearts compared to wildtypes at baseline (Figure 7.7). 
This is in agreement with several previous studies suggesting that DJ-1 knockout 
increases mitochondrial fragmentation in mouse embryonic fibroblasts and mitochondria 
isolated from brain and skeletal muscle (Irrcher et al., 2010; Krebiehl et al., 2010). 
However, there was no difference in mitochondrial morphology in DJ-1 knockout and 
wildtypes following a sublethal ischaemic insult (Figure 7.11; 20 minutes ischaemia).  
This was unexpected, although it is possible that a greater ischaemic insult may have 
elicited a significant difference in mitochondrial morphology. However, for the reasons of 
differential cell death in DJ-1 knockout hearts discussed above, it was not feasible to 
investigate the effect of an extended lethal ischaemic insult. It should also be noted 
however, that the proportion of fragmented mitochondria at baseline in wildtype mice is 
higher than expected (Figure 7.7: DJ-1 wildtype mitochondria approximately 74% 
fragmented). There is no clear reason for this however, given that the extent of 
mitochondria fragmentation in DJ-1 knockout hearts at baseline was already 93%, it is 
likely that this would preclude observation of a further increase in fragmentation. 
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Additional investigation of the effect of DJ-1 in maintaining mitochondrial morphology at 
baseline and following sublethal myocardial ischaemia may benefit from a more 
sensitive method for measuring mitochondrial morphology. The development and 
validation of an improved assay of mitochondrial morphology represents a substantial 
undertaking and was outside of the defined remit of this thesis. 
Myocardial ATP levels: Given that previous studies have shown that DJ-1 is important 
for maintaining mitochondrial function in the brain, it was hypothesised that DJ-1 adult 
hearts may have lower ATP levels at baseline and further upon myocardial ischaemia. 
Indeed, Giaime et al. (2012) showed reduced basal ATP levels in mouse embryonic 
fibroblast cells (Giaime et al., 2012). The effect of genetic ablation of DJ-1 on myocardial 
ATP levels was investigated in DJ-1 knockout and wildtype hearts at baseline and 
following a sublethal global ischaemic insult. This ex vivo approach allowed a large 
amount of tissue to be sampled from each heart and confirmed that all tissue sampled 
was ischaemic, which could not be ensured using an in vivo approach. There was no 
difference in myocardial ATP levels between DJ-1 knockout and wildtype littermates at 
baseline (Figure 4.19) suggesting that DJ-1 is not crucial for myocardial energy 
production, despite its effects on mitochondrial morphology.  
Since the 20 minute sublethal ischaemic insult employed in this study did not elicit a 
statistically significant reduction in myocardial ATP (Figure 7.12), it was not possible to 
draw any firm conclusions regarding the role of DJ-1 in regulating ATP levels following 
ischaemia. This sublethal ischaemic duration was used to avoid any confounding effects 
of differential cell death following ischaemia-reperfusion injury that were expected to be 
present between DJ-1 knockout and wildtype animals, as described above. It was 
therefore not possible to increase the ischaemic duration since this may have resulted in 
increased cell death in the DJ-1 knockout animals and thus a reduction in myocardial 
ATP levels due increased cell death rather than providing a measure of mitochondrial 
function. Billia et al. (2013) showed that myocardial samples from DJ-1 knockout hearts 
subjected to transaortic constriction exhibited decreased ATP levels compared to 
equivalent treated wildtype hearts. However, the potential confounding effects of 
increased severity of cardiac failure in the knockout animals was not considered in this 
study (Billia et al., 2013). It is therefore difficult to conclude what role DJ-1 plays in 
mitochondrial ATP production following stress. 
In summary, this suggests that although DJ-1 appears to be involved in maintaining 
cardiomyocyte mitochondrial dynamics, DJ-1 does not seem to be crucial for cardiac 
function. The second part of this chapter sought to investigate the role of DJ-1 following 
oxidative stress induced by myocardial ischaemia-reperfusion. 
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7.5.2. Role of DJ-1 in the pathophysiology of ischaemia-reperfusion injury 
Previous studies of DJ-1 demonstrate that its genetic ablation renders the brain more 
susceptible to ischaemia-reperfusion injury (Andres-Mateos et al., 2007). This 
suggested the intriguing possibility that DJ-1 may also play a cardioprotective role in the 
heart, whereby genetic ablation of DJ-1 would be expected to increase infarct size upon 
myocardial ischaemia-reperfusion. Indeed, Billia et al. (2013) showed that DJ-1 
knockouts were more susceptible to myocardial infarction induced by in vivo permanent 
coronary artery ligation. The second part of this chapter aimed to investigate the 
involvement of DJ-1 in the more clinically relevant setting of ischaemia-reperfusion. 
Initial in vitro studies investigating the role of DJ-1 in HL-1 cardiac cells within our 
laboratory demonstrated that DJ-1 overexpression conferred several beneficial effects, 
notably reduced cell death in response to simulated ischaemia-reperfusion (Figure 6.1; 
Dongworth and Mukherjee et al., in submission). This is in agreement with previous 
studies of neuronal cell lines where DJ-1 overexpression protected against oxidative 
stress induced cell death (summarised in chapter 1; reviewed by Wilson, 2011). This is 
also supported by a recent study by Yu et al. (2013) in which DJ-1 overexpression in rat 
H9c2 myoblasts protected against simulated ischaemia-reperfusion. 
The possible involvement of DJ-1 in the susceptibility to cell death following ischaemia-
reperfusion was investigated further using the in vivo ischaemia-reperfusion model 
developed in chapter 4. A modified protocol of 45 minutes ischaemia and 24 hours 
reperfusion was applied to this study since a pilot study using 30 minutes ischaemia and 
2 hours reperfusion did not detect a statistically significant difference in infarct size 
between DJ-1 knockout and wildtype animals. Following this extended ischaemic insult, 
these experimented indicated that DJ-1 knockout mice were more susceptible to 
myocardial infarction (Figure 5.5), exhibiting a 25.9% relative increase in infarct size 
(IS/AAR%). This is in agreement with the recent study by Billia et al. (2013) showing that 
genetic ablation of DJ-1 reduced myocardial infarct size resulting from permanent 
coronary artery ligation (often used as a model of cardiac failure) (Billia et al., 2013).  
It should be noted however, that the control infarct size in the present model of 45 
minutes ischaemia and 24 hours reperfusion is lower than that expected from previous 
control infarct data. The infarct size resulting from 45 minutes ischaemia and 24 hours 
reperfusion in DJ-1 wildtype mice was 37.7% (Figure 5.5) compared to 46.9% in Sirt-3 
wildtype mice subjected to these same ischaemia and reperfusion durations (see 
chapter 6; Figure 6.7). These mice are of the same approximate genetic background 
(C57BL/6) and so the infarct sizes would be expected to be similar. By comparison with 
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infarct sizes from the in vivo ischaemia-reperfusion experiments presented in this thesis 
and others not presented here, the DJ-1 wildtype infarct size is lower than expected.  
A potential explanation for this is the longer surgical protocol applied in this study, which 
was extended by an additional 15 minutes anaesthetic duration compared to all other 
surgeries in this thesis. The surgical protocols undertaken in the rest of this thesis were 
designed such that the surgical, and thus anaesthetic duration, could be matched by 
adjustment of the stabilisation period where ischaemic preconditioning is to be 
undertaken. However, since the protocol applied here used a longer ischaemic duration 
with application of IPC, an extended surgical time was required. It is possible therefore 
that the smaller infarct observed in this chapter resulted from some effect of anaesthetic 
conditioning. This may also be demonstrated by the slightly lower extent of 
cardioprotection elicited by IPC in these animals, where IPC reduced infarct size in DJ-1 
wildtypes by approximately 42.2% (Figure 4.12 A). A detailed discussion of the potential 
pathways and the influence of anaesthetic conditioning evoked isoflurane anaesthesia in 
this model is provided in chapter 4 (see 4.6.1). However, a preliminary investigation of 
infarct size in these animals using the non-recovery in vivo protocol (with injectable 
anaesthesia) also showed that this standard IPC protocol did not elicit a significant 
cardioprotective effect in DJ-1 knockout mice, therefore confirming that the resistance to 
cardioprotection by IPC in these animals is a true effect of DJ-1 genetic ablation. 
Overall this study suggests that endogenous DJ-1 may represent an important target for 
cardioprotection. This conclusion is supported by recent studies by Yu et al. (2013) and 
Billia et al. (2013) showing similar effects of DJ-1 in vitro overexpression and in vivo 
knockout. This thesis provides the first demonstration that DJ-1 genetic ablation 
increases the susceptibility to myocardial infarction upon in vivo ischaemia-reperfusion. 
Susceptibility to cardioprotection by IPC: This study also showed that DJ-1 knockout 
mice were partially resistant to cardioprotection by a widely used standard IPC protocol 
(Figure 7.14). This suggests that DJ-1 may contribute to the signalling pathway 
underlying IPC. It is possible that a greater IPC stimulus (for example 3 cycles of 5 
minutes ischaemia and 5 minutes reperfusion) could elicit a significant cardioprotective 
effect; however, this was not investigated further. A previous study by Lu et al. (2012) 
also suggested that DJ-1 may act as a mediator of hypoxic preconditioning in H9c2 rat 
myoblasts (Lu et al., 2012). Interestingly, it has been reported that neuronal DJ-1 can 
increase the activity of the pro-survival kinase, Akt (Kim et al., 2005a; Aleyasin et al., 
2007; Lu et al., 2012). Whether DJ-1 is required for Akt activation in the setting of IPC is 
an intriguing question which remains to be explored and should now be investigated. 
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This study suggests that DJ-1 may modulate the response to myocardial ischaemia-
reperfusion by its effects on the survival kinase (RISK) pathways known to be important 
in cell survival in this setting (for an overview of these pathways see 1.3.1). Overall, it 
appears that DJ-1 plays an important role in the pathophysiology of myocardial 
ischaemia-reperfusion injury, whereby genetic ablation of DJ-1 renders the heart more 
susceptible to myocardial infarction and less amenable to cardioprotection by IPC. This 
study concludes that DJ-1 may represent an important target for cardioprotection. 
7.5.3. Summary of potential limitations 
The results presented in this chapter confirm an important role for DJ-1 in ischaemia-
reperfusion whereby genetic ablation of DJ-1 renders the heart more susceptible to 
infarction upon in vivo ischaemia-reperfusion. From this data, one could hypothesise 
that DJ-1 may represent an important therapeutic target for cardioprotection. However, 
the experiments described here have not explored the potential therapeutic application 
of DJ-1 to cardioprotection which would involve overexpression of DJ-1, which would be 
expected to reduce infarct size in this model. This is a key limitation of this study 
however; this could not be overcome here since we did not have access to DJ-1 
overexpressing mice. Current pharmacological approaches to evoke increased DJ-1 
expression have not been shown to be sufficiently selective to allow evaluation of the 
therapeutic benefit of DJ-1 overexpression (see 1.4.3).  
In addition, all studies presented in this chapter were undertaken on young animals (12-
16 weeks old). It is possible that the role of DJ-1 is exacerbated in aged animals, and as 
such, DJ-1 knockout mice may display an overt cardiac phenotype in aged animals. 
Given the demonstration of more overt neuronal phenotypes in aged DJ-1 animals 
(Andres-Mateos et al., 2007), it is possible that the increased susceptibility to myocardial 
infarction in DJ-1 knockout mice shown here may be exacerbated by aging. It may be 
particularly pertinent to investigate the cardioprotective efficacy of DJ-1 overexpression 
in aged animals to ensure that this therapeutic benefit translates to the aged heart. The 
importance of considering co-morbidities and ageing in pre-clinical studies was 
discussed in chapter 1 (see 1.5.1). This has not been investigated here but would be 
interesting to examine in further studies of the role of DJ-1 in myocardial ischaemia-
reperfusion in order to examine the potential of this protein as a cardioprotective target. 
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7.5.4. Summary 
The main research objective of this chapter was to investigate the role of DJ-1 in the 
heart and examine its potential as a therapeutic target to protect against ischaemia-
reperfusion injury. This thesis, and the preliminary in vitro studies undertaken by our 
group, provides a solid proof-of-concept demonstration of the involvement of DJ-1 in the 
pathophysiology of myocardial ischaemia-reperfusion injury.  
(1) Global genetic ablation of DJ-1 did not significantly affect cardiac phenotype in terms 
cardiac structure or function at baseline or following isoproterenol stress. Although 
DJ-1 cardiac mitochondria were shown to be significantly more fragmented at 
baseline conditions compared to wildtype control hearts, there was no significant 
difference in myocardial ATP levels in these hearts. These findings suggest that DJ-
1 is dispensable for normal cardiac development and function.  
 
(2) Investigation of the effects of ischaemia on mitochondrial morphology and 
myocardial ATP levels showed no significant difference between DJ-1 knockout and 
wildtype hearts. However, the relatively high extent of mitochondrial fragmentation at 
baseline is likely to have masked any further effect of ischaemia. Further 
examination of the effect of ischaemia on myocardial ATP levels in these animals 
was hindered by the absence of any significant effect of the 20 minute ischaemic 
insult, whereby the expected differential susceptibility to cell death precluded 
examination of a more severe ischaemic insult. 
 
(3) DJ-1 knockout mice were more susceptible to infarction following myocardial 
ischaemia-reperfusion. Interestingly, DJ-1 knockout mice were partially resistant to 
cardioprotection by ischaemic preconditioning, suggesting that DJ-1 in the heart may 
be involved in the RISK pathway of cardioprotection. 
The results presented here confirm that DJ-1 mediates an important role in the 
pathophysiology of myocardial ischaemia-reperfusion injury, whereby genetic ablation of 
DJ-1 renders the heart more susceptible to infarction in vivo. This chapter of the thesis 
suggests that DJ-1 overexpression may be an important cardioprotection strategy. 
 
  
272 
CHAPTER 8: INVESTIGATION OF IN VIVO IMAGING OF THE 
MYOCARDIUM USING CARDIAC MRI 
 
8.1. Introduction 
The overall research hypothesis of this thesis concerns the potential long-term efficacy 
of modulation of mitochondrial proteins to elicit cardioprotection. Previous chapters have 
highlighted and examined three important mitochondrial proteins that may represent 
therapeutic targets for cardioprotection. The in vivo model of myocardial ischaemia-
reperfusion injury established in chapter 4 theoretically allows assessment of 
cardioprotective efficacy following extended reperfusion durations to evaluate the long-
term efficacy of such interventions. However, this is complicated by the availability and 
validity of current methods for assessing cardioprotective efficacy, described previously. 
Since myocardial infarct size is known to be a strong predictor of the prognosis of acute 
myocardial infarction patients, infarct size has become a widespread and important 
endpoint in pre-clinical and clinical cardioprotection studies. However, to determine the 
efficacy of cardioprotective therapies for reducing myocardial infarct size it is essential to 
consider the extent of ‘myocardial salvage’. Typically myocardial salvage is defined as 
the proportion of myocardium at-risk (the AAR) that was salvaged by the intervention 
(calculated as: AAR minus infarct size divided by AAR). In practice, the majority of basic 
science studies evaluate the extent of injury normalised to the AAR (calculated as 
IS/AAR%, as presented in this thesis) since this also considers the extent of the AAR. 
Variability in the AAR between animals in this model arises from subtle differences in 
coronary anatomy and the location of the occluding suture. This was discussed 
previously in relation to the establishment of the in vivo model developed in this thesis. 
Since the AAR is a critical determinant of infarct size, methods of controlling infarct size 
to AAR provide a more sensitive measure of cardioprotective efficacy than absolute 
infarct size. The importance of this was demonstrated in chapter 5 where assessment of 
absolute infarct size (IS/LV%) reduced the statistical power such that a statistical 
difference could not be detected (corresponding to a type II error) and required a sample 
size of 25 animals per group to obtain statistical power (see 5.3.3 iii, Figure 5.7).  
Current methods for determining myocardial infarct size and AAR in experimental animal 
studies largely rely on ex vivo histological staining methods, for example using TTC and 
Evans blue as described in this thesis (see chapter 3; reviewed by Black and Rodger, 
1996). Although these histological methods have been widely employed and validated 
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over many decades, there are some limitations to these approaches; most notably their 
terminal nature allowing only a single time-point to be assessed and the potential 
interference of long-term remodelling processes adversely affecting their validity; as 
discussed in detail in chapter 4 (see 4.6.3). Longitudinal animal studies and clinical 
studies investigating long-term cardioprotective efficacy require an in vivo method to 
determine AAR to allow assessment of myocardial salvage. This chapter investigates 
the use of cardiac MRI to assess myocardial salvage in the reperfused mouse heart. 
Cardiac MRI has emerged as a possible non-invasive imaging modality for investigating 
cardioprotective efficacy in both in vivo experimental animal and clinical studies. An 
overview of the cardiac MRI methods investigated for in vivo quantification of infarct size 
and AAR is provided in chapter 1 of this thesis (see 1.5.2). This chapter evaluates the 
validity of cardiac MRI methods for quantifying AAR in vivo in reperfused hearts with the 
aim of providing a fully validated in vivo method of assessing myocardial salvage. 
 
Investigation of the use of cardiac MRI for evaluation of myocardial salvage presented in 
this chapter was undertaken in collaboration with Prof M. Lythgoe at the Centre for 
Advanced Biomedical Imaging (CABI) at University College London, UK. MRI 
sequences were developed by Dr A. Campbell-Washburn and imaging undertaken in 
collaboration with Mr T Roberts; their contributions to this work are duly noted below. 
 
8.2. Research objective and aims 
The main objective of this chapter was to characterise and validate a method for the in 
vivo quantification of AAR in the mouse heart following in vivo ischaemia-reperfusion 
injury. The principal research aims to achieve this objective were: 
(1) Develop and validate an in vivo cardiac MRI method for accurate assessment of 
myocardial AAR in mice subjected to ischaemia reperfusion injury; 
 
(2) Investigate the validity of these in vivo cardiac MRI assessments of AAR in the 
presence of cardioprotective strategies. 
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8.3. Aim 1: Develop and validate an in vivo MRI method to assess 
myocardial area-at-risk 
8.3.1. Background 
A number of cardiac MRI methods have been investigated for the quantification of 
myocardial AAR in the reperfused heart, as outlined in chapter 1 (see 1.5.2, Table 1.5). 
These methods have had variable success at quantifying AAR, where T2-weighted MRI 
approaches have been most widely investigated and applied in both experimental and 
clinical settings. This chapter investigates the use of a T2-weighted cardiac MRI 
approach to in vivo AAR quantification. In addition, we also sought to investigate the use 
of a perfusion based cardiac MRI method to interrogate the reperfused mouse heart and 
potentially provide an additional method for quantifying AAR. 
T2-weighted cardiac MRI methods: Numerous studies have suggested that T2-weighted 
cardiac MRI provides an accurate method to quantify myocardial AAR following 
ischaemia-reperfusion. This method is based on the rationale that ischaemia-reperfusion 
causes oedema to develop within the AAR. The pathophysiological processes which 
cause myocardial oedema to develop in response to ischaemia-reperfusion are outlined 
in chapter 1 (see section 1.2). Since T2-weighted MRI exploits the known linear 
correlation between tissue water content and T2-relaxation time, this imaging modality 
allows delineation of areas of myocardial oedema which are hypothesised to equate to 
the AAR. Indeed, in vivo quantification of AAR by T2-weighted cardiac MRI methods has 
been validated in a number of experimental animal species (Aletras et al., 2006; Bohl et 
al., 2010; Mewton et al., 2011; Beyers et al., 2012) and acute myocardial infarction 
patients (Berry et al., 2010; Fuernau et al., 2011). A detailed overview of the application 
and validation of T2-weighted based cardiac MRI approaches for this purpose is 
provided in chapter (see 1.5.2 iii, Table 1.6). 
Given the success of T2-weighted cardiac MRI methods for quantifying AAR in vivo, this 
method is becoming more widely accepted and used in pre-clinical and clinical studies. 
However, applications of this technique to the reperfused mouse heart have been 
complicated by its small size and rapid heart rate, which impose signal-to-noise 
constraints. However, studies using this approach have provided promising results (Bohl 
et al., 2010; Beyers et al., 2012) and suggest that this could provide a feasible method 
for determining AAR and myocardial salvage in vivo in the mouse heart. 
Perfusion cardiac MRI methods: Perfusion-based cardiac MRI methods have also been 
suggested as a potential approach to quantify myocardial AAR in vivo. These methods 
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are based on the premise that ischaemia-reperfusion causes some impairment to 
coronary perfusion even upon release of the coronary artery occlusion. The precise 
biological mechanism of this perfusion deficit has not been investigated to any 
significant extent; however, it is likely to represent decreased perfusion at the micro-
circulatory level. Myocardial perfusion can be assessed ex vivo by perfusion of labelled 
microspheres of known diameters to allow identification of regions with poor perfusion. 
First-pass gadolinium (Gd) imaging has been the mostly widely investigated cardiac MRI 
method to quantify myocardial AAR (as detailed in chapter 1, see 1.5.2 iii) (reviewed by 
Arai, 2011a). Indeed, Gonzalez et al. (2008) used first-pass Gd MRI and histological 
analysis of microsphere perfusion to confirm the presence of subendocardial perfusion 
deficits in reperfused dog hearts following myocardial injury (Gonzalez et al., 2008). 
Despite the success of first-pass perfusion imaging in larger hearts, its application to the 
mouse heart is likely to be hindered by its smaller size and rapid heart rate, which limit 
the spatial and temporal resolution which are essential to this method.  
Arterial spin labelling (ASL) is a newer MRI method of examining tissue perfusion which 
was first developed to examine cerebral blood flow but has since been applied to other 
organs, including the heart (reviewed by Petersen et al., 2006). The theoretical basis of 
this MRI method is described in detail in chapter 3 of this thesis (see 3.8.3). ASL MRI 
allows quantification of tissue perfusion and therefore allows comparison of relative 
perfusion rates within tissues. Indeed, ASL techniques have been shown to provide 
robust and reproducible quantification of myocardial blood in vivo in rodent hearts (Belle 
et al., 1998). Our collaborators at CABI have developed a multi-slice ASL MRI sequence 
for imaging the mouse heart (as described by Campbell-Washburn et al., 2012; 2013). 
This method has been shown to allow accurate interrogation of perfusion in the naïve 
mouse heart (Campbell-Washburn et al., 2012) and represents a valuable method to 
assess perfusion following ischaemia-reperfusion.  
Since myocardial perfusion may provide a method of visualising the AAR in the 
reperfused heart following ischaemia-reperfusion injury, this thesis examines the 
application of this multi-slice ASL cardiac MRI method to detect areas of reduced 
perfusion in the mouse heart following in vivo ischaemia-reperfusion injury. Experiments 
here describe the first application of a multi-slice ASL MRI sequence to the reperfused 
mouse heart and its potential as a novel method for quantifying AAR in vivo. 
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Aim 1: The first aim of this chapter was to investigate the use of T2-mapping and 
arterial spin labelling cardiac MRI protocols to assess AAR in vivo. The central 
hypotheses in relation to this research objective were: 
(1) T2-mapping cardiac MRI would allow accurate quantification of AAR in vivo in the 
reperfused mouse heart following ischaemia-reperfusion injury. 
 
(2) ASL cardiac MRI would allow accurate quantification of area-at-risk in vivo in the 
reperfused mouse heart following ischaemia-reperfusion injury. 
 
8.3.2. Detailed methods 
All experiments presented in this chapter were undertaken using commercially available 
male B6/SV129 mice aged 10-14 weeks (Harlan Laboratories, UK). Mice were provided 
with a minimal acclimatisation period of one week prior to surgery and a further 2 days 
acclimatisation at the cardiac MRI facility prior to MRI investigation. 
i Ischaemia-reperfusion injury in vivo 
Surgical protocol: B6/SV129 mice underwent the standard protocol of in vivo 
ischaemia-reperfusion comprising 30 minutes ischaemia and approximately 72 hours 
reperfusion as described previously (see 3.2.1). Animals were monitored closely during 
the post-operative period and providing they displayed suitable surgical recovery they 
were transferred to the small animal cardiac MRI facility 16-24 hours following surgery. 
ii Cardiac magnetic resonance imaging 
Cardiac MRI was undertaken with Dr A. Campbell-Washburn and Mr T. Roberts, Prof M. 
Lythgoe (Centre for Advanced Biological Imaging, University College London, UK). 
 
Following approximately 72 hours reperfusion, mice underwent cardiac MRI for the 
assessment of putative myocardial AAR and infarct size, as described in detail below. 
Small animal cardiac MRI setup: A detailed description of the MRI instrumentation at 
CABI is provided by Price et al (2011), where the experimental setup used here was 
exactly as described in chapter 3 (see 3.8.1). The cardiac MRI protocol comprised: (1) 
ASL imaging and (2) T2-mapping and (3) late-gadolinium enhancement imaging. An 
overview of the theoretical basis and methodological details of these of these methods is 
provided in chapter 3 (see section 3.8, Figure 3.20) and briefly described below. 
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Cine imaging – Cardiac function: Cinematic (cine) images of the heart were acquired 
to allow calculation of cardiac volumes and function. The precise MRI sequence 
parameters were exactly as described by Price et al. (2011) and detailed previously (see 
3.8.2). Ten short-axis slices were imaged covering the whole heart from apex to base. 
Quantification: Cardiac function was assessed from short-axis cine images. 
Segmentation of the myocardium was completed by semi-automated delineation of the 
epicardial and endocardial borders using Segment software version 8 (Segment, 
http://segment.heiberg.se/) with manual correction as required. The blood pool volume 
was plotted against time to determine the phases of cardiac cycle for quantification of 
cardiac function from images at end-diastole (ED) and end-systole (ES); see Table 8.1. 
 
ENDPOINT CALCULATION METHOD 
Anatomical measurements  LV myocardial wall mass (LVM) [µg] = myocardial wall volume x 
1.05 g/ml 
Heart rate (BPM) Calculated as: mean time between ECG trace R-waves 
Stoke volume (SV) (µl) Calculated as: (ED volume) – (ES volume)  
Cardiac output (µl/min) Calculated as: (Heart rate * stroke volume) 
Ejection fraction (%) Calculated as: (SV/EDV) x 100%  
 
Table 8.1: Cine imaging cardiac MRI assessment of cardiac structure and function 
Summary of cine imaging measurements of left ventricular end diastolic and systolic dimensions 
and measurements to assess principal features of cardiac function.  
 
Cardiac MRI was performed by Dr A. Campbell-Washburn and Mr T. Roberts; analysis of MRI 
data was undertaken by Dr A. Campbell-Washburn. 
 
 
Arterial spin labelling – Putative area-at-risk: ASL MRI evaluates tissue perfusion 
and was therefore considered as a potential method for evaluating perfusion defects and 
potentially quantifying myocardial AAR in this study. This thesis applied a multi-slice flow 
alternating inversion recovery (FAIR) ASL sequence developed by Campbell-Washburn 
et al. (2012; 2013). The theoretical basis of this technique is described in chapter 3 (see 
3.8.3). Two acquisitions of three slices were used to image the whole heart (6 slices). 
Quantification: Myocardial perfusion was assessed from the ASL perfusion maps of the 
6 myocardial slices. Perfusion maps were produced for each slice by MATLAB 
compilation of the raw T1-values and were displayed as heat-maps, in which normal 
perfusion appears in ‘hot’ colours (red – orange) and low perfusion appears in ‘cold’ 
colours (blue). Normal perfusion values were defined for each heart by selection of a 
region of interest in the second from most basal slice. Pixels with perfusion values less 
than 1 standard deviation below the ‘normal’ perfusion value for that heart were 
considered to have reduced perfusion. This threshold analysis of ASL maps was 
undertaken using a custom MATLAB script; as shown in Figure 8.1 (A – ASL). 
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Figure 8.1: ASL-map 
threshold analysis of AAR  
A) Example images for a 
mid-slice of the myocardium 
interrogated by cardiac MRI 
ASL perfusion mapping (A) 
and histological staining (B). 
Regions of reduced 
perfusion were visible in 
ASL-maps and these 
appeared to be in the region 
of the AAR determined by 
histology. B) Threshold of 
AAR applied to cardiac MRI 
ASL-map (i) and histology 
(ii) – areas highlighted red 
were considered ‘AAR’ by 
these methods. 
 
The area of reduced perfusion was calculated as a percentage of the total number of 
myocardial pixels (area of perfusion deficit / myocardial area %). Statistical analysis of 
the putative AAR defined by this method is described below (see section iv). 
T2-mapping – Putative area-at-risk: T2-weighed MRI can be used to evaluate tissue 
water content as described above. Since myocardial ischaemia (and reperfusion) are 
known to cause tissue oedema within the AAR, T2-weighted cardiac MRI has been 
investigated as a method to quantify AAR in vivo (reviewed by Garcia-Dorado et al., 
2012). A T2-mapping cardiac MRI protocol was applied to assess myocardial water 
content and investigate the potential use of this method to quantify AAR. A description of 
the theoretical basic of T2-mapping is provided in chapter 3 (see 3.8.4).  
Quantification: T2-maps of the myocardium were produced by fitting exponential decay 
curves of T2-relaxation time to T2-signal intensity on a pixel-wise basis for each slice 
using MATLAB scripts (MATLAB Student Version R2008b, The MathWorks, USA). 
These T2-maps were displayed as heat-maps, in which normal T2-signal appears in 
‘colder’ colours (green-yellow) and elevated T2-signal appears in ‘hot’ colours (red). 
Normal T2-signal values were defined by selection of a region of interest in the second 
from most basal slice. Pixels with T2 values greater than 1 standard deviation above the 
‘normal’ T2-signal were considered to have elevated T2-signal. This analysis method was 
in accordance with that used for a similar T2-mapping interrogation of reperfused mouse 
hearts by Bohl et al. (2010). Threshold analysis was undertaken using a custom 
MATLAB script; an example of this approach is shown in Figure 8.2 (A – T2-map). 
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Figure 8.2: T2-map 
threshold analysis of AAR  
A) Example images for a mid-
slice of the myocardium 
interrogated for AAR by 
cardiac MRI T2-mapping (A) 
and histological staining (B). 
Regions of elevated T2-signal 
were present in T2-maps of 
the myocardium and these 
appeared to be in the region 
of the AAR determined by 
histology. B) Threshold of 
AAR applied to cardiac MRI 
T2-map (i) and histology (ii) – 
areas highlighted red were 
considered ‘AAR’ by these 
methods. 
 
The area of elevated T2-signal was calculated as a percentage of the total number of 
myocardial pixels (area of elevated T2 / myocardial area %). Statistical analysis of the 
putative AAR defined by this method is described below (see section iv). 
Late-gadolinium enhancement – Infarct size: Late-gadolinium enhancement (LGE) 
cardiac MRI is a well-validated method of quantifying myocardial infarct size in vivo. A 
LGE cardiac MRI protocol was applied to allow quantification of myocardial infarct size 
and ultimately potentially myocardial salvage. A description of the theoretical basis of 
LGE imaging for infarct size quantification is provided in chapter 3 (see 3.8.5).  
Quantification: The area of infarction was determined using an automated delineation 
method constrained by the myocardial borders using Segment software (version 8). 
Infarct size was calculated as the number of pixels with enhanced T1 signal as a 
percentage of the total number of pixels. Analysis of infarct size is described below. 
 
Figure 8.3: LGE threshold 
analysis of infarct size  
A) Example images for a mid-slice of 
the myocardium interrogated for 
infarction by LGE imaging (A) and 
histological staining (B). The area of 
enhanced signal (bright area) 
corresponding to infarction was 
analysed to calculate infarct size. 
Analysis of area of infarct was 
completed using semi-automated 
Segment software: endocardial 
border red, epicardial border green, 
area of infarct encompassed in 
yellow. B) Threshold of LGE image 
(i) and histology (ii) – areas 
highlighted red were considered 
‘infarct’ by these methods. 
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iii Histological staining for infarct size and area-at-risk 
In order to validate cardiac MRI measurements of infarct size and AAR, animals 
evaluated by these MRI protocols were also subjected to classical ex vivo histological 
staining using perfusion of TTC and Evans blue, as described previously (chapter 3; see 
3.2.4). Seven transverse slices of approximately 1 mm thickness were taken from the 
apex of the heart towards the base. Heart slices were processed and imaged exactly as 
described previously. Examples of histological staining of these hearts are presented in 
the preceding sections of this chapter describing threshold analysis of cardiac MRI 
images (see Figure 8.1 - Figure 8.3). It is important to note that it was not possible to 
completely align the histological and cardiac MRI myocardial slices due to the manual 
method of ex vivo slicing and possible effects of formalin storage of ex vivo heart slices; 
this is discussed in detail later in this chapter (see 8.5.1). 
iv Statistical analysis of cardiac MRI and histological measurements 
Percentage areas are reported as mean ± SEM for the endpoints determined by cardiac 
MRI and histological staining. All statistical analysis was completed using GraphPad 
Prism® version 5.0 (GraphPad Software, USA).  
Validation of cardiac MRI quantification of myocardial infarct size and AAR was 
assessed by paired t-test comparisons of MRI and histology endpoints for each group. 
Statistical significance was reported where P<0.05 using standard significance coding.  
Correlation analysis of this data for each group was not appropriate given the relatively 
small group sizes and close spread of data thereby invalidating any correlation statistics. 
Bland-Altman plots were constructed for each experimental group to assess the overall 
agreement in cardiac MRI and histological methods. Although Bland-Altman plots do not 
provide a formal structure for statistical testing, they provide a useful method of 
visualising the differences between these two methods. The endpoint for each method 
was plotted for each heart as the difference between histological and MRI quantification 
(Δ = cardiac MRI – histology endpoint) against the average quantification by these two 
methods. Bland-Altman plots were used to informally assess the size of bias (mean 
difference between methods) and the spread of variability. Details of statistical analyses 
and sample sizes are provided alongside the results presented in this chapter. 
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8.3.3. Results 
This first part of this chapter examined the use of T2-mapping and ASL cardiac MRI 
methods to quantify AAR in the reperfused mouse heart following 72 hours reperfusion. 
An initial pilot study was undertaken to assess the feasibility of these cardiac MRI 
protocols to assess myocardial infarct size and AAR (n=4 animals; data not shown). This 
was the first application of LGE to reperfused mouse hearts by our research groups and 
demonstrated very good enhancement of areas of infarction which permitted accurate 
quantification of infarct size in line with those previously described by Price et al. (2011). 
In addition, this pilot study showed that the initial multi-slice T2-mapping sequence 
investigated here allowed clear delineation of a region of the myocardium with increased 
T2-signal indicating increased tissue water content (oedema). Interestingly, application of 
a preliminary single-slice ASL MRI sequence to a mid-ventricular slice of these hearts 
showed the presence of defined regions of reduced perfusion which appeared to be 
located in the approximate region of the AAR judged by histological staining. This 
suggested that ASL MRI of the full extent of the heart may provide a method of 
visualising, and potentially quantifying, myocardial AAR in vivo.  
A multi-slice ASL cardiac MRI protocol was developed and applied in the subsequent 
studies in this thesis (Campbell-Washburn et al., 2012). The data from these pilot 
studies is not presented here since the small sample sizes investigated did not permit 
robust analysis of AAR quantification by these methods. All subsequent investigations of 
cardiac MRI methods to determine infarct size and AAR used multi-slice analysis of 6 or 
7 myocardial slices, as described in section 8.3.2. The results of these studies of control 
operated animals are presented below for each cardiac MRI method. 
i LGE – Myocardial infarct size 
LGE cardiac MRI has been widely-validated and applied to quantify infarct size in small 
animals, including the reperfused mouse heart. This method was applied to all animals 
imaged in this chapter to allow final assessment of myocardial salvage. 
This study showed that LGE imaging highlighted a clearly defined region of signal 
enhancement (bright appearance) within the LV which appeared to be spatially localised 
to the area of infarction determined by TTC staining (Figure 4.12). Although a slice-by-
slice comparison of cardiac MRI and histology images was limited by subtle variations in 
the location and thickness of the histological slices, gross alignment of the slices for 
each heart provided a valid comparison of the identification of infarction. 
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Figure 8.4: LGE imaging of myocardial infarction 
Representative images for a control operated animal subjected to myocardial ischaemia-
reperfusion. A) LGE images from base to apex. B) Histology images at approximate locations of 
MRI slices. Gross alignment of the 7 myocardial slices showed a good agreement of spatial 
localisation of infarction with ‘gold-standard’ histological staining for infarction using TTC. 
 
Furthermore, quantification of myocardial infarct size as a percentage of the total 
ventricle area showed very good agreement between these two methods (Figure 4.12 A: 
IS/LV% histology TTC 30.9±0.6 versus MRI LGE 30.7±2.6; n=6/group, NSP>0.05). 
Although some difficulties were encountered with delineation of the myocardial borders 
in LGE images of the most apical slices, this did not appear to affect the overall 
quantification of infarct size in these hearts. Bland-Altman analysis of this dataset 
showed a bias of -0.6±4.4 (standard deviation) (Figure 4.12 B) further indicating the 
robust nature of infarct size quantification by LGE cardiac MRI. Quantification of infarct 
size by this method is further investigated in the second part of this chapter.  
 
 
Figure 8.5: Infarct size assessment by LGE cardiac MRI 
A) Quantification of infarct size as a percentage of LV area by histological TTC staining and 
cardiac MRI LGE imaging. There was no significant difference in infarct size quantification: 
IS/LV% histology TTC 30.9±0.6 versus MRI LGE 30.7±2.6. Statistical significance assessed by 
paired t-test, n=6, 
NS
P>0.05. B) Bland-Altman comparison of histological and LGE quantification 
of infarct size shows good agreement: bias -0.6 ± standard deviation 4.4. 
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ii Area-at-risk 
The use of T2-mapping and ASL cardiac MRI was assessed for in vivo quantification of 
AAR in this same cohort of animals. The results of these methods for AAR quantification 
for control operated animals are described in this section. 
T2-mapping MRI: A multi-slice T2-mapping protocol was used to detect areas of 
increased tissue water content in reperfused mouse hearts. T2-mapping highlighted 
clearly defined regions of enhanced of T2-signal (seen as hot colours on T2-maps) which 
appeared to be approximately localised to the AAR determined by ‘gold-standard’ 
histological staining (i.e. the area not stained by Evans blue) (Figure 8.6).  
 
Figure 8.6: T2-mapping imaging of myocardial oedema 
Representative images for a control operated animal subjected to myocardial ischaemia-
reperfusion. A) T2-maps from base to apex: normal T2-signal defined in septal region of slice 2. B) 
Histology images at approximate locations of MRI slices. Gross alignment of the 7 myocardial 
slices showed a good agreement of spatial localisation of oedema (putative measure of AAR) 
with histological staining for AAR by Evans blue (in which the AAR is the area not stained blue). 
 
The area of oedema was defined as the area of myocardium exhibiting T2 signal greater 
than 1 standard deviation above the ‘normal’ T2 signal for that heart. This area of 
oedema (the putative AAR) was in very good agreement with that determined by 
histological staining in these control operated animals (Figure 8.7: AAR/LV% histology 
64.3±2.5 versus MRI T2-mapping 60.4±2.4; n=6/group, 
NSP>0.05). Bland-Altman 
analysis of this dataset showed a bias of -3.9±11.4 (standard deviation) (Figure 8.7 B). 
This mean difference between histology and T2-mapping quantification of AAR (-3.9% 
AAR/LV) is unlikely to be biologically significant for assessment of myocardial salvage. 
Other threshold methods with subtle variations in the selection of the ‘normal’ T2-value 
and threshold levels showed worse outcomes upon Bland-Altman analysis and were not 
investigated further. The threshold analysis method described here (see 8.3.2 ii) was 
used to quantify AAR by T2-mapping MRI for all analyses presented in this thesis. 
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Figure 8.7: Putative AAR assessment by T2-mapping cardiac MRI in control mice 
A) Quantification of AAR as a percentage of LV area by histological staining and cardiac MRI T2-
mapping. There was no significant difference in AAR quantification by these methods, AAR/LV% 
histology 64.3±2.5 versus MRI T2-mapping 60.4±2.4. Statistical significance assessed by paired 
t-test, n=6, 
NS
P>0.05. B) Bland-Altman comparison of histological and T2-mapping AAR 
quantification shows acceptable agreement: bias -3.9 ± standard deviation 11.4. 
 
 
ASL MRI: ASL cardiac MRI was used to assess myocardial perfusion in the same 
cohort of animals. This showed that distinct regions of the myocardium exhibited 
decreased perfusion and these appeared to correspond to the AAR judged by 
histological staining (Figure 8.9 A). The most apical slice commonly showed abnormal 
perfusion values which did not reflect biologically valid measurements and therefore this 
slice was excluded from quantification of the area of myocardial perfusion deficit.  
 
Figure 8.8: ASL imaging of myocardial perfusion 
Representative images for a control operated animal subjected to myocardial ischaemia-
reperfusion. A) ASP perfusion maps from base to apex: normal T1 value defined in septal region 
of slice 2. B) Histology images at approximate locations of MRI slices. Gross alignment of the 6 
myocardial slices shows a good agreement of spatial localisation of perfusion deficit (putative 
measure of AAR) with staining for AAR by Evans blue perfusion (AAR not stained in blue). 
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The area of reduced perfusion was defined as the area of myocardium exhibiting a T1-
perfusion value less than 1 standard deviation below the ‘normal’ T1-perfusion value for 
that heart. The area of decreased perfusion (putative AAR) showed very good 
agreement with that determined by histological staining in control operated animals 
(Figure 8.9: AAR/LV% histology 64.3±3.9 versus MRI ASL 60.6±4.3; n=6/group, 
NSP>0.05). Bland-Altman analysis of this dataset showed a bias of -3.7±11.9 (standard 
deviation) (Figure 8.9 B). This mean difference between histology and ASL 
quantification of AAR (-3.7% IS/LV) is unlikely to be biologically significant for the 
subsequent assessment of myocardial salvage. 
 
Figure 8.9: Area-at-risk assessment by ASL cardiac MRI and histology in control mice 
A) Quantification of AAR as a percentage of left ventricle area by histological staining and cardiac 
MRI ASL perfusion imaging. There was no significant difference in infarct size quantification by 
these methods, AAR/LV% histology 64.3±3.9 versus MRI ASL 60.6±4.3. Statistical significance 
assessed by paired t-test, n=6, 
NS
P>0.05. B) Bland-Altman comparison of histological and ASL 
AAR quantification shows acceptable agreement: bias -3.7 ± standard deviation 11.9. 
 
In summary, this study has shown that T2-mapping and ASL cardiac MRI appear to 
provide valid and robust measures of myocardial AAR in the reperfused mouse heart. 
The bias calculated by Bland-Altman analysis was very similar between these methods 
(Bland-Altman bias: Figure 8.7 T2-mapping bias -3.9±11.4; Figure 8.9 ASL -3.7±11.9; 
n=6). This suggests that either of these techniques could be used to assess myocardial 
salvage (reported here as IS/AAR%) in control operated animals. Indeed, comparison of 
IS/AAR% calculated by these cardiac MRI methods and ‘gold-standard’ histology shows 
that there is a striking agreement in mean IS/AAR% determined by these methods 
(Figure 8.10: paired t-tests comparing histology and cardiac MRI IS/AAR% confirmed 
there were no significant differences in quantification by histology and cardiac MRI). 
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Figure 8.10: Quantification of infarct size controlled to AAR by cardiac MRI 
Quantification of IS/AAR% in control animals. There was no significant difference in IS/AAR% 
calculation by cardiac MRI (black bars) and histological staining (white bars) for (A) T2-mapping 
or (B) ASL cardiac MRI. Statistical significance assessed by paired t-test, n=6, 
NS
P>0.05. 
 
The validity of these cardiac MRI methods for quantifying AAR in vivo is examined in the 
presence of cardioprotective interventions in the second part of this chapter below. 
 
 
8.4. Aim 2: Validity of cardiac MRI assessments of area-at-risk in 
the presence of cardioprotective strategies 
8.4.1. Background 
To assess the validity of AAR quantification by these cardiac MRI methods it was crucial 
to determine whether cardioprotective interventions that reduce myocardial infarct size 
also affect the measure of AAR. This is a particularly pertinent research question 
concerning the use of T2-weighted based cardiac MRI for this purpose since it has been 
previously suggested that certain cardioprotective interventions may reduce the extent 
of myocardial oedema. Notably, an early study of cardioprotection by IPC and ischaemic 
postconditioning (IPost) in dogs showed that both of these interventions significantly 
reduced the extent of myocardial oedema (Zhao et al., 2003). Furthermore, two recent 
landmark studies of clinical applications of T2-weighted MRI showed that IPost (Thuny et 
al., 2012) and remote ischaemic postconditioning (RIPost) (Crimi et al., 2013) 
significantly reduced myocardial oedema. Although this is perhaps not surprising given 
that oedema is an outcome of injury, these studies suggest that T2-weighted cardiac 
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MRI methods may not be appropriate for quantifying AAR in the presence of certain 
cardioprotective interventions. Since this study represents the first application of ASL 
cardiac MRI to quantify myocardial AAR, it is not known whether this technique will also 
be subject to these complications. The second part of this chapter investigates the effect 
of a cardioprotective interventions on AAR quantification by the T2-mapping and ASL 
cardiac MRI methods described in part 1. 
 
Aim 2: The second aim of this chapter was to investigate the validity of these cardiac 
MRI methods for assessing in vivo AAR in the presence of important cardioprotective 
interventions. The central hypotheses in relation to this research objective were: 
(1) Cardioprotective interventions may reduce the extent of oedema meaning that these 
interventions T2-mapping cardiac MRI may underestimate the AAR in vivo. 
 
(2) Cardioprotective interventions are not expected to affect myocardial perfusion and 
thus ASL cardiac MRI should provide accurate quantification of AAR in vivo in the 
presence of cardioprotective interventions. 
 
8.4.2. Detailed methods 
The experiments presented in this section were undertaken using the exact 
experimental setup described previously (see 8.3.2) with the following additions. 
i Ischaemia-reperfusion injury in vivo – Cardioprotective interventions 
To investigate the effect of cardioprotective interventions on AAR quantification by these 
cardiac MRI methods, three interventions were examined: IPC, CsA and exenatide. The 
surgical procedure was exactly as described as above (see 8.3.2 i); 30 minutes 
ischaemia and 72 hours reperfusion with application of the interventions below. 
Ischaemic preconditioning: A standard IPC protocol of 5 minutes ischaemia and 5 
minutes reperfusion was applied immediately prior to the main 30 minute ischaemic 
insult exactly as described in chapter 4 (Figure 4.10). The IPC data presented in this 
section of thesis was conducted contiguously with the control data presented above (see 
8.3.3) where these animals were randomised to receive either control or IPC treatment. 
Cyclosporine-A: CsA treated animals received 10 mg/kg CsA as a single intravenous 
tail vein injection given 5 minutes prior to the onset of reperfusion, exactly as described 
in chapter 4 (Figure 4.11). Control animals received a matched volume of vehicle 
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(cremophor/ethanol-94%) 5 minutes prior to the onset of reperfusion. This study was 
completed as a separate experiment following completion of the IPC study. 
Exenatide: Exenatide treated animals received 2.5 µg/kg given 5 minutes prior to the 
onset of reperfusion. Control animals received a matched volume of vehicle (saline) 5 
minutes prior to the onset of reperfusion. Exenatide (trade name Byetta) was obtained 
from Eli Lilly and Company, UK as a pre-made solution of 0.25 mg/ml (pre-filled 
syringe). Exenatide was diluted in sterile saline to give an intermediate stock of 1.25 
µg/ml (200-fold dilution). Dosing solutions were made fresh on each operating day to 
ensure that there was no loss of drug activity between experiments. This exenatide 
dosing stock was administered at 2 ml/kg both intravenously and subcutaneously; 
corresponding to 60 µl per 30 g mouse to give a final dosing concentration of 2.5 µg/kg 
I.V. and 2.5 µg/kg S.C.. Dosing was completed as described in chapter 3; animals were 
excluded where successful administration could not be confirmed. 
 
Figure 8.11: Exenatide dosing protocol 
B6/SV129 mice were randomised to receive vehicle or exenatide administered 5 minutes prior to 
the onset of reperfusion. All dosing was as a single bolus administered I.V. immediately followed 
by a second bolus administered S.C.. A) Vehicle treated mice received a matched volume of 
saline. B) Exenatide treated received exenatide 2.5 µg/kg I.V. and S.C.. All mice were subjected 
to 15 minutes stabilisation, 30 minutes ischaemia and 72 hours reperfusion. Mice were subjected 
to histological staining for infarct size and AAR in a pilot study. 
  
Stabilisation
45 min
Extract
Anaesthetic Duration0 5 50 55
Stabilisation
15 min
Ischaemia
30 min
24 hrs
Stabilisation
45 min
Extract
Anaesthetic Duration0 5 50 55
Stabilisation
15 min
Ischaemia
30 min
24 hrs
A. Vehicle (saline)
B. Exenatide
Vehicle I.V.
45
45
Exenatide
2.5 µg/kg I.V.
+ 2.5 µg/kg S.C.
289 
8.4.3. Results 
i Pilot study – Cardioprotection by exenatide 
Since both IPC and CsA cardioprotective interventions were previously investigated in 
this thesis, further pilot studies of these cardioprotective regimes were not required for 
this study (for details see chapter 4: IPC Figure 4.12 and CsA Figure 4.13). However, 
since exenatide had not been investigated in this model previously, an initial pilot study 
was required to evaluate the cardioprotective efficacy of this intervention. This pilot 
study showed that this exenatide dose (2.5 µg/kg I.V. and 2.5 µg/kg S.C. 5 minutes prior 
to the onset of reperfusion) did not elicit significant cardioprotection in this model (Figure 
4.13: IS/AAR% vehicle control 42.5±4.4 versus exenatide 49.0±4.2; n=5/group, 
NSP>0.05). There was no significant difference in AAR (AAR/LV% vehicle 65.4±4.2 
versus exenatide 59.4±4.9; n=5/group, NSP>0.05) or survival between these groups 
(survival to 24 hours reperfusion: vehicle 100% versus exenatide 100%, NSP>0.05, 
excluding animals excluded due to unconfirmed dosing). 
 
Figure 8.12: Pilot study of exenatide treatment 
Pilot study investigating the effect of exenatide treatment on infarct size assessed by histological 
staining. B6/SV129 mice were randomised to receive either vehicle control or exenatide (2.5 
µg/kg I.V. + 2.5 µg/kg S.C.). There was no significant difference in infarct size between these 
groups: IS/AAR% vehicle control 42.5±4.4 versus exenatide 49.0±4.2, n=5/group. Statistical 
significance assessed by unpaired t-test, 
NS
P>0.05. 
 
 
Given the time and animals required to optimise this therapeutic strategy to evoke 
cardioprotection in this model, this therapeutic regime was not investigated further. 
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ii Cardioprotection by IPC and CsA 
Histological analysis confirmed that IPC and CsA significantly reduced myocardial infarct 
size. Importantly, there was no significant difference in AAR between control and 
cardioprotected groups; thereby validating the comparison AAR quantification by cardiac 
MRI and histology in control and protected groups presented below. 
A summary of the assessment of cardiac function in these animals is provided in Table 
8.2. Although there were trends towards improved cardiac function in treated groups 
compared to the respective control group, there were no significant differences. 
 
TREATMENT 
GROUP 
Heart rate 
(BPM) 
Stoke volume 
(µl) 
Cardiac output 
(µl/min) 
Ejection 
fraction (%) 
Control 514.2 ±17.0 27.5 ±1.5 45.3 ±3.2 14.2 ±0.9 
IPC 530.0 ±15.2 28.7 ±1.7 54.8 ±3.9 15.3 ±0.9 
Vehicle 505.7 ±20.1 24.8 ±1.7 51.3 ±4.6 12.5 ±1.0 
CsA 500.0 ±11.8 29.7 ±1.8 61.1 ±2.7 14.8 ±0.9 
 
Table 8.2: Summary of MRI assessment of cardiac function  
Endpoints of cardiac function for control and cardioprotected animals. Although there was a trend 
towards increased stroke volume, cardiac output and ejection fraction in cardioprotected animals 
compared to their respective controls (control versus IPC and vehicle versus CsA), there were no 
statistically significant differences. Significance assessed by unpaired t-test between control and 
treatment groups, 
NS
P>0.05.  
 
 
iii Myocardial infarct size in cardioprotected hearts 
To examine the validity of T2-mapping and ASL cardiac MRI methods for quantifying 
myocardial AAR in the presence of cardioprotective interventions, the putative AAR 
determined by these cardiac MRI methods was compared with the histological AAR. 
Quantification of absolute infarct size (IS/LV%) by LGE in these animals confirmed that 
there was no significant difference between ‘gold-standard’ histology and LGE methods 
for animals treated with IPC (Figure 8.13 A: histology IS/LV% 16.8±1.1 versus LGE MRI 
18.0±1.6, n=10, P>0.05) or CsA (Figure 8.13 B: histology IS/LV% 21.9±1.5 versus LGE 
MRI 19.2±2.3, n=9, P>0.05). Bland-Altman analysis of LGE quantification of infarct size 
showed similar degrees of bias to that previously reported in control animals (Bland-
Altman analysis bias ± standard deviation: IPC 1.2±3.9 versus CsA -2.7±9.4). 
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Figure 8.13: Infarct size assessment by LGE cardiac MRI 
Quantification of infarct size as a percentage of LV area by histological TTC staining and cardiac 
MRI LGE imaging. A) IPC: IS/LV% histology TTC 16.8±1.1 versus MRI LGE 18.0±1.6, n=10, 
P>0.05. B) CsA: IS/LV% histology TTC 21.9±1.5 versus MRI LGE 19.2±2.3, n=9, P>0.05. 
Statistical significance assessed by paired t-test, 
NS
P>0.05. 
 
iv Area-at-risk in cardioprotected hearts 
To evaluate the validity of T2-mapping and ASL cardiac MRI quantification of myocardial 
AAR in the presence of cardioprotective interventions, IPC and CsA treated animals 
were imaged using these methods and the putative AAR calculated. It should be noted 
that the IPC control group data is described in the previous section and comparable 
results were obtained for control vehicle treated animals for the CsA study. 
T2-mapping MRI: This study showed that IPC significantly reduced the area of 
myocardial oedema meaning that T2-mapping cardiac MRI significantly underestimated 
myocardial AAR (Figure 8.14 Ai: AAR/LV% histology 59.8±7.9 versus T2-mapping 
cardiac MRI 46.0±13.2, n=10, *P<0.05). This was also evident in Bland-Altman analysis 
which showed a bias of -13.8 AAR/LV% (Figure 8.14 Aii). This degree of bias is likely to 
be biologically significant and therefore precludes the use of this T2-mapping cardiac 
MRI method for AAR assessment in IPC treated animals in the model.  
Interestingly, cardioprotection by CsA did not appear to affect the assessment of 
myocardial AAR using T2-mapping cardiac MRI (Figure 8.14 Bi: AAR/LV% histology 
58.0±4.2 versus T2-mapping cardiac MRI 55.5±5.7, n=9, P>0.05). Bland-Altman analysis 
of AAR quantification by these methods in CsA treated animals showed reasonable 
agreement between the two methods with a mean bias of -2.50 AAR/LV% (Figure 8.14 
Bii). This suggests that CsA does not significantly affect the area of oedema meaning 
that T2-mapping cardiac MRI may be appropriate to assess AAR in these animals. 
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Figure 8.14: Area-at-risk assessment by T2-mapping cardiac MRI in cardioprotected mice 
Quantification of AAR as a percentage of LV area by histology (white bars) and cardiac MRI ASL 
(black bars) in cardioprotected mice. A) IPC: i) T2-mapping cardiac MRI significantly 
underestimated myocardial AAR in IPC treated hearts; AAR/LV% histology 59.8±7.9 versus T2-
mapping MRI 46.0±13.2. Statistical significance assessed by paired t-test, n=10, *P<0.05. ii) 
Bland-Altman comparison of histological and T2-mapping AAR quantification shows a large 
difference between AAR quantification by these two methods: bias -13.8±14.8 (SD). B) CsA: i) 
AAR/LV% histology 58.0±4.2 versus T2-mapping MRI 55.5±5.7. Statistical significance assessed 
by paired t-test, n=8, 
NS
P>0.05. B) Bland-Altman comparison of AAR quantification shows 
acceptable agreement: bias -2.50±16.8 (SD). 
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Comparison of mean T2-values showed no difference between control and IPC hearts 
(Figure 8.15 A: mean T2-value; normal T2 control 17.0±0.6 versus IPC 19.8±1.4; 
elevated T2 control 25.8±1.7 versus IPC 27.6±2.4; control n=6, IPC n=10) or vehicle and 
CsA hearts (Figure 8.15 B: mean T2-value; normal T2 vehicle 17.6±0.7 versus CsA 
18.1±0.6; elevated T2 vehicle 23.1±0.6 versus CsA 24.2±0.9; control n=7, IPC n=9). 
 
 
Figure 8.15: Absolute T2-values for cardioprotected mice 
Comparison of mean absolute T2-values in areas deemed ‘normal’ and ‘elevated’ by threshold 
analysis. A) IPC: There was no difference in T2-values between groups: normal T2-value control 
17.0±0.6 (n=6) versus IPC 19.8±1.4 (n=10) and elevated T2 control 25.8±1.7 versus IPC 
27.6±2.4. B) CsA: There was no difference in T2-values between groups: normal T2 control 
17.6±0.7 (n=7) versus CsA 18.1±0.6 (n=9) and elevated T2-value control 23.1±0.6 versus CsA 
24.2±0.9. Statistical significance assessed by one-way ANOVA and Bonferroni test; 
NS
P>0.05. 
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This suggests that the absolute magnitude of myocardial oedema caused by ischaemia-
reperfusion in these animals is not affected by the application of IPC or CsA and it is 
mainly the area of oedema that is changed in IPC treated mice (see Figure 8.14). 
ASL MRI: ASL cardiac MRI was used to assess myocardial perfusion and quantify the 
putative AAR in the same cohort of animals. Importantly, this ASL method appeared to 
provide accurate quantification of AAR in IPC treated animals (Figure 8.16 Ai: AAR/LV% 
histology 58.0±3.0 versus T2-mapping cardiac MRI 53.4±7.9, n=8, P>0.05). Bland-
Altman analysis of this dataset showed a bias of -4.7 AAR/LV%, although it should be 
noted that the variation between these two methods is larger than is ideal. ASL cardiac 
MRI provided a good assessment of AAR in CsA treated animals (Figure 8.16 B: 
AAR/LV% histology 57.3±4.0 versus ASL cardiac MRI 63.0±4.3, n=9, P>0.05).  
Comparison of the mean normal and decreased perfusion values from ASL-maps of 
these hearts showed no significant difference between control and IPC treated hearts 
(Figure 8.17 A: mean perfusion ± SEM; normal perfusion control 18.2±2.0 versus IPC 
22.4±2.1; reduced perfusion control 5.6±0.6 versus IPC 6.4±0.5; control n=6, IPC n=7). 
Interestingly, the mean absolute perfusion value of ‘normal’ areas in the CsA treated 
group was significantly increased compared to vehicle controls (Figure 8.15 B: mean 
perfusion ± SEM; normal perfusion vehicle 16.9±0.5 versus CsA 29.5±3.6; reduced 
perfusion vehicle 4.8±0.7 versus CsA 9.1±1.2; vehicle n=6, CsA n=9). The increased 
magnitude of perfusion in CsA treated hearts does not appear to affect quantification of 
AAR from ASL-maps (Figure 8.16); discussed further later in this chapter (see 8.5.2). 
 
In summary, IPC appears to reduce myocardial oedema thus invalidating the use of T2-
mapping cardiac MRI to asses AAR in these animals; interestingly, CsA did not appear 
to affect myocardial oedema. ASL cardiac MRI appeared to provide an appropriate 
measure of AAR in control, IPC and CsA treated animals.  
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Figure 8.16: Area-at-risk assessment by ASL cardiac MRI in cardioprotected mice 
Quantification of AAR as a percentage of LV area by histological staining (white bars) and 
cardiac MRI ASL (black bars) in cardioprotected mice. A) IPC: i) AAR/LV% histology 58.0±3.0 
versus ASL MRI 53.4±7.9. Statistical significance assessed by paired t-test, n=8, 
NS
P>0.05. ii) 
Bland-Altman comparison of histological and ASL AAR quantification showed an acceptable 
average difference between AAR quantification by these two methods: bias -4.7±19.0 (SD). B) 
CsA: i) AAR/LV% histology 57.3±4.0 versus ASL MRI 63.0±4.3. Statistical significance assessed 
by paired t-test, n=9, 
NS
P>0.05. i) Bland-Altman comparison of histological and ASL AAR 
quantification showed an acceptable average difference between AAR quantification by these 
two methods: bias 5.7±7.9 (SD). 
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Figure 8.17: Absolute perfusion values for cardioprotected mice 
Comparison of mean absolute perfusion values in areas of myocardium deemed ‘normal’ and 
‘AAR’ by threshold analysis. A) IPC: There was no significant difference in perfusion between 
groups: normal perfusion control 18.2±2.0 (n=6) versus IPC 22.4±2.1 (n=7) and reduced 
perfusion control 5.6±0.6 versus IPC 6.4±0.5. Note: one IPC treated heart was excluded due to 
aberrant raw perfusion values. B) CsA: There was a significant increase in perfusion in ‘normal’ 
areas of CsA treated hearts (n=9) compared to vehicle controls (n=6): normal perfusion vehicle 
16.9±0.5 versus CsA 29.5±3.6 and reduced perfusion vehicle 4.8±0.7 versus CsA 9.1±1.2. Note: 
one vehicle treated heart was excluded due to aberrant raw perfusion values. Significance 
assessed by one-way ANOVA and Bonferroni test comparing relevant groups. 
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Since this ASL method allows reasonably accurate AAR quantification, this method can 
be used to calculate IS/AAR%. This study demonstrated that there was no significant 
difference in IS/AAR% quantification by cardiac MRI (ASL and LGE) and histological 
staining for either IPC or CsA treated hearts. Crucially, this method allows detection of 
significant cardioprotection by these cardioprotective interventions compared to their 
respective controls (Figure 8.18; statistical significance assessed by unpaired t-tests). 
 
Figure 8.18: Quantification of infarct size controlled to AAR by cardiac MRI 
Quantification of IS/AAR% by LGE and ASL cardiac MRI in animals subjected to IPC and CsA 
treatment (black bars) compared to respective control animals (white bars). A) IPC: IS/AAR% 
control 47.2±6.2 (n=6) versus IPC 28.7±5.5 (n=8), *P<0.05. B) CsA: IS/AAR% vehicle control 
43.4±3.1 (n=6) versus CsA 28.4±3.7 (n=8). Statistical significance assessed by unpaired t-test. 
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8.5. Discussion 
This chapter aimed to investigate and validate a cardiac MRI method of determining 
myocardial AAR in vivo. The need for this was highlighted in chapter 5 of this thesis 
where considering only absolute infarct size (IS/LV%) meant that very large sample 
sizes would be required to reach the appropriate statistical power to detect a significant 
difference in myocardial salvage between Cyp-D wildtype and knockout animals (see 
5.3.3 iii, Figure 5.7). It had originally been intended that these mice would undergo long-
term assessment of infarct size by serial cardiac MRI investigation; however, the lack of 
a fully validated method of determining AAR by cardiac MRI precluded this experiment. 
The development of a robust and valid in vivo method for quantifying AAR would be 
widely applicable to many research projects within our laboratory and the wider field of 
ischaemia-reperfusion research. This chapter sought to investigate and validate a 
cardiac MRI method for quantifying AAR to complement LGE infarct size assessment. 
8.5.1. Aim 1: Cardiac MRI for in vivo assessment of area-at-risk in control 
reperfused mouse hearts 
Given the proposed use of T2-weighted based cardiac MRI methods for quantifying AAR 
(reviewed by Garcia-Dorado et al., 2012), a T2-mapping method was investigated in this 
chapter. In addition, an ASL perfusion based method was also applied to assess 
perfusion in the reperfused heart and potentially provide a measure of AAR. An initial 
pilot study developed and optimised multi-slice T2-mapping and ASL cardiac MRI 
sequences to allow interrogation of the left ventricle (6-7 slices). This chapter describes 
the application of these sequences to mice following ischaemia-reperfusion where the 
validity of quantifications of putative AAR by these methods could be assessed by 
comparison with the AAR defined by ‘gold-standard’ histological staining methods. 
T2-mapping MRI: As expected from previous studies, T2-mapping analysis of 
myocardial water content revealed spatially distinct regions of elevated T2-signal which 
appeared to be located within the AAR judged by histological staining. Precise 
comparisons of the spatial distribution of the putative AAR determined by this method 
were hindered by the imprecise alignment of myocardial slices. This could be improved 
for future studies aimed at validating these cardiac MRI approaches, for example by 
using a slicing template for ex vivo preparation of hearts. However, since these methods 
provide a measure of the AAR over the whole heart (AAR/LV%), it is possible to 
compare the putative AAR calculated by cardiac MRI method to that obtained from 
‘gold-standard’ histological staining. Evaluation of the putative AAR determined by T2-
mapping MRI showed that this was not significantly different to the quantification of AAR 
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by histology (Figure 8.7: bias -3.9±11.4 AAR/LV% ±SD). This indicates that on average 
across the control group examined here the T2-mapping method slightly underestimated 
AAR by 3.9%. Although it should be noted that there is some spread in this dataset, it is 
unlikely that this bias in AAR calculation would be biologically significant. 
This study therefore confirms that T2-mapping cardiac MRI appears to be an appropriate 
method for quantifying myocardial AAR in control operated mice. This study is in 
accordance with previous studies in other experimental species and clinically (as 
summarised in chapter 1; see 1.5.2, Table 1.6). The validity of this cardiac MRI 
sequence for AAR quantification in cardioprotected animals is discussed below. 
ASL MRI: This study also examined the use of an ASL approach to evaluate tissue 
perfusion in reperfused mouse hearts. Previous studies have shown that ischaemia-
reperfusion causes impaired myocardial reperfusion and it has been hypothesised that 
the area of decreased perfusion may be confined to the AAR; thereby allowing potential 
quantification of AAR. Perfusion-based cardiac MRI has mainly examined the use of 
first-pass perfusion imaging where the perfusion of a contrast agent is used to identify 
areas of differential perfusion (an overview of these methods is provided in chapter 1; 
see 1.5.2 iii). The success of contrast perfusion methods in the mouse heart has been 
limited by the spatial and temporal resolution due to its small size and rapid heart rate.  
The multi-slice ASL cardiac MRI sequence used here has been previously extensively 
developed by our collaborators at CABI. Application of this sequence to naïve mice 
showed good reproducibility of perfusion quantification between animals and scanning 
session to reveal normal perfusion values in the region of 10-15 ml/g/min with mean 
perfusion of 11.8±2.8 ml/g/min in standard CD1 mice (Campbell-Washburn et al., 2012). 
The studies undertaken in this thesis represents the first application of this multi-slice 
cardiac MRI sequence to the reperfused mouse heart.  
ASL perfusion maps of the reperfused myocardium showed spatially distinct regions of 
reduced tissue perfusion which appeared to be spatially localised to the regions of AAR 
determined by histological staining. Given that the area of perfusion deficit was always 
larger than the area of infarction, it is unlikely that the measurement here reflects 
decreased perfusion within the infarcted area only. Quantification of the area of 
myocardium exhibiting decreased myocardial perfusion displayed good agreement with 
the AAR calculated by histological staining (Figure 8.9, bias -3.7±11.9 AAR/LV%±SD). 
This study provides the first suggestion that multi-slice ASL labelling may provide a 
means to determine myocardial AAR in reperfused hearts. The validity of this 
measurement is examined further below. 
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The biological basis of the perfusion deficit identified within the myocardial AAR has not 
been investigated here. The reduced perfusion within the AAR is not expected to 
correspond to unsuccessful reperfusion of the LAD coronary artery in this model but 
instead some impairment of microvascular perfusion within the capillary bed of these 
hearts. This is discussed below in relation to validity of ASL MRI for AAR quantification. 
It should be noted that the extent of ‘normal’ tissue perfusion in these animals appeared 
to be higher than those previously published using this model (Figure 8.18 B: normal 
tissue perfusion in control mice 18.2±2.0 ml/g/min compared to the previous published 
study showing normal perfusion of 11.8±2.8 ml/g/min) (Campbell-Washburn et al., 
2012). Previous investigations have shown that myocardial perfusion is very sensitive to 
isoflurane dosing, whereby increasing isoflurane concentration from 1.25% to 2.0% 
caused an approximate 2.5-fold increase in tissue perfusion (Kober et al., 2005; 
Campbell-Washburn et al., 2013). The slightly higher perfusion observed here could 
derive from a difference in isoflurane dosing of these animals. Although the experiments 
presented here used the minimal dose of isoflurane required to maintain steady 
anaesthesia, there may be subtle differences of anaesthetic sensitivity of the reperfused 
B6/SV129 mice compared to the CD-1 mice previously investigated. Tissue perfusion 
rates are discussed below in relation to the effect of cardioprotective interventions.  
It should also be noted that the procedural survival of animals subjected to this cardiac 
MRI scanning protocol was lower than would ideally be expected. A number of animals 
did not survive to the end of the scanning protocol, likely due to complications arising 
from the prolonged duration of anaesthesia (which on occasion reached 3 hours). 
Animals which did not survive to the completion of the MRI protocol were excluded from 
the analyses of infarct size and area-at-risk quantification in this chapter. Further 
refinement of the MRI sequences in future may allow the overall scan time to be 
reduced. The resultant decrease in anaesthetic duration would likely improve procedural 
survival and would therefore be an important development for future applications of 
these methods for long-term studies of cardioprotective efficacy. 
A further caveat to the interpretation of the quantification of AAR using both T2-mapping 
and ASL methods presented here is the potential limitations of the thresholding 
technique used for analysis. The threshold method used here relied on the identification 
of a region-of-interest within the myocardium corresponding to the non-AAR to allow 
comparison of the rest of the tissue with this ‘normal’ region. This threshold approach 
was based on deviance in T2-signal or perfusion value of 1 standard deviation from this 
mean normal value. There is significant future potential to improve this analysis method 
and this may improve the quantification of AAR using these methods in future studies. 
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8.5.2. Aim 2: Validity of cardiac MRI area-at-risk quantification in the 
presence of cardioprotective interventions 
The second part of this chapter therefore sought to investigate the effect of 
cardioprotective interventions on the quantification of myocardial AAR by T2-mapping 
and ASL cardiac MRI. This is particularly pertinent given the recent suggestions that 
certain cardioprotective interventions may reduce the extent of myocardial oedema 
(Thuny et al., 2012; Crimi et al., 2013). Since clinical assessments of the validity of 
cardiac MRI methods of determining AAR rely on imprecise comparisons with 
angiographic scores to infer the true AAR, the ability to directly compare AAR 
measurements across equivalent myocardial slices subjected to ‘gold-standard’ 
histological staining provides an important tool for accurate validation. 
This thesis examined the effects cardioprotection by IPC and CsA on the validity of AAR 
assessment by these MRI methods. Histological analysis of these hearts showed that 
both of these cardioprotective interventions significantly reduced myocardial infarct size 
(IS/AAR%). Importantly, there was also no difference in AAR between groups thereby 
allowing comparison of the validity of AAR assessment by cardiac MRI. 
T2-mapping MRI: This study showed that IPC significantly reduced the area of 
myocardium exhibiting an elevated T2-signal, therefore suggesting that IPC reduces the 
extent of myocardial oedema. Quantification of the putative AAR using this T2-mapping 
protocol underestimated the AAR by approximately 13.8% in IPC treated animals 
(Figure 8.14; bias -13.8±14.8 AAR/LV% ±SD). This underestimation of AAR by T2-
mapping MRI is clearly shown by Bland-Altman analysis of AAR. Crucially, this 
corresponded to a statistically significant underestimation of AAR by T2-mapping in this 
IPC treated group (Figure 8.14 A). This extent of bias in AAR quantification is likely to be 
biologically significant for any subsequent calculation of myocardial salvage and 
therefore suggests that T2-mapping cardiac MRI is not appropriate for AAR 
quantification in the presence of cardioprotection by IPC in this model. 
Interestingly, CsA did not appear to significantly affect the area of myocardium exhibiting 
an elevated T2-signal and provided a reasonably accurate quantification of AAR in these 
animals (Figure 8.14 B; bias -2.5±16.8 AAR/LV% ±SD). The slight underestimation of 
AAR by ASL cardiac MRI (-2.5% AAR/LV) is unlikely to be biologically significant, 
although the variation in AAR assessment by this method was larger than is ideal. This 
may reflect the increased variation in the response to this intervention which is perhaps 
expected given the natural variation of any in vivo system and the potential variation in 
the success of intravenous drug dosing. This suggests that despite the cardioprotective 
effect of CsA in reducing infarct size, it does not appear to affect the development of 
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oedema. This could perhaps be taken as evidence that these interventions exert 
differential protective effects against ischaemia-reperfusion, this is discussed below. 
The potential differential effects of IPC and CsA on the extent of myocardial oedema 
could provide support to the previous clinical studies which showed that the mechanical 
interventions, IPost and RIPost, but not the pharmacological intervention exenatide 
reduced myocardial oedema (Thuny et al., 2012; Lonborg et al., 2012a; 2012b; Crimi et 
al., 2013). However, these early studies do not provide sufficient evidence of a 
mechanistic difference between these mechanical and pharmacological interventions for 
which extensive further studies are now required. It is important to note however, that in 
the present study, there was a slight increase in the control infarct size caused by the 
vehicle meaning that despite significant cardioprotection by CsA, there was a difference 
in the infarct sizes between IPC and CsA treated animals. This may, therefore, account 
for some difference in the degree of myocardial oedema between these groups. It is 
therefore not possible to conclude from this study alone that IPC and CsA mediate 
differential effects on myocardial oedema. 
These findings could suggest that myocardial oedema is related to the extent of 
myocardial infarction whereby it would be expected that myocardial oedema would 
increase with the duration of ischaemia. This may pose an additional confounding factor 
to the use of T2-weighted based cardiac MRI methods for quantifying AAR clinically, 
where there is substantial variation in the ischaemic duration between patients. This has 
not yet been investigated directly, although Abel-Aty et al. (2009) showed that sublethal 
ischaemic durations caused myocardial oedema (Abdel-Aty et al., 2009). Since previous 
clinical studies have shown reasonably accurate assessment of AAR by T2-weighted 
based MRI, it is likely that any potential effects of ischaemic duration do not preclude the 
use of this approach with large sample sizes. A measure of AAR that is not significantly 
affected by ischaemic duration may provide a more sensitive method of evaluating 
myocardial salvage and may therefore reduce the sample sizes required for clinical 
studies of cardioprotection; this is discussed further below.  
The potential influence of reperfusion duration on the pathophysiology of myocardial 
oedema is also an important consideration for the further application of T2-weighted 
based MRI approaches to quantifying AAR. Future studies could undertake an in-depth 
analysis of the time-course of manifestation of myocardial oedema over the initial period 
of reperfusion. Mather et al. (2011) showed significant resolution of myocardial oedema 
in acute myocardial infarction patients between days 2 and 7 of reperfusion (Mather et 
al., 2011). Oedema may become an interesting additional endpoint to assess the effects 
of potential therapeutic interventions in modulating the degree of myocardial injury. To 
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this end, it would be of value to assess the effect of interventions on the time-course of 
the development and resolution of oedema following ischaemia-reperfusion. However, 
since this study has shown that T2-mapping MRI does not provide a reliable measure of 
AAR in the presence of IPC, this was not investigated further in this thesis. 
ASL MRI: Given the promising nature of ASL perfusion mapping for quantification of 
AAR in control animals, the effect of cardioprotective interventions on the validity of this 
approach was also examined. This study showed that neither IPC nor CsA significantly 
affected the quantification of AAR by ASL cardiac MRI (Figure 8.16). It should be noted 
that there was a degree of bias associated with AAR quantification by this method 
(Figure 8.16: %AAR/LV bias in animals treated with IPC -4.7±19.0 and CsA 5.7±7.9). 
However, it was not expected that this would have a biologically significant effect for the 
quantification of myocardial salvage using this method of AAR calculation. Indeed, 
calculation of infarct size as a percentage of AAR (IS/AAR%) by LGE and ASL cardiac 
MRI showed that it was possible to detect significant cardioprotection by these 
interventions (Figure 8.18). This study therefore suggests that ASL cardiac MRI provides 
a valid method for quantifying myocardial AAR even in the presence of the 
cardioprotective interventions tested here. 
It remains possible that other cardioprotective interventions may affect the validity of 
AAR quantification by ASL cardiac MRI. It could be expected that if an intervention were 
to modify myocardial perfusion that this may in turn affect the calculation of AAR by ASL 
MRI, since this method is based on detection of a perfusion deficit. Indeed, nitrate 
treatment has been shown to improve myocardial perfusion in reperfused canine hearts 
(Gonzalez et al., 2008). Interestingly, analysis of myocardial perfusion by ASL MRI 
showed that CsA treatment significantly increased the rate of ‘normal’ perfusion in the 
non-AAR (Figure 8.17: normal perfusion in vehicle 16.9±0.5 versus CsA 29.5±3.6 
ml/g/min). Since an equivalent increase was not observed in IPC treated animals, it is 
unlikely that this corresponds to increased cardiac function in these animals. Although 
this remains an intriguing and unexplained effect of CsA, it did not influence the 
calculation of AAR by this method since the area of decreased perfusion was defined by 
a threshold approach based on this normal value (as described in section 8.3.2 ii). This 
study therefore suggests that ASL cardiac MRI may provide a valid method for AAR 
quantification even in the presence of cardioprotective interventions which increase 
myocardial perfusion. This should be investigated further in order to fully validate the 
use of this cardiac MRI method for assessing myocardial salvage. 
It also remains to be seen whether the duration of myocardial ischaemia significantly 
affects the extent of perfusion deficit and AAR calculation by ASL MRI. However, the 
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immediate purpose of this study was to provide an in vivo method for AAR quantification 
for use in small animal studies, where the ischaemic duration is precisely controlled 
between animals. Investigation of the reliability of ASL AAR quantification at varied 
ischaemic durations would be required prior to clinical investigation of this method. 
Overall, this study shows that ASL cardiac MRI may provide a more suitable method for 
quantifying myocardial AAR in vivo following ischaemia-reperfusion injury. Further 
studies are now required to complete the validation of this method for its wider use. 
 
8.5.3. Summary 
The main research objective of this chapter was to investigate and validate a cardiac 
MRI method to quantify myocardial AAR in vivo in the reperfused mouse heart. The 
ultimate aim of this study was to provide a fully validated method for calculating 
myocardial salvage in order to accurately assess the cardioprotective efficacy of novel 
therapeutic interventions. The main findings of this chapter are summarised below: 
 
(1) T2-mapping cardiac MRI detected clearly defined regions of elevated T2-signal which 
appeared to be spatially localised within the known AAR. Although this T2-mapping 
approach allowed accurate quantification of AAR in control operated animals, IPC 
significantly reduced the area of myocardial oedema and thus resulted in a 
significant underestimation of AAR by this method in IPC treated animals. 
 
Interestingly, CsA treatment did not appear to significantly affect the area of elevated 
T2-signal meaning that this T2-mapping approach still allowed accurate AAR 
quantification in CsA treated animals. Further studies are required to investigate the 
potential differential effects of cardioprotective interventions on myocardial oedema. 
 
(2) ASL perfusion cardiac MRI showed clearly defined regions of decreased myocardial 
perfusion which appeared to be spatially localised within the known AAR. 
Quantification of the area of myocardium exhibiting decreased perfusion showed 
good agreement with the true AAR and therefore suggested that ASL cardiac MRI 
may provide a novel method to quantify AAR in vivo following ischaemia-reperfusion. 
Importantly, this study showed that cardioprotection by IPC and CsA did not 
significantly affect the validity of the quantification of AAR by ASL cardiac MRI.  
Further investigations are now required to fully validate the use of ASL cardiac MRI to 
assess myocardial salvage. Since ASL cardiac MRI sequences are also available for 
use in clinical MRI, the work presented here may provide an important platform for the 
future direction of studies of cardioprotection in both the pre-clinical and clinical settings. 
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CHAPTER 9: OVERALL CONCLUSIONS 
 
The overall aim of this thesis was to investigate the potential modulation of important 
mitochondrial proteins to confer long-term cardioprotection against myocardial 
ischaemia-reperfusion. This thesis has examined the potential cardioprotective efficacy 
of targeting cyclophilin-D, sirtuin-3 and DJ-1 to affect mitochondrial function and survival 
to ultimately affect cell survival. The cardioprotective efficacy of these potential targets 
has been discussed in detail in the previous chapters and since these represent distinct 
targets, the overall discussion of the findings of this thesis necessarily focuses on the 
main themes and future directions highlighted during the course of these studies. 
Overall, it appears that modulation of each of these mitochondrial proteins may provide 
a therapeutic target for cardioprotection against myocardial ischaemia-reperfusion injury. 
This thesis highlights the importance of mitochondria for the maintenance of cellular 
function and survival in this pathological setting. Mitochondria are likely to represent 
important therapeutic targets for a number of pathologies involving cell death. The 
importance of mitochondrial function in the heart may be particularly acute given its high 
metabolic demand which means that mitochondrial dysfunction may manifest as a more 
severe phenotype. Further studies of the potential adverse side-effects of therapeutic 
targets aimed at mitochondrial proteins are required given the potential severity of 
metabolic dysfunction which could occur. This is particularly important for modulation of 
Cyp-D activity which has been shown to confer some adverse long-term effects (Oie et 
al., 2000; Elrod and Molkentin, 2013) and should be investigated further. 
Although the use of genetic knockout models in this thesis has been fundamental to 
identifying the potential involvement of these mitochondrial proteins in the 
pathophysiology of ischaemia-reperfusion injury, their use may introduce further 
confounding effects. Global genetic ablation of proteins may result in compensatory 
mechanisms, which in turn may affect the phenotype of these animals at baseline and 
under pathological stress (reveiwed by Davis et al., 2012). This has been discussed in 
the relevant chapters of this thesis in relation to the proteins examined here and 
highlights the need for improved pharmacological inhibitors and activators of these 
proteins. Improvements to the chemical derivation of targeted drug therapies may 
facilitate the investigation of these mitochondrial targets in future. Mitochondrial-
targeting of compounds presents an interesting and potentially improvement advance to 
this field. Although the development and characterisation of mitochondrial-targeted CsA 
is still in its infancy (Malouitre et al., 2010; Dube et al., 2012), this chemical approach 
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may provide further selectivity to existing pharmacological compounds and is likely to be 
an interesting direction of future research in the field of cardioprotection. 
The importance of examining the long-term cardioprotective efficacy of potential 
therapeutic interventions has been discussed in detail in this thesis. The model of 
ischaemia-reperfusion injury developed here permits evaluation of myocardial infarct 
size, cardiac function and survival at prolonged durations of reperfusion. The 
assessment of cardioprotective efficacy however, requires assessment of both infarct 
size and the AAR to evaluate the extent of protection conferred by an intervention. 
Although the T2-weighted cardiac MRI approaches currently in use in pre-clinical and 
clinical studies provide a reasonable measure of AAR under control conditions, there is 
mounting evidence that this may not be valid in all circumstances. The investigation of 
T2-mapping cardiac MRI here showed that cardioprotection by a mechanical 
intervention, IPC, significantly reduced myocardial oedema and thus invalidated the 
quantification of AAR by this approach. In combination with the similar findings of two 
recent clinical studies (Thuny et al., 2012; Crimi et al., 2013), it appears that caution 
should be exercised with the use of T2-weighted based cardiac MRI for quantifying 
myocardial AAR in the presence of cardioprotective interventions.  
Investigation of a perfusion-based cardiac MRI method, ASL, to assess areas of the 
reperfused myocardium exhibiting decreased tissue perfusion, suggests that this may 
present a more appropriate and robust method for quantifying the AAR in this setting. 
Although further studies are required to fully validate this approach, the studies 
presented here support the use of ASL cardiac MRI as a novel method for determining 
AAR. Since ASL cardiac MRI sequences are already available clinically, it would be 
intriguing to now investigate the application of this method for clinical studies of 
cardioprotection. Further development of in vivo imaging methods has the potential to 
improve experimental pre-clinical and clinical studies of cardioprotection and thus 
potentially facilitate development and identification of novel cardioprotective therapies. 
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